An X-ray Microtomography Study of the Effect of an Experimental Statherin-like Peptide on Demineralisation and Remineralisation of Enamel by Davies, Janet Ann
An X-ray Microtomography Study of the Effect of an Experimental
Statherin-like Peptide on Demineralisation and Remineralisation of
Enamel
Davies, Janet Ann
 
 
 
 
 
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11580
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
  
 
An X-ray Microtomography Study of the Effect of an 
Experimental Statherin-like Peptide on 
Demineralisation and Remineralisation of Enamel  
 
 
 
 
Janet Ann Davies 
BSc (Hons), BDS, MFDS RCS (Eng), MPaed Dent RCS (Eng), FDS Paed Dent 
RCS (Eng) 
 
 
 
 
 
Thesis submitted in partial fulfilment of the requirements for the degree of Doctor of 
Philosophy, University of London  
 
 
December 2013 
Centre for Oral Growth and Development  
Institute of Dentistry  
Barts and the London School of Medicine and Dentistry 
Queen Mary University of London  
2 
 
  
 
 
 
Statement of Originality 
 
I, Janet Ann Davies, confirm that the research included within this is my own work or 
that where it has been carried out in collaboration with, or supported by others, that 
this is duly acknowledged below and my contribution indicated. Previously published 
material is also acknowledged below. 
I attest that I have exercised reasonable care to ensure that the work is original, and 
does not to the best of my knowledge break any UK law, infringe any third party’s 
copyright or other Intellectual Property Right, or contain any confidential material. 
I accept that the College has the right to use plagiarism detection software to check 
the electronic version of the thesis. 
I confirm that this thesis has not been previously submitted for the award of a 
degree by this or any other university. 
The copyright of this thesis rests with the author and no quotation from it or 
information derived from it may be published without the prior written consent of the 
author. 
 
Signature:  
Date: 11/12/2013 
  
3 
 
Abstract 
 
The salivary protein, statherin, plays an important role in enamel homeostasis. It 
forms a bioactive complex with calcium and phosphate releasing these ions when 
pH decreases. Statherin also forms part of the enamel pellicle forming a protective 
barrier against bacterial and dietary acids.  The purpose of this thesis was two-fold: 
firstly, to study the effect of a 21 amino acid peptide identical to the N terminus of 
Statherin (StN21) on enamel de - and remineralisation in vitro and secondly, to 
undertake biocompatibility assays of this peptide to demonstrate its safety for use in 
a clinical trial. 
 
X-ray microtomography (XMT) is a quantitative, non-destructive method of 
measuring mineral change. Using XMT to quantify mineral changes, StN21 
demonstrated a statistically significant decrease in demineralisation rate when 
compared to control lesions exposed to phosphate buffered saline (PBS). Whole 
Statherin protein and sodium fluoride solutions were used as positive controls and 
were found to have demineralisation rates equivalent to those seen with StN21. 
Remineralisation was neither enhanced and nor inhibited by StN21.  
 
Biocompatibility assays were undertaken using a well-established buccal mucosal 
model. Viability assays measured enzyme activity within the mitochondria of the cell; 
after 48 hours in growth medium, the cell cultures remained viable with no difference 
between PBS and StN21 exposed cells. Enzyme linked immunosorbant assays 
measuring IL-1α and IL-8 production by mucosal cells exposed to StN21 showed no 
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difference when compared with PBS and whole protein Statherin exposed samples. 
StN21 does not irritate or sensitise the mucosa and cells indicating a lack of toxicity. 
 
In conclusion, StN21 significantly decreases the rate of enamel demineralisation in 
vitro and is non-toxic to the oral mucosa. StN21 has potential as a therapeutic agent 
for prevention of dental caries and erosion. Further clinical research is required. 
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Chapter 1 – Introduction 
 
De- and remineralisation of enamel is a complex, dynamic process. Saliva has a 
multifactorial preventive role in the protection of enamel against demineralisation 
and enhancement of remineralisation (Bardow et al., 2001). Of particular interest are 
the proteins which form the enamel pellicle. Statherin is a 43 amino acid, calcium 
binding phosphopeptide which is present in parotid and submandibular saliva (Raj et 
al.,1992). Recently, a synthetic peptide based on the 21 amino acid N-terminus of 
Statherin was developed as a preventive agent against hydroxyapatite 
demineralisation (Kosoric et al., 2007). This thesis uses X-ray Microtomography to 
study the effect of this experimental peptide in enamel de- and remineralisation. 
This peptide may have clinical applications as a topical preparation in the prevention 
of dental caries and erosion. It was therefore necessary to demonstrate that it is not 
toxic to oral mucosa cells. 
 
This thesis is divided in four parts. Part I consists of background information 
including the literature review, aims and objectives and materials and methods 
common to all experiments. Parts II and III are experimental sections. Each chapter 
within these parts is discusses a specific set of experiments and contains an 
introduction, materials and methods, results and a brief discussion. Part II is 
devoted to in vitro work and Part III to proof of concept experiments. Part IV consists 
of a general discussion including clinical implications and details of planned future 
work.  
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Chapter 2 – Literature Review 
 
 
2.1 Dental Caries and Erosion 
 
 
Dental diseases include dental caries, periodontal disease, erosion and 
developmental defects of enamel/dentine and are a major worldwide health issue. 
They are the most common chronic diseases affecting 5 billion people worldwide 
(Peterson et al., 2005). Treating dental problems represents a significant financial 
burden. In the U.K. for the financial year 2010/2011, the cost of dental treatment 
was 3.31 billion pounds which accounted for approximately 3% of the total NHS 
budget (Harker, 2012). Dental disease affects both children and adults causing pain, 
eating difficulties, disfigurement and low self-esteem.  
 
2.1.1 Dental Caries 
 
When measured using the dmft/DFMT epidemiological tool, the mean number of 
decayed, missing or filled teeth has decreased since the 1970s (Pitts et al., 2006). 
For 5 and 8 year olds in the U.K., data reported that a plateau had been reached 
with no further significant decreases in mean dmft (decayed, missing or filled 
primary teeth) between 1993 and 2003. This does not report the full story: in 2003, 
the mean DMFTs (decayed, missing or filled permanent teeth) for UK 8, 12 and 15 
year olds were 0.3, 1.1 and 2.0 respectively. In Northern Ireland, these figures were 
0.8, 2.7 and 4.4, twice that of the U.K. as a whole. The proportion of children in 
Northern Ireland with obvious decay experience for each of the age groups was at 
least 50% higher than for English children (Pitts et al., 2006). It would seem 
therefore that the distribution of dental caries has become heavily skewed to certain 
groups within population (Peterson et al., 2005). This disease which was once the 
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preserve of developed world is now increasing in prevalence in developing countries 
(Edelstein, 2006). This is linked to increased affluence, availability of sugary 
foodstuffs and paucity of oral hygiene practices particularly fluoride use (Moynihan, 
2005). 
 
Dental caries is defined as destruction of dental enamel/dentine by bacterial 
metabolic acids. As this thesis will focus on enamel demineralisation, the following 
description will review the caries and erosive process in enamel.  
 
A bacterial biofilm or plaque is necessary to initiate the caries process (Kidd and 
Fejerskov, 2004). Plaque has the potential to form on any tooth surface rendering 
them susceptible to demineralisation. Certain areas are, however, relatively 
susceptible for plaque growth causing mature acidogenic plaque to develop. These 
include the pits and fissures of erupting teeth of erupting teeth, cervical and proximal 
regions (Batchelor and Sheiham, 2004; Psoter et al., 2009). Bacteria metabolise 
fermentable carbohydrate from the human diet to form a variety of organic acids 
(lactic, acetic, propionic), which cause the pH within the plaque to drop below pH 5 
within 1-3 minutes (Margolis and Moreno, 1992). This is below the critical pH where 
dissolution of enamel can occur although this is dependent on host protective 
factors (see section 2.2.1). Dental caries is a dynamic process where periods of 
demineralisation and remineralisation occur(ten Cate and Duijsters, 1982). 
 
Both dental caries and erosion result in a net demineralisation of enamel by acids, 
but to understand the differences we need to examine the histological processes 
involved. Much of our understanding of dental caries comes from examining “white 
spot” lesions – the kidney- or oval-shaped, early enamel lesion which is formed on 
the proximal surface between the contact point and gingival margin (Moreno and 
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Zahradnik, 1974; Anderson and Elliott, 1992). After 4 weeks of undisturbed plaque 
accumulation, a white, chalky, opaque lesion can be visualised macroscopically 
without the need to air dry the tooth. Scanning electron micrographs of the surface 
show widened intercrystalline spaces, loss of perikymata and irregular 
developmental pits due to Tome’s processes or focal holes all of which contribute to 
enamel porosity and the resulting macroscopic appearance of the lesion (Arends et 
al., 1987; Wang et al., 2006). 
 
Histological studies of ground sections (80-100µm thick, perpendicular to enamel 
surface) using polarised light microscopy and microradiography have demonstrated 
wedge or triangular-shaped lesions (Arends and ten Bosch, 1992). When imbibed 
with water, the outer most layer (surface zone) is a seemingly intact layer 20-50µm 
thick where little or no demineralisation has occurred; the porosity in this layer is 
approximately 1%. Beneath this layer is the body of the lesion where the porosity is 
greater than 5% (ten Cate et al., 2008). Imbibing the section with quinolone 
demonstrates the presence of two further zones in some lesions: the translucent 
and dark zones. The translucent zone is located at the advancing front of the lesion 
and appears structureless due to the very early demineralisation along the junction 
between the prismatic and interprismatic enamel forming relatively large pores. The 
pore density in this zone is about 1%. The dark zone is located between this 
translucent zone and body of the lesion with pore volumes of between 2 and 4%. In 
this area along with the large pores seen in the translucent layer, there also exist 
micropores which are thought to be pores where deposition of mineral has occurred 
reducing their diameter – reprecipitation of previously demineralised mineral from 
deeper within the lesion (Orams et al., 1980). 
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2.1.2 Dental Erosion 
 
Dental erosion is defined as the “irreversible loss of dental hard tissue due to a 
chemical process of acid dissolution but not involving bacterial plaque acid, and not 
directly associated with mechanical or traumatic factors, or with dental caries” 
(O'Sullivan and Milosevic, 2008). Erosion usually co-exists with a degree of attrition 
or abrasion leading to a diagnosis of tooth surface loss (TSL) clinically. TSL is an 
increasing in problem in both adults and children. The Children’s Dental Health in 
the U.K. 2003 reported that 22% of 5 year olds and 5% of 12 year olds had tooth 
wear of the upper primary and permanent incisors respectively (Chadwick et al., 
2006). The aetiology in dental erosion may be intrinsic (gastro-oesophageal reflux, 
vomiting) or extrinsic (consumption of acidic drinks, foods and medication). 
 
Clinically, erosive lesions are smooth, shiny and feel hard when probed. The 
histology of the early lesion demonstrates a surface phenomenon where there is a 
bulk mineral loss with a very thin base of lesion layer approximately 1 – 10μm thick 
of softened, but intact enamel (ten Cate et al., 2008). There is controversy about 
how the lesions progresses. The hypothesis is that the enamel is stripped away in 
layers, therefore remineralisation of eroded enamel is impossible and that fluoride 
treatment is of little value. At present, it is impossible to replace bulk loss enamel 
naturally and restoration with a plastic material such as dental composite or glass 
ionomer would be required. The remineralisation of the thin softened layer would 
have little overall effect on progression of demineralisation. It has however been 
shown that certain formulations of fluoride may have a protective effect and this is 
discussed in section 2.2.2.1. 
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2.1.3 Chemistry of Enamel Dissolution 
 
Dental enamel is the most highly mineralised component in the human body 
consisting of 99% dry weight calcium phosphate crystals mostly in the form of 
substituted hydroxyapatite (HAp). Enamel apatite crystals are long (more than 
100µm) and thin (50nm in cross section) (Elliott, 1997); they are tightly packed 
forming enamel prisms with water and organic material found between the crystals. 
It is important to recognise that enamel crystals are heterogeneous with 
substitutions of carbonate, sodium, magnesium and fluoride. Calcium phosphate 
also exists within enamel in different forms such as brushite, octacalcium phosphate 
and β-tricalcium phosphate. Enamel and HAp have many similarities. The physical 
properties of enamel such as colour, translucency, hardness and density are similar 
to HAp. In addition, enamel solubility is closely related to the solubility of HAp, an 
important consideration in both dental caries and erosion (Shellis and Wilson, 2004). 
 
Mineral solubility in pure water is inherent and occurs at a fixed rate dependent 
upon temperature. Dissolution is initially fast and slows when crystal ions 
accumulate in the solution, eventually ceasing when the solution is saturated with 
respect to these ions. At the saturation point, ion activity can be used to calculate 
the solubility product of the crystal (KSP). In HAp, this is determined using Equation 
2.1 (ten Cate et al., 2008): 
 
KSPHAP = (Ca
2+)5 x (PO4
3-)3 x (OH-) 
          Equation 2.1 
 
Ion substitutions therefore have an influence on the KSP of a crystal. When the 
complete substitution of OH- in HAp with F- occurs, the fluorapatite (FAp) crystals 
formed are less soluble. Partial substitution to form fluorhydroxyapatite results in the 
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lowest solubility product for unknown reasons (Moreno et al., 1974). Dental enamel 
has relatively little fluoride content compared to the amount of carbonate present 
and has a relatively quoted high solubility product compared to other apatites (Table 
2.1). The KSPEnamel however has been debated in the literature as enamel is very 
heterogeneous. There is evidence to suggest that the actual figure is closer to 10-58 
(Shellis, 1996; Shellis and Wilson, 2004). 
 
Mineral Solubility Product (KSP, mol9 l-9 at 370C) 
HAp  7.4 x 10-60 
FAp  3.2 x 10-61 
Fluorhydroxyapaptite (50% substitution) 6.6 x 10-63 
Enamel 5.5 x 10-55 
Table 2.1 Solubility products of apatites (from ten Cate et al., 2008) 
 
While HAp dissolution is not greatly affected by temperature unlike other salts such 
as sodium chloride, a decrease in solution pH has a profound effect. The following 
equations illustrate this phenomenon.  
 
Ca5 (PO4)3OH ↔ 5Ca
2+ + 3PO4
3- + OH- 
Equation 2.2 
 
Ca5 (PO4)3OH ↔ 5Ca
2+ + 3PO4
3- + OH- 
↓ + H+ ↓ 
3H2PO4
2- +H2O 
Equation 2.3 
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In Equation 2.3, the addition of H+ ions drives the reaction to the right resulting in the 
production of dihydrogen phosphate and water leaving the solution undersaturated. 
Further dissolution must then occur to reach equilibrium. The pH at which a 
supersaturated solution becomes undersaturated is known as the critical pH. 
 
Oral fluids are supersaturated with respect to HAp and FAp at neutral pH resulting in 
formation of calculus and remineralisation of previously demineralised lesions 
(Moreno EC, 1979; Sreebny, 2000). As the pH is decreased, plaque fluid is reduced 
in saturation until critical pH is reached and it becomes undersaturated in relation to 
HAp (Figure 2.1). Due to the difference in KSP, the plaque fluid remains saturated in 
respect to FAp. Under these conditions between pH 4.0 and 5.5, a subsurface 
carious lesion forms whereby the fluorhydroxyapatite surface layer is preserved with 
dissolution of HAp underneath (Moreno and Zahradnik, 1974). Under experimental 
conditions, increased supersaturation with respect to FAp demonstrates the 
formation of a thicker, less demineralised surface layer. Erosive type lesions form 
when the pH of the oral fluid drops to between pH 2.5 and 4 and is therefore 
undersaturated with respect to both FAp and HAp (Larsen 1991; Bashir and 
Lagerlöf, 1996). 
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pH 
Figure 2.1- Solubility of HAp and FAp as a function of pH in the range 4-6 (from ten Cate et al., 2008). 
 
 
The major differences between dental caries and erosion are thus the origin of the 
acids, the pH at which the demineralisation occurs (erosion occurs at levels of pH2 -
4) and the lack of a surface layer within the erosive lesion. The sub-surface 
demineralised carious lesions with intact surface layers have the potential to be 
remineralised. For erosive lesions, the lost surface layer cannot be regenerated 
through remineralisation. 
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2.2 Protective Mechanisms 
 
2.2.1 Saliva 
 
The term “saliva” is used for the fluid which bathes the teeth and the oral cavity 
(Sreebny, 2000; Leone and Oppenheim, 2001). Healthy individuals produce 
between 0.5 and 1.5L of saliva daily and at any one time have approximately 1ml in 
the oral cavity (Pedersen et al., 2002). The production of saliva is largely dependent 
on the adequate function of the major salivary glands. The major salivary glands 
which are paired consist of the parotid, submandibular and sublingual glands. In 
addition, each person has between 600 and 1000 minor salivary glands present in 
the oral mucosa. The basic secretory unit of all salivary glands is the acinus; these 
are clusters of fluid producing cells which drain into collecting ducts. Within the 
ducts, the composition of the originally isotonic (plasma derived) fluid is altered to a 
hypotonic solution through ion transport and protein secretion under the control of 
autonomic nervous system. A minor proportion of saliva is made up of gingival 
crevicular fluid, microorganisms and host derived cells. 
 
The composition and functions of saliva are indelibly linked. Saliva is over 99% 
water; less than 1% is made up of proteins and salts (Larsen et al., 1999; Pedersen 
et al., 2002). Saliva lubricates the oral mucosa which is important for mastication 
and swallowing of food; it solubilises dried food enabling taste. It is important in 
facilitating speech and has antimicrobial properties (Nieuw Amerongen and 
Veerman, 2002). Stimulation of saliva results in the flushing of oral debris, bacteria 
and other agents. 
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2.2.1.1 Salivary Flow Rate and Buffering 
 
The flushing and neutralising effects of saliva are thought to be the most important 
protective mechanisms against enamel demineralisation. A generalised lack of 
saliva can be a serious oral health issue. Hyposalivation can be measured and is 
defined as those with unstimulated flow rates of 0.1ml min-1 and stimulated flow 
rates of 0.5-0.7 ml min-1 (Sreebny, 2000). Not only does hyposalivation lead to the 
uncomfortable sensation of a dry mouth (xerostomia), it can also be extremely 
detrimental to the oral mucosa and teeth. Patients with hyposalivation have 
increased rates of demineralisation (Bardow et al., 2001) which, in turn, leads to 
increased levels of smooth surface dental caries (Leone and Oppenheim, 2001). 
Erosion has been associated with low salivary flow/low buffering capacity (Jarvinen 
et al., 1991). 
 
The ability of saliva to buffer acids has been shown to protect against 
demineralisation (Leone and Oppenheim, 2001). The three major buffering systems 
in saliva are bicarbonates, phosphates and proteins which all act at different pH 
levels. The bicarbonate system which operates at a pK value of 6.1 - 6.3 is the most 
important buffer during food consumption and acts as the following equilibrium: 
 
HCO3
- + H+ CO2 + H2O 
Equation 2.4 
 
In resting saliva the concentration of carbonate is low, around 1 - 3 mM and pH 6.5 -
7.5 (Jensdottir et al., 2005). At high flow rates, the carbonate concentration may rise 
to 40mM and pH may increase to 8. The above equilibrium is shifted to the right, 
CO2 released and a major part of the bicarbonate buffering system is lost. 
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Bicarbonate buffering particularly important in combating erosive insults; in dental 
caries, salivary flow rate is more important (Bardow et al., 2003). 
 
2.2.1.2 Homeostasis of Inorganic Components 
 
An important function of saliva is the homeostasis of calcium and phosphate. 
Calcium and phosphate in saliva are essential for prevention of dissolution and 
promotion of remineralisation of in dental hard tissues. This is achieved by 
maintaining them at supersaturated levels. These levels can vary greatly within an 
individual: 1.1 - 4.2 mmol l-1 for calcium and 2.0 - 12.6 mmol l-1 for phosphate 
(Larsen et al., 1999). Theoretically, the consequence of this supersaturation would 
be spontaneous precipitation calcium phosphate crystals, but this does not normally 
occur. Specific phosphoproteins such as Statherin and proline-rich proteins (PRP) 
prevent this precipitation occurring. They would seem to have a protective effect 
against dental caries as subjects with low levels of salivary PRPs (Banderas-
Tarabay et al., 2002) or Statherin (Vitorino et al., 2005) have a higher DMFT than 
those with higher levels of protein. 
 
Statherin is a 43 amino acid protein with a molecular weight of 5380. Its name is 
derived from the Greek statheropio, which means to stabilise. The full length 
Statherin protein demonstrates charge polarity with the N-terminal region (residues 
1-13) containing all of the charged amino acid residues and the remaining portion is 
primarily composed of tyrosine, proline, and glutamine residues (Schlesinger and 
Hay, 1977). There are 3 other shorter length peptide variants of Statherin which are 
demonstrated in the below figure: 
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DpSpSEEKFLRRIGRFGYGYGPYQPVPEQPLYPQPYQPQYQQYTF (Statherin)  
DpSpSEEKFLRRIGRFGYGYGPYQPVPEQPLYPQPYQPQYQQYT_ (StNV1)  
DpSpSEEYGYGPYQPVPEQPLYPQPYQPQYQQYTF (StNV2)  
DpSpSEEYGYGPYQPVPEQPLYPQPYQPQYQQYT_ (StNV3)  
 
Figure 2.2 – Amino acid sequences for Statherin and its 3 shorter variants 
 
 
Statherin and variant 1 (StNV1) differ by one amino acid; in StNV1, the final 
phenylalanine residue is missing. Variants 2 (StNV2) and 3 (StNV3) lack the 
segment K6 – G15; StNV3 also lacks the final phenylalanine residue. These 
differences affect the secondary protein structure. 
 
The secondary structure of Statherin is important when studying its function. The N-
terminus amino acids (pS2-G12) form an α-helix when bound to hydroxyapatite. The 
amino acids with the strongest bond are D1-E5, whereas the other amino acids bind 
more weakly. The C-terminus and middle section of the protein did not demonstrate 
any higher order structures and are therefore thought to be more flexible. The 
middle section of Statherin is proline rich suggesting that a poly-L-proline II (PPII) 
helix structure. It has been suggested that these 2 helices interact to protect 
hydrophobic residues and render the protein more stable.  
 
Statherin is the only salivary protein, which is known to prevent primary precipitation 
of hydroxyapatite and enamel. It is also an important inhibitor of crystal growth. 
These functions are mediated by the N-terminus. Similarly charged protein 
segments are also found in other calcium binding proteins such caseins, enamel 
matrix proteins and dentine/bone sialoproteins. This would suggest that inhibition of 
calcium phosphate precipitation is mediated by the binding of Ca2+ ions. While 
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secondary precipitation can occur in the presence of a peptide consisting of the 6 
amino acids in the N-terminus, the whole protein is required to inhibit primary 
precipitation. 
 
Belonging to a unique superfamily of proline, glycine and glutamate-rich salivary 
phophoproteins, PRPs form 2 main groups: basic or acidic and are encoded by six 
closely linked genes on chromosome 12p13.2 (Beeley, 2001). While the role of 
basic PRPs is largely unknown, acidic PRPs (PRP 1, PRP 2, PIFs, PRP 3, PRP 4 
and PIFf) have a high affinity for calcium and are found in pellicle (Schüpbach et al., 
2005).  
 
Acidic PRPs account for 25-30% of all proteins in saliva. They share some 
similarities with the Statherin proteins in that they have a negatively charged N-
terminus coupled with repetitive sequences of proline and glutamine residues 
(Schlesinger and Hay, 1977; Lamkin and Oppenheim, 1993). They are also capable 
of binding to hydroxyapatite and calcium ions and inhibiting growth of calcium 
phosphate crystals. They are however unable to induce primary precipitation at 
physiological pH. In caries free individuals, both Statherin and PRPs levels are 
higher than in those individuals with caries (Lenander-Lumikari and Loimaranta, 
2000; Vitorino et al., 2005). 
 
2.2.1.3 Lubrication and Aggregation 
 
Lubrication of the oral mucosa facilitates speech and swallowing, but also has a 
protective function. The salivary proteins most associated with this are the Mucin 
group. This group comprises of two genetically distinct types of mucin glycoprotein – 
MG1 and MG2 originating from the MUC5B and MUC7 respectively (Thomsson et 
al., 2005). MG1 is a high molecular weight glyco protein containing blood group 
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active carbohydrates of the ABO system and is functionally and structurally related 
to mucins found in the gastrointestinal, genitourinary and respiratory tracts. These 
are active in slime layer formation which, in turn, protects the epithelium from 
irritants and entry of microorganisms, and provides lubrication (Hay and Bowen, 
1996). MG2, in contrast, is a small molecular weight (Mr 125kDa) glycoprotein which 
lacks blood group active carbohydrates. It has been shown to bind a variety of 
microorganisms (eg. Streptococcus sanguis, S. mitis, S. gordonii, Actinobacillus 
actinomycetemcomitans, Pseudomonas aeruginosa) causing agglutination of 
bacteria and also the bactericidal effect of membrane disruption (Nieuw Amerongen 
and Veerman, 2002). 
 
A second protein which when found in saliva and has a protective effect through 
aggregation is Agglutinin. Agglutinin, a 340kDa glycoprotein also carries blood 
group active antigens. It is closely related to gp-340, a glycoprotein found on the 
respiratory surface of the lungs. Its action is similar to that of MG1 in that it is “sticky” 
and causes agglutination of bacteria facilitating their removal from the oral cavity 
during swallowing. It has been shown to bind to S. Mutans (Tao et al., 2005) as well 
as S.salivarius and S.sanguis (Ligtenberg et al., 2001). 
 
2.2.1.4 Antibacterial Properties 
 
Bacteria, viruses and fungi flourish in the warm, moist oral cavity. While commensal 
bacteria such as streptococci and lactobacillus sp. are present in almost all of the 
population, these are potentially virulent and require defences against this. Anti 
bacterial proteins can be non-specific (innate) or acquired (specific) to a particular 
target. The innate anti microbial defences have been well studied in vitro. The main 
ones are peroxidases, lysozyme, lactoferrin, histatins and defencins. These are not 
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only found in saliva, but are commonly found in other exocrine secretions such as 
tears, milk, and seminal, vaginal and gastrointestinal fluids. 
 
The majority of peroxidases in saliva are produced not by the salivary glands, but by 
polymorphonucleocytes (PNM) (Ihalin et al., 2006). Peroxidases catalyse the 
reaction of the bacterial metabolic product hydrogen peroxide (H2O2) with iodine, 
bromine and thiocyanate resulting in oxidised halides. These have both 
bacteriostatic and bactericidal effects including inhibition of glucose metabolism and 
transport, oxidation of cellular proteins in Gram-positive organisms, inhibition of 
respiratory chain enzymes, impairment of DNA replication and induction of DNA 
damage in Gram-negative organisms. Interestingly, H2O2 is toxic to human cells 
such fibroblasts and epithelium as it is converted within the cells to hydroxyl 
radicals. Peroxidase production of halides therefore also protects mucosal integrity 
(Ihalin et al., 2006). 
 
Lysozyme is a 14-kDa protective enzyme which hydrolyses specific bonds in the 
murein-containing layer of the bacterial cell wall causing lysis and cell death 
(Edgerton and Koshlukova, 2000). Bacteria which have a cell capsule or are 
embedded in plaque are resistant to this form of attack. Lysozyme has an additional 
role in defence of the oral cavity: in combination with inorganic salts, it has the ability 
to induce the action of bacterial autolysins causing bacteria “suicide” (Wilkens et al., 
1982). Lactoferrin has the ability to bind ferric iron (Fe3+) which confers a 
bacteriostatic effect as Fe3+ is essential for bacterial nutrition. The protein is 80-kDa 
with the C-terminus responsible for iron binding and the N-terminus containing a 25 
amino acid bactericidal fragment (Edgerton and Koshlukova, 2000). The periodontal 
pathogen, A. Actinomycetemcomitans, appears to be a particular target of 
lactoferrin, but it is also active against candida species. The role of lactoferrin is 
complex and as yet not fully understood. 
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The histatin family consists of several small, cationic histidine-rich peptides of 3-
4kDa (Smet and Contreras, 2005). Histatins 3 and 5 are basic proteins which both 
bactericidal and fungicidal. Histatin 5 is the most potent and therefore has been 
studied in great detail. Its toxic effects are related to its ability to bind to heat shock 
protein 70 on the plasma membrane and through this become internalised into the 
cell. Once in the cell, it targets the mitochondria, causing release of ATP and 
potassium and cell lysis. Development of a 12 amino acid peptide fragment of 
histatin 5 and its use as a mouthwash/dental gel has been shown to be effective 
against plaque and gingivitis (Paquette et al., 2002; Van Dyke et al., 2002) 
 
Defencins are cationic non-glycosylated peptides which contain 3 disulphide bridges 
and have molecular masses of between 3.5 and 6 kDa (Smet and Contreras, 2005). 
In humans, these are classified as α- or β-defencins.  α-defencins are referred to as 
enteric defencins, found mostly in the gut and female genito-urinary tract and highly 
active against Staphylococcus aureus, Escherichia coli and Salmonella 
typhimurium. β-defencins share little sequence homology with α-defencins and are 
more widely expressed in epithelia. They have a broad spectrum of antimicrobial 
action and are particularly active against Streptococcus mutans and Candida 
species. The β-defencins’ mechanism of action involves electrostatic binding to the 
targets’ outer surface, insertion of the peptide into the cytoplasmic membrane and 
cell lysis (White et al., 1995). 
 
Immunoglobulins differ from other salivary proteins in that their defensive action is 
specific. SIgA is the principal immunoglobulin isotype found in saliva and indeed all 
secretions (Molinari et al., 1974). It is formed of two IgA monomers (300KDa), a J 
(joining) chain (15KDa), and a secretory component (70KDa) (Marcotte and Lavoie, 
1998). SIgA is produced by plasma cells found either locally in the salivary glands or 
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which migrate from the gut-associated lymphoid tissues (GALT) to salivary glands 
when sensitised. Inhibition of bacterial adhesion; inactivation of bacterial enzymes 
and toxins; synergism with other antibacterial factors and prevention of antigens 
penetrating the oral mucosa have all been suggested as protective mechanisms of 
sIgA in the oral cavity. The role of IgA in caries prevention is a matter of debate. 
Some studies of children have demonstrated increased levels of S. mutans specific 
IgA associated with decreases in both dmft and DMFT (Lee et al., 2004), however 
others have demonstrated no association. DMFT/dmft are widely used 
epidemiological tools which is used to measure caries experience. Unfortunately it is 
not an accurate measure of early carious lesions and represents only past caries 
history not current caries susceptibility. 
 
2.2.1.5 Pellicle Formation 
 
Salivary enamel pellicle is formed almost immediately when a cleaned tooth surface 
is exposed to saliva; a detectable pellicle is present after just 60 seconds, although 
it takes 2 hours to reach an equilibrium and achieve full thickness of 30 to 100 nm 
(Lendenmann et al., 2000). The formation of this is mediated by specific salivary 
proteins which have a high affinity for hydroxyapatite - PRP, histatins and statherins 
(Schüpbach et al., 2005). Other salivary proteins such as IgA, MG1, lactoferrin, 
lysozyme and amylase form part of the pellicle as well bacteria derived proteins. 
 
The primary role of the pellicle in vivo is that of protection of the dental enamel. It 
reduces friction between teeth during mastication and parafunction preventing 
attrition. Pellicle has a role in bacterial adherence and plaque formation. 
Hydroxyapatite has the ability to bind many different strains of bacteria even when 
there is no saliva present. When saliva is present, however, the bacterial binding 
patterns were different with fewer S. mutans, S. salivarius and Actinomycetes 
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naeslundii and larger numbers of S. Mitis and A. Viscosus (Clark et al., 1978). 
Despite pellicle being a plaque precursor, it would seem that its presence leads 
selection of less virulent bacteria and is therefore protective. 
 
The other protective effect of the pellicle is the reduction in rate of demineralisation 
(Zahradnik et al., 1976). Pellicle has been shown in vitro to reduce the erosive effect 
of carbonated drinks and orange juice (Amaechi et al., 1999). Initial pellicle forms 
very quickly on polished enamel surfaces; proteins can be detected after only a 2 
minute exposure to saliva (Wetton et al., 2006; Santos et al., 2008). The maturity of 
the pellicle is thought to have an effect on demineralisation. Some studies have 
shown that a pellicle formation time of at least 18 hours in vivo or 4 days in vitro is 
required to show any effects on the rate of demineralisation (Featherstone et al., 
1993). A more recent study however demonstrated that a 2 hour salivary exposure 
provided sufficient pellicle formation to reduce demineralisation (Hannig et al., 
2003). Further work is required on the optimum pellicle maturation time for the 
prevention of demineralisation. 
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2.2.2 Protective Products 
 
2.2.2.1 Fluoride 
 
Fluoride has for many years been the panacea of dental caries. Dr Frederick McKay 
working in Colorado, U.S.A. in the early twentieth century was the first provide 
epidemiological evidence on “Colorado Brown Stain” – brown, mottled dental 
enamel affecting 90% of the local residents which, despite all expectations, was less 
susceptible to dental decay (McKay, 1953). While McKay suspected that the water 
supply was the aetiological factor, it was Dr. H. Trendley Dean, a US Public Health 
Officer, who mapped the prevalence and severity of this mottled enamel throughout 
the U.S.A. and demonstrated a clear dose response curve between this and fluoride 
concentration in drinking water. Their work also demonstrated an “optimum” water 
fluoride concentration of 1 part per million (ppm) where mottled enamel was not of 
public health significance. Dean and co-workers used intervention studies in Grand 
Rapids, Michigan to establish a cause and effect relationship with 1ppm fluoride 
reducing decay experience by 50% (Dean, 1953). 
 
Water fluoridation has never been established in the U.K., but the introduction of 
fluoride dentifrices has been widely credited in the reduction of dental caries (Pitts et 
al., 2006). Fluoride toothpastes are the commonest method of fluoride delivery 
worldwide. There have been over 100 clinical trials comparing different formulations 
of toothpaste (Walsh et al., 2010). In the 1960s, stannous fluoride was widely used, 
but early formulations caused staining. Sodium monofluorophosphate and sodium 
fluoride have largely replaced stannous fluoride and there is no evidence to suggest 
that one of these modalities is more effective than the other. Meta-analysis of 
clinical trial data demonstrates a reduction of 25% in caries increment with an 
average of 0.7 carious surfaces saved per year when comparing fluoridated 
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dentifrice with a non-fluoride toothpaste (Clarkson et al., 1993). There is good 
evidence to support a fluoride level of greater than 1000ppm, twice daily brushing 
and spitting rather than rinsing in reducing caries activity (Walsh et al., 2010). 
 
Other applications of fluoride include tablets, gels, rinses and varnishes. Fluoride 
tablets were popular in the 1970s, but as fluoride exerts its cariostatic effect during 
the post eruptive phase, their ingestion is likely to have little effect on caries 
development with the increased risk of dental fluorosis. Meta-analysis of clinical 
trials of fluoride mouthrinses and gels have shown a 26% (95% CI, 23% to 30%) 
and a 21% reduction (95% CI, 14 to 28%) in D(M)FS respectively (Marinho et al., 
2002; Marinho et al., 2003). Both these methods give a topical effect, but 
compliance is also an issue. When fluoride varnishes are applied professionally 
between 2 and 4 times a year, the DMFS pooled prevented fraction estimate is 43% 
(Marinho et al., 2013). When different combinations of fluoride treatment are used, 
there is no real benefit in caries reduction, therefore their use is limited to patients 
with high caries rates and the medically compromised (Marinho et al., 2004). 
 
Fluoride has most effect as topical application. Its protective effects work in three 
different ways (Featherstone, 1999): 
 
 Inhibition of bacterial metabolism 
 Inhibition of demineralisation 
 Enhancement of remineralisation. 
 
Inhibition of bacterial metabolism occurs when hydrogen fluoride is formed at low pH 
levels. This diffuses through the cell wall and dissociates. F- ions negatively affect 
enolase, the enzyme necessary for metabolism of carbohydrate.  
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As discussed in section 2.1.3, dental enamel is comprised mainly of carbonated 
HAp (Shellis, 1996), which can be described approximately using this formula: 
 
Ca10-x (Na)x(PO4)6-y (CO3)y (OH)2-z (F)z 
Equation 2.5 
 
This crystal structure is more soluble than either pure HAp [Ca10(PO4)6(OH)2] or FAp 
[Ca10(PO4)6F2] (ten Cate et al., 2008). If fluoride is present in an aqueous solution, it 
is absorbed strongly to surface carbonated HAp crystals in dental enamel protecting 
it from dissolution. In the presence of bacterially derived acid, fluoride will travel with 
the acid into the subsurface and prevent dissolution. Fluoride also has 
remineralisation properties; in a demineralised lesion, absorption of F- occurs 
attracting first calcium then phosphate ions. This leads to crystal formation. 
Carbonate is excluded so the new mineral is highly resistant to further dissolution 
(Moreno et al., 1974). 
 
The effect of fluoride in preventing dental erosion is not well understood. Its effect in 
remineralisation of erosive lesions is minimal due to the very thin layer of 
demineralised enamel present in erosive lesions. Conventional fluorides such as 
sodium and amine fluoride result in the deposition of a calcium fluoride layer on the 
enamel surface (Magalhães et al., 2011). This layer may form a physical barrier 
against acidic challenge, but is dependent on the frequency of fluoride application, 
its concentration and the pH of the environment. At acidic pH, this layer is more 
vulnerable than at neutral pH particularly when toothbrushing is also undertaken 
(Lussi et al., 2004). The effect of fluoride toothpastes on erosion, even at a 
concentration of 5000ppm, appears to be limited (Ganss et al., 2013) although high 
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concentration sodium fluoride (42,500ppm) varnish does have some effect for very 
short periods (Austin et al., 2011). The use of conventional fluoride formulations 
would therefore seem not to be useful at reducing erosive demineralisation. 
 
Recent studies have concentrated on formulations of fluoride compounds containing 
polyvalent metals ions such as stannous fluoride. In tin containing fluoride 
formulations, a metal-rich precipitate layer containing Ca(SnF3), SnOHPO4 and 
Sn3F3PO4 is formed which is known to be highly resistant to acid (Magalhães et al., 
2011). In vitro and in situ studies have shown that tin-containing toothpastes 
mouthwashes and solutions reduce erosive demineralisation compared to controls 
(Yu et al., 2010; Huysmans et al., 2011; Rakhmatullina et al., 2013). The 
weaknesses of these studies are that the exposure period is very short (typically 7 
days per treatment) and the controls vary greatly so the experiments are not 
comparable (Ganss et al., 2013). It should be noted that in one experiment where 
1900ppm Sn2+ was used and an 82% reduction in tissue loss was demonstrated, 
43% of participants completing the experiment complained of taste disturbances 
(Schlueter et al., 2011b). Along with the risk of staining, this means that the optimal 
levels of stannous fluoride in erosion reducing products still needs further research 
including randomised controlled trials before clinical use can be recommended. 
 
2.2.2.2 Casein Phoshopeptides 
 
The anticariogenic effect of dairy products such as milk and cheeses has been 
demonstrated both in animal and human models (Reynolds, 1987). This protective 
effect can attributed to the presence of calcium phosphate and casein 
phosphopeptides (Harper et al., 1986). Casein phosphopeptides (CPP) contain a 
phosphoseryl residues in the following motif –Ser(P)-Ser(P)-Ser(P)-Glu-Glu 
(Reynolds, 1997). Milk casein genes are part of the same evolutionary family as 
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enamel matrix proteins (EMP) and salivary proteins such as Statherin and histatins. 
Many of these genes encode secretory Ca-binding phosphoproteins, which regulate 
the Ca-phosphate concentration of the extracellular environment, but have 
diversified into specialist environments (Kawasaki and Weiss, 2003). 
 
 
Figure 2.3 - Divergence of the primordial EMP gene (Kawasaki and Weiss, 2003) 
 
 
Reynolds (1997) demonstrated, under neutral and alkaline conditions, the formation 
of colloidal casein phosphopeptide – amorphous calcium phosphate complexes 
(CPP-ACP). These increased levels of calcium and phosphate in plaque and thus 
the anticariogenic effect is thought to be through the CPP-ACP acting as a calcium 
phosphate reservoir and maintaining supersaturation in respect to dental enamel. 
CPP-ACP (RecaldentTM) has been shown to remineralise carious lesions in enamel 
(Cross et al., 2007). Incorporation into lozenges (Cai et al., 2003), mouthrinses 
(Reynolds et al., 2003), and glass ionomer cements (Mazzaoui et al., 2003) have 
demonstrated this remineralising effect. Remineralisation of enamel lesions has also 
been demonstrated in CPP-ACP chewing gum (Shen et al., 2001; Cochrane et al., 
2012b). Chewing gum in itself stimulates saliva production enhancing the natural 
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protective effects. CPP-ACP chewing gum produces significantly greater 
remineralisation than standard xylitol containing chewing gum (Manton et al., 2008). 
 
2.2.2.3 Xylitol 
 
Xylitol is a naturally occurring 5-carbon sugar alcohol which has a caries protective 
effect. Mutans streptococci (MS) take up xylitol in the same way as glucose, but 
cannot use it as an energy source restricting bacterial growth (Ly et al., 2006). After 
several months of habitual xylitol use (6–10 g consumed in at least 3 doses per 
day), resistant MS species develop which do not take up xylitol (Mäkinen, 2000). 
These resistant MS species, however, are not as virulent as their predecessors. 
They are less adherent to tooth structures and are therefore more easily shed in 
saliva. The initial evidence for xylitol’s anti-caries effectiveness come from a series 
of investigations undertaken by a Finnish dental research group in the 1970s, known 
as the ‘Turku Sugar Studies’ (Mäkinen, 2000). They developed over 100 products, 
including sweets, cakes and drinks, which contained xylitol. Participants substituted 
these products into their diets over a 2-year period. At the end of the study, 
reductions of up to 85% in caries levels were seen when compared with the control 
group who consumed sucrose-based foodstuffs instead (Scheinin et al., 1975a). 
They also undertook a 1-year study into the effect of a xylitol chewing gum 
compared with a gum containing sucrose, which also demonstrated a similar 
reduction in caries levels in the xylitol group (Scheinin et al., 1975b). 
 
These experiments were undertaken in era when fluoride toothpastes were just 
becoming readily available in patients at high risk of dental caries. As discussed in 
Section 2.1, caries experience in children in the U.K. has plateaued and further 
targeted interventions in certain groups are required. Xylitol could be the ideal 
adjunct in these cases particularly when incorporated to foodstuffs such 
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confectionary. An Estonian study examined the effect of xylitol sweets in a group of 
10-year-old school children which resulted in a 33–59% reduction in caries levels 
(Milgrom et al., 2012). A similar result was seen in a Finnish study which examined 
xylitol chewing gum (Kovari et al., 2003). A novel approach to preventing early 
childhood caries involves the maternal transmission of xylitol-resistant MS to her 
gnotobiotic infant. Studies have been undertaken in Finland, Sweden and Japan 
demonstrating lower levels of both MS and dentinal caries in young children whose 
mothers consumed xylitol gum habitually during the first 6 months of their infants’ 
lives (Isokangas et al., 2000; Milgrom et al., 2012).  
 
These studies should be viewed with caution as the study groups are children who 
are high caries risk. Trials where participant children are low caries risk do not 
demonstrate a statistically significant reduction in caries levels (Lenkkeri et al., 
2012). A recent systematic review concluded that the evidence for use of xylitol in 
caries prevention is weak and inconclusive and that further large scale randomised 
control trials are necessary (Antonio et al., 2011). Furthermore, a xylitol lozenge 
placebo-based, randomised control trial in adults (X-ACT) demonstrated no 
statistically significant difference between groups (Bader et al., 2013). Xylitol can, 
therefore, not be recommended as a caries preventive agent.  
 
2.2.2.4 Nanotechnology 
 
Nanotechnology is a rapidly expanding research field which has potential 
applications in dentistry particularly in remineralisation and caries therapy (Hannig 
and Hannig, 2012). Biomimetic treatment of early caries lesions using nano-
hydroxyapatite (nano-HAp) particles has received particular attention. In vitro pH 
cycling experiments have shown that a 10% suspension of nano-HAp (10-20 nm 
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diameter, 60-80 nm length) promotes remineralisation of the surface layer of caries 
lesions compared with a control solution containing the equivalent concentration of 
free ions (Huang et al., 2011). Mineral deposit in the body of the lesion only 
occurred when the pH of the remineralising solution was adjusted to pH4; the nano-
HAp is thought to act as a reservoir of calcium and phosphate, although an acidic 
remineralising solution is not clinically desirable. 
 
A further application of nano-HAp is in the synthesis of enamel-like materials. 
Enamel is non-regenerative, but self-assembling peptides such as P11-4 have been 
shown to act as nano-ribbon templates for de novo HAp nucleation (Kirkham et al., 
2007; Brunton et al., 2013). P11-4 was designed so that it also interacted optimally 
with the enamel surface. Net mineral gain has been demonstrated in vitro (Kirkham 
et al., 2007). A clinical trial has been undertaken where a single P11-4 application 
was applied to white spot caries lesions and monitored for 180 days (Brunton et al., 
2013). After 30 days, statistically significant progression to remineralisation was 
demonstrated. This trial has its limitations due to the lack of a control group and 
therefore the results should be viewed with caution. P11-4 may have a role in the 
clinical promotion of mineral deposition, but future work is required. 
 
2.2.2.5 Bioactive Glasses 
 
NovaMin® is a bioactive glass containing calcium sodium phosphosilicate (CSP) as 
its active ingredient; research in this field has primarily focussed on its role in 
prevention of dentine hypersensitivity. When exposed to saliva, calcium and 
phosphate ions are released from the glass and form a hydroxy-carbonate apatite 
(HCA) (Wefel, 2009). HCA has a higher solubility product than HAp or FAp and 
therefore its precipitation, while useful in the occlusion of dentine tubules and 
subsequent reduction in sensitivity, is not ideal for remineralising carious enamel 
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particularly the body of the lesion. There is some evidence in vitro that CSP pastes 
have an effect on remineralisation of demineralised enamel using surface 
microhardness to measure this (Turssi et al., 2011; Mehta et al., 2014). A further in 
vitro study using scanning electron microscopy (SEM) and SEM/energy dispersive 
X-ray analyses demonstrated mineral deposition on the surface of demineralised 
enamel exposed to a CSP containing toothpaste (Gjorgievska et al., 2013). 
Bioactive glasses would seem to have a role in in vitro remineralisation, but further 
work is required. 
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2.3 Models for studying Dental Caries and Erosion 
 
2.3.1 In vitro Studies 
 
In vitro studies are the most commonly used methods in dental research. These 
models have been developed and improved over many years. Studies examining 
mineral changes in enamel can be grouped as remineralisation, demineralisation or 
pH cycling. In remineralisation and demineralisation, either a constant volume of 
super- or undersaturated solution or a flow through constant composition solution 
can be used (Anderson et al., 1998; Anderson et al., 2004). The only difference is 
the enamel used which is intact, artificially demineralised or has naturally occurring 
erosion/caries. pH cycling refers to experiments where substrates are exposed to 
combinations of demineralisation and remineralisation in order to mimic the in vivo 
situation and are regarded as the method of choice (White, 1995).  
 
These systems however do suffer from limitation. From a biological point of view, it 
is virtually impossible to adequately simulate the complexities of the oral 
environment. Some research has used ‘artificial mouth’ models using saliva and 
bacterial plaque, but these have not been successful. It is impossible to simulate the 
volume and composition of tooth surface and saliva volume encountered in in vivo 
de/remineralisation. In closed systems, supersaturation of Ca2+ and P- is difficult to 
modulate; even in flow through systems, the intra oral surface area/saliva volume is 
not perfect. Artefacts can also be a problem. By necessity, in vitro systems must 
accelerate the time frame for mineral change to occur from years to days/weeks; 
this can cause artefacts. Also substrate selection can be critical as different 
substrates may react differently to de/remineralising agents.  
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2.3.2 Animal Models 
 
Animal models, particularly rodents, have been used extensively to study dental 
caries (Bowen, 2013). They have provided key contributions in the areas of diet, oral 
microbiology, salivary factors and the effect of fluoride confirming the relationship 
between frequency of application and efficacy and the dose-response activity 
(White, 1992). Animal models were popular due to the speed, economy, 
adaptability, degree of control and simulation of the caries effect in humans. Caries 
development in rats occurs in fissures and on smooth surfaces close to the cervical 
margin and has a similar histological appearance to that seen in humans (Bowen, 
2013). Rats have been used to model the effects of drug induced hyposalivation on 
caries levels (O’Connell et al., 1993). 
 
Animal models do have disadvantages. They do not completely mimic the human 
situation. This is demonstrated by experiments which showed that in rats, amine 
fluoride had a superior anti caries effect when compared to monofluorophosphate 
(Schmid et al., 1984). Under human clinical conditions, a similar effect cannot be 
demonstrated. This could be due to differences in salivary clearance or in dental 
anatomy. Animal model experiments are often not well controlled and not 
comparable across laboratories. Caries scoring in rodents can be difficult to interpret 
due to enamel fractures (Kingman et al., 1981). From an ethical point of view, 
animal caries models can be difficult to justify and are now infrequently used by 
dental researchers.  
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2.3.3 Randomised Controlled Trials 
 
In clinical medical research, randomised controlled trials (RCT) are considered to be 
the “Gold Standard” for empirical evidence of treatment efficacy (Levin, 2007). 
Participants are allocated into a treatment or control group through randomisation. 
This reduces the degree of bias that is introduced the study and ensures that 
confounding factors are evenly distributed between the control and treatment groups 
(Sibbald and Roland, 1998). RCTs are often expensive to run, meaning that 
sponsorship from pharmaceutical companies may be required. They also require 
long term 2-3 years, study periods which may be affected by subject non-
compliance (Levin, 2007). A degree of subject supervision is therefore required; 
supervised brushing in schools is a popular way to improve compliance (Twetman, 
2009).  Decreased caries incidence and rate of progression in populations has led to 
a need for increased numbers of participants in order to fulfil the requirement of 
statistical power (Ellwood et al., 2012). 
 
In caries RCTs, visual inspection using DMFT/dmft scoring is the most commonly 
used system. This can vastly underestimate caries prevalence as enamel caries is 
not scored, only cavitated dentine caries. More accurate assessment of depth and 
progression of carious lesions can be monitored using bitewing radiography, but this 
is potentially harmful and cannot be ethically justified from a research point of view. 
The International Caries Detection and Assessment System (ICDAS) has been 
devised which scores both enamel and dentine lesions visually as well as providing 
a classification of severity (Ismail et al., 2007), and whether lesions are active 
(Ferreira Zandoná et al., 2012). The system has been validated and used in a 
recent fluoride varnish RCT (Arruda et al., 2012). For any anti-caries treatment to be 
recommended, several good quality RCTs are required. However, shorter clinical 
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studies are needed to test efficacy prior to embarking on expensive and time 
consuming RCTs. 
 
2.3.4 In Situ Models 
 
In situ caries models have been defined as “appliances or other devices which 
create defined conditions in the human mouth that simulate the process of dental 
caries” (Zero, 1995). Initially conceived to study the mechanism of action of fluoride 
on enamel (Kolourides et al., 1974), many different models and many experimental 
variables have been tested in the last thirty years. In situ caries models have been 
adapted to study other processes such as erosion (West et al., 1998; Pontefract et 
al., 2001; Hughes et al., 2002) and abrasion (Lussi et al., 2004; Joiner et al., 2004; 
Attin et al., 2004). The importance of in situ models should not be underestimated; 
they bridge the experimental gap between the highly controlled in vitro situation and 
the more unpredictable clinical study. With in situ studies, highly sensitive 
investigations can be carried out. Time periods for the study are reduced, as are the 
risks to the participant. Sensitive experimental measures may be applied allowing 
small changes to be monitored. 
 
There are numerous advantages of in situ models. While in vitro studies provide a 
highly controlled experimental environment in which to study the progression of 
dental caries, the natural oral state is complicated by the presence of saliva, dietary 
habits and plaque growth. There are also disadvantages to in situ caries models. 
Due to the complexity of these models, the numbers in the study are usually limited 
to a maximum of forty (Zero, 1995). Limitation of subject numbers leads to a 
limitation of statistical power. Patients will be clustered in a geographical area and 
are often “dentally aware”; this may mean they are not representative of the 
population as a whole. There is always a certain degree of artificiality – the 
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appliance itself may alter the oral environment. An example of this would be 
increased plaque retention Studies need careful planning and require clinical and 
analytical expertise. They also require approval from the appropriate research ethics 
committee (REC), which is not needed in in vitro studies. 
 
2.3.4.1 Appliance Design 
 
The physical appearance of the appliance is integral to the design of the 
experiment; these can be either fixed or removable. Fixed systems include 
cemented bands (Leach et al., 1989; Manning and Edgar, 1998), cast gold crowns 
(Wefel et al., 1987) and the direct bonding of enamel to the tooth (Shore et al., 
2001). Each of these systems has advantages and disadvantages. The major 
advantage of all fixed systems is that compliance is not an issue. They are not bulky 
to wear and the enamel/dentine substrate can be placed to imitate either an 
interproximal stagnation site or smooth surface caries. Trials involving pre formed 
bands and direct bonding to teeth will be relatively cheap as there is little input from 
a dental technician. The disadvantages are that the hard tissue substrate is 
relatively vulnerable to being lost; in one study 16 out of 88 samples were lost over 
a 28 day period (Shore et al., 2001). In models that require a cast gold crown, the 
number of subjects will be limited and these will be costly to produce. Also once the 
trial is complete, crown will need to be replaced which may cause loss of vitality and 
further weakening of tooth structure and is therefore ethically difficult to justify. 
 
Removable appliances can be orthodontic type (Creanor et al.,1986; Stephen et al., 
1992; Zero et al., 1992; Kielbassa et al., 1999; Kielbassa, 2000; Arweiler et al., 
2004) or based on a partial denture (Lagerweij et al., 1997; Zaura and ten Cate, 
2004). The advantage of these models is that the appliance is easily removed from 
the mouth, although the substrate is not necessarily easily removed from the 
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appliance. The ability to remove the appliance from the mouth is important not only 
for evaluation, but also for extra oral exposure to treatment solutions (Wefel, 1990). 
The major disadvantage is compliance. This may be improved by using a partial 
denture, as the patient is motivated to wear it. By opting for a partial denture design, 
however, the selected subjects may be more susceptible to caries or have an 
altered oral microflora (for example, increased numbers of Candida Albicans or 
periodontal pathogens). 
 
2.3.4.2 Experimental Substrate  
 
The substrate used is dependent on the area of research interest. Bovine (Lagerweij 
et al., 1997) or human (Leach et al., 1989; Kielbassa et al., 1999; Kielbassa, 2000) 
hard tissues are most commonly used. Bovine enamel is more uniform, more 
porous and demineralises more quickly than human enamel (Zero, 1995), however, 
bovine enamel can be considered an acceptable substitute for human enamel. Initial 
studies used blocks of enamel which were mounted in the buccal flanges of lower 
dentures (Kolourides et al., 1974). Where blocks continue to be used (Øgaard and 
Rølla, 1992; Lagerweij et al., 1997; Shore et al., 2001), examining the lesion may 
require that the specimen is sectioned and thus is of no further experimental use. 
Single section models have been devised to enable the same site to be examined 
before, during and after experimentation. These can be placed in a removable or 
fixed appliance. Creanor et al. (1986) developed a lower removable appliance with a 
lingually placed trough which was open to the oral cavity yet protected the enamel 
section. The subject could also carry out oral hygiene procedures without disturbing 
the accumulated plaque. Single section models were also used with crowns (Wefel 
et al., 1987) or bands (Leach et al., 1989; Manning and Edgar, 1998). While, 
technically, these could also be examined part way through the experiment, it would 
be difficult to replace them in their exact previous position. 
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Previous in situ models have used enamel lesions which mimic smooth surface 
such as buccal or interproximal caries. Occlusal or fissure caries are the most 
common type of primary carious lesions (Fejerskov et al., 2008). A recent in situ 
study has examined artificially-induced occlusal caries and the effect of fissure 
sealing over these lesions (Kantovitz et al., 2013). In this study, human third molar 
occlusal enamel was used with carious lesions induced using a 0.05M sodium 
acetate solution at pH5 prior to in situ insertion and a sucrose rinse plus mesh used 
to produce a biofilm and continued demineralisation. Further in situ studies using 
occlusal enamel as a substrate are important as the demineralisation pattern is 
different to that seen in smooth surface lesions (Fejerskov et al., 2008). 
 
 
2.3.4.3 Methods of Demineralisation and Plaque Accumulation 
 
Demineralisation can be achieved by encouraging plaque to accumulate or by 
artificially inducing lesion formation by using acetate or lactate buffered solutions 
(ten Cate et al., 1992) or acidified gel (Wefel et al., 1987; Stephen et al., 1992). 
Artificial lesion induction is particularly useful for studying the remineralisation 
potential of certain agents, for example, fluoride. Demineralisation caused by plaque 
is a longer process producing a more natural pattern of substrate loss. A popular 
method of plaque accumulation is by placement of a Dacron® or Teflon® gauze 
across the enamel/dentine surface (Koulourides and Chien 1992; Cochrane et al., 
2012b). A uniform plaque thickness was achieved; this is extremely important as 
differences in thickness of 0.5mm or less can have profound effects on the response 
of an in situ model (Zero, 1995). 
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There are other methods of plaque accumulation that avoid the use of gauze. A 
group in Oslo (Øgaard and Rølla, 1992) produced an in vivo orthodontic banding 
model where premolar teeth destined for orthodontic extraction were used. Two 
metal posts were welded to the inside of an orthodontic band; once this was 
cemented to the tooth, a crevice was created between the band and the buccal 
enamel. After four weeks, the teeth were extracted and enamel slabs were either 
analysed or placed in a removable appliance to study remineralising solutions. 
There are numerous advantages to this model. Vital teeth in young subjects 
(typically teenagers) are studied; normal oral hygiene can be carried out without 
disturbing the experimental plaque. This type of study however is time consuming. 
 
Accumulation of plaque may also be achieved by recessing the enamel slab within 
the acrylic of a denture or removable appliance (Zero et al., 1992) or within a hollow 
in the full gold crown model (Wefel et al., 1987). Shore et al. (2001) attached a nylon 
ring over an enamel slab containing a pre formed carious lesion. The slab was 
trimmed and attached to the buccal side of the tooth. Plaque was allowed to 
accumulate in the niche created by the ring. These models are likely to be more 
inconsistent than using gauze as plaque thickness cannot be carefully controlled 
(Zero, 1995). 
 
 
2.3.4.4 Subject Selection 
 
The physical design of the appliance used may limit the choice of subject by 
selecting, for example, subjects who require a partial denture, full gold crown or 
orthodontic extractions. The use of an orthodontic type removable appliance 
increases the number of possible subjects, however some form of standardisation is 
appropriate. A balance of age, gender and ethnic background should be achieved. 
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The subjects should be in good general health and not taking medication that 
causes xerostomia (Sreebny and Schwartz, 1997; Bardow et al., 2001). Any subject 
who has taken antibiotics in the last two months or during the study should be 
excluded as these can affect the endogenous microflora (Zero, 1995). They should 
have no active carious lesions, but a range of past caries experience, indicated by 
number of restorations/extracted teeth, would improve relevance as would a range 
of salivary flow rates (Edgar and Higham, 1995). 
 
The information related to the above variables can be either measured or obtained 
easily. Other variables have been suggested including fluoride exposure, oral 
hygiene practices and dietary habits. Water fluoridation levels are readily 
standardised. Subjects, especially those with some dental knowledge, may not 
accurately report how often they brush their teeth or eat sugary snacks. 
Consideration, however, should be given to these variables. 
 
 
2.3.4.5 Evaluation Techniques previously used in in situ studies 
 
Demineralisation or remineralisation is essentially measured by loss or gain of 
mineral (Arends and ten Bosch, 1992). A recent systematic review of in situ models 
(Sung et al., 2014) has shown that a variety of techniques have been used to 
evaluate demineralisation and remineralisation. Microhardness was the original 
measurement from the first in situ studies (Kolourides et al., 1974) and was the most 
popular method used in the systematic review (West et al., 1998; Shore et al., 
2001). A diamond tip (either Knoop or Vickers) is placed on the sample under a 
given load for a given time and the indentation is measured. There are two types of 
measurements: surface microhardness (where the indenter load is perpendicular to 
the polished surface, SMH) and cross-sectional microhardness (where the indenter 
61 
 
load is parallel to the anatomical surface of the tooth) (Arends and ten Bosch, 1992). 
SMH measures hardness at the surface lesion, whilst cross-sectional assesses 
lesion depth. The square root of the results obtained have a linear relationship to 
mineral concentration of enamel at the site under test (ten Bosch and Angmar-
Månsson, 1990; Kielbassa et al., 1999). 
 
Microhardness measurements, however, have issues in that they are inherently 
destructive due to the permanency of the indentations. In addition, measurements 
are almost impossible unless the natural enamel surface has been polished and 
flattened (Wefel, 1990). It is not possible to measure microhardness in the same 
area pre and post treatment so the comparison is made indirectly with a control 
piece of unexposed enamel (Shore et al., 2001). Furthermore, evaluation of erosion 
type demineralisation using SMH only measures the softened surface layers rather 
than the bulk of enamel lost during the process (West et al., 1998; Magalhães et al., 
2011). Microhardness, therefore, especially in erosion in situ studies is often used in 
combination with other evaluation techniques (Sung et al., 2014). 
 
Another technique used in in situ studies, polarised light microscopy (PLM) is a 
sensitive technique for showing mineral change (Wefel et al., 1987). Thin sections 
(80µm) are cut, viewed under polarising light and measurements carried out noting 
the differences between sound and carious enamel. From this, the birefringence is 
calculated giving a qualitative estimation of mineral loss/gain (Featherstone, 1992). 
It is also useful for measuring porosity and for examining lesion characteristics. 
Porosity can also be measured using the iodine permeability (Ip) test; this test 
however does not consistently correlate to mineral loss and cannot reliably be used 
to measure this. Due to the destructive and non quantitative nature of PLM, it is not 
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an ideal sole measure for in situ caries study (ten Bosch and Angmar-Månsson, 
1990). 
 
The most popular evaluation technique used in in situ studies is microradiography 
which uses X-ray absorption to quantify the amount of mineral in hard tissues 
(Angmar et al., 1963). Three types of microradiography are used: TMR (transverse), 
LMR (longitudinal) and WIM (wavelength independent). TMR takes thin 
planoparallel slices (up to 90μm for enamel), which are sectioned perpendicular to 
the anatomical tooth surface, and exposes them to monochromatic X-radiation (ten 
Bosch and Angmar-Månsson, 1990). The absorption of x-rays onto a film is 
calibrated using a step-wedge, typically aluminium, and mineral content can be 
calculated as vol% or kg m-3 using Angmar’s formula denoted by ΔΖ (Angmar et al., 
1963). The advantages of this technique are that mineral loss (or gain) can be 
quantified and mineral distribution can be determined. TMR and microhardness also 
show a strong correlation in mineral change (Kielbassa et al., 1999) and can be 
used in tandem to verify results. TMR has long been recognised as the “Gold 
Standard” for de- and remineralisation research (Cochrane et al., 2012c). 
 
Unfortunately, for TMR, the sample needs to be prepared into planoparallel slices, 
which can be difficult especially obtaining a sample which is homogeneous in 
thickness (ten Bosch and Angmar-Månsson, 1990). Also the presence of ions with a 
high absorption coefficient can lead to spurious results. The technique is destructive 
in nature so evaluating the same sample pre and post experiment is not possible 
unless single sections are used (Stephen et al., 1992). A control slice is obtained 
from the lesion prior to treatment while the bulk of the lesion exposed to the oral 
environment and sectioned post treatment (Manning and Edgar, 1998; Walker et al., 
2010). To overcome the inherent destructiveness of TMR, different 
microradiography techniques have been developed.  
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LMR is similar to TMR except thicker samples (up to 3mm) are scanned; the density 
is calculated following X-ray exposure (de Josselin de Jong et al., 1988). With LMR, 
the sample is preserved whole and consecutive changes are monitored (Ganss et 
al., 2004). LMR would therefore seem an ideal evaluation technique to be used in in 
situ studies. WIM is capable of measuring mineral in whole tooth samples; 
polychromatic high energy x-rays (≤60Kv) and a step-wedge with a mass 
attenuation coefficient (MAC) that has a wavelength-independent ratio to the MACs 
of enamel and dentine are used. These methods, however, have been shown that 
while useful in following and mapping mineral change, they demonstrate little 
correlation with other methods of mineral measurement especially in erosion studies 
where there is little surface loss (<20µm) (Ganss et al., 2005) and have now been 
superseded by quantitative light-induced fluorescence (QLF). 
 
QLF uses the auto-fluorescence of enamel under certain visible light conditions 
(usually monochromatic blue light at a wavelength of 370nm) as its main principle 
(Pretty et al., 2003). Demineralised enamel is less fluorescent; this change can be 
detected, monitored and quantified (as vol% change) without destruction of the 
sample, ideal characteristics for an in situ caries trial (Higham et al., 2005). QLF can 
be used on the intact enamel surface and also to monitor the progression of white 
spot lesions intraorally. QLF has been used in conjunction with in situ de- and 
remineralisation models (Higham et al., 2005). QLF has been calibrated against 
TMR demonstrating a moderate, but significant linear correlation coefficient (0.63< r 
<0.86) (Angmar-Månsson and ten Bosch, 2001; Cochrane et al., 2012c). However, 
the best fit relationship is two linear slopes with an initial steep line then a second 
line with a smaller gradient. This relationship is thought to be attributable to the 
greater sensitivity of QLF to detect surface changes and a lower sensitivity to detect 
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subsurface changes in mineral content compared with TMR (Cochrane et al., 
2012c). 
 
One of the potential issues at the QLF analytical stage is that of repeatability and 
reproducibility, however, studies demonstrate excellent intra- and interexaminer 
reliability (correlation coefficient r between 0.93 and 0.99) (Angmar-Månsson and 
ten Bosch, 2001). Dehydration of lesion can affect QLF measurements by a factor of 
up to 0.15; this occurs within 15 minutes in a still atmosphere and within seconds 
when a lesion is air dried. When undertaking an in situ trial, it would therefore be 
imperative that the sample was not left dry for even a short length of time. QLF, 
however, has great potential as a non destructive, longitudinal analysis of enamel 
lesions (Higham et al., 2005).  
  
The previously discussed techniques have been used in in situ de- and 
remineralisation caries studies, but are not always appropriate for the evaluation of 
erosive type demineralisation. Measurement of surface loss is most commonly 
undertaken using profilometry (Sung et al., 2014). In profilometry, the surface of the 
specimen is scanned in 2D or 3D using either a diamond stylus (contact 
profilometry) or, more recently, a laser light probe (non-contact profilometry) (West 
et al., 1998; Schlueter et al., 2011a). For non-contact profilometry, erosive lesions 
as little as 0.5μm in depth can be detected as long as the natural surface is polished 
to establish a flat surface. The technique is less sensitive when the natural enamel 
surface is investigated and detection limits of between 15 and 50μm have been 
reported (Schlueter et al., 2011a).  
 
A major disadvantage of contact profilometry is that the surface of the enamel lesion 
can easily be damaged which leads to an overestimate in erosion depth (West et al., 
1998). A further issue with profilometry techniques is that lesion depth and tissue 
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surface loss are measured, but not the depth of softened enamel. In order to 
overcome this limitation, profilometry measurements were undertaken before and 
after ultrasonic treatment with saline in order to estimate the depth of softened 
enamel. This method was shown, using scanning electron microscopy (SEM), not to 
remove the full softened layer (Eisenburger et al., 2004). Furthermore, profilometry 
is highly reproducible in the hands of experienced operators (differences of 
±0.06μm), but less so in mixed ability operator groups (differences of ±0.18μm) 
(Schlueter et al., 2011a). 
 
SEM can be used to study in situ erosive demineralisation (Featherstone, 1992; 
Øgaard and Rølla, 1992). The surface ultra structural characteristics are examined 
at a very high resolution (~1nm). The method is qualitative so needs to be used in 
conjunction with quantitative methods (Schlueter et al., 2011a). Additionally, 
samples are placed in a vacuum and coated with non-charged substances such as 
gold or carbon and, therefore, only a single post treatment observation can be 
made. Drying artefacts can also occur. SEM has been also been used to study 
remineralisation in situ (Eisenberger et al., 2001) and in vitro (Reynolds, 1997; Milly 
et al., 2014). Visualisation of form and location of mineral deposition provides high 
resolution information to the effect of remineralisation agents and allows comparison 
with standard treatments such as fluoride. It can also be used to determine whether 
remineralisation is as a result of primary precipitation or crystal growth (Yanagisawa 
and Miake, 2003). 
 
Transmission electron microscopy (TEM) is similar to SEM, but is able to operate at 
a higher resolution (~0.2nm) (Yanagisawa and Miake, 2003; Wilson and Bacic, 
2012). TEM has been used in situ to study pellicle formation and the effect of citric 
acid exposure on these layers (Hannig et al., 2003). It has also been used in vitro to 
de- and remineralisation at enamel crystal level (Yanagisawa and Miake, 2003) and 
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to examine experimental nano-HA particles as a potential remineralising agent 
(Huang et al., 2011). The major disadvantage of this technique, along with being a 
qualitative method, is the need for extensive preparation of the sample which can 
result in changes to the specimen and the difficulty of obtaining a representative 
sample (Wilson and Bacic, 2012). 
 
2.3.4.6 Evaluation Techniques with potential for use in in situ studies 
 
Optical coherence tomography (OCT) has not previously been used in in situ 
studies, however it has been in in vivo to monitor the progression of early carious 
lesions (Fried et al., 2002). This non-destructive technique employs near-infrared 
light to capture three-dimensional images of biological hard tissues at micrometer-
resolution (<20μm). The lack of ionising radiation is a major advantage of this 
technique. It can also be used to evaluate both subsurface and erosive type 
demineralisation as well as remineralisation in vitro (Louie et al., 2010). Areas of 
demineralisation appear with increased reflectivity in the OCT images; this can be 
directly measured and is reported as integrated reflectivity ΔR (reflectivity dB units × 
lesion depth µm) (Kang et al., 2010). A further advantage of OCT is that the natural 
enamel surface requires no preparation or flattening in order for measurements to 
be undertaken (Louie et al., 2010).  
 
Several studies have been undertaken to correlate ΔR measurements to the mineral 
loss measurements using TMR (ΔΖ). A positive correlation exists, but this is variable 
in strength dependant on the study undertaken with correlation coefficients (r) 
between 0.5 and 0.76 (Jones et al., 2006; Louie et al., 2010). A further study has 
demonstrated a positive correlation between demineralisation measurements 
obtained by OCT and QLF, but QLF was more sensitive to early changes (Chew et 
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al., 2014). The main disadvantage, however, of OCT is that the enamel surface can 
produce a strong specular reflection in the resulting images. This increased surface 
reflectivity can make quantification of mineral loss/gain difficult, although cross 
polarisation can be used to reduce this effect (Kang et al., 2010). OCT shows 
promise as an evaluation technique for in situ studies. 
 
Confocal scanning laser microscopy (CSLM) is a further method of analysing de- 
and remineralisation not previously used in in situ studies. This high-resolution 
technique has the advantage of being non destructive and producing 3D images of 
up to 200μm below the enamel surface (Øgaard et al., 1996). The 3D images are 
built up from a series of 2D laser generated optical sections from successive focal 
planes. The results and resolution obtained with CLSM are similar to those seen in 
SEM, but with the benefit of avoiding drying artefacts (Yamada and Watari, 2003). 
With CLSM, lesion depth and % volume change can be measured (Heurich et al., 
2010; Banerjee et al., 2011), but is often used in conjunction with other more 
quantitative methods of analysis such as TMR (Øgaard et al., 1996) or profilometry 
(Heurich et al., 2010). 
 
Raman microspectroscopy is another non-destructive, quantitative technique which 
has been used in vitro demineralisation studies, but not for in situ studies. It has 
been used to study both naturally (Kinoshita et al., 2008) and artificially formed 
carious lesions (Mohanty et al., 2013). It has also been used to examine erosive 
lesions (Gilchrist et al., 2007) as well as remineralisation of white spot lesions (Milly 
et al., 2014). The technique uses a monochromatic laser light source with a high 
spatial resolution limit (<1μm) which is applied to the specimen; the intensity of 
Raman scattering measured is proportional to the molecules present in the sample 
volume. In enamel, the spectral region from 375cm-1 to 1175cm-1 is measured. The 
strongest peak observed is that of the symmetric P-O stretching vibration of the 
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phosphate ions (PO4)3- at around 959cm-1 and the peak/area can be used to 
quantify mineral change (phosphate intensity decreases in demineralisation) 
provided that the experimental parameters are not changed (Milly et al., 2014).   
 
The advantages of Raman microspectroscopy are that the technique requires little 
or no sample preparation and that high resolution and good signal to noise ratio 
allow for accurate analysis of specimens (Mohanty et al., 2013). Analysis of 
specimens can be undertaken quickly. The disadvantage is that the measurements 
obtained do not measure of total mineral change for the whole sample, rather 
phosphate intensity percentage change and lesion depth (Milly et al., 2014). 
Additionally in early caries-like demineralisation, illumination from the surface layer 
may interfere with detection of the highly demineralised subsurface layer (Mohanty 
et al., 2013). Raman microspectroscopy is suitable for analysis in in situ studies, but 
would benefit from being used in combination with other techniques. 
 
2.3.4.7 Ethical Considerations 
 
While the process of demineralisation is potentially damaging to the hard tissues, a 
well-designed in situ study can minimize this damage. Time periods are reduced in 
comparison with clinical trials with the use of artificial lesion induction. 
Demineralising solutions can be used extra orally. Good Clinical Practice (GCP) 
should be adhered to (as set out by EMEA) and ethical approval sort from the 
relevant REC. Subjects should give informed consent and be provided with written 
information.  
 
It is imperative that dental hard tissue is sterilised prior to use in an in situ caries 
model. There are various methods of sterilisation: autoclaving, formalin fixation, 
sodium hypochlorite, ethylene oxide and gamma radiation (DeWald, 1997; Amaechi 
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et al., 1999a). Gamma radiation appears not to structurally alter enamel (Amaechi et 
al., 1999a; Kielbassa et al., 2000) and dentine (White et al., 1994) unlike chemical 
methods and autoclaving although the evidence is not clear-cut (Pashley et al., 
1993). None of these methods of sterilisation are completely effective against prion 
contamination. As prions have been detected in the trigeminal ganglion in patients 
with vCJD, there is a theoretical risk of contamination of pulpal tissue, although this 
was not been borne out by Western blotting (Smith et al., 2003). Gamma radiation 
at high doses can inactivate hamster-adapted scrapie (Miekka et al., 2003); other 
research groups, who use in situ devices, have found that hypochlorite in 
conjunction with autoclaving reduces prion infection risk (Watson et al., 2004). 
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2.4 X-ray Microtomography 
 
2.4.1 Introduction 
 
The discovery of X-rays is credited to Röntgen, who published his findings in 1895. 
While previous researchers had observed X-rays, he was the first to recognise their 
significance and investigate them. He was also the first person to perform medical 
radiography by taking an image of his wife’s hand (Mould, 1995). While many 
advances have been made since, the basic principal remains the same. X-rays pass 
through the body with denser structures and higher atomic numbers (such as bones 
and teeth) absorbing more radiation and producing a paler image on the receptor 
(Weber, 2001). 
 
 
2.4.2 Definition of X-radiation 
 
X-radiation is electromagnetic radiation of high quantum energy (greater than 1 
KeV) (Patton, 1998; Seibert, 2004). It may be regarded as waves or quanta of 
energy (known as X-ray photons). X-rays are produced by bombarding a metal 
target with electrons from a negative cathode towards a positive anode (Mould, 
1995). The electrons can interact with the orbital electrons of the target atom which 
results in either the production of heat or characteristic X-rays: 99% of the kinetic 
energy of the projectile electrons is converted into heat. Characteristic X-rays occur 
when an inner shell electron is removed and the target atom is ionised. As the atom 
is very unstable in this state, electrons from the outer orbits drop into their place 
giving off X-rays of very specific energies according to the target material (Patton, 
1998). This is called a line spectrum. Characteristic radiations are dependent on 
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which orbits they drop into. K X-rays are most useful for diagnostic imaging (Seibert, 
2004). 
 
In addition to producing characteristic X-rays, electrons interacting with the nuclear 
field of the target atom also produce a type of radiation called bremsstrahlung 
(Goldman, 2007). Bremsstrahlung is a German word meaning “braking radiation” 
which describes the course of the projectile electron when it passes by the positively 
charged nucleus (Seibert, 2004). In this situation, the energy lost by the slowing of 
the electron is converted to x-rays. The maximum energy of these x-rays is equal to 
the maximum energy (Emax) of the bombarding electrons, however their energy 
value can be anywhere between 0 and Emax along a continuous spectrum (Patton, 
1998). 
 
 
2.4.3 CT Scanning 
 
Computed tomography (CT) was first demonstrated in 1972 by Hounsfield and 
Cormack (Weber, 2001). The word “tomography” is derived from the Greek tomos 
(slice) and graphia (describing). When a series of projected (transmitted) X-ray 
images taken around a single axis of rotation are produced, these images can be 
reconstructed to form an image that will reveal the internal structure of the object 
(Goldman, 2007). The first generation CT scans consisted of a pencil beam through 
the object to a single detector. The rigidly coupled source-detector pair were then 
translated across the patient to produce a set of parallel projections which was 
repeated at different angulations. Second generation CT was an adaption of this 
translate - rotate system which used slot collimation to produce a fan-shaped beam 
of radiation and multiple detectors. The advantage of this was that the rate of data 
acquisition was much faster (Goldman, 2007). 
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Third generation scanners saw an improvement in data acquisition and detector 
technology. The fan beam and detectors are wide enough to encompass the entire 
patient and the tube-detector assembly simply rotates around the patient rather than 
using a translate-rotate mechanism. This system used X-rays more efficiently, but 
could be prone to ring artefacts due to the motion and/or non-linearity of the 
detector. Fourth generation scanners have overcome this problem by using a 
stationary detector ring and a rotating X-ray source (known as rotate-stationary or 
rotate only geometry) (Schultz and Felix, 1980). A larger number of receptor cells 
are required which increases costs. Most medical CT scanners are now fourth 
generation CT scanners.  
 
 
2.4.4 X- ray Microtomography 
 
X-ray Microtomography (XMT) is a miniaturised version of the medical CT scanner. 
XMT has developed alongside CT and differs in two ways. Firstly, the scale is 
greatly reduced to microns as opposed to millimetres. Secondly, in CT scans, the X-
ray source moves around the patient; in XMT, the specimen moves and the X-ray 
source remains stationary. The first generation of XMT used a single source of 
radiation and a pinhole collimator producing a 15μm X-ray beam directed at a single 
scanner (Elliott and Dover, 1982). The scanner used a “translate-rotate” mechanism 
whereby the x-ray source and detector are fixed in position and the specimen was 
rotated through either 1800 or 3600 perpendicular to the beam. The projections were 
then “reconstructed” to produce the 3D image. Advantages of this system include a 
lack of blurring caused by scattering and can use an energy dispersive detector to 
simulate monochromatic radiation. The major disadvantage as with first generation 
CT scanners was the long data acquisition time. Area-arrays have greatly improved 
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the speed at which data is acquired (Seibert and Boone, 2005). These are able to 
detect the full cone-shaped beam produced by the X-ray source and each projected 
image is essentially a conventional plain film X-ray view of the specimen (Davis and 
Wong, 1996).  
 
Fourth generation medical CT scanners utilise a ring of detectors. The position of 
this ring is fixed as is the patient with only the x-ray source moving. This is important 
in overcoming the effect of “ring” artefacts.  These appears as full or partial circles 
centred on the rotational axis and are systematic errors which occur due to high 
exposure times and heterogeneity of detector responses (Davis et al., 2013). This 
X-ray source/detector arrangement, however, is complex, costly and impractical in 
the laboratory situation. Hence, the laboratory based fourth generation XMT 
employs a fixed laboratory X-ray source (e.g. 160keV max, 5μm Ultrafocus, X-Tek, 
UK) with a tungsten target; the specimen is mounted and rotates through 3600. A 
cooled slow scan charge coupled detector (CCD) camera is used to detect the X-ray 
image. The principle of time delay integration is used with the camera traversing the 
through the X-ray beam as the CCD is being read out. The average read-out of the 
whole row of detectors reduces/eliminates ring artefacts (Davis and Elliott, 1997). 
Small random movements of the camera or detector can further reduce ring 
artefacts (Davis et al., 2013). 
 
 
2.4.4.1 Correction for Beam Hardening 
 
The phenomenon of beam hardening occurs as a result of the polychromatic X-ray 
beams used in XMT (and other medical X-ray imaging) with a mean energy in the 
region of half the accelerating potential (Seibert and Boone, 2005; Davis et al., 
2013). As the X-ray beam passes through a substance, the radiation becomes more 
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attenuated and harder with the photon energies shifted to higher energies as the 
lower energy photons are attenuated (Davis and Elliott, 2003). The amount of beam 
hardening depends on the initial X-ray spectrum as well as on the composition of 
the material or tissue traversed. If uncorrected, the effective attenuation coefficient 
of the specimen is dependent on its thickness and can result in a “dishing” or 
“cupping” artefact in the centre of the specimen where the object appears less 
dense. The basic structure of the object is preserved, but quantification will be 
inaccurate (Davis et al., 2008). For quantification of dental specimens, this is a 
particular issue due the mineral concentration gradient that exists within enamel and 
dentine. 
 
 
To reduce this effect, a symmetrical seven step aluminium wedge (99.98% pure) is 
periodically scanned (Zou et al., 2011). A linearisation curve is derived which allows 
correction of the recorded projections at a nominal monochromatic energy. While, 
technically, the attenuation vs. energy characteristic of the specimen should match 
that of aluminium to remove all “dishing” artefacts, beam hardening in most 
specimens is greatly reduced. As biological hard tissues such as bone and dentine 
have similar attenuation co-efficients to aluminium, it is a suitable material to use for 
calibration. 
 
2.4.4.2 Advantages of XMT 
 
The major advantage of XMT over other analytical techniques used in conjunction 
with in situ caries models is the ability to produce a time series of scans of the same 
specimen. For example, a sample of enamel can be scanned pre, during and post 
treatment allowing an accurate picture of the dynamic process of de/remineralisation 
at different points. This is due to the fact that the technique is non-destructive (Davis 
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and Wong, 1996; Davis et al., 2013). Other techniques are mainly destructive, thus 
have to use standardised samples such as HAp. Enamel mineral concentration is 
very variable. XMT, by measuring the same specimen multiple times, allows each 
specimen to act as their own “control” (Wong et al., 1995; Ahmed et al., 2011). 
 
Other advantages of XMT include its ability to produce high resolution scans at 
micron level and measure mineral concentration quantitatively. This allows very  
changes in mineral density to be examined, reducing the time period of the 
experimental conditions and hence improving subject compliance. 
De/remineralisation of teeth occurs in three dimensions and thus the 3D images 
produced by XMT provide an accurate representation of this (Cochrane et al., 
2012a). Recent XMT studies of caries in primary teeth have demonstrated that in 
dentine a bowl shaped lesion, as opposed to the previous cone shape seen on 2D 
radiographs, is formed (Willmott et al., 2006; Ahmed et al., 2012). The XMT system 
used in the following study has a further advantage in that calibration takes place as 
part of image pre-processing. In commercial systems, mineral density is calculated 
post-processing using data from phantoms which reduces accuracy (Farah et al., 
2010). 
 
2.4.4.3 Previous Applications in Mineralised Tissue 
 
One of the first images produced using XMT was of the shell of biomphalaria 
glabrata (freshwater snail) with a resolution of 12μm. Much of the previous XMT 
work has examined biological hard tissue specimens such as bone and teeth, but 
other applications in fields such as materials, archaeology and geology are possible. 
The use in enamel and dentine is summarised below. 
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Wong et al. (2000) investigated the 3D mineral concentration distribution in rat 
incisor enamel noting a decrease in mineral concentration gradient from the incisal 
edge (2.7gcm-3) towards the apex (1.0gcm-3). A gradient in enamel mineral 
concentration also existed between the outer enamel and the enamel near the 
amelodentinal junction. Mineral concentration in rat incisor dentine has been studied 
(Wong et al., 1995). While no mineral concentration gradient exists from the apex to 
the incisal edge, circumpulpal dentine was shown to have a lower mineral 
concentration (1.3 gcm-3) compared to peripheral dentine (1.5 gcm-3). Mineral 
concentration in the primary teeth of low birth weight children was found to be lower 
than teeth from control children, range 2.3 - 2.6gcm-3 compared to 2.65 - 2.78gcm-3. 
 
Willmott et al (2007) used XMT to determine distribution of caries in primary dentine. 
The mean mineral concentration of sound dentine was 1.42gcm-3. For carious 
dentine, a mean range 0.37 – 0.5gcm-3 mineral concentration was calculated as it is 
impossible to know how much collagen was degraded in the caries process. This 
study also examined cavity preparation with respect to demineralised dentine. 
Overpreparation of between 8.5 and 44.3% volume was noted; in a field where 
“minimal intervention” is the accepted caveat, this has serious clinical implications. 
 
 
 
 
  
77 
 
Chapter 3 – Aims, Objectives and Null Hypotheses 
 
The overall aims of this thesis are twofold. The first section is dedicated to studying 
the effect of an experimental peptide, StN21, on enamel de- and remineralisation. 
StN21 is a 21 amino acid peptide based on the N terminus of statherin, a salivary 
protein. The N terminus of statherin has been shown to be important in calcium 
homeostasis and enamel adsorption, while the C terminus is responsible for 
bacterial binding. Previous work has demonstrated that StN21 reduces HAp 
demineralisation, but has no effect of remineralisation using scanning 
microradiography to measure mineral change (Kosoric et al., 2007; Alfawaz et al., 
2008; Grosvenor et al., 2009). For this study, XMT was selected as it can be used 
for both for mineral density measurement and 3D visualisation of lesions.  
 
The second section is devoted to providing proof of concept data for a clinical study. 
This includes developing an in situ device which can be used in conjunction with 
XMT to study HAp and enamel de- and remineralisation. The non-destructive nature 
of XMT renders it the ideal in vitro method for the serial quantification of mineral 
change that is undertaken during in situ studies. In order to undertake a full clinical 
trial, data is required on the safety of StN21. As StN21 is a truncated form of native 
Statherin protein, toxicity would not be expected to be an issue. The aim therefore 
was to undertake assessment of cell viability, sensitivity and irritation in mucosal 
models exposed to StN21. 
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The objectives are: 
 
1. To examine the effect of StN21 on caries-like enamel demineralisation in 2D 
and 3D in vitro. 
2. To quantify the effect of a range of StN21 concentrations between 0.06 and 
0.88 x 10
-4 
mol l
-1 on caries-like enamel demineralisation.  
3. To compare this demineralisation with that seen in samples exposed to 
Statherin, Fluoride and Polyglycine protein. 
4. To study the effect of StN21 on erosive enamel demineralisation in 2D and 
3D in vitro. 
5. To measure the effect of StN21 on remineralisation of enamel in 2D and 3D. 
6. To develop an in situ device and associated de- and remineralisation 
protocol for its use in conjunction with XMT. 
7. To test the biocompatibility of StN21 in a buccal mucosal model using cell 
viability and irritant/sensitising cytokine release assays and compare with 
exposure to Statherin and sodium lauryl sulphate. 
8. To investigate the feasibility of studying the effects of StN21 in an in situ 
model. 
 
Null Hypotheses: 
 
1. There is no difference in caries-like enamel demineralisation rates between 
control and StN21 exposed lesions. 
2. There is no difference in caries-like enamel demineralisation between 
different concentrations of StN21. 
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3. There is no difference in caries-like enamel demineralisation rates in control 
samples compared with those exposed to statherin, fluoride and polyglycine 
protein. 
4. There is no difference in caries-like enamel demineralisation rates in StN21 
exposed samples compared with those exposed to statherin, fluoride and 
polyglycine protein. 
5. There is no difference in enamel remineralisation rates in control and StN21 
exposed samples.  
6. There is no difference in erosion-like enamel demineralisation rates in 
control and StN21 exposed samples. 
7. There is no difference in cell viability of cultures exposed StN21, statherin, 
phosphate buffered saline and sodium lauryl sulphate. 
8. There is no difference in production of IL-1α by cultures exposed to StN21, 
compared with those exposed to statherin, phosphate buffered saline and 
sodium lauryl sulphate. 
9. There is no difference in production of IL-8 by cultures exposed to StN21, 
compared with those exposed to statherin, phosphate buffered saline and 
sodium lauryl sulphate 
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Chapter 4 – General Materials and Methods 
 
This chapter describes materials and methods common to the experiments reported 
in this thesis.  
 
4.1 Measurement of Mineral Concentration by X-Ray 
Microtomography (XMT) 
 
The following technical description is taken from Davis and Elliott (2003). This study 
used a 4th generation XMT scanner which has the ability to eliminate ring artefacts 
and reduce beam hardening effects. A basic diagram is shown in Figure 4.1. The 
system used, MuCAT (Figure 4.2), was an enhanced scanner using Time-Delay 
Integration (TDI) and an X-Tek (UK) ultrafocus system with a spot size down to 
5μm. A cooled slow-scan CCD camera (Spectral Instruments Inc, USA) with a 1:1 
lens-coupling to a 70μm thick columnar Caesium Iodide (CsI) scintillator (Applied 
Scintillation Technologies Ltd, UK) was used. The CCD detector in this system had 
1152 x 770 square detector elements of dimension 22.5μm which was binned 3 x 3 
giving 384 x 256 effective elements of dimension 67.5μm. The geometric 
magnification can be varied to give voxel sizes with a side length of 8, 15 or 30μm. 
The TDI CCD readout method (Davis, 1997) eliminates ring artefacts by averaging 
out the characteristics of each row of the detector elements in each projection. The 
camera moves across the X-ray beam while the CCD is being read simultaneously. 
These are timed in such a way that the relative motion charge along the CCD 
matches that of the focused image. Each recorded image pixel is derived from the 
accumulation of charge as it is shifted along the corresponding CCD column, thus 
the sensitivities of all the recorded pixels in the same CCD column are identical 
(Davis and Wong, 1996). In order to ensure dimensional stability during data 
acquisition, the temperature inside the X-ray enclosure is maintained at 26ºC ± 
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0.1ºC. While undertaking the work for this thesis, the MuCAT2 system was 
developed using a larger CCD detector (see Table 4.1) and reduced scan times. 
The majority of the earlier work has been undertaken using MuCAT, but for some of 
the later experiments, MuCAT2 was used instead (Chapter 6). 
 
 
Figure 4.1 – Diagram illustrating the MuCAT (XMT) system (from G. Davis, Queen Mary University of London) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 – Photograph illustrating the MuCAT system shown in figure 4.1 (from P. Grosvenor, Queen Mary, 
University of London)  
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 MuCAT MuCAT2 
CCD detector dimensions 1152 x 770 4096 x 4096 
Pixel Dimension (μm) 22.5 15 
Binning ratio 3 x 3 4 x 4 
Binned pixels 384 x 256 1024 x 1024 
Binned Pixel Dimension (μm) 67.5 60 
Geometric magnification (μm) 8, 15 or 30 5 - 30 
Table 4.1 Table demonstrating the differences between MuCAT and MuCAT2. MuCAT2 is a newer system with a 
larger CDD detector. 
 
 
4.1.1 Signal to Noise ratio (SNR) 
 
This is the ratio of the mean absorption coefficient to its standard deviation, an 
indication of the uncertainty of the measurement, due to photon counting statistics 
(Davis, 1997). When the step size is halved, the number of X-ray photons must be 
quadrupled in order to maintain the same signal to noise ratio (SNR); the detector 
element size is also halved in one dimension. To achieve a high SNR either the size 
of the specimen is reduced (this may limit experimental validity), or the data 
collection time is increased. With this high resolution XMT system, data acquisition 
times vary from an hour to several days per block depending on the size and 
attenuation coefficient of the specimen (Davis and Elliott, 2003). To optimise 
experimental time and SNR, a 0.5mm aluminium filter was used (Davis, 1997). 
 
 
4.1.2 Calibration 
 
As previously discussed in Section 2.4.4.1, beam hardening due to polychromatic 
radiation was corrected. A symmetrical ten step wedge (Figure 4.4), made of 
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99.98% aluminium was scanned periodically (single projection) at each combination 
of accelerating potential and filter thickness used. This method was described by 
Davis and Elliott (2003) and was shown to reduce beam hardening artefacts in XMT 
images. In order to reduce scattering, this step wedge was replaced by the 
“Manhattan” step wedge (Figure 4.5) in the MuCat2 scanner (Davis et al., 2008). 
Aluminium was used for the calibration material because the pattern of its 
attenuation coefficient versus energy behaviour is similar to that of biological hard 
tissues such as enamel and dentine. 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 - Symmetrical ten step wedge (from G. Davis, Queen Mary, University of London). This is used to reduce 
beam hardening artefacts in the MuCAT system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 – Manhattan step wedge (from G. Davis, Queen Mary, University of London). This is used to reduce 
beam hardening artefacts in the MuCAT2 system.  
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4.1.3 Data Collection and Processing 
 
The minimum number of projections was calculated for each specimen using 
equation 4.1: 
 
Number of projections = π/2 * N            Equation 4.1 
 
N = the diameter of the specimens in pixels 
 
 
The total time for the complete specimen scan was calculated using the time for 
each projection multiplied by the number of projections. The time for each projection 
is made up of transverse time (expressed in equation 4.2 below) and the fly back 
time (dependant on sample size, between 1 and 4 seconds). 
 
tt = tx (1+ (N+64 / 384))      Equation 4.2 
 
In this case, tx is the exposure time (minimum 6 seconds). N is the specimen width in 
pixels. The constant, 64, represents 32 pixels either side of the specimen giving a 
total distance across the field of view. The constant, 384, is the width of the CCD 
detector. 
 
In the initial data processing stage, a correction was applied to the polychromatic 
radiation data to provide a good approximation of equivalent monochromatic 
radiation (40KeV). For each specimen, a dark reference (CCD shuttered) and a light 
reference, whereby the specimen is completely removed from the exposure, were  
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taken. The dark reference was subtracted from the light reference and the logarithm 
(log) taken. For each CCD column, a parabola is fitted. The dark reference was then 
subtracted from each projection in turn and the log taken. This was then subtracted 
from the appropriate reference parabola and an adjustment was made based on the 
mean log value of the 32 pixels either side of the specimen. The resultant values 
were then corrected using a 5th order polynomial for each CCD column. This 
polynomial was fitted to the measured attenuation against the calculated attenuation 
for a nominal monochromatic energy (Davis and Elliott, 2003). 
 
Reconstruction of the corrected data was conducted using a modified Feldkamp 
cone beam algorithm. For each slice, the projected centre of mass was located and 
the centre of rotation calculated. The centre of rotation remained constant, the 
central slice was reconstructed first with the remaining data set reconstructed 
around this. The data was then “trimmed” (using IDL® Research Systems Inc., 
Colorado, USA) to reduce the data to a minimum cuboidal volume incorporating the 
region of interest. This data was converted to 256 grey levels (maximum – minimum 
levels) and the data points were further corrected so that their LAC was relative to 
an aluminium wire placed beside the specimen (LAC of aluminium 1.5336 cm-1 at 40 
KeV, (Weast, 1976). Each voxel is assigned a grey value based on its contents. 
Where one voxel contains 2 materials the average of the grey levels is calculated 
and used. This can lead to partial volume effect where the grey values at the 
enamel air or enamel dentine interface are less accurate. 
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Calculation of mineral concentration from LAC assumes that the mineral phase of 
enamel is pure HAp with a density of 3.15 gcm-3. The following equation 4.3 is used 
to calculate mineral concentration: 
 
CE = μE / μmHAp              Equation 4.3 
 
Where: 
CE = mineral concentration of enamel (gcm
-3) 
μE = measured linear attenuation coefficient of enamel (cm
-1) 
μmHAp = mass attenuation coefficient of HAp (0.99 cm
2g-1 at 40 KeV) 
 
Visualisation and manipulation of data was achieved using 3 software packages: 
TomView (in house software by Graham Davis), ImageJ (National Institutes of 
Health, USA) and Drishti (Australia National University, Canberra, Australia). 
TomView was used as a reference programme and to convert .tom files into 2D 
image stacks (.bmp). ImageJ was used to produce mass histograms and line probe 
profiles. Drishti was used mainly for manipulation of 3D images. 
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4.1.4 Data Analysis 
 
4.1.4.1 2D Analysis 
 
The image stacks were opened using ImageJ. For each lesion, the total number of 
slices was calculated and the central slice was identified (Slice thickness typically 
29.55µm unless otherwise stated). A line probe was taken through the centre of this 
slice perpendicular to enamel surface from the outside the lesion, through the 
enamel and into the dentine. Four further line probes were taken: two through the 
central slice 500µm mesial and distal to the central line probe, plus two central line 
probes from slices 500µm distant in the occlusal and apical directions (Figure 4.5). 
Due to the non-destructive nature of XMT, the five line probes could be accurately 
reproduced for all the time samples measuring lesion progression over time. 
 
 
 
Figure 4.5 - Diagram of lesion to demonstrate position of the 5 line probes within an artificial lesion. 
 
 
The mineral concentration was calculated from grey levels along the line probe 
using equation 4.3. Mineral concentration (gcm-3) was plotted against distance 
(mm). The line probes were used to calculate total lesion depth defined as the depth 
from the lesion surface (Figure 4.6, Point A) to start of sound enamel (Figure 4.6, 
Point B) (Cochrane et al., 2012a). The mean depth of each specimen was 
calculated from the five line probes. 
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Figure 4.6 – Illustration of sample line probe showing the enamel surface (A), sound enamel (B) and Enamel 
dentine junction (C).Subsurface demineralisation is shown along with the method of measuring lesion depth. 
 
 
 
4.1.4.2  3D Analysis 
 
An in house subtraction algorithm (programmed in IDL 6.4, Exelis Visual Information 
Solutions, Inc) was used to analyse mineral change. The pre and post treatment 
data sets were first aligned by using the program over 7 degrees of freedom (3 
translate, 3 rotate and isotropic scale). The data set for each lesion time point was 
aligned with and subtracted from the pre-treatment data set (0h for demineralisation; 
after 60h demineralisation for remineralisation experiments). A series of subtracted 
images were produced. ImageJ software was used to open the subtraction stacks 
and a histogram plotted with grey levels on the x axis and number of voxels on the y 
axis. Using equation 4.3, mineral concentration was calculated from grey levels. 
Equation 4.4 was used to calculate total mineral mass change from each lesion. 
Lesion mineral change was rendered comparable between experiments by 
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normalising the mass lost/gained for the surface area exposed to de- or 
remineralising solution; measurement of area is undertaken from the XMT scan. 
 
 
M = ∑ CE V  
               Equation 4.4 
 
M =total mineral mass lost (g) 
CE=mineral concentration of enamel (gcm
-3) 
V = Volume (cm3) 
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4.2 Materials 
 
4.2.1 Enamel 
 
Human premolar and molar teeth extracted for orthodontic reasons from young 
patients attending the Department of Paediatric Dentistry, Royal London Hospital 
(aged ≤ 18 years) were used as the enamel source. The patients all come from the 
same geographical area which is non-fluoridated. Specimens were checked visually 
using x2.5 magnification for caries/erosion and cracks. A further check was 
undertaken after 0h XMT scan and the specimen discarded if defects were present.. 
Ethical approval was obtained (East London and the City Local Research Ethics 
Committee). Following extraction, any soft tissue was removed, the natural surface 
polished with a prophy brush and the teeth placed in 70% volume ethanol solution. 
The teeth were sectioned perpendicular to the enamel surface (size dependant on 
the experiment) using an internal edge annular diamond blade (Microslice annular 
blade, Ultratec, USA) mounted on the Microslice 2 saw (Malvern Instruments Ltd., 
UK). The cut surfaces and parts of the natural surface not to be exposed to 
de/remineralising solutions were protected with 2 layers of acid resistant nail 
varnish. 
 
 
4.2.2 Hydroxyapatite 
 
Enamel has been shown to show enormous variety in composition between not only 
different subjects, but between different teeth from the same subject and within the 
same tooth. For this reason, HAp is often used as an enamel substitute. While the 
non-destructive nature of XMT reduces need for enamel uniformity, HAp was used 
for in situ work where infection control was an issue. HAp was purchased as pellets 
from Plasma-Biotal Ltd. (UK). These pellets were made of sintered powder (Captal® 
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S, D50), approximately 4µm particle size with a porosity of 20%. HAp powder was 
pressed uniaxially in a standard tablet dye (diameter 26mm) under 6895kPa. The 
pellets were then sintered in an atmospheric electric furnace at 1250-1300°C for 2 
hours. Samples were sectioned as above and nail varnish applied to surfaces which 
would not exposed to de/remineralising solutions. 
 
 
4.2.3 Peptides 
 
StN21 peptide, a synthesised version of the 21 N-terminus amino acids of the 
salivary protein Statherin, was used for the majority of this study. Its efficacy was 
also compared to a full length Statherin protein (StN43). StN21 and StN43 were 
synthesised using Fmoc solid phase step-wise synthesis at Peptide Research Ltd., 
Southampton, UK. Briefly, this is based on the attachment of amino acid carboxyl 
groups to a chloromethylated polystyrene polymer (Merrifield, 1963). The peptide is 
then lengthened from its N-terminus by successive coupling reactions. The amino 
acids are protected with 9-Fluorenylmethyloxycarbonyl groups (Fmoc) (Sheppard, 
2000). Once the peptide reaches the required length, the protected groups are 
cleaved to separate the peptide from the polystyrene polymer using a 2 hour 
treatment of 4% trifluoroacetic acid (Chan and White, 2000). The peptides are 
filtered and isolated using centrifugation. The peptides were stored at -20°C in 
powder form until used. When required, StN21 was thawed and dissolved in 
phoshate buffer (PB, 137 mMNaCl, 2.7 mMKCl, 10 mM Na2HPO4, 2 mM KH2PO4, 
pH of 7.4). The pH was adjusted to 7.0 – 7.2 with 1M NaOH. Polyglycine stock 
powder (Mr 500-5000) was stored at -200C and then reconstituted with PBS when 
required. 
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4.2.4 Fluoride 
 
Fluoride was used a positive control as it is the most well documented inhibitor of 
enamel demineralisation in the dental literature (McKay, 1953; Koulourides et al., 
1974; Marinho et al., 2004; Walsh et al., 2010). A solution of 1000ppm NaF (2.21g 
dissolved in 1L distilled water) was used. This concentration was used it is the 
lowest fluoride concentration where a statistically significant caries prevented 
fraction benefit is demonstrated compared to placebo (Walsh et al., 2010). 
 
 
4.2.5 Demineralising solutions 
 
The demineralising solution used was 0.1M acetic acid, buffered to pH 4.5 with 1M 
NaOH. Acetic acid has been previously used as a caries simulating agent in this 
laboratory and other research centres (Featherstone and Rodgers, 1981; Anderson 
et al., 1998; Dowker et al., 1999; Dowker et al., 2003; Anderson et al., 2004; Bollet-
Quivogne et al., 2005). The demineralising solutions were prepared to include 1.0 
mM CaCl2 and 0.6 mM KH2PO4 giving a partial saturation to the demineralising 
solutions with respect to HAp. To simulate erosive conditions, 0.1M acetic acid (pH 
4) was used. 
 
4.2.6 Remineralising solutions 
 
The in vitro remineralising solution used was prepared with the following: 1.5 mM 
CaCl2, 0.9 mM NH4H2HPO4, 1ppm NaF and 112.5mM NaCl (Gao et al., 1993). This 
has previously been shown to promote remineralisation in enamel. For intra-oral 
use, a 225ppm F- mouthwash (Boots®, Nottingham, UK) was used. 
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4.3 Statistical Analysis 
 
The data was analysed using Excel (Microsoft Excel 2010, Microsoft Corporation, 
U.S.A.) and SPSS statistical package (SPSS 13.0 for Windows, SPSS Inc., U.S.A.). 
The data was analysed and demonstrated to be normal. When comparing 2 data 
sets, a standard Student’s t test was used; for comparison of 3 or more data sets, 
one-way analysis of variance (ANOVA) was used. A confidence level of 0.05 
indicated a statistically significant difference. 
  
94 
 
 
 
 
 
 
Part II: 
 
In Vitro Mineralisation Studies 
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Chapter 5 – The Effect of StN21 on Enamel Demineralisation 
(Caries-like lesions) 
 
5.1 Introduction 
 
A 21 amino acid peptide designed to be identical to the N-terminus of Statherin 
(StN21) has previously been shown in vitro to reduce rates of demineralisation by 
40% using HAp as a substrate (Kosoric et al., 2007); measurements were made 
using Scanning Microradiography (SMR). Enamel is composed of 80 - 90% by 
volume calcium HAp with the remaining 10 - 20% being made up mostly of proteins 
and water (Angmar et al., 1963; Robinson et al., 2000). Initial work using enamel 
demineralised in the presence of StN21 and measured using SMR indicated a 
similar reduction in demineralisation rates. While SMR has the benefit of being a 
non-destructive and quantifiable technique, the measurement is limited to 2 
dimensions of a three dimensional lesion. 
 
The aim of this chapter is to measure the effect of StN21 on demineralisation of 
sound enamel in 3 dimensions using XMT. The mean concentration of Statherin in 
saliva ranges from 0.05 to 0.75 x 10-4mol l-1 (Hay et al., 1984). It was therefore 
decided to examine concentrations of StN21 from 0.06 to 0.88 x 10-4mol l-1. The 
effect was studied using a once and twice daily dosing strategy. These effects were 
then compared with phosphate buffer (negative control), fluoride solution, 
polyglycine peptide and whole Statherin protein (StN43). Fluoride is a well-known 
ion used to reduce demineralisation and has been studied extensively so acts as a 
positive control. A commercially available polyglycine peptide was chosen as a 
negative peptide control (Kennedy and Bryant, 1990). This peptide has an alpha 
helical structure analogous to the N terminus of the StN21 peptide and has been 
shown not to effect mineralisation of hydroxyapatite (Garcìa-Ramos and Carmona, 
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1982; Chrissanthopoulos et al., 2006). The efficacy was also compared with StN43 
in order to confirm that by reducing the peptide length there was no loss of efficacy. 
 
The Null hypotheses tested in this chapter are: 
1. There is no difference in caries-like enamel demineralisation rates between 
control and StN21 exposed lesions. 
2. There is no difference in caries-like enamel demineralisation between 
different concentrations of StN21. 
3. There is no difference in caries-like enamel demineralisation rates in control 
samples compared with those exposed to statherin, fluoride and polyglycine 
protein. 
4. There is no difference in caries-like enamel demineralisation rates in StN21 
exposed samples compared with those exposed to statherin, fluoride and 
polyglycine protein. 
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5.2 Materials and Methods 
 
The StN21 and StN43 were synthesised by Peptide Research Ltd, UK as described 
in section 4.2.3 and dissolved in phosphate buffer. StN21 was diluted with PBS to 
produce a series of 5 serial dilutions to cover the range of Statherin found in saliva 
(Table 5.1). Fluoride solution contained sodium fluoride at a concentration of 
1000ppm F-. The phosphate buffer was used as a negative control. 
 
Reagent Concentration (mol l-1) 
StN21 
(Once daily dose) 
0.88 x 10-4 
0.44 x 10-4 
0.22 x 10-4 
0.11 x 10-4 
0.06 x 10-4 
StN21 
(Twice daily dose) 
0.88 x 10-4 
StN43 0.8 x 10-4 
Polyglycine (-ve protein control) 250mg l-1 
Fluoride (+ve control) 1000ppm 
PBS (-ve control) - 
Table 5.1 – Experimental reagents used in Chapter 5 
 
 
Premolar teeth (20 in total) were sectioned vertically into 3 sections, two buccal and 
one lingual. A square window of ~3x3mm was masked out on the natural surface of 
each section. The tooth sections were then varnished. Once the varnish was dry, 
the masking tape was removed to create a window per section. Three sections from 
three different teeth (two buccal and one lingual) were mounted on a stage using 
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epoxy resin with a 1 mm diameter aluminium wire for calibration. Each experimental 
group consisted of six sections mounted as two separate experimental groups of 
three. As more than one tooth was extracted from each patient, the samples were 
grouped, as much as possible, to ensure that each group contained samples from a 
spread of patients. The samples were scanned using XMT pre experiment (0 hour 
scan). The samples were exposed for 5 minutes to the relevant peptide/fluoride/PBS 
control solution to mimic use as a mouthwash, then placed in a separate 
demineralising solution (without rinsing) at room temperature and stirred gently at 
100rpm. The demineralising solution used was 1.0 mmol l-1 acetic acid buffered to 
pH 4.5 (containing 1.0 mmol l-1 CaCl2 and 0.6mmol l
-1 KH2PO4) and was renewed on 
a daily basis. After 20 hours exposure to the demineralising solution, the tooth 
samples were rinsed with distilled water and wrapped in cling film to prevent drying 
out during the 4 hour XMT scan. 
 
The above steps were repeated twice to provide a 40 and a 60 hour post exposure 
XMT scan. In the experiment where a twice daily exposure of StN21 was required, 
the sample was removed from the demineralising solution after 10 hours and a 
second 5 minute exposure of StN21 undertaken (StN21 x2). 
 
The XMT data was analysed in both 2 and 3 dimensions as described in section 
4.1.3. 
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5.3 Results 
 
5.3.1 Control (Phosphate Buffer) compared with StN21 exposed Lesions  
(0.88 x 10-4 mol l-1) 
 
 
5.3.1.1 2D Analysis 
 
Single exposure of StN21 
 
For each lesion, a stack of 2D images (29.55μm thickness, 102 images per stack) 
was produced. The central slice for each lesion was identified in the 0, 20, 40 and 
60 hour data sets and five line probes measured as detailed in section 4.1.4.1. The 
following figures illustrate the typical appearance of the progression of a 
demineralised lesion in the central slice exposed to phosphate buffer (control, 
Figure 5.1) and its paired StN21 exposed equivalent (Figure 5.2) at 0, 20, 40 and 60 
hours. 
 
The control lesion had a smooth arc shape area of radiolucency with uniform depth 
which increased in both magnitude of radiolucency and depth towards dentine over 
time. The surface layer of the lesion while demineralised was still present indicating 
that the demineralisation was a subsurface phenomenon. The StN21 exposed 
lesion demonstrates areas of demineralisation which increased in depth and 
radiolucency over time, but not to the same extent as the control lesion. The 
appearance of the demineralisation did not have a uniform arc shape form with the 
central area of this particular lesion remaining relatively intact. This lack of uniformity 
was also found within four out of sixStN21 exposed lesions (concentration 0.88x10-4 
mol l-1). 
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Line probe measurements were used to confirm the anatomy of the lesions (Figures 
5.4, 5.5 and 5.6). The outer surface of the enamel while demineralised has not been 
lost as shown in all three line probes through the control and StN21 exposed lesion. 
The StN21 line probe represented by the dashed line showed very minimal loss of 
mineral (Figure 5.5). 
 
Multiple-exposure of StN21 
 
The concentration of StN21 (0.88 x 10-4 mol l-1) used in the above experiment was 
approximately twice the highest previously measured concentration of native 
Statherin protein in human saliva. In order to study whether increasing exposure to 
StN21 would improve the effect, further applications were undertaken after 10, 30 
and 50 hours. This mimics a twice daily clinical application. Stacks of 2D images 
were produced and the central slice from a typical lesion shown below (Figure 5.3) 
 
A further reduction in demineralisation was observed as shown by the greatly and 
visibly reduced lesion depth in comparison with both the control and the single 
exposure StN21 slices above. The demineralisation seen was again non uniform in 
depth, a pattern which is demonstrated across the lesions (Figure 5.7). 
 
 
Line Probe Summation and Analysis 
 
For each experimental set of lesions, the mean line probe depth and standard 
deviation (sd) were calculated (Figure 5.8 and Table 5.2). Using ANOVA, a 
statistically significant reduction in lesion depth was demonstrated at 20h 
(p=0.0008), 40h (p=0.0007) and 60h (p=0.0001) between the control, single 
exposure StN21 and twice daily exposure StN21 (StN21 x2).  
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Figure 5.1 - Typical XMT mid slice of a PBS exposed lesion (control) after 0 (A), 20 (B), 40 (C) and 60 (D) hours 
immersion in 0.1M acetic acid (pH4.5). An intact, but demineralised surface layer is present (white arrows) and the 
demineralisation has progressed in a uniform fashion with a smooth demineralising front (black arrows). The 
coloured arrows show the positions of the corresponding central line probes (LP1) in Figure 5.4. 
 
 
Figure 5.2 Typical XMT mid slice of a StN21 exposed lesion (concentration 0.88 x 10
-4
 mol l
-1
, single daily exposure) 
after 0 (A), 20 (B), 40 (C) and 60 (D) hours immersion in 0.1M acetic acid (pH4.5). The solid coloured arrow 
represents the central line probe (LP2) in Figure 5.5 through an area where little or no subsurface demineralisation 
has occurred (black arrows), the dashed arrow represents an accessory line probe (LP3) shown in Figure 5.6 where 
there is subsurface demineralisation (white arrows). Even in the areas where demineralisation has occurred, the 
depth is less than shown in the PBS control lesion (Figure 5.1). 
 
 
Figure 5.3 – Typical XMT mid slice of a StN21 exposed lesion (concentration 0.88 x 10
-4
 mol l
-1
, twice daily 
exposure) after 0 (A), 20 (B), 40 (C) and 60 (D) hours immersion in 0.1M acetic acid (pH4.5). There are areas of 
little or no subsurface demineralisation (white arrows) adjacent to areas where demineralisation can be readily 
visualised (black arrows), although these areas are less extensive than those in the PBS control lesion (Figure 5.1) 
and the single StN21 exposure lesion (Figure 5.2). The coloured arrows show the position of the corresponding 
central line probes (LP2) in Figure 5.7.  
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Figure 5.4 – Central line probes from the PBS exposed lesion (control) after 0, 20, 40 and 60 hours immersion in 
0.1M acetic acid (pH4.5) shown in Figure 5.1 (LP1). The surface of the lesion has been preserved (black arrow). 
The lesion depth increases over time. 
 
 
Figure 5.5 – Central line probes from the StN21 lesion (concentration 0.88 x 10
-4
 mol l
-1
, single daily exposure) after 
0, 20, 40 and 60 hours immersion in 0.1M acetic acid (pH4.5) shown in Figure 5.2 (LP2, solid arrows).  No 
demineralisation has occurred in this particular area of the lesion. 
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Figure 5.6 – Accessory line probes from the StN21 lesion (concentration 0.88 x 10
-4
 mol l
-1
, single daily exposure) 
after 0, 20, 40 and 60 hours immersion in 0.1M acetic acid (pH4.5) shown in Figure 5.2 (LP3, dashed arrow).  The 
surface has been preserved (black arrow) and although demineralisation has occurred in this particular area of the 
lesion, the lesion depth is less than that of the control lesion (Figure 5.4). 
 
 
 
 
 
Figure 5.7 – Central line probes from the StN21 lesion (concentration 0.88 x 10
-4
 mol l
-1
, twice daily exposure) after 
0, 20, 40 and 60 hours immersion in 0.1M acetic acid (pH4.5) shown in Figure 5.3 (LP4).  The surface has been 
preserved (black arrow). The lesion depth is less than that of the control (Figure 5.4) and StN21 once daily 
exposure (Figure 5.6) lesions. 
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Figure 5.8 – The mean lesion depths after 20, 40 and 60 hours for Control (PBS), StN21 (concentration 0.88 x 10
-4
 
mol l
-1
)
 
and twice daily StN21 (concentration 0.88 x 10
-4
 mol l
-1
)
 
calculated from line probes. The bars represent the 
standard deviation of lesion depth.  
 
 
 After 20h After 40h After 60h 
Mean Lesion 
Depth (mm) 
sd Mean Lesion 
Depth (mm) 
sd Mean lesion 
depth (mm) 
sd 
Control 
(n=6) 
0.364 0.075 0.457 0.090 0.558 0.084 
StN21  
(n=6) 
0.242 0.058 0.306 0.081 0.354 0.098 
StN21 twice 
daily (n=6) 
0.203 0.035 0.248 0.049 0.296 0.061 
Table 5.2 – Mean Lesion depths for lesions exposed to PBS (control), StN21 (concentration 0.88 x 10
-4
 mol l
-1
)
 
and 
twice daily StN21 (concentration 0.88 x 10
-4
 mol l
-1
) after 20, 40 and 60 hours calculated from line probes. 
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5.3.1.2  3D Analysis 
 
Rate of demineralisation  
 
From each lesion data set, a subtraction file was created using in house software 
programmed in IDL 6.4 (Section 4.1.4.2). The subtraction files were used to 
calculate the mineral lost from each lesion using Equations 4.3 and 4.4 After 
normalising the total mineral change to the exposed area, mineral loss was 
compared between the control and StN21 exposed lesions (both once and twice 
daily). The mineral change was plotted against time along with a line of best fit to 
determine the rate of demineralisation (Figure 5.9).  
 
For each lesion, the rate of demineralisation was calculated; and the results of the 
control, StN21 and twice daily StN21 groups compared (Table 5.3). The 
demineralisation rate was decreased by 52% in the StN21 exposed group and by 
65% in the twice daily StN21 exposed group when compared with the control group.  
T tests were used to compare the three groups (Table 5.8). There were statistically 
significant differences between the PBS control and the StN21 once daily 
(p=0.0016) and the StN21 twice daily (p<0.001) groups. When the StN21 once and 
twice daily groups were compared, there was no statistically significant difference 
between them (p=0.16). 
 
From these results, it is possible to reject the following Null hypothesis:  
 
1. There is no difference in caries-like enamel demineralisation rates between 
control and StN21 exposed lesions.  
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Figure 5.9 - Change in mineral concentration against time for lesions exposed to PBS (control), StN21 
(concentration 0.88 x 10
-4
 mol l
-1
)
 
and twice daily StN21 (concentration 0.88 x 10
-4
 mol l
-1
) after 20, 40 and 60 hours 
immersion in 0.1M acetic acid (pH4.5), calculated from subtraction data sets. The total mineral loss is markedly 
reduced in the StN21 exposed lesions compared to the control lesions. A further reduction in mineral loss is seen 
when the lesions are exposed twice daily to StN21. 
 
 Rate of Demineralisation (x 10-4g/h)  sd 
Control (PBS) 
 (n=6) 
4.75 0.99 
StN21                    
(0.88 x10-4 mol l-1) 
(n=6) 
2.27 1.21 
StN21 x2               
(0.88 x10-4 mol l-1) 
(n=6) 
1.67 0.68 
 
Table 5.3 - Demineralisation rates normalised for area in lesions exposed to PBS (control), StN21 and twice daily 
StN21 after 60h immersion in 0.1M acetic acid (pH4.5), calculated from subtraction data sets.  
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3D Visualisation  
 
The 3D appearance of the lesions after 60 hours demineralisation was visualised 
using Drishti software (Figure 5.10). In these images, sound enamel has been 
rendered transparent to show the pattern of demineralisation at the advancing edge 
of the lesion. A false colour scale has been applied where blue equals areas of 
greatest mineral loss, red equals moderate mineral loss and yellow areas 
represents areas of least demineralisation. These images show that in the control 
lesion, the interface between the demineralised and the sound enamel was 
relatively uniform across the whole lesion with the greatest mineral loss, whereas, 
for the StN21, the interface was irregular in shape with pits of demineralisation. This 
mirrors the 2D images (Figures 5.1 and 5.2). 
 
 
 
Figure 5.10 – XMT 3D representations of PBS (control, A) and once daily StN21 (concentration 0.88 x 10
-4
 mol l
-1
, 
B) lesions after 60h immersion in 0.1M acetic acid (pH4.5). The lesions are visualised with Drishti (dentine 
represented by *, normal enamel has been rendered translucent)  
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5.3.2 The Effect of reducing StN21 concentration on demineralisation 
 
5.3.2.1  2D Analysis 
 
A further set of experiments were undertaken to examine whether there was a dose 
dependent increase in the amount of demineralisation as the concentration of StN21 
was decreased; each group contained 6 samples. The concentrations used (Table 
5.1) represent the range of concentrations of native Statherin protein in saliva (Hay 
et al., 1984). XMT scans were undertaken at 0, 20, 40 and 60 hours. Stacks of 2D 
images were produced, the central slice identified and shown below for 
concentrations 0.44, 0.22, 0.11 and 0.06 x 10-4 mol l-1 (Figure 5.11, 5.12, 5.13 and 
5.14) 
 
The depth of demineralisation does not appear to be dose dependent, although the 
0.06 x 10-4 mol l-1 concentration of StN21 was not as effective as the other 
concentrations. However, the demineralisation patterns were more uniform in 
comparison to the previous lesions exposed to higher StN21 concentration 0.88 x 
10-4 mol l-1. 
 
For each experimental set of lesions (n=6), the mean line probe depth and sd were 
calculated (Figure 5.11 and Table 5.4). Using ANOVA, there was no statistically 
significant difference in mean lesion depth at 20h (p=0.406) and 40h (p=0.148) 
between the different concentrations of StN21. There was however a statistically 
significant difference at 60h (p=0.01) between the lesion depths of exposures to 
various concentration of StN21. This slightly higher loss of enamel is particularly 
evident at concentrations of 0.11 and 0.06 x 10-4 mol l-1 (Figure 5.13D and 5.14D)  
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Figure 5.11 – Typical XMT mid slice of a StN21 exposed lesion (concentration 0.44 x 10
-4 
mol l
-1
) following 
immersion in 0.1M acetic acid (pH4.5) after 0 (A), 20 (B), 40 (C) and 60 (D) hours. The demineralisation is 
subsurface, uniform and has a smooth advancing front. 
 
 
Figure 5.12 – Typical XMT mid slice of a StN21 exposed lesion (concentration 0.22 x 10
-4 
mol l
-1
) following 
immersion in 0.1M acetic acid (pH4.5) after 0 (A), 20 (B), 40 (C) and 60 (D) hours. The demineralisation is 
subsurface, uniform and has a smooth advancing front. The lesion depth is similar to that seen in Figure 5.11. 
 
 
Figure 5.13 – Typical XMT mid slice of a StN21 exposed lesion (concentration 0.11 x 10
-4 
mol l
-1
) following 
immersion in 0.1M acetic acid (pH4.5) after 0 (A), 20 (B), 40 (C) and 60 (D) hours. The demineralisation is 
subsurface, uniform and has a smooth advancing front. The lesion depth after 60h demineralisation is greater that 
seen in Figures 5.12D and 5.13D. 
 
 
Figure 5.14 – Typical XMT mid slice of a StN21 exposed lesion (concentration 0.06 x 10
-4 
mol l
-1
) following 
immersion in 0.1M acetic acid (pH4.5) after 0 (A), 20 (B), 40 (C) and 60 (D) hours. The demineralisation is 
subsurface, uniform and has a smooth advancing front. The lesion depth after 60h demineralisation is greater that 
seen in Figures 5.12D, 5.13D and 5.14D. 
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Figure 5.15 – Line probe measured mean lesion depths for PBS (control) and StN21 (concentrations 0.88, 0.44, 
0.22, 0.11 and 0.06 x 10
-4 
mol l
-1
) exposed lesions following demineralisation by 0.1M acetic acid (pH4.5) for 20, 40 
and 60 hours. The error bars represent standard deviation) 
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StN21 
Concentration 
(x 10-4 mol l-1) 
(n=6) 
After 20h After 40h After 60h 
Mean 
Lesion 
Depth (mm) 
sd 
Mean 
Lesion 
Depth (mm) 
sd 
Mean 
lesion 
depth (mm) 
sd 
0.88 0.242 0.058 0.306 0.081 0.354 0.098 
0.44 0.247 0.020 0.293 0.033 0.343 0.042 
0.22 0.245 0.017 0.308 0.029 0.379 0.037 
0.11 0.247 0.032 0.334 0.026 0.433 0.023 
0.06 0.279 0.028 0.357 0.036 0.462 0.368 
 
Table 5.4 - Mean Lesion depths measured using line probes for StN21 (concentrations 0.88, 0.44, 0.22, 0.11 and 
0.06 x 10
-4 
mol l
-1
) exposed lesions following demineralisation by 0.1M acetic acid (pH4.5) for 20, 40 and 60 hours 
as illustrated in Figure 5.15. 
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5.3.2.2  3D Analysis 
 
Using the subtraction files, the total amount of mineral lost was calculated using 
Equation 4.3 and 4.4 The mineral loss was then normalised for surface area of 
exposure of the lesion (calculated from the Tom view files) to allow comparison of 
the lesions. Mineral loss was plotted against time to calculate rate of mineral loss 
per lesion. Mean mineral loss for each StN21 concentration was calculated along 
with the standard deviation. The mean mineral loss was similar for concentrations of 
0.88, 0.44 and 0.22 x 10-4 mol l-1. An increase in demineralisation rate was seen in 
concentrations of 0.11 and 0.06 x 10-4 mol l-1 with the greatest increase associated 
with the lowest StN21 concentration (Table 5.5 and Figure 5.16). The rate of 
demineralisation for each StN21 concentration was compared using t tests to the 
results of the PBS control and StN21 0.88 x 10-4 mol l-1 (Table 5.8). For all 
concentrations of StN21, there was a statistically significant difference when 
compared with the PBS control, however there were no statistically significant 
differences with any of the StN21 concentrations when compared with StN21 0.88 x  
10-4 mol l-1. The standard deviations for the samples are large indicating variation 
across the samples as might be expected when using a variable natural substrate 
such as enamel.  
 
For this set of experiments, the following Null hypothesis cannot be rejected:  
 
2. There is no difference in caries-like enamel demineralisation between different 
concentrations of StN21.  
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StN21 Concentration 
(x10-4 mol l-1) (n=6) 
Rate of Demineralisation (x 10-4g h-1)  sd 
0.88 2.27  1.21 
0.44 2.11  
 
0.83 
0.22 2.18  
 
0.86 
0.11 2.40  
 
1.07 
0.06 2.71  0.42 
 
Table 5.5 – Mean demineralisation rates normalised for area in lesions exposed to StN21 (concentrations 0.88, 
0.44, 0.22, 0.11 and 0.06 x 10
-4 
mol l
-1
) after 60h immersion in 0.1M acetic acid (pH4.5), calculated from 3D XMT 
subtraction data sets illustrated in Figure 5.16. 
 
 
   
Figure 5.16 – Mean demineralisation rates normalised for area in lesions exposed to PBS (control) and StN21 
(concentrations 0.88, 0.44, 0.22, 0.11 and 0.06 x 10
-4 
mol l
-1
) after immersion in 0.1M acetic acid (pH4.5), calculated 
from 3D XMT subtraction data sets. Error bars indicate standard deviation.  
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5.3.3 The effects of Fluoride, Polyglycine and Statherin 
 
5.3.3.1  2D Analysis 
 
The central slice of typical lesions exposed to Fluoride, Polyglycine and whole 
protein Statherin (StN43) with position of central line probes is shown in Figures 
5.17, 5.18 and 5.19. The fluoride exposed lesions are of similar or increased depth 
to those seen in the StN21 (concentration 0.88 x 10-4 mol l-1) exposed lesions. These 
lesions are also less radiolucent and have a more uniform appearance than the 
StN21 exposed lesions. The shape of the Fluoride exposed lesions was similar to 
those seen in the control PBS lesions, but had an increased radiopacity. 
 
The Polyglycine exposed lesions appear (visually) to be similar to the control PBS 
exposed lesions – uniform arc shaped and relatively radiolucent compared to StN21 
and Fluoride exposed lesions. StN43 demonstrates an effect close to that seen in 
the lesions exposed to StN21 (concentration 0.88 x 10-4 mol l-1) with an irregular 
advancing front. The line probe quantification graphs are shown in Figures 5.20, 
5.21 and 5.22. Mean line probe depths, along with sd, were calculated (Figure 5.23 
and Table 5.6) and compared statistically with control and StN21 exposed lesions 
(0.88 x 10-4 mol l-1). Using ANOVA, there were statistically significant differences in 
line probe depths at 20h (p=0.001), 40h (p=0.0005) and 60h (p=0.0002). 
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Figure 5.17 – Typical XMT mid slice of a fluoride exposed lesion (concentration 1000ppm, positive control) showing 
subsurface demineralisation of the exposed area after 0 (A), 20 (B), 40 (C) and 60 (D) hours of immersion in 0.1M 
acetic acid (pH4.5). The lesions are less radiolucent in those exposed to PBS (control, Figure 5.1). The solid 
coloured arrows represent the central line probes depicted in Figure 5.20. 
 
 
Figure 5.18 – Typical XMT mid slice of a Polyglycine exposed lesion (concentration 250mg L
-1
, negative protein 
control) showing subsurface demineralisation of the exposed area after 0 (A), 20 (B), 40 (C) and 60 (D) hours of 
immersion in 0.1M acetic acid (pH4.5). The lesions are a similar radiolucency and depth compared to those 
exposed to PBS (control, Figure 5.1). The solid coloured arrows represent the central line probes depicted in Figure 
5.21. 
 
 
 
Figure 5.19 – Typical XMT mid slice of a statherin exposed lesion (StN43, concentration 0.8 x 10
-4 
mol l
-1
, positive 
protein control) showing subsurface demineralisation of the exposed area after 0 (A), 20 (B), 40 (C) and 60 (D) 
hours of immersion in 0.1M acetic acid (pH4.5). The lesions have an undulating advancing front as seen in StN21 
(concentration 0.88 x 10
-4 
mol l
-1
, Figure 5.2). The solid coloured arrows represent the central line probes depicted in 
Figure 5.22.  
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Figure 5.20 – Central line probe for the fluoride exposed lesion in Figure 5.17. The surface is preserved (black 
arrow), but has a reduced mineral content. The depth of the lesion is similar to that seen in the StN21 exposed 
lesions. 
 
Figure 5.21 – Central line probe for the polyglycine exposed lesion in Figure 5.18. The surface has been preserved 
(black arrow). The depth of the lesion is similar to that seen in the PBS (control) lesion shown in Figure 5.4. 
 
 
Figure 5.22 – Central line probe for the StN43 exposed lesion in Figure 5.19. The surface is demineralised, but 
preserved (black arrow). The lesion depth is similar to that seen in Figure 5.6 (StN21 concentration 0.88 x10
-4 
mol
-1
).  
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Figure 5.23 – Comparison of mean lesion depths for PBS (control), StN21 (concentration 0.88 x10
-4 
mol
-1
), StN43, 
fluoride and polyglycine. 
 
 
After 20h After 40h After 60h 
Mean 
Lesion 
Depth (mm) 
sd 
Mean 
Lesion 
Depth (mm) 
sd 
Mean 
lesion 
depth (mm) 
sd 
Fluoride 
(n=6) 
0.274 0.030 0.338 0.033 0.392 0.033 
Polyglycine 
(n=6) 
0.325 0.024 0.409 0.017 0.504 0.039 
StN43    
(n=6) 
0.262 0.024 0.324 0.032 0.383 0.034 
Table 5.6 – Comparison of mean lesion depths for StN43, fluoride and polyglycine as illustrated in Figure 5.23  
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5.3.3.2  3D Analysis 
 
Subtraction data was analysed as discussed in Chapter 4. The results are shown in 
Figure 5.24 and Table 5.6. The mineral loss in the Polyglycine exposed lesions was 
similar to that see in the control lesions; fluoride and StN43 exposed lesions were 
similar to StN21 exposed lesions. Using t tests, the demineralisation rates were 
compared with the PBS control and StN21 concentration 0.88 x 10-4 mol l-1 (Table 
5.8).  
 
From these experiments, the following Null hypotheses can be rejected: 
1. There is no difference in caries-like enamel demineralisation rates in control 
samples compared with those exposed to statherin and fluoride. 
2. There is no difference in caries-like enamel demineralisation rates in StN21 
exposed samples compared with those exposed to polyglycine protein. 
 
The following Null hypotheses cannot be rejected: 
3. There is no difference in caries-like enamel demineralisation rates in control 
samples compared with those exposed to polyglycine protein. 
4. There is no difference in caries-like enamel demineralisation rates in StN21 
exposed samples compared with those exposed to statherin and fluoride. 
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 Rate of Demineralisation (x 10-4g h-1) sd 
Fluoride (n=6) 1.93 0.38 
Polyglycine (n=6) 4.31 1.16 
StN43 (n=6) 2.38 
 
1.08 
 
 
Table 5.7 – Rate of mineral loss calculated from XMT subtraction data of fluoride, polyglycine and StN43 exposed 
lesions. The rate is normalised for exposed area in order to allow comparsison between lesions. Data illustrated in 
Figure 5.24. 
 
 
 
 
 
Figure 5.24 - Rate of mineral loss calculated from XMT subtraction data  of PBS (control), StN21 (concentration 
0.88 x10
-4 
mol
-1
), fluoride, polyglycine and StN43 exposed lesions normalised for area. Values are shown in Table 
5.7.  
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Control (PBS) 
 
StN21 Concentration 
(0.88 x 10-4 mol l-1) 
 
StN21 Concentration 
(0.88 x 10-4 mol l-1) 
 
0.0016 
 
N/A 
StN21 Concentration 
(0.88 x 10-4 mol l-1) twice daily 
 
<0.001 
 
 
0.16 
 
StN21 Concentration 
(0.44 x 10-4 mol l-1) 
 
0.0025 
 
 
0.40 
 
StN21 Concentration 
(0.22 x 10-4 mol l-1) 
 
<0.001 
 
0.15 
 
StN21 Concentration 
(0.11 x 10-4 mol l-1) 
 
0.0012 
 
 
0.38 
 
StN21 Concentration 
(0.06 x 10-4 mol l-1) 
 
0.0013 
 
 
0.23 
 
 
Fluoride 
 
<0.001 0.53 
 
Polyglycine 
 
0.49 0.014 
 
StN43 
 
0.0027 0.87 
 
Table 5.8 – Summary of t test results for 3D analysis of demineralisation rates. Each reagent was compared with 
Control (PBS) and StN21 (Concentration 0.88 x 10-4 mol l-1) exposed lesions (grey shaded boxes = statistically 
significant difference) 
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5.4 Discussion 
 
 
Quantification in both two and three dimensions demonstrated a statistically 
significant difference in the rate of demineralisation of StN21 exposed enamel when 
compared to PBS control. As shown in the 2D graphs, the surface layers remained 
intact. This confirms that acetic acid is the correct agent for an in vitro study to 
induce lesions mimicking those in natural carious enamel.  
 
The pattern of demineralisation when using higher concentrations of StN21 (0.88 
and 0.44 x 10-4 mol l-1) was variable. In the majority of the samples, there were 
areas of little or no demineralisation whereas in lesions exposed to lower 
concentrations (0.22, 0.11 and 0.06 x 10-4 mol l-1), the demineralisation was uniform. 
This can be seen visually in the 2D central slices and 3D Drishti images. This is an 
important finding to show that demineralising patterns need to be examined in 3D, 
and using a single line profile, and/or single section may give erroneous results, 
therefore, in this study, the lesion depths were examined in 5 parts of the sample to 
give a representation of depth. Arguably, it would be better to calculate the mean 
lesion depth in 3D. However, because of partial volume effects and irregularity of 
the lesion, we were not able to find a practical method of doing so. Nevertheless, 
with 3D volumetric data, we were able to calculate the total mineral loss, and the 
bulk rate of demineralisation.  
 
The non-uniform pattern of demineralisation and the large sd of lesion depths for 
StN21 concentration 0.88 x 10-4 mol l-1 is increased compared to the lower 
concentrations. Natural enamel mineral concentration varies which may explain 
some of the differences, but this is unlikely to be the full story. The N-terminus of 
native Statherin protein binds with great tenacity to the enamel surface. The areas 
122 
 
where little or no demineralisation has occurred may be related to areas of adhesion 
of StN21 peptide. The variable demineralisation pattern was also present in samples 
exposed to StN21 twice daily. Further experiments to analyse the pattern of StN21 
and StN43 binding and its relationship to demineralisation are required. This is 
discussed in Chapter 11. 
 
Statherin protein is found in higher concentrations in low caries rate individuals than 
in high caries rate individuals (Vitorino et al., 2005). In this experiment, whole 
Statherin (StN43) at a concentration equivalent to the higher end of the published 
normal range demonstrated a quantitative effect similar to that seen in StN21 0.88 x 
10-4 mol l-1 exposed lesions. There was a 50% reduction in demineralisation rate 
when compared to the PBS control. Also the demineralisation pattern in 2D was not 
always uniform mirroring the appearance seen in the 0.88 x 10-4 mol l-1 exposed 
lesions. Reducing the peptide length, therefore, does not impair the ability to prevent 
demineralisation.  
 
In contrast, Polyglycine peptide had no effect on demineralisation and demonstrated 
no statistically significant difference compared to the PBS experiments as has been 
demonstrated in previous studies (Garcìa-Ramos and Carmona, 1982; 
Chrissanthopoulos et al., 2006). Choosing a protein to act as a negative control was 
challenging. Lysozyme has been used in StN21/hydroxyapatite demineralisation 
studies and these experiments demonstrated no difference on mineralisation 
(Kosoric et al., 2007). Lysozyme is an enzyme which is not only found in saliva, but 
also in tears, human milk, mucous and avian eggshells. More recent work has 
demonstrated that lysozyme has an effect on calcium precipitation in egg shell 
formation (Rose and Hincke, 2009). Saliva is a complex protein mixture. Further 
studies using other proteins are required, particularly other salivary proteins, and 
also combinations of several proteins to test for synergistic behaviour. 
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Exposure of enamel to a standard fluoride solution also resulted in a reduction in 
demineralisation. Analysis in two dimensions indicates that lesion depth in fluoride 
exposed enamel was equal to those seen in StN21 exposed enamel; the lesions are 
however less demineralised than their StN21 exposed counterparts. In 3D analysis, 
overall mineral loss in fluoride exposed lesions was less. It is well established that 
fluoride can remineralise enamel caries lesions. These results indicate that StN21 
may not have a role in remineralisation; this will be further explored in Chapter 6.  
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Chapter 6 – The Effect of Experimental Peptide StN21 on 
Enamel Remineralisation 
 
 
6.1  Introduction 
 
 
In previous chapters, it has been demonstrated that StN21 has a significant effect 
on reducing the rate of demineralisation of dental enamel. This rate reduction was 
equivalent to that seen with 1000ppm fluoride solution. The mechanism of action of 
fluoride in carious lesions is such that it does not just reduce enamel 
demineralisation, but also enhances remineralisation. Previous studies using HAp 
as a substrate have demonstrated that StN21 has no effect on remineralisation 
rates (Alfawaz et al., 2008; Grosvenor et al., 2009). These studies used SMR to 
measure mineral gain. The aim of this experiment was to measure the effect of 
StN21 on remineralisation of artificial caries-like lesions in 3D using XMT. 
 
For this experiment, the Null hypothesis is as follows: 
3. There is no difference in enamel remineralisation rates in control and StN21 
exposed samples.  
 
 
 
  
125 
 
 
6.2  Materials and Methods 
 
Five intact premolar and molar teeth were sectioned (n=5), ~3mm x 3mm windows 
were masked out and the teeth varnished. The enamel samples were mounted on a 
scanning stage using epoxy resin and demineralised for 60 hours as described in 
Chapter 4 with XMT scans pre-treatment (0 hours) and post demineralisation (60 
hours). Control samples were exposed to a daily 5 minute rinse with PBS. StN21 
was dissolved in PBS (0.88 x 10-4 mol l-1 concentration) and the test samples 
exposed daily to this solution for 5 minutes. The samples were placed in 1L 
remineralising solution detailed in Section 4.2.6; this solution was gently stirred at 
100rpm and renewed on a daily basis. The samples were rescanned after 160, 350 
and 500 hours of remineralisation (corresponding to approximately 1, 2 and 3 
weeks).  
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6.3  Results 
 
6.3.1 2D Analysis 
 
Typical control and StN21 exposed lesions are shown in Figure 6.1 and 6.2 at the 5 
different time points (pre-treatment 0h, after 60h demineralisation and after 160, 350 
and 500 hours remineralisation). Lesion remineralisation progressed at a much 
slower rate than demineralisation. Visually, a difference was seen in the 
demineralisation rates between the control and StN21 exposed samples, but the 
appearance of the remineralisation is similar in both samples. Line probes were 
plotted as described in 4.1.4 1; typical central line probes for the control and StN21 
exposed lesions were represented graphically in figure 6.3 and 6.4 respectively. For 
each line probe, the reduction in depth at 160h, 350h and 500h was calculated and 
mean reduction and sd are shown in Figure 6.5 and Table 6.1. There was no 
statistically significant difference in mean reduction of depth at 160 (p=0.7), 350 
(p=0.59) or 500 hours (p=0.90). 
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Figure 6.1 – Typical XMT mid slice of a PBS (control) lesion prior to demineralisation (0h, A), after 60h 
demineralisation in 0.1M acetic acid at pH4.5 (B) and following 160h (C), 350h (D) and 500h (E) in remineralisation 
solution detailed in section 4.2.6. The coloured arrows indicate the position of the central line probe (Figure 6.3). 
Demineralisation is uniform as seen previously in Figure 5.1. Remineralisation cannot be easily visualised in the 
XMT slices. 
 
 
Figure 6.2 – Typical XMT mid slice of a StN21 (0.88 x 10
-4 
mol l
-1 
concentration) lesion prior to demineralisation (0h, 
A), after 60h demineralisation in 0.1M acetic acid at pH4.5 (B) and following 160h (C), 350h (D) and 500h (E) in 
remineralisation solution detailed in section 4.2.6. The coloured arrows indicate the position of the central line probe 
(Figure 6.4). Demineralisation is not uniform with some areas of little or no mineral loss as shown in Figure 5.2. 
Remineralisation cannot be easily visualised in the XMT slices. 
 
 
A 
 
500µm 
 
E 
 
D 
 
C 
 
B 
 
A 
 
B 
 
 C 
 
 E 
 
 D 
 
500µm 
 
128 
 
 
 
 
 
 
 
 
 
 
 0h pre treatment  
After 60h demineralisation treatment/ pre remineralisation 
After 160h remineralisation 
After 350h remineralisation 
After 500h remineralisation 
 
  
0 
1 
2 
3 
0 0.5 1 
M
in
e
ra
l 
C
o
n
c
e
n
tr
a
ti
o
n
 (
g
c
m
-3
) 
Distance (mm) 
0 
1 
2 
3 
0 0.5 1 
M
in
e
ra
l 
C
o
n
c
e
n
tr
a
ti
o
n
 (
g
c
m
-3
) 
Distance (mm) 
Figure 6.3 – Typical central PBS (control) line 
probes as shown in Figure 6.1. Marked 
demineralisation is demonstrated with a slight 
mineral gain following the period of 
remineralisation. 
Figure 6.4 – Typical central StN21 (0.88 x 10
-4 
mol l
-1 
concentration) line probes as shown in 
Figure 6.2. There was marked demineralisation 
after 60h with a slight mineral gain following 
remineralisation which is similar to that seen in 
Figure 6.3. 
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Figure 6.5 – Mean reduction in line probe depth calculated from XMT data plotted against time for control (PBS) and 
StN21 (0.88 x 10
-4 
mol l
-1 
concentration) lesions exposed to remineralising solution. There were no statistically 
significant differences between these values at the three difference time point. 
 
 
After 160h After 350h After 500h 
Mean 
Reduction in 
Lesion Depth 
(mm) 
sd 
Mean 
Reduction in 
Lesion Depth 
(mm) 
sd 
Mean 
Reduction in 
lesion depth 
(mm) 
sd 
 
Control 
(n=5) 
0.024 0.011 0.060 0.017 0.087 0.018 
 
StN21 
(n=5) 
0.027 0.016 0.055 0.010 0.087 0.011 
Table 6.1 – Mean reduction in line probe depth calculated from XMT data plotted against time for control (PBS) and 
StN21 (0.88 x 10
-4 
mol l
-1 
concentration) lesions exposed to remineralising solution as illustrated in Figure 6.5. 
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6.3.2 3D Analysis 
Subtraction data sets were used to calculate the rate of remineralisation over time 
normalised for area of exposure. These results are shown in Figure 6.6. For each 
lesion, the rate of remineralisation was calculated and the control and StN21 
samples were compared; there was no statistically significant difference between 
the control and StN21 samples (t test, p= 0.66).  
For this experiment, the following Null hypothesis cannot be rejected: 
5. There is no difference in enamel remineralisation rates in control and StN21 
exposed samples.  
 
 
Figure 6.6 – Total mineral gain calculated from XMT subtraction data sets for PBS (control) and StN21 (0.88 x 10
-4 
mol l
-1 
concentration) lesions exposed to remineralising solution plotted against time normalised for lesion area. 
There was no statistically significant difference in the rates of mineral gain. 
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 Rate of Remineralisation (x 10-6g/h)  sd 
Control (PBS) (n=5) 6.52 1.35 
StN21 (n=5) 6.64 0.91 
Table 6.2 – Mean rate of remineralisation for PBS (control) and StN21 (Concentration 0.88 x10
-4 
mol l
-1
) exposed 
lesions as illustrated by the trend line in Figure 6.6. There was no statistically significant difference in the rates of 
mineral gain.  
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6.4 Discussion 
 
This experiment demonstrates that StN21 neither enhances nor inhibits 
remineralisation in demineralised enamel at a concentration higher than that of 
native Statherin in saliva (Hay et al., 1984). The same results were previously 
demonstrated in experiments using hydroxyapatite (Alfawaz et al., 2008; Grosvenor 
et al., 2009). The rate of remineralisation was linear, although there was a degree of 
variation as would be expected in enamel samples. Using matched tooth samples 
reduced the effect of this variation. In natural carious lesions, the physicochemical 
process is complex with demineralisation and remineralisation occurring in cycles. 
The conditions of this experiment were necessarily artificial to elucidate the role of 
StN21 in remineralisation. A further experiment using a pH cycling 
de/remineralisation model would better mimic in vivo lesion formation with short 
periods of demineralisation (up to 1 hour) followed by longer periods of 
remineralisation (Stookey et al., 2011). It would also be interesting to compare these 
results to a 1000ppm standard fluoride solution. 
 
The effect seen in these experiments was somewhat surprising. One of the roles of 
Statherin is calcium and phosphate management preventing both primary and 
secondary precipitation in solution (Hay et al., 1984). At neutral pH (pH 6.46 - 7), the 
whole protein is required to prevent primary precipitation, whereas prevention of 
secondary precipitation needs only the N terminus (Schwartz et al., 1992). A 
reduction in rate of remineralisation would therefore be expected when comparing 
the StN21 exposed lesions with the control ones. However, in the present study, it 
appears that though StN21 binds calcium, its adsorption on the enamel surface may 
also provide a reservoir of ion releasing calcium ions under acidic conditions, 
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thereby preventing enamel demineralisation and mopping up excess calcium ions 
when pH returns towards neutrality, preventing unwanted precipitation (Vitorino et 
al., 2005). Its prohibitive effect may be on accretion rather than on nucleation of 
calcium phosphate crystals. Calcium phosphate management would therefore seem 
to be more complicated than previously thought and further chemical analysis of the 
lesion surface is required. 
 
An alternative hypothesis to explain this phenomenon would be that StN21 acts as a 
simple barrier. Statherin is just one of up 130 proteins which have been found to 
make up the acquired enamel pellicle (Siqueira et al., 2012). Many of these 
proteins/peptide fragments have been shown to protect against demineralisation 
particularly those with a strong affinity to hydroxyapatite as is seen in StN21 (Santos 
et al., 2008). Originally, it was thought that a mature pellicle was important in 
protection against demineralisation, but formation times from 3 minutes to 7 days 
demonstrated limited differences (Hannig et al., 2003; Wetton et al., 2006). The 
pellicle might therefore act as a non-specific, acid-resistant protein mesh. Further 
work using high resolution techniques such as micro- Raman spectroscopy should 
be undertaken to determine the characteristics of the mineral gain in the lesions. In 
conclusion, there is no statistically significant difference between mineral gain in 
PBS (control) and StN21 (Concentration 0.88 x10-4 mol l-1) exposed lesions, but 
further work is required including use of other remineralising solutions and analytical 
techniques.  
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Chapter 7 – The Effect of StN21 on Enamel Demineralisation 
(Erosive type lesion) 
 
7.1 Introduction 
Previous chapters have examined the effect of StN21 on caries-like lesions. Due to 
the effect seen in these subsurface lesions, it was hypothesised that the same 
protective effect would also be seen in erosive-type lesions. The dental pellicle of 
which Statherin represents an important constituent is known to reduce the amount 
of mineral loss in short-term erosion (Amaechi et al., 1999b; Hannig et al., 2003; 
Lussi et al., 2012). Over a longer period, however, acid exposure removes the 
surface layer of the pellicle and the protective effect is reduced (Siqueira et al., 
2012). The aim of this set of experiments was to examine the effect of StN21 on 
erosion type demineralisation of surface dental enamel over a period of 90 hours. 
The following Null hypothesis was applied to this experiment: 
6. There is no difference in erosion-like enamel demineralisation rates in 
control and StN21 exposed samples. 
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7.2 Materials and Methods 
 
Six intact molar teeth were sectioned and mounted as previously described in 
Chapter 4. As molar teeth, providing a greater surface area than premolar teeth, 
were used, unvarnished window areas ~ 3x5mm were prepared; the final analysis 
allows for normalisation of area. A pre-treatment XMT scan was undertaken (0h) at 
a resolution of 15µm using the MuCAT2 scanner (Table 4.1). The samples were 
exposed for 5 minutes to PBS (Control) or StN21 solution (0.88 x 10-4mol l-1 
concentration), then placed in 1L demineralising solution (without rinsing) at room 
temperature and stirred at 800 rpm. In these experiments, the demineralising 
solution used was 1.0 mmol l-1 acetic acid buffered to pH 4.0. After 20h exposure, 
the tooth samples were rinsed in distilled water, wrapped in cling film and scanned. 
Prior to replacing the samples in demineralising solution, a further 5 minute 
exposure to PBS or StN21 was undertaken. Every 20 hours, the samples were 
exposed for 5 minutes to PBS or StN21 and the demineralising solution renewed. 
Further XMT scans were undertaken after 60h and 90h demineralisation. Scans and 
treatment exposures followed the timetable detailed in Figure 7.1.  
 
Figure 7.1 – Experimental Timetable for Erosion-like Lesions described in Section 7.2. 
X-ray 
Microtomography Scan 
(XMT) – 0 hours 
Control : 5 mins in 
phosphate buffer – 1 
exposure per 20 hours 
0.1M acetic acid (pH4) 
renewed every 20 
hours StN21:5 minutes in 
0.88 x 10-4 mol l-1 
StN21 - 1 exposure per 
20hrs 
 20, 60 and 90 hours 
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Erosive lesion depths in 2D were measured using line probe graphs, an example of 
which is shown in Figure 7.2.  Erosive lesion depth was defined as the depth from 
pre experiment enamel surface (Figure 7.2, Point A) to the minimum mineral content 
advancing front point (Figure 7.2, Point B) (Chuenarrom and Benjakul, 2008). As the 
surface was not preserved in these lesions, relocation of the line probe relied on the 
EDJ and dentine pulp junction as static points. A pilot study was undertaken and 
intraexaminer reliability with a kappa value of 0.75 was demonstrated for depth of 
lesion. Five line probes were measured per lesion and the mean calculated (Section 
4.1.4.1). The total mineral loss in 3D was analysed using alignment and subtraction 
of data sets as described in Section 4.1.4.2. 
 
Figure 7.2 – Erosive lesion sample line probe from a typical XMT mid slice: A = Pre experiment enamel surface, B = 
Lesion advancing front (minimum mineral content) 
 
   
A B 
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7.3 Results 
 
7.3.1 2D Analysis 
 
The time series of the central XMT slices for the control and StN21 samples, and 
the position of the central line profiles are shown in Figures. 7.3 and 7.4 
respectively. These line probes are shown in Figures 7.5 and 7.6. In contrast to the 
subsurface demineralisation experiments demonstrated after exposure to acetic 
acid pH 4.5 in the two previous chapters, acetic acid pH 4 caused loss of the 
surface layer of the enamel at 60 and 90 hours. For both the control and StN21 
slices at 20 hours, the surface layer remained intact with subsurface 
demineralisation demonstrated. At 60 and 90 hours, the surface layer was lost 
progressively with an advancing demineralising front. The demineralising front, 
however, was not kinked rather than smooth (Figure 7.5 and 7.6). This may 
represent a softened layer which is removed as the depth of lesion increases. The 
mean and standard deviations of erosive lesion depth are shown in Figure 7.7 and 
Table 7.1. The difference in erosive lesion depth was not statistically significant for 
either the 20h (p=0.083) or 60h (p=0.085) samples. After 90h, however, the 
difference was statistically significant (p=0.039). 
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Figure 7.3 – Typical XMT central slice of PBS (control) exposed lesion after 0 (A), 20 (B), 60 (C) & 90 (D) hours 
immersion in 0.1M acetic acid (pH4). The coloured arrows represent the line probes shown in Figure 7.5. Surface 
mineral loss has been demonstrated.  
 
Figure 7.4 – Typical XMT central slice of StN21 (0.88 x 10
-4
mol l
-1 
concentration) exposed lesion after 0 (A), 20 (B), 
60 (C) & 90 (D) hours immersion in 0.1M acetic acid (pH4). The coloured arrows represent the line probes shown in 
Figure 7.6. Surface mineral loss has been demonstrated though to a lesser extent than shown in Figure 7.3 
 
A B C D 
A B C D 
500µm 
500µm 
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Figure 7.5 – Central Control PBS Line Probe as shown in Figure 7.3 following exposure to 0.1M acetic acid (pH4) 
after 0, 20, 60 & 90 hours. 
 
 
 
Figure 7.6 – Central StN21 (0.88 x 10
-4
mol l
-1 
concentration) Line Probe as shown in Figure 7.4 following exposure 
to 0.1M acetic acid (pH4) after 0, 20, 60 & 90 hours. 
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Figure 7.7 – Mean line probe depth against time for control PBS and StN21 (0.88 x 10
-4
mol l
-1 
concentration) 
exposed lesions after 20, 60 & 90 hours immersion in 0.1M acetic acid (pH4). 
 
 
After 20h After 60h After 90h 
Mean 
Lesion 
Depth (mm) 
sd 
Mean 
Lesion 
Depth (mm) 
sd 
Mean 
Lesion 
Depth (mm) 
sd 
 
Control 
(n=6) 
 
0.101 0.087 0.284 0.093 0.373 0.070 
 
StN21 
(n=6) 
 
0.056 0.041 0.190 0.054 0.234 0.060 
Table 7.1 – Mean erosive lesion depths for control PBS and StN21 (0.88 x 10
-4
mol l
-1 
concentration) exposed 
lesions demineralised in 0.1M acetic acid (pH4). The grey shading represents a statistically significant difference 
(p<0.05). 
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7.3.2 3D Analysis 
 
Rate of Demineralisation 
Subtraction datasets were used to calculate the amount of mineral loss over time 
(normalised for area) in control and StN21 exposed lesions as described in 
Chapters 3 and 5. The mean rate of demineralisation in samples exposed to StN21 
was 30% less than the control samples (Figure 7.8, Table 7.2). This difference was 
statistically significant (t test, p=0.0414). The following Null hypothesis can therefore 
be rejected: 
4. There is no difference in erosion-like enamel demineralisation rates in 
control and StN21 exposed samples. 
 
Figure 7.8 – Mineral change against time for control PBS and StN21 (0.88 x 10
-4
mol l
-1 
concentration) exposed 
lesions demineralised in 0.1M acetic acid (pH4).  
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Rate of Demineralisation (x 10-4g/h) 
normalised for area 
sd 
Control (PBS)  
(n=6) 
5.22 1.53 
StN21                  
(0.88 x10-4 mol l-1) 
(n=6) 
3.69 0.74 
 
Table 7.2 – Mean rate of demineralisation for Control PBS and StN21 (0.88 x 10
-4
mol l
-1 
concentration) exposed 
lesions demineralised in 0.1M acetic acid (pH4). The difference in demineralisation rates is statistically significant 
(p<0.05). 
 
3D Visualisation  
 
The lesions after 90h demineralisation were visualised in 3D using Drishti software 
(Figures 7.9 and 7.10). The first image set (Figure 7.9) was representative of the full 
sectioned tooth sample with dentine in yellow and the outer sound enamel rendered 
semi-opaque. The demineralised enamel was rendered translucent to demonstrate 
lesion pattern and depth. As previously shown in the 2D slices, both lesions were 
uniform in appearance; no difference in lesion depth was seen. The second set of 
images (Figure 7.10) visualised the subtraction data set. A false colour scale has 
been used where red equals areas of greatest mineral loss, the blue and yellow 
areas of least demineralisation. These images showed that there was a greater 
amount of mineral was lost in the control sample compared to the StN21 sample. 
Also, in the control sample, the loss appeared to be complete enamel loss as 
indicated by the red pseudocolour, which represented mineral concentration of 
~3gcm-3, the mineral concentration of normal enamel. 
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Figure 7.9 – 3D Drishti Images of typical Control PBS (A) and StN21 (0.88 x 10
-4
mol l
-1 
concentration, B) lesions 
after 90h demineralisation in 0.1M acetic acid (pH4).  
 
 500µm 
A 
B 
 500µm 
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Figure 7.10 – 3D Drishti Subtraction images of control (A) and StN21 (0.88 x 10
-4
mol l
-1 
concentration, B) exposed 
lesions in Figure 7.9. The pseudo colour scale indicates the amount of mineral loss.  
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7.4 Discussion 
 
Using both 2D and 3D analysis, there was a decrease in erosive demineralisation 
when comparing the StN21 to the control PBS exposed lesions. The difference was 
less marked than seen in caries-like demineralisation. The rate of 0.1M acetic acid 
pH4 mineral loss, when compared with the rate of 0.1M acetic acid pH4.5 
demineralisation, was increased. This would be expected as the solution was 
undersaturated with respect to calcium and phosphate, had a decreased pH and an 
increased agitation rate was used (Gao et al., 1991). The demineralisation pattern 
seen in these erosion-like lesions was uniform and appeared less varied with a 
smooth arc shape in all the samples whether exposed to PBS or StN21. The line 
probes shown in Figures 7.5 and 7.6 demonstrate surface loss after 60 and 90 
hours of demineralisation suggesting that the lesions progressed in a layer by layer 
manner similar to that seen in the clinical situation. Previous studies have 
demonstrated that an initial softened layer of enamel less than 2µm thick is formed 
followed by bulk loss of this layer (Lussi et al., 2011), however, the present 
resolution of MuCAT2 was more than 5µm. Other methods with higher resolution 
such as scanning electron microscopy are required to verify the presence of this 
demineralised softened layer. 
 
Acetic acid has previously been shown to be a more potent erosive demineralisation 
agent at higher pH than citric, lactic and phosphoric acids (Hannig et al., 2005). The 
effect of StN21 on demineralisation with these acids may result in a change in rate 
or a different pattern of mineral loss particularly when a lower pH (≤2.5) is used. 
From a clinical point of view, although acetic acid in vinegar has been shown to 
cause dental erosion, citric acid found fruit juices are a more common aetiological 
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agent (Järvinen et al., 1991). Citric acid is also known to chelate calcium and this 
therefore may adversely affect StN21 calcium management (Lussi and Jaeggi, 
2011). In order to examine the clinical relevance of StN21, further experimental 
groups comparing different erosive acids such as citric, lactic and phosphoric acids 
would be necessary. Dental pellicle proteins adhere to enamel even under 
aggressive demineralisation conditions and provide protection from erosion 
(Amaechi et al., 1999b; Hannig et al., 2009). Further experiments are also required 
to determine whether multiple applications of StN21 further decrease 
demineralisation rates and whether the pattern of StN21 absorption is related to 
patterns of demineralisation (Santos et al., 2008). 
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Part III: 
 
Proof of Concept Experiments 
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Chapter 8 – Development of an Intra Oral Appliance 
 
8.1 Introduction 
 
As previously discussed, intra oral or in situ devices offer an intermediate step in the 
translation of in vitro caries or erosion research into a randomised clinical trial (Zero, 
1995). In situ studies enable the application of the sensitive and quantitative 
measurements used in vitro studies rather than relying on the more subjective 
methods used in clinical trials. Quantitative measurements have the advantages of 
shortening study times, reducing potential risks to the participants and increasing 
participant compliance with experimental regimens. In situ devices may take either a 
fixed or removable form. In most cases, the removable form is preferred as it gives 
control to the participant in case of any unexpected problems and enables the 
maintenance of oral hygiene practices (Creanor et al., 1986; Zero et al., 1992; 
Stephen et al., 1992; Kielbassa et al., 1999; Kielbassa, 2000). The purpose of this 
study was to design an intra-oral device with components that are compatible with 
the XMT mounting equipment and provide proof of concept data for an application to 
the Medicines and Healthcare Products Regulatory Agency (MHRA) to study StN21 
using this intra-oral device. 
 
 
8.2 Aims, Development and Design of Appliance 
 
The primary aim was to develop and test the in situ model in conjunction with XMT 
in order to quantify mineral change in HAp and enamel using a series of scans. The 
secondary aims were to test the durability and comfort of the appliance over the four 
week experimental period. 
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Development of the in situ device required the development of two separate parts. 
Firstly, a cassette was designed which could easily be detached from the in situ 
device itself for XMT scanning, but was robust enough to withstand 4 weeks of intra 
oral wear which is the typical length of an in situ type experiment (Creanor et al., 
1986; Featherstone and Zero, 1992). The cassette needed to be made of a non 
radiopaque substance and be of the correct dimensions for the XMT scanner. 
Taking this into consideration, a Perspex® cassette (12.5mm x 6mm x 2mm) was 
designed containing a full thickness well 3mm by 3mm in size into which the 
experimental substrate (HAp or enamel slabs) was glued using an 
octylcyanoacrylate adhesive (Dermabond®). The adhesive was chosen for its non-
irritant properties. Two full thickness holes (~2mm in diameter) either side of the well 
were drilled for 2 microscrews to hold the cassette in place within the in situ device 
(Figure 8.1A). An XMT scan was undertaken to ensure that the Perspex® and 
Dermabond® adhesive did not interfere with scanning of the HAp/enamel substrate 
and that the scan time was not onerously long (data not shown). 
 
The second part of the design is that of removable appliance in situ device to house 
the Perspex® cassette. This enables the appliance to be used in young, healthy 
participants with full or almost full dentitions (Zero, 1995). The Perspex® cassette 
needed to be held in place using 2 microscrews (2.8mm in diameter, initially 6.4mm 
in length, but trimmed as necessary, Figure 8.2) and 2 nuts cemented within the 
flange (3mm in diameter). Initially, an upper removable appliance type design was 
considered similar to that used that used in West et al. (1998) whereby the Perspex® 
cassettes were located palatally with Adam’s cribs to retain the appliance. One of 
the issues with such a design was that the palatal flange would need to be at least 
5mm thick in comparison to a standard Hawley retainer thickness of 2-3mm (Agha 
and Ghaib, 2005). Secondly, in participants with a narrow or high vaulted palate, it 
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could be difficult to fit two Perspex® cassettes into the available baseplate surface 
area. Thirdly, in order for plaque to accumulate, palatal placement of the substrate is 
not optimal due to the cleansing pressure of the tongue against the palate during 
swallowing (Pedersen et al., 2002). 
 
Due to the issues stated above, a lower removable appliance was designed in 
preference with reference to Stephen et al. (1992) and Arweiler et al. (2004). The 
appliance used in this experiment, however, differed in that the substrate was 
housed in two buccal flanges rather than lingually. The two flanges joined by a 
sublingual wire and retained in the mouth by reverse Southend clasps over the 
molar teeth (Figure 8.1). A recess was created in each buccal flange to house the 
removable Perspex® cassette (12.5mm x 6mm x 2mm).  
 
Experimental samples were placed buccally to the lower molars as statherin protein 
is found submandibular gland saliva which is released into the oral cavity lingual to 
the lower incisors (Sabatini et al., 1989; Isola et al., 2008). The intra oral distribution 
of statherin in saliva is variable from person to person, but is, on average highest, in 
the buccal vestibule opposite the opening of the parotid duct (Sas and Dawes, 
1997) as stimulated parotid saliva is a rich source of native statherin protein 
(Schlesinger and Hay, 1977). The placement of the experimental substrate buccal to 
the lower dentition was desirable this area is not subjected to the large increases in 
stimulated salivary flow rates (Dawes et al., 1989) and therefore lower 
concentrations of statherin protein. 
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Figure 8.1 – Photographs of in situ appliance with associated Perspex
®
 cassettes. The appliance is 
shown extra orally concentrating on the buccal flange and Perspex
®
 cassette (A). The arrow shows the 
HAp/enamel slab. The appliance is also shown worn intra-orally: (B) Occlusal view and (C) Anterior view 
in occlusion. 
 
 
 
 
Figure 8.2 – Technical diagram in situ appliance 
1cm 
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8.3 Hydroxyapatite 
 
8.3.1 Materials and Methods 
 
Ethical approval was obtained from the East London and the City Research Ethics 
Committee 3 for use of the appliance with HAp (Reference Number 05/Q0605/147, 
Appendix 3). The study designed and conducted to conform with the Guidelines for 
Good Clinical Practice (GCP) (Appendix 6). A single participant was recruited (n=1). 
HAp slabs, approximately 4mm by 4mm by 2mm, were cut using a microtome. The 
surfaces not exposed to the oral environment were polished using Sof-lexTM discs 
(3MTM ESPETM) to ensure that a close fit within in the cassette was obtained. Nail 
varnish was applied to the non-exposed surfaces and the HAp slab attached to the 
Perspex® cassette with octyl cyanoacrylate glue. The whole cassette was scanned 
using XMT (resolution 29.55μm) using a 1mm diameter aluminium wire as internal 
calibration (Davis and Wong, 1996; Wong et al., 2004; Willmott et al., 2007). Rather 
than attaching the sample with epoxy resin to the XMT stage, a more flexible 
substance was required from which the cassettes could be removed easily and 
replaced without deformation and would hold the cassettes in the same scanning 
position. Extrude Xtra® dental putty (Kerr UK Ltd., Peterborough) was used.  
 
After the scan, the cassettes were replaced into the flanges of the in situ appliance 
and secured with microscrews. The appliance was worn intraorally by the participant 
for 14 days, exposed to normal eating and drinking plus a once daily 5 minute extra 
oral application of 225ppm fluoride solution (detailed in Section 4.2.6). The 
appliance was removed twice daily to allow tooth brushing with a standard 1450ppm 
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fluoride dentifrice. This was to mimic as much as possible a standard fluoride 
regime of two exposures of toothpaste and one exposure of a standard, clinically 
available, fluoride mouthrinse and well as eating and drinking (van Strijp et al., 
1999). The clinical relevance was to determine how acidogenic the participant’s oral 
environment was to sound HAp. After this period, the cassette was removed from 
the appliance and rescanned with XMT carefully repositioning the cassette within 
the scanning apparatus and covering it with Clingfilm. After the XMT scan, the 
cassette was removed, placed in a standard demineralising solution 0.1M acetic 
acid (1mmol CaCl2, 0.6mmol KHPO4, pH 4.5) for 60 hours following the in vitro 
demineralising protocol in section 5.2 which has previously shown a caries-like 
demineralisation. The cassette was rescanned and replaced in the appliance and 
was then worn for a further 14 days using the same experimental conditions as 
before. A final XMT scan was taken at the end of the protocol.  
 
8.3.2 Results 
 
 
2D Analysis 
 
As previously stated, the XMT images were made up of voxels (volume elements) 
29.55 x 29.55 x 29.55μm. With this 3D data, virtual 2D slices can be visualised in 
any plane. An example of a sagittal slice through one of the specimens is shown 
below. The same slice from the pre and end of experiment scans were visualised 
using Tom View® software (Figure 8.3). The third image is that of the 2D subtraction 
file slice which demonstrates the mineral that has been lost from that slice during 
the experiment. The surface exposed to the oral environment is shown by the blue 
arrow in Figure 8.3A. The areas are that have been demineralised as part of the 
experimental protocol are shown by the red arrows (Figure 8.3B and C). The 
remaining areas of mineral loss are due to fracturing and subsequent bulk loss of 
154 
 
HAp (demonstrated by the orange stars). These areas were not exposed to the oral 
environment. In order to better visualise the surface mineral change reaction, other 
HAp block has been used to show the sagittal mid slice images (Figure 8.4). 
 
Figure 8.3 – A sagittal XMT slice through the HAp sample shown pre experiment (A) and post experiment (B) . 
The file produced by subtraction is also shown (C). Blue arrow indicates the surface exposed to the oral 
environment. Red arrows show areas that have become demineralised during the experiment and the orange star 
represents an area where there has been bulk loss due to fracturing of HAp. 
 
The pre experiment scan shows a uniform block of HAp (Figure 8.4A). After 14 days 
in situ following the standard fluoride regime, the visual appearance of the exposed 
surface is no different to the pre experiment scan (Figure 8.4B) apart from some 
cracks which have been propagated. After 60h exposure to 0.1M acetic acid (1mmol 
CaCl2, 0.6mmol KHPO4, pH4.5) (Figure 8.4C), the experimental surface 
demonstrated demineralisation, both sub surface and surface. After 14 days in situ 
with daily exposure to eating/drinking and the fluoride regime, there were no obvious 
visual differences of the HAp surface, however the crack had increased in size 
(Figure 8.4D).  
 
Surface mineral change was quantified in 2D using 5 line probes per slab as 
described (Section 3). The mid-point line probe from Figure 8.4 is quantified in 
Figure 8.5. After the first intra oral period, the mean lesion was 0.006mm (Figure 
8.6). There was marked increase in lesion depth (mean depth = 0.35mm) after 60h 
demineralisation; the surface remained intact. After the second intra oral period and 
fluoride exposure, the lesion depth demonstrated a minimal decrease (mean depth 
= 0.33mm) and remineralisation of the surface (Figure 8.5, purple LP). Mean line 
probe values are shown in Figure 8.6. The lesion depths were relatively uniform.  
500µm 500µm 500µm 
A B C C 
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Figure 8.4 – Tom view® sagittal images through HAp slabs pre experiment  (A), after 14 days intra oral exposure to 
eating/drinking and fluoride regime (B), after 60h extra oral demineralisation (0.1M acetic acid, 1mmol CaCl2, 
0.6mmol KHPO4, pH4.5, C) and after 60h demineralisation followed by a second period of intra oral wear (D).  The 
exposed surface is visually altered after 60h demineralisation (C). The coloured arrows represent the position of the 
central line probe, white arrows indicate cracks in the slab which are much wider after the second period of intra oral 
wear (D). 
 
 
 
 
 
Figure 8.5 – Mid-point line probe illustrated in Figure 8.4. There is subsurface demineralisation after 60h 
demineralisation (0.1M acetic acid, 1mmol CaCl2, 0.6mmol KHPO4, pH4.5) (green LP). Some remineralisation has 
occurred after the second period of intra oral exposure and fluoride regime (purple LP). 
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Figure 8.6 - Mean lesion depths (HAp) as measured using LPs (Figure 8.5). Demineralisation for 60h (0.1M acetic 
acid, 1mmol CaCl2, 0.6mmol KHPO4, pH4.5) demonstrated a marked increase in lesion depth. The second period of 
intra oral wear and fluoride exposure resulted in a slight decrease in lesion depth. 
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3D Analysis 
 
Reconstruction of the surface appearance using 3D surface rendering was 
undertaken with Amira 3.2 software (Figure 8.7). The surface rendered images were 
produced using a mineral density cut off point (3.0gcm-3). This was chosen as HAp 
has a calculated density of 3.15 gcm-3 (Kosoric et al., 2007), but the LPs 
demonstrated a slightly lower surface mineral concentration. Only areas of surface 
mineral concentration over this threshold were shown. As demonstrated by the 2D 
data, the pre-treatment (Figure 8.7A) and after initial 14 day in situ/fluoride exposure 
(Figure 8.7B) images were similar in appearance. The post-60h demineralisation 
image (Figure 8.7C) demonstrated an effect on the surface, but due to the limitation 
of the imaging technique, it was not possible to determine whether this was surface 
or subsurface loss. After the second in situ/fluoride exposure period, the image 
(Figure 8.7D) demonstrated little difference when compared with the 
demineralisation image except that there was a noticeable crack present (indicated 
by the arrow).  
 
While the 3D images of the slab give a qualitative assessment of the mineral 
changes, the strength of XMT over other microtomography systems is the ability to 
quantify these changes. The mean change in mineral was shown in Figure 8.8. After 
2 weeks in situ, there was a very small net mineral gain (mean gain = 0.025g, 
normalised for area) when compared with the pre experiment slab. A more marked 
mineral loss was seen after 60h of 0.1M acetic acid demineralisation gain (mean 
loss = 0.17g, normalised for area) compared with the previous post intra-oral 
exposure scan (Figure 8.7B). After the second period in situ, net remineralisation 
had occurred (mean gain = 0.065g, normalised for area) when compared with the 
post demineralisation scan (Figure 8.7B).  
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Figure 8.7 – 3D surface rendering of HAp slabs using Amira 3.2. The surface is shown pre experiment (A), after 14 
days of intra oral exposure and fluoride (B), 60h exposure to demineralisation (0.1M acetic acid, 1mmol CaCl2, 
0.6mmol KHPO4, pH4.5, C) and following a second period of intra oral and fluoride exposure (D). The arrow indicate 
cracks in the HAp slab. Demineralisation demonstrated a marked surface loss (Figure 8.7C) 
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Figure 8.8 – Mean mineral change (HAp) calculated using IDL 6.4 and in house virtual alignment/subtraction 
software. A small mineral gain was seen after both periods of intra oral and fluoride exposure. A net loss of mineral 
was measured after a period of 60h demineralisation (0.1M acetic acid, 1mmol CaCl2, 0.6mmol KHPO4, pH4.5). 
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8.4 Enamel 
 
8.4.1 Materials and Methods 
 
Ethical approval was obtained from the East London and the City Research Ethics 
Committee 3 for use of the appliance with enamel (Reference Number 
06/Q0605/77, Appendix 4). The study designed and conducted to conform with the 
Guidelines for Good Clinical Practice (GCP) (Appendix 6). A single participant was 
recruited (n=1).   
 
The 2 Perspex® cassettes were set up as above with 2 slabs of buccal enamel in 
place of the hydroxyapatite. The slabs were paired – 2 premolar teeth were 
sectioned sagitally. Two adjacent sagittal sections were cut per tooth and one 
section was glued into each of the cassettes. The cut enamel surface was coated in 
nail varnish and only the natural enamel surface was exposed to de/remineralisation 
and the oral environment. This was to mimic a contact point. For each cassette, a 
pre treatment 29.55μm resolution XMT scan was performed as described 
previously. An example of a transverse and sagittal XMT slice were shown in Figure 
8.9 demonstrating the set up of the enamel within the cassette, the exposed/non 
exposed enamel surfaces and the aluminium calibration wire (1.5mm diameter, 
99.99% pure).The cassettes were replaced in the appliance and worn intraorally by 
the participant for 14 days exposing the enamel to normal eating and drinking plus a 
once daily extra oral application of 225ppm fluoride solution (detailed in Chapter 3). 
The appliance was removed twice daily to allow tooth brushing with a standard 
1450ppm fluoride dentifrice without rinsing to mimic a clinically relevant fluoride 
exposure (van Strijp et al., 1999). The cassettes were scanned following this 
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exposure. Demineralisation was undertaken using to a standard cariogenic solution 
(0.1M acetic acid, 1mmol CaCl2, 0.6mmol KHPO4, pH4.5) for 60 h and the cassettes 
rescanned. The appliance was then worn for a period of 14 days following the same 
protocol. A final end of experiment XMT scan was undertaken. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.9 - Transverse (A) and sagittal (B) Tom view® sections through enamel samples in a Perspex® cassette 
from the pre-treatment XMT scan. The dashed blue line represents the outline of the sample well, the solid blue 
lines represent the varnished surfaces and the red line represents the surface exposed to re and demineralisation. 
The green star shows an area of dentine, the orange star is the aluminium calibration wire. 
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8.4.2 Results 
 
2D Analysis  
 
Virtual mid slab transverse slices were cut through the four enamel blocks and one 
of the cassettes is shown in Figure 8.10. No visible difference was seen between 
pre-treatment and after 14 days in situ slices (Figure 8.10A and 8.10B). After 60h 
demineralisation, non-uniform demineralisation occurred (Figure 8.10C). In some 
areas, obvious demineralisation was visualised; in other areas, there was no or very 
little demineralisation. The final XMT scan following a 14 day period of in situ 
remineralisation was very similar in appearance the previous scan (Figure 8.10D). 
The final XMT scan showed a decrease in the size of gap between the two enamel 
slabs where the upper slab (indicated by the purple star) had become partially 
detached from the cassette. Alignment software was used to ensure that the line 
probes were in the same position for the four scans. The line probe demonstrated in 
Figure 8.10 was plotted in Figure 8.11. After 14 days in situ, there was minimal 
demineralisation. After 60h demineralisation in 0.1M acetic acid (1mmol CaCl2, 
0.6mmol KHPO4, pH4.5), there was a marked increase in lesion depth. The second 
period of intra oral exposure resulted in a very slight reduction in mineral depth. 
 
For each experimental time point, the mean lesion depth was calculated (See Figure 
8.12). After 2 weeks in situ, mean lesion depth was minimal (0.024mm). There was 
a increase in lesion depth after 60h demineralisation with 0.1M acetic acid (CaCl2, 
0.6mmol KHPO4, pH4.5) (mean = 0.38mm). Following the second 14 days in situ 
period with fluoride application, the mean lesion depth was decreased when 
compared to that following demineralisation (mean = 0.35mm).  
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Figure 8.10 – Transverse mid slice of 2 enamel slabs contained in a Perspex® cassette pre experiment ()h, A), after 
14 days intra oral and fluoride exposure (B), after 60h demineralisation with 0.1M acetic acid (CaCl2, 0.6mmol 
KHPO4, pH4.5, C) and following a second 14 day period of intra oral and fluoride exposure (D). The 
demineralisation seen in Figure 8.10C is not uniform. The coloured arrows demonstrate the line probe shown in 
Figure 8.11; White arrows demonstrate exposed experimental surfaces. Purple star (Figure 8.10D) indicates the 
upper slab which became dislodged during the experiment. 
 
 
  
A 
500µm 500µm 
500µm 500µm 
D C 
B 
164 
 
 
 
Figure 8.11 – Typical Line probe illustrated in Figure 8.10. There was marked subsurface demineralisation in this 
area of the lesion after 60h in 0.1M acetic acid (CaCl2, 0.6mmol KHPO4, pH4.5, green line). A decrease in lesion 
depth was seen following the second period of intra oral and fluoride exposure (purple line). 
 
 
 
Figure 8.12 - Mean lesion depths (Enamel). Mean lesion depth was markedly increased following 60hexposure to 
0.1M acetic acid (CaCl2, 0.6mmol KHPO4, pH4.5). After the second period of intra oral and fluoride exposure, the 
lesion depth decreased slightly. 
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3D Analysis  
 
As described for hydroxyapaptite, IDL 6.4 and in house virtual alignment/subtraction 
software was used to quantify the amount of mineral change at the three different 
time points (Section 8.3.2). The alignment software was of particular importance in 
the final XMT scan after one of the enamel slabs was dislodged within the cassette 
(Figure 8.10D). The mineral change was normalised for lesion area to allow 
comparison of the four enamel slabs. After the two periods of in situ wear, there was 
a small mean increase in mineral – 0.0013g for the first period and 0.0018g for the 
second period. After demineralisation, there was a marked mean mineral loss 
(0.012g) as demonstrated in the 2D slices (Figure 8.13). 
 
 
Figure 8.13 - Mean mineral change (Enamel). There was a small mean mineral gain after both periods of intra oral 
and fluoride exposure. After 60h demineralisation (0.1M acetic acid, CaCl2, 0.6mmol KHPO4, pH4.5), there was a 
marked loss of mineral. 
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8.5 Discussion 
 
 
The in situ appliance designed itself withstood the experimental protocol without 
sustaining any damage. The appliance was comfortable to wear and easy to keep 
clean. The Perspex® cassettes were easily removed from the appliance, reinserted 
and securely fixed with microscrews. Using Extrude Xtra® dental putty (Kerr UK 
Ltd., Peterborough) as a substitute for epoxy resin allowed the cassette to be 
replaced in the XMT scanning apparatus in approximately the same position, both in 
height and rotational translation, for repeated measurements. This approximate 
physical repositioning was adequate as the two experimental volumes were aligned 
using in-house software Tomaligns written in IDL 6.4. Precise virtual repositioning 
allowed accurate placement of sequential line probes and thus 2D analysis and 
quantification. Following alignment, another in-house IDL routine was used to 
subtract the images from each other to produce a third volume which demonstrated 
the difference in grey levels between them. The mineral change was then quantified 
from this subtraction volume; this quality along with in-house align/subtract software 
sets the XMT system apart from other commercial micro CT systems.  
 
The intra oral device was used with some success with both HAp and enamel. HAp 
was used as enamel substitute because it does not pose the same biological risks 
as enamel. It is inexpensive, readily available and without the natural concentration 
gradient present in enamel.. In vitro StN21 exposed HAp and enamel demineralise 
at similar rates (Kosoric et al., 2007). These in situ studies have shown that when 
subjected to the oral environment, HAp and enamel reacted in the same manner. 
The major disadvantage of HAp was the tendency to fracture, especially in small 
specimens, leading to loss of substrate which could affect the experimental results. 
This is because HAp is weak under tensile and shear strengths (Martin and Brown, 
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1995). HAp lacks the organic content of enamel leading to its brittleness. 
Hybridisation with organic compounds improves HAp’s resistance to brittleness (Im 
et al., 2005). These compounds are therefore more biostable when used clinically. 
Furthermore, the pore size in HAp can vary greatly and this needs to be 
compensated for. The in situ experiment was therefore repeated using enamel. 
 
Enamel was also used in the in situ device. Gamma irradiation was undertaken to 
sterilise the enamel samples and negate any biological risk to the participant within 
altering the mineral content or porosity of the specimen (Kielbassa, 2000). The 
enamel however needs to be carefully prepared before placing in the Perspex® 
cassette to ensure that the natural surface is the only part exposed to the oral 
environment. One perceived disadvantage of enamel is that of the inherent 
variability in mineral content (Elliott et al., 1998). By using XMT to accurately study 
the same lesion over time, the variation was less of an issue (Dowker et al., 2003). 
The demineralisation of the enamel slabs was more variable than seen in the control 
in vitro experiments. The variable demineralisation pattern had a similar appearance 
to the effect seen in some of the StN21 exposed enamel samples. The difference 
may be related to the previous exposure of the enamel to the oral environment. 
Statherin and its shorter peptide fragments form the initial constituent of salivary 
pellicle which attaches tenaciously to enamel and cannot be removed by tooth 
brushing (Li et al., 2004). In this experiment, the presence of this protective barrier 
could have interfered with demineralisation mimicking the effect of StN21. 
 
For both enamel and HAp, the initial 14 day exposure to the intra oral environment 
resulted in seemingly contradictory results after 2D and 3D analysis – 2D analysis 
represented a mean mineral loss whereas 3D analysis resulted in a net mineral 
gain, although both were not significant. As the samples were exposed to both sides 
of the mouth, chewing side preference cannot account for this difference. Another 
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explanation for this difference could be that 2D measurements may overestimate 
the lesion depth due to partial volume effect which could be improved using a higher 
resolution scan. The oral environment could also have contributed to this 
discrepancy. Exposure of the HAp and enamel to an oral environment prone to 
erosion could have resulted in removal of the outer enamel layers. Fluoride 
exposure while not restoring the lost enamel will result in some precipitation 
fluoridated calcium phosphates. In future, participants will be requested to complete 
diet diaries to establish the type of experimental environment.  
 
In conclusion, the use of XMT to quantify mineral change in conjunction with an in 
situ device has been demonstrated. Both HAp and enamel were suitable substrates, 
although enamel was more robust and therefore more likely to be used in future 
experiments. An improved method of stabilising the enamel slab also needs to be 
addressed. These experiments were undertaken using the original MuCAT system 
at a resolution of ~30µm due to scan times. The development of MuCAT2 has led to 
decreased scan times and improved resolution (~5µm). The current in situ Perspex® 
cassette can be used in MuCAT2; using this system would improve the accuracy of 
the results in future experiments. The current experiments provide proof of concept 
data with the future goal of obtaining ethical approval for an XMT in situ study using 
StN21 to reduce demineralisation. 
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Chapter 9 - Biocompatibility Testing 
 
9.1 Introduction 
 
The most common caries preventive agent used in oral hygiene products is fluoride. 
Although fluoride has a long history of safety at low doses, it is in fact highly toxic in 
high doses. Based on previous acute and chronic toxicity cases, the “probably toxic 
dose” of fluoride is 5mg F/kg body weight (Whitford, 1992). This is a particular 
problem in children less than 6 years old as a single tube of toothpaste could 
contain a “probably toxic dose”. The safety of a new anti-demineralisation agent 
must be ensured prior to testing in vivo. Statherin is a biological molecule which is 
present in the oral cavity (Schlesinger and Hay, 1977). This protein is broken down 
and exists naturally in a variety of shorter peptide sequences (Jensen et al., 1991). 
The evidence suggests that the STN21 peptide is likely to be non-toxic, but 
biocompatibility testing is necessary. In this study, an in vitro model was used rather 
than a live animal model. To understand how the model works, understanding of 
normal oral mucosa architecture is essential. The normal oral mucosa consists of 
surface epithelium supported by a fibrous layer of connective tissue, the lamina 
propria. The epithelial layer which may be keratinised or non-keratinised consists of 
four layers of cells: basal, spinous, granular and superficial (the latter is only in 
keratinised mucosa). The basal layer cells are progenitor cells that undergo 
differentiation as they migrate to the surface. Other cells such as melanocytes, 
Langerhans and Merkel cells are also found in the epithelium. Models have been 
developed to mimic this complex structure (Rosdy and Clauss, 1990; Rosdy et al., 
1993; Schmalz et al., 2000; Moharamzadeh et al., 2012). 
 
Initial experiments produced a method of growing human keratinocytes in serial 
culture in vitro, using a feeder layer composed of irradiated 3T3 mouse fibroblasts 
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and Green’s culture medium (Rheinwald and Green, 1975). This method is 
frequently used to cultivate keratinocytes and to produce a single-layer epithelial 
sheet and has been adapted so the irradiated feeder layer is no longer required, 
simplifying the production process. Monolayer cultures are extremely useful for 
studying basic biology and the reaction of cells to a stimulus. They are however 
fragile, difficult to handle and liable to contract. They also lack the structural 
complexity and terminal differentiation that is seen in normal oral epithelium and 
therefore fall short of the in vivo situation (Moharamzadeh et al., 2007). 
 
To overcome the weaknesses of the monolayer system, multilayer systems were 
developed. The original multilayer models were skin models used to test irritation 
properties of cosmetic products (Bernhofer et al., 1999; Coquette et al., 1999). This 
technology has now been applied to oral mucosa models (Khawaja et al., 2002). In 
order to produce a model which displays properties as close to the normal oral 
mucosa, certain factors must be considered namely scaffolding, cell source and 
culture medium. In multilayer cultures, scaffolds are essential to support the cells 
and need to be biocompatible and biostable while displaying ideal porosity and 
mechanical properties. Naturally derived scaffold materials include acellular dermis, 
collagen, gelatin and fibrin. These have advantages, but also disadvantages such 
as the fact they are often isolated from animal or human tissue and are therefore not 
available in huge quantities. They suffer from a lack of homogeneity between 
batches and are expensive. This has lead to the consideration of synthetic scaffolds. 
In the epithelial model chosen for this experiment (SkinEthic Laboratories, Nice, 
France), a polycarbonate – permeable membrane is used as a scaffold. It has good 
mechanical properties with no risk of infection (Schmalz et al., 2000). 
 
The origin of the fibroblasts and keratinocytes is an important factor to be 
considered. Fibroblasts can be isolated by oral mucosal biopsy and then cultured. 
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Careful use is required; as the number of passages increases, the amount of 
extracellular matrix produced decreases (Moharamzadeh et al., 2007). Normal 
human keratinocytes can also be obtained by biopsy of the hard palate, gingival or 
buccal mucosa and should also be used only from very early passages. To 
overcome the passage effect, immortalised cells lines (HaCaT or TR146), (Schmalz 
et al., 2000) can be used at extended passages in the construction of oral mucosal 
test models. Immortalised cell lines do not produce a perfect epidermal 
differentiation, but still perform adequately as a model. They could not however be 
used as a graft in the clinical situation. The most commonly used medium for 
culturing oral mucosa lines is Dulbecco’s modified Eagle medium (DMEM) – Ham’s 
F-12 medium which is supplemented with foetal calf serum (FCS), glutamine, 
epidermal growth factor, hydrocortisone, adenine, insulin and antibiotics. Other 
researchers developed serum free culture mediums as FCS may contain slow 
viruses (Moharamzadeh et al., 2007). While no model system is perfect, they offer 
advantages over animal models in the reduction of laboratory space and licensing 
required. They can be constructed so that they meet the requirements for 
standardised testing, in the same way as animal models, but by using human 
derived cells may also prove closer to the in vivo situation (Schmalz, 2002). 
 
Previous studies, using this model system, have enabled researchers to determine 
whether a material is an irritant and/or sensitiser of the oral mucosa. Irritants act in a 
non specific manner to cause an inflammatory reaction. Sodium benzoate, a food 
preservative (Coquette et al., 2003), and sodium lauryl sulphate, a detergent 
commonly found in toothpaste (Skaare et al., 1997), are known irritants of the oral 
mucosa. When these agents are applied topically to the oral mucosal model, a 
marked increase in extracellular IL-1α is seen (Coquette et al., 2003; Whiley et al., 
2012). In contrast, sensitisers produce a reaction to a specific antigen following 
induction of immunological memory. Oral mucosa sensitisers include mercury (Koch 
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and Bahmer, 1999) and nickel (Garner, 2004). Previous studies have shown that 
although topical exposure to these sensitisers results in IL-1α mRNA upregulation, 
there is no related increase in IL-1α cytokine production (Coquette et al., 2003). In 
contrast, a sharp increase in IL-8 production has been measured (Whiley et al., 
2012). A protocol has, therefore, been established that uses IL-1α and IL-8 
production as a method of discriminating between irritant and sensitisation 
properties of a new material. When combined the MTT cytotoxicity assay, this 
protocol provides a reliable in vitro method of determining toxicity of an agent 
(Coquette et al., 1999). 
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9.2 Experimental Protocol 
 
9.2.1 Aims and Objectives 
 
The aim of this is experiment to determine the toxicity of StN21 compared to PBS, 
statherin protein and the foaming agent, sodium lauryl sulphate (SLS), which is 
commonly added to toothpastes. The objectives are to determine cell viability after 
48 hours exposure to the reagents and to measure the levels of IL1α and IL8 
produced by cultures exposed to the reagents. 
 
The Null hypotheses are: 
5. There is no difference in cell viability of cultures exposed to PBS compared 
to those exposed to StN21, statherin and sodium lauryl sulphate (SLS). 
6. There is no difference in production of IL-1α by cultures exposed to PBS, 
compared with those exposed to StN21, statherin and SLS. 
7. There is no difference in production of IL-8 by cultures exposed to PBS, 
compared with those exposed to StN21, statherin and SLS. 
 
 
9.2.2 Cultures 
 
A reconstituted human buccal epithelial model was chosen for this experiment 
(purchased from SkinEthic Laboratories, Nice, France) rather than a monolayer 
fibroblast system. This is because it consists of a three-dimensional tissue culture 
model of transformed oral keratinocytes so mimicking the architecture and reaction 
of the normal buccal mucosa accurately and improving standardisation between 
experiments. The cultures are derived from the TR 146 cell line which was originally 
established from a biopsy specimen of a squamous cell carcinoma of the buccal 
mucosa that has infiltrated a lymph node. The cells were seeded (8x105 cells cm-2) 
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on a 0.5 cm2 inert polycarbonate membrane. They were then cultivated for 12 days 
in a defined medium at the air-liquid interface. The resulting stratified culture is 10-
12 cells in thickness and lacks a stratum corneum (Figure 9.1). 
 
 
Figure 9.1 – Microscopic section of the buccal mucosal model (SkinEthic website, France) demonstrating the 
polycarbonate membrane (A) and stratified cell layer (B). There is no stratum corneum. 
 
Growth medium was also supplied (SkinEthic Laboratories, Nice, France) containing 
5μg ml-1 insulin, 1.5mM Ca2+, 25μg gentamycin and 0.4μg hydrocortisone. The 
cultures were shipped on agar and were transferred on arrival to a 24 well culture 
plate (Sigma–Aldrich, Poole, UK) containing 500μl of growth medium per well. The 
cultures were incubated over night at 370C in a humidified atmosphere containing 
5% CO2. The next morning, the cultures were transferred to 6 well plates (Figure 
9.2) containing 1.5ml of fresh growth media. At intervals of 4, 24 and 48 hours, the 
growth media was collected and fresh media applied. 
 
200 μm 
A 
B 
175 
 
 
Figure 9.2 – Diagram of the mucosal model showing a section through a single well (Courtesy of Dr Alan Cruchley, 
Queen Mary University of London). The cultures were treated by applying StN21, statherin, SLS or PBS to the 
epithelial surface. 
 
 
 
9.2.2 Treatment of Cultures 
 
Five different treatments were applied to the tissue cultures: StN21 (at 
concentrations of 0.88 x 10-4 mol l-1 and 1.76 x 10-4 mol l-1 in PBS), whole statherin 
protein (concentration 0.8 x 10-4 mol l-1 in PBS – average concentration in normal 
saliva), PBS (negative control), and 0.5% SLS (positive control). SLS was chosen 
as a positive control as it is an irritant of the oral mucosa resulting in an increase in 
cytokine release, disruption to mucosal structure and, at high enough 
concentrations, cell death (Baert et al., 1996; Neppelberg et al. 2007). Both 
concentrations of StN21, statherin and PBS were applied and left for 48 hours; 0.5% 
SLS was applied for 5 minutes, then aspirated off and PBS applied for the 
remainder of the experiment. SLS was only applied for 5 minutes due to the risk of 
causing cell death (Hagi-Pavli et al., 2004). The cultures were incubated at 370C in a 
humidified atmosphere containing 5% CO2 for 48 hours with media collection at 4, 
Epithelial Surface 
Insert 
Culture Medium Polycarbonate Membrane 
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24 and 48 hours. The culture medium was stored at -200C until being used for 
cytokine measurement. At the end of the experiment the cultures were washed 3 
times with PBS. 
 
9.2.3 Viability Assay 
 
The purpose of this was to study cell survival and proliferation. This assay used 
MTT {3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide} (Mosmann, 
1983). MTT is yellow in colour, but is reduced by enzymes in mitochondria to 
insoluble purple-coloured formazan. A calibrated multiwell scanning 
spectrophotometer (Pye Unicam PU 8650, Philips Scientific, Cambridge, UK) was 
used to measure this colour change (Optical Density, OD, = 570nm). The amount of 
formazan present can be measured giving an estimate of cytotoxicity of the product. 
 
9.2.3.1 Flow Chart of MTT Assay 
 
 
 
 
 
 
 
 
 
 
Cultures (n=12) were transferred to new 
24 well plate 300μl of MTT solution (0.5mg 
ml-1 in PBS) 
 
 
 
370C humidified atmosphere, 
5% CO2 for 1 hour 
Cultures transferred to new 24 well plate  
1.5ml of isopropyl alcohol 
 
 
 
Room temperature for 1 hour 
Cultures removed and discarded. OD of 
supernatant determined by plate reader 
 
 
Cell viability calculated as a % of PBS 
control 
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9.2.4 ELISA (Enzyme Linked Immunosorbant Assay) 
IL-1α and IL-8 production by the cultures (n=12) was assessed using commercially 
available assay kits (Duoset® ELISA Development kit, R & D Systems Europe, Ltd., 
U.K.). 
 
9.2.4.1 Flow Chart of ELISA (for reagents see Appendix 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Room Temperature, overnight 
Wash step: 3 applications of 400μl wash buffer by aspiration 
 
 
 
Room Temperature, 1 hour 
Room Temperature, 2 hours 
100μl of capture antibody applied to each well of a 96-well microplate 
 
 
 
Block step: 300μl of Block buffer per well 
 
 
 
Room Temperature, 2 hours 
Detection step: Antibody 100μl per well 
 
 
 
Wash step 
 
 
100μl of samples or standards per well 
Room Temperature, 20 minutes, foil cover 
100μl of Streptavidin-HRP per well 
 
 
 
OD measured using micro plate reader at 450nm, wavelength correction at 570nm. 
 
 
 
 
50μl Stop Solution per well, microplate tapped gently to ensure mixing 
 
 
 
Wash step 
 
 
Wash step 
 
 
Room Temperature, 20 minutes, foil cover 
100μl of Substrate solution per well 
 
 
 
Wash step 
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9.2.4.2 Calculation of cytokine release 
 
For each standard series, a standard curve was plotted (Figure 9.3). The x-axis is 
the log of the known standard concentrations with the y-axis being the log of the 
optical density (OD). Regression analysis produced a line of best fit; Microsoft 
Excel® was used for this. Straight line graphs are represented by the equation: 
 
y = mx + c 
 
M represents the gradient and c the y-axis intercept. The absorbance of the test 
sample gives the cytokine release in pg/ml by rearranging the equation thus: 
x = (y - c)/m 
 
 
Figure 9.3 – Example of a standard curve for IL-1α ELISA 
 
 
9.2.5 Statistical Analysis 
 
The results were analysed using Microsoft Excel® t-test (2 sample assuming 
unequal variances) data analysis tool and a p≤0.05 standard level of significance. 
y = 0.531x - 1.028 
R² = 0.995 
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9.3 Results 
 
9.3.1 Viability Assay 
 
MTT reduction as previously stated is a measurement of enzyme activity mostly 
within the mitochondria of the cell. In this study, all cultures remained viable after 48 
hours in growth medium. There is no dose dependent response between the 2 
concentrations of StN21. There was a statistically significant difference between the 
SLS and PBS with some proliferation of the mucosa cells. Table 9.1 demonstrates 
metabolic activity of a percentage of the PBS negative control. 
 StN21  
0.88 x 10-4 
mol l-1  
StN21 
1.76 x 10-4 
mol l-1   
Statherin  
0.2 x 10-4 
mol l-1  
SLS 
0.5%vol  
PBS 
Mean % 
metabolic activity 
of PBS 
108.31 99.28 99.70 119.75 100 
P value  0.047 0.66 0.92 0.00035 N/A 
 
Table 9.1 – Results from MTT assay demonstrating statistically significant differences for cultures exposed to StN21 
(Concentration 0.88 x 10
-4
 mol l
-1
) and SLS when compared to those exposed to PBS (shaded grey). 
 
The following Null hypothesis can therefore be rejected: 
7. There is no difference in cell viability of cultures exposed to PBS compared 
to those exposed to StN21 (concentration 1.76 x 10-4 mol l-1) and statherin. 
 
The following Null hypothesis cannot be rejected: 
7. There is no difference in cell viability of cultures exposed to PBS 
compared to those exposed to StN21 (concentration 0.88 x 10-4 mol l-1) 
and SLS. 
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9.3.2 ELISA - IL-1α 
 
9.3.2.1   4 Hours exposure to reagents 
 
Oral mucosal irritation can be measured using IL-1α as a marker (Coquette et al., 
2003). After 4 hours exposure to the 2 concentrations of StN21 and statherin, the 
reconstituted oral epithelium showed no significant difference in IL-1α release in 
comparison to the PBS control. The exposure to 0.5% vol SLS had demonstrated a 
statistically significant (p < 0.001) increased release of IL-1α compared to the PBS 
control (Table 9.2) 
n=12 
StN21  
0.88 x 10-4 
mol l-1  
StN21  
1.76 x 10-4 
mol l-1  
Statherin  
0.8 x 10-4 
mol l-1  
SLS  
0.5% vol  
PBS              
Mean  
(pg ml-1) 
5.30 5.29 5.51 14.92 5.26 
SD  
(pg ml-1) 
1.72 1.18 1.31 1.39 1.37 
P value  
 
0.92 
 
0.97 
 
0.64 
 
< 0.001 N/A 
 
 Table 9.2 – ELISA IL-1α measurements after 4 hours exposure to reagents. Statistically significant results indicated 
by grey shading. Illustrated in Figure 9.4. 
 
 
9.3.2.2    24 Hours exposure to reagents 
 
After 24 hours exposure, a similar picture was seen to the 4 hour exposure. There 
was a slight increase in IL-1α production for the StN21 and statherin, but not 
statistically significant when compared with PBS. The 0.5%vol SLS exposed 
samples demonstrated a statistically significant (p < 0.001) increase in release of IL-
1α compared to the PBS control. The amount of IL-1α production had decreased 
slightly in the 0.5%vol SLS samples compared to the results for 4 hour exposure 
(Table 9.3). 
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n=12 
StN21 
 0.88 x 10-4 
mol l-1  
StN21  
1.76 x 10-4 
mol l-1  
Statherin  
0.8 x 10-4 mol 
l-1  
SLS  
0.5% vol  
PBS 
Mean  
(pg ml-1) 
6.53 6.32 6.11 13.34 6.25 
SD  
(pg ml-1) 
1.19 1.28 0.80 4.06 0.96 
P value  
 
0.45 
 
0.89 
 
0.63 
 
< 0.001 
 
N/A 
 
Table 9.3 – ELISA IL-1α measurements after 24 hours exposure to reagents. Statistically significant results 
indicated by grey shading. Illustrated in Figure 9.4.   
 
 
9.3.2.3   48 Hours exposure to reagents 
 
After 48 hours exposure, there was a slight increase in IL-1α production when 
compared to the 24 hour exposures in the StN21, statherin and PBS samples. 
There are no statistically significant differences for either of the StN21 
concentrations when compared to the PBS control. The exposure to 0.5% SLS and 
statherin protein had demonstrated a statistically significant (p < 0.05) increase and 
decrease, respectively, in release of IL-1α compared to the PBS control (Table 9.4). 
 
StN21  
0.88 x 10-4 
mol l-1  
StN21  
1.76 x 10-4 
mol l-1  
Statherin  
0.8 x 10-4 
mol l-1  
SLS  
0.5% vol 
PBS 
Mean  
(pg ml-1) 
7.40 8.73 7.18 9.08 8.02 
SD  
(pg ml-1) 
2.05 3.73 2.79 3.33 3.40 
P value  
 
0.58 
 
0.22 
 
0.046 
 
0.014 
 
N/A 
 
Table 9.4 – ELISA IL-1α measurements after 48 hours exposure to reagents. Statistically significant results 
indicated by grey shading. Illustrated in Figure 9.4  
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The following Null hypothesis can therefore be rejected: 
8.There is no difference in production of IL-1α by cultures exposed to PBS, 
compared with those exposed to SLS and statherin protein (after 48 hours). 
 
The following Null hypothesis cannot be rejected: 
8.There is no difference in production of IL-1α by cultures exposed to PBS,   
compared with those exposed to StN21 and statherin protein (after 4 and 24 hours). 
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Figure 9.4 – Summary of IL-1α ELISA as shown in Tables 9.2, 9.3 and 9.4. Error bars represent standard deviation. Statistical significance when compared with PBS of p<0.05 
is indicated by * and of p<0.001 by **. 
 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
StN21 0.88 x 10-4 
mol l-1  
StN21 1.76 x 10-4 
mol l-1  
Statherin SLS  PBS 
IL
1
α
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
 m
l-
1
) 
4h 
24h 
48h 
 * 
 **   ** 
 * 
184 
 
 
9.3.3 ELISA - IL-8 
 
9.3.3.1   4 Hours exposure to reagents 
 
IL-8 production is a marker of tissue sensitisation (Coquette et al., 2003). After 4 
hours exposure to the 2 concentrations of StN21 and statherin protein, the 
reconstituted oral epithelium showed no significant difference in IL-8 release in 
comparison to the PBS control. The exposure to 0.5% SLS had demonstrated a 
statistically significant (p < 0.05) increased release of IL-8 compared to the PBS 
control (Table 9.5) 
 
n=12 
StN21  
0.88 x 10-4 
mol l-1  
StN21  
1.76 x 10-4 
mol l-1  
Statherin  
0.8 x 10-4 
mol l-1 
SLS 
0.5%vol  
PBS 
Mean  
(pg ml-1) 
152.88 168.57 143.01 231.15 139.16 
SD (pg 
ml-1) 
29.53 50.56 33.29 91.45 31.76 
P value  
 
0.25 
 
0.10 
 
0.82 
 
0.045 
 
N/A 
 
Table 9.5 – ELISA IL-8 measurements after 4 hours exposure to reagents  Statistically significant results indicated 
by grey shading. Illustrated in Figure 9.5. 
 
 
9.3.3.2   24 Hours exposure to reagents 
 
After 24 hours exposure, all reagents had resulted in an increase in IL-8 production. 
For the 2 concentrations of StN21 and statherin, this increase was not statistically 
significant (p < 0.05) when compared with PBS. The 5% SLS however resulted in a 
statistically significant increase in IL-8 production (Table 9.6). 
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n=12 
 
StN21  
0.88 x 10-4 
mol l-1  
StN21  
1.76 x 10-4 
mol l-1  
Statherin  
0.8 x 10-4 
mol l-1 
SLS 
0.5%vol  
PBS 
Mean  
(pg ml-1) 
933.70 770.75 864.40 2066.21 805.28 
SD  
(pg ml-1) 
153.85 166.75 156.77 538.11 205.21 
P value 
0.22 
 
0.75 
 
0.57 
 
<0.001 
 
N/A 
 
Table 9.6 – ELISA IL-8 measurements after 24 hours exposure to reagents  Statistically significant results indicated 
by grey shading. Illustrated in Figure 9.5. 
 
 
9.3.3.3   48 Hours exposure to reagents 
 
After 48 hours exposure, StN21, Statherin and PBS all resulted in a small rise in IL-
8 production. IL-8 production by the mucosa exposed to SLS was reduced 
compared to the 24 hour sample. None of the treatments demonstrated a 
statistically significant difference when compared to the PBS control (Table 9.7). 
 
n=12 
StN21  
0.88 x 10-4 
mol l-1  
StN21  
1.76 x 10-4 
mol l-1  
Statherin  
0.8 x 10-4 
mol l-1  
SLS 
0.5%vol  
PBS 
Mean  
(pg ml-1) 
1104.93 1072.32 1185.26 1028.96 1119.32 
SD  
(pg ml-1) 
418.72 369.24 265.06 389.59 346.11 
P value  
 
0.89 
 
0.62 
 
0.30 
 
0.39 
 
N/A 
 
Table 9.7 – ELISA IL-8 measurements after 48 hours exposure to reagents  There were no statistically significant 
results. Illustrated in Figure 9.5. 
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The following Null hypothesis can therefore be rejected: 
9.There is no difference in production of IL-8 by cultures exposed to PBS, compared 
with those exposed to SLS (after 4 and 24 hours). 
 
The following Null hypothesis cannot be rejected: 
9.There is no difference in production of IL-8 by cultures exposed to PBS,   
compared with those exposed to StN21, statherin protein and SLS (after 48 hours). 
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Figure 9.5 - Summary of IL-8 ELISA as shown in Tables 9.5, 9.6 and 9.7. Error bars indicate standard deviation. Statistical significance when compared with PBS of p<0.05 is indicated by * and 
of p<0.001 by **.  
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9.4 Exposure of 0.5%vol SLS to the oral mucosal model for 
up to 48 hours 
 
 
9.4.1 Introduction 
 
The above experiments were based on an established protocol (Lundqvist et al., 
2002; Hagi-Pavli et al., 2004). As SLS is such a potent irritator of the buccal 
mucosa, it is only applied for 5 minutes, then pipetted off and replaced with PBS for 
the remaining time. The StN21 and statherin were applied for the full 48 hours 
duration of the experiment, as these proteins absorb onto the tooth surface so 
would be present in the oral cavity for longer periods of time than SLS which is none 
adherent. It was also thought that any differences in cytokine production would be 
small, so longer exposure would be required to produce any effects. The results of 
sections 9.3.1, 9.3.2 and 9.3.3 indicate that there is very little effect on the oral 
mucosa after 48 hours exposure to StN21 or statherin. For completeness and as it 
has never previously been examined in this system, the effect of a longer exposure 
to 5% vol SLS was measured. 
 
The aim of this experiment was to measure the production of IL-1α and IL-8 when 
the samples were exposed to 4, 24 and 48 hours of 0.5% SLS compared with the 
results from the previous experiments (sections 9.3.2 and 9.3.3) using a 5 minute 
application of 0.5% SLS at 4, 24 and 48 hours and PBS. 
 
 
  
189 
 
 
9.4.2 Materials and Methods 
 
The buccal mucosal cultures were set up as per the previous experiment except 
0.5% SLS was applied to the cell surface of the culture and left for the full 48 hours 
of the experiment (n=4). In previous experiments, 0.5% SLS was applied to the 
cultures for 5 minutes, pipetted off and replaced with PBS as this is a standard 
protocol The cultures were incubated at 370C in a humidified atmosphere containing 
5% CO2 for 48 hours with media collection at 4, 24 and 48 hours. 
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9.4.3 Results 
 
9.4.3.1 IL-1α ELISA 
 
After 4 hours exposure to 0.5% vol SLS, there was a sevenfold increase in the 
amount of IL-1α produced when compared to the 5 minute exposure time. A 
threefold increase was seen at 24 hours over the 5 minute exposure. By 48 hours, 
IL-1α production was similar in both exposure times to SLS (see Tables 9.8, 9.9 and 
9.10 and Figure 9.6). 
 
 PBS 
5 minutes exposure 
0.5%vol SLS 
4 hours exposure 
0.5%vol SLS 
Mean (pg ml-1) 5.26 14.92 104.17 
SD (pg ml-1) 1.37 1.39 25.97 
Sample size (n) 12 12 4 
Table 9.8 – Comparison of IL-1α production following PBS exposure, 5 minute SLS exposure and full 4 hour SLS 
exposure. 
 
 
 PBS 
5 minutes exposure 
0.5%vol SLS 
24 hours exposure 
0.5%vol SLS 
Mean (pg ml-1) 6.25 13.34 49.30 
SD (pg ml-1) 4.06 0.96 10.08 
Sample size (n) 12 12 4 
Table 9.9 – Comparison of IL-1α production following PBS exposure, 5 minute SLS exposure and full 24 hour SLS 
exposure. 
 
 
 PBS 
5 minutes exposure 
0.5%vol SLS 
48 hours exposure 
0.5%vol SLS 
Mean (pg ml-1) 8.02 9.08 8.90 
SD (pg ml-1) 3.40 3.33 4.03 
Sample size (n) 12 12 4 
Table 9.10 – Comparison of IL-1α production following PBS exposure, 5 minute SLS exposure and full 48 hour SLS 
exposure. 
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Figure 9.6 - Comparison of IL-1α production - PBS, 5 minute exposure of 0.5%vol SLS and full duration exposure of 
0.5%vol SLS at 4, 24 and 48 hours. The error bars indicate standard deviation. 
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9.4.3.2  IL-8 ELISA 
 
After 4 hours exposure to 0.5%vol SLS, there was a substantial decrease in the 
amount of IL-8 produced when compared to the 5 minute exposure time. This 
marked decrease was also seen at 24 and 48 hours (See Tables 9.11, 9.12 and 
9.13 and Figure 9.7). 
 
 PBS 
5 minutes exposure 
0.5%vol SLS 
4 hours exposure 
0.5%vol SLS 
Mean (pg ml-1) 139.16 231.15 12.02 
SD (pg ml-1) 31.76 91.45 3.35 
Sample size (n) 12 12 4 
Table 9.11 – Comparison of IL-8 production following PBS exposure, 5 minute SLS exposure and full 4 hour SLS 
exposure. 
 
 
 
 
PBS 
5 minutes exposure 
0.5%vol SLS 
24 hours exposure 
0.5%vol SLS 
Mean (pg ml-1) 805.28 2066.21 6.02 
SD (pg ml-1) 205.21 538.11 1.11 
Sample size (n) 12 12 4 
Table 9.12 – Comparison of IL-8 production following PBS exposure, 5 minute SLS exposure and full 24 hour SLS 
exposure. 
 
 
 PBS 
5 minutes exposure 
0.5%vol SLS 
48 hours exposure 
0.5%vol SLS 
Mean (pg ml-1) 1119.32 1028.96 3.81 
SD (pg ml-1) 346.11 389.59 0.46 
Sample size (n) 12 12 4 
Table 9.13 – Comparison of IL-1α production following PBS exposure, 5 minute SLS exposure and full 48 hour SLS 
exposure. 
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Figure 9.7 - Comparison of IL-8 production - PBS, 5 minute exposure of 0.5%vol SLS and full duration exposure of 
0.5%vol SLS at 4, 24 and 48 hours. Error bars indicate standard deviation. 
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9.5 Discussion 
 
Using the MTT assay, cultures exposed to StN21 and statherin demonstrated no 
decrease in viability when compared with PBS. There was a statistically significant 
increase in the cultures exposed to SLS. This may represent an abnormal 
proliferation as a protective mechanism against the irritant effect of SLS. 
Hyperplasia of oral mucosa exposed to SLS has previously been demonstrated in 
hamster cheek oral mucosa in vitro (Baert et al., 1996), although fortunately this 
would seem to be benign in nature. StN21 (concentration 0.88 x 10-4 mol l-1) also 
demonstrated a statistically significant cell proliferation, although this was less than 
that seen by the SLS exposed samples and was not dose dependant as STN21 
1.76 x 10-4 mol l-1 did not produce a proliferation effect. It would therefore be 
important to study further concentrations of StN21 to see if proliferation occurs. All 
the cell cultures remained viable at 48 hours. The MTT method is a crude 
determinant of toxicity to the cell cultures which only measures cell proliferation or 
death and more sensitive measurements are required (Coquette et al., 2003). 
Measurement of IL-1α and IL-8 using ELISA was undertaken. 
 
IL-1α is a pro-inflammatory cytokine involved in immune defence against infections 
such as candida (Wiley et al., 2012) and inflammatory conditions such as oral lichen 
planus (Lu et al., 2013). In this study, SLS acts as a positive control, contact irritant 
stimulating the production of both IL-1 α compared with PBS which acts as a 
negative control (Wiley et al., 2012). Even when the oral mucosal model is exposed 
to StN21 for 48 hours, the reaction is not statistically significant when compared with 
the PBS, however SLS does show a statistically significant result as seen in 
previous work (Lundqvist et al., 2002; Hagi-Pavli et al., 2004). SLS is a common 
detergent which is added toothpastes to enhance foaming usually at a concentration 
of 1.5%. In this experiment, 0.5% is used as this concentration takes into account 
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dilution in saliva. When comparing the StN21 to the SLS particularly where the SLS 
is applied for a full 48 hours (section 9.4.3.1), StN21 would appear to be inert and 
can thus be considered a non-irritant in this mucosal system. 
 
IL-8 is a major mediator of the inflammatory response producing a well-established 
response when the oral mucosa is sensitised (Garner, 2004). In this study, SLS 
stimulates the production of IL-8 compared with PBS when applied for 5 minutes 
during the first 4 hours and between 4 and 24 hours. In previous studies, SLS and 
PBS exposed cultures produced similar amounts of IL-8 up to 24 hours (Lundqvist 
et al., 2002). These studies, however unlike the ones undertaken in this thesis, did 
not use growth medium. When SLS was applied for 4, 24 or 48 hours (rather than a 
5 minute application), IL-8 production is almost completely stopped in this mucosal 
model; this phenomena has not previously been reported. SLS applied for 4 or more 
hours would therefore seem to have an effect on the ability of the oral mucosa to 
mount a full immunological response. By contrast, when StN21 is applied to the oral 
mucosal model, the production of IL-8 mirrors that seen in the PBS and statherin 
exposed samples, demonstrating StN21’s lack of toxicity to the oral mucosa. 
 
It has been suggested that the MTT assay in association with IL-1α and IL-8 ELISAs 
are the minimum experimental assays to determine cytotoxicity of a new material 
(Coquette et al., 2003). Other cytokines which have been studied in these models 
include IL-1β, IL-6 and TNF-α (Moharamzadeh et al., 2009; Sheikh et al., 2011; 
Whiley et al., 2012) and consideration should be given to whether adding further 
cytokine assays are necessary. Previously fibroblast monolayer systems have been 
considered the “Gold Standard” for in vitro toxicity testing. The 3D oral mucosal 
system is however a potentially more clinically relevant model for studying 
cytotoxicity of new materials due it’s structural similarity to human buccal mucosa 
(Moharamzadeh et al., 2009). Comparison of these results with those seen in a 
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fibroblast monolayer system could be useful to prove the lack of cytotoxicity of 
StN21. In conclusion, the results presented indicate that StN21 is not toxic to the 
oral mucosa when compared with SLS, but further studies may be required. 
  
197 
 
 
 
 
 
Part IV: 
Discussion 
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Chapter 10 - General Discussion and Conclusions 
 
10.1 General Overview 
 
X-ray Microtomography (XMT) has previously been used in studies of enamel and 
dentine mineralisation (Elliott et al. 1994; Dowker et al. 2003; Ahmed et al., 2012).  
It has the advantage of visualising carious lesions in three dimensions rather than in 
two dimensions like transverse microradiography and SMR. It also has the 
advantage of being non-destructive which enables accurate measurement of 
mineral content within dynamic caries/erosive lesions over a period of time. Along 
with the ability to scan samples at resolutions of 5µm, a beam hardening correction 
and the use of IDL programming to align and subtract the XMT scans increases 
quantification accuracy (Davis et al., 2013). These software manipulations are 
unique to XMT; other commercial micro CT systems do not have these 
modifications. It is therefore an ideal method to study the effect of salivary proteins 
such as Statherin and StN21 on de- and remineralisation of enamel. 
 
The first part of this thesis describes in vitro studies into the effect of StN21 on 
caries-like and erosive demineralisation and remineralisation of enamel using XMT. 
Previous studies have used scanning microradiography to quantify mineral changes 
in HAp as a model system for enamel (Kosoric et al., 2007). StN21 was shown to 
reduce demineralisation rates by 40% using acetic acid (pH4). Enamel has been 
shown to be highly variable in chemical composition not only between different 
types of teeth, but also between different tooth surfaces. In order to reduce these 
differences, only intact premolar (caries-like demineralisation) and molar 
(remineralisation and erosion-like demineralisation) teeth, extracted as part of an 
orthodontic treatment plan from young patients, were used. The patients all came 
from the same area which had a non-fluoridated water supply. Only buccal and 
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palatal samples were cut (with similar enamel thickness); control and test samples 
were paired either from the same tooth or same patient. The ability to quantify 
mineral content both pre and post acidic exposure also reduces the effect of enamel 
variability. 
 
Individuals with high levels of salivary Statherin have been shown to have reduced 
caries rates (Vitorino et al., 2004). It was therefore decided to study concentrations 
of StN21 within the normal salivary Statherin levels quoted in the literature (Hay et 
al., 1984). The range investigated was 0.06 - 0.88 x 10-4 mol l-1 and no statistically 
significant difference in total mineral loss was demonstrated between the different 
concentrations. An unusual phenomenon was, however, seen in five of the six 
samples exposed to high concentrations of StN21 (0.88 x 10-4 mol l-1) whereby the 
advancing front of the caries-like lesion was undulating and non-uniform. There are 
no other examples of this in the literature. It demonstrates the importance of 
studying caries-like lesions in 3D as well as 2D. A traditional microradiography 
technique such as TMR (Arends and Ten Bosch, 1992) would demonstrate the 2D 
pattern seen in these samples, but due to the destructive nature of the technique, 
the extent of non-uniformity could not be verified in the same way as using a 3D 
technique such as XMT. 
 
 Previous studies using HAp disks as a control substrate for enamel and a similar 
reduction in StN21 concentration also demonstrated statistically significant 
differences in mineral loss rates (Kosoric et al., 2007). Interestingly, these 
experiments used a 24 hour period of StN21 exposure as opposed to just five 
minutes used in the experiments in this thesis. It is known that pellicle salivary 
proteins bind rapidly, within minutes, to dental enamel (Wetton et al., 2006; Santos 
et al., 2008) so it would seem logical that a 24 hour exposure period would not 
necessarily confer any extra demineralisation resistance when compared to shorter 
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exposure times. When considering a clinical application for StN21 preparations, a 
short exposure time would be beneficial to ensure patient compliance in using the 
preparations. It would therefore seem that a five minute exposure time mimic the 
clinical situation more accurately and was used in these experiments. By using a 5 
minute exposure time to StN21, there was little difference in demineralisation rates 
when compared to the 24 hour exposure time (Kosoric et al., 2007). 
 
For caries-like lesions, StN21 has been shown to be comparable to the full Statherin 
protein (StN43) decreasing both lesion depth and total mineral loss at high 
concentrations (~0.8 x 10-4 mol l-1) when compared with the control lesions. The 
Statherin N-terminus would therefore seem to be the “active” portion of the protein 
in reducing the demineralisation process. The N terminus residues D1- Y16 mediate 
the adsorption of Statherin to enamel in an α helical conformation (Schlesinger and 
Hay, 1977; Ramasubbu et al., 1993). This portion of the protein binds strongly to 
HAp and is immobilised as opposed to the intermediate region (residues G19-Q35) 
and C terminus residues (P36-F43) which are mobile and only interact weakly with 
the HAp surface (Goobes et al., 2006). The hypothesis is that StN21 adheres and 
coats the surface acting as a barrier to permeation of acids. The function of the C 
terminus is understood to be related to lubrication and to the binding of bacterial 
fimbriae of Gram negative species such as Actinomyces viscosus and 
Fusobacterium nucleatum (Sekine et al., 2004). These bacteria are more commonly 
associated with periodontal diseases rather than dental caries, but reduction of 
Statherin bacterial binding sites may occur when StN21 is introduced to the oral 
environment. The effect of this disturbance of the bacterial biofilm is not known and 
would need to be investigated. 
 
Fluoride exposed caries-like lesions were compared to those exposed to StN21. 
The former lesions were similar in depth to the latter lesions, but were visually more 
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radio opaque within the body of lesion. The rate of mineral loss was slightly less in 
the fluoride exposed lesions although this was not statistically significant. Exposure 
to fluoride therefore resulted in reprecipitation of a variety of fluoride substituted 
calcium phosphate crystals within the lesion (Robinson et al.,2000). StN21 does not 
have the same action as fluoride. It has no effect on remineralisation as shown in 
Chapter 6. As StN21 lacks the ability to enhance remineralisation, its utility within an 
oral hygiene product might be questionable. An important point, however, is that 
remineralisation in the presence of calcium, phosphate and fluoride is not inhibited 
at low concentrations. Further experiments are required using higher concentrations 
of fluoride to determine if StN21 and fluoride demonstrate any competitive inhibition 
and whether this is dose dependant. If these products produce a synergistic effect, 
an StN21-containing product would be hypothesised to reduce demineralisation 
rates while the addition of fluoride would enhance remineralisation. 
 
Previous studies demonstrate that Statherin is a potent inhibitor of both primary and 
secondary precipitation maintaining the supersaturation of saliva with respect to 
calcium and phosphate and acting as an ion reservoir releasing ions when the pH 
drops (Moreno et al., 1979; Hay et al., 1984). Previous work has demonstrated that 
secondary precipitation is inhibited at very low concentrations of Statherin (~1µM) 
and even lower concentrations of truncated N-terminus Statherin peptides (~0.4µM) 
(Schwartz et al., 1992). For primary precipitation, the opposite has been shown 
where N-terminus peptides need to be present in higher concentrations for complete 
inhibition to occur (approx 10µM) compared whole Statherin protein (~1µM) 
(Schwartz et al., 1992). In addition, the peptide concentration/precipitation inhibition 
relationship is not linear and has a sigmoidal function. In the remineralisation 
system used in these experiments, a high StN21 concentration (0.88 x 10-4 mol l-1) 
was used, but precipitation occurred at the same rate as the samples that were 
exposed to PBS. From these experiments, it is impossible to know how much StN21 
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had adsorbed to the enamel during the 5 minute exposure; further dilution is likely 
due to placement of the samples in a large volume of remineralising solution which 
was refreshed on a daily basis. StN21 protein remaining in solution could have been 
measured (Pearce and Bibby, 1966); this is discussed in section 11.1. It would be 
understandable that StN21 did not inhibit all precipitation in this system. It is 
hypothesised that primary precipitation has occurred and calcium phosphate salts, 
possibly amorphous in structure, deposited on the enamel surface. The appearance 
on the line probes in Figure 5.4 and the reduction in mean lesion depth would 
support this. Further work is required into remineralisation which would include 
examination of enamel surface using X-ray microdiffraction, SEM and energy-
dispersive X-ray spectroscopy (Elliott, 1997; Cheng et al, 2010). 
 
Erosive type demineralisation was also decreased in the presence of StN21 when 
compared to control lesions. Erosive type lesions progress as a layer by layer 
dissolution whereby the enamel pellicle acts as a protective barrier (Siqueira et al., 
2007). It is hypothesised that StN21 acts as a barrier in a similar manner as enamel 
pellicle. If this is the case, StN21 would need to be renewed regularly to replace the 
peptide layer which is lost following the dissolution of the enamel surface layer. 
Pellicle is a complex mesh-work of saliva-derived proteins and enzymes (Siqueira et 
al., 2012). A recent study has shown that in situ casein and colostrum proteins 
effectively reduce progression of erosive type lesions in the presence of saliva-
derived dental pellicle (Jager et al., 2013). It therefore would be interesting to 
examine the effect of StN21 on erosion in the presence of other proteins like aPRPs 
and Histatins which are found in pellicle and also casein phosphopeptides which 
have been shown to reduce demineralisation (Reynolds, 1987; Reynolds 1997; 
Cross et al., 2007).  
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The second part of the experimental section concentrates on proof of concept data 
for a future StN21 in situ study using XMT to quantify mineral change. XMT has 
previously been used in vitro to measure demineralisation and remineralisation of 
enamel (Gao et al., 1993; Elliott et al. 1994; Dowker et al. 2003). The accuracy of 
the XMT system is constantly being improved; the most recent innovations include 
automatic calibration following every scan and post reconstruction programming in 
IDL to accurately align and subtract subsequent scans of the same lesion (Davis et 
al., 2013). In situ studies have previously used surface microhardness, profilometry, 
transverse microradiography and SEM to quantify mineral change (Yassen et al., 
2011). This is the first in situ study undertaken using the MuCAT XMT system, 
however a similar pilot study using synchrotron-based X-ray microtomography 
system has recently been published which highlights the advantages of the former 
(Lautensack et al., 2013). The Lautensack study is semi-quantitative as data 
mineral concentration data was produced post image reconstruction rather than part 
of the reconstruction algorithm (Davis et al., 2013). Furthermore their images 
contained ring artefacts distorting the image quality. The XMT system has greater 
potential for measuring de/remineralisation in situ due to the stringent internal 
calibration and lack of ring artefacts. 
 
As StN21 is a peptide based on the N-terminus of native Statherin protein, no 
toxicity issues would be expected. Buccal mucosa cell models demonstrated no 
toxic reactions when exposed to high StN21 concentrations; SLS by contrast is 
highly irritant and caused cell death at levels found in toothpastes (Chapter 9). 
These models do however have limitations in that it is not known how they compare 
to normal oral mucosa (Moharamzadeh et al., 2007). In a recently reported clinical 
safety trial, a bio mimetic self-assembling peptide was applied topically to white spot 
caries lesions in 15 volunteers in accordance with GCP (Brunton et al., 2013). The 
participants were then asked to report any adverse events which occurred up to 180 
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days post application, even if they felt they were unrelated to the treatment. A 
similar a clinical safety trial will be required to ensure that there are no adverse 
effects when StN21 is used in human participants.  
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10.2 Clinical Implications 
 
Recent caries research and clinical focus has been centred on the main principle of 
minimally invasive dentistry which is “a systematic respect for the original tissue” 
(Ericson 2004). Caries and erosion are dynamic and once demineralisation has 
started, it does not necessarily continue unchecked. An evidence based approach 
to diagnosis, risk assessment, prevention, remineralisation and conservative 
restorative techniques are combined to ensure that changes to the oral environment 
are balanced towards repair and maintenance of enamel integrity (Mount and 
Hume, 1997; Ricketts and Pitts, 2009; Ricketts et al., 2013). StN21 could be an 
important addition to the minimally invasive, biological approach armamentarium. 
The results of these studies will be discussed below as to how StN21 might be used 
in conjunction with other available products. 
 
It is hypothesised that StN21 acts in a similar manner to the enamel pellicle as a 
protective barrier. It does not enhance remineralisation, but at low concentrations 
does not inhibit primary precipitation, possibly resulting in the formation of a calcium 
phosphate layer on the outer layer. The main mode of action is thus protecting and 
strengthening the surface layers of both carious and erosive lesions from further 
demineralisation. These experiments have been based on a daily renewal of StN21 
to reduce carious or erosive demineralisation. Consideration should therefore be 
given to the idea of a morning or day toothpaste or mouthwash containing StN21 
and fluoride to protect the teeth from acidic foods and beverages. The salivary 
proteome is dynamic, adapting throughout the day and night. Parotid saliva 
Statherin levels are peaks at 9am and then decreases during the day; this is in 
contrast to Histatin levels which increase throughout the day (Hardt et al. 2005; 
Helmerhorst and Oppenheim 2007). A morning application of StN21/fluoride paste 
would mimic this natural diurnal pattern and a complementary evening toothpaste 
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containing fluoride, CPP-ACP or other agents which enhance remineralisation 
would be necessary.   
 
Separate toothpastes for morning and evening might have issues with regards to 
patient compliance. One of the aims of minimally invasive dentistry is to educate 
and empower patients to take care of their oral health and careful, consistent, 
directed advice would improve patient compliance. To improve uptake of StN21, 
however, it may be possible to add the peptide along with calcium and phosphate to 
food and beverages such as chewing gum (Shen et al., 2001; Manton et al., 2008; 
Cochrane et al., 2012b) or soft drinks (Hughes et al., 2002; West et al., 2004; 
Hooper et al., 2007). StN21 would then available at the time of acidic exposure and 
negate their harmful effects.  
 
The most important area where StN21 could be important is in saliva substitutes for 
those who suffer from hyposalivation and/or an alteration in saliva composition. 
Xerostomia is an increasingly common problem with up to 64.9% of the population 
suffering from it to some degree (Orellana et al., 2006). It is not only present in the 
older population, but in those with Sjögern’s Syndrome, diabetes mellitus, as a 
complication of head and neck radiotherapy, who smoke and who take one of the 
many common medications which cause hyposalivation (Sreebny and Schwartz, 
1997). A sharp rise has also been seen in 20 to 40 year olds who take 
antidepressants or indulge in recreational drugs; whether the associated xerostomia 
is temporary or the damage is long term remains to be seen. The reduction in 
salivary protein levels in xerostomic patients results in a loss of protective effect. 
Addition of StN21 to saliva substitutes would not only reduce demineralisation, but 
may also aid lubrication of the oral mucosa reducing friction from food stuffs. 
Salivary enzymes such as lysozyme, lactoferrin and lactoperoxidase have been 
added to a range of products developed for dry mouth (Biotène®) (Kirstilä et al., 
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1996; Tenovuo 2002). Biotène® mouthwash however has a pH of 5.5 and has been 
shown to cause mineral loss in both sound and demineralised enamel (Kielbassa et 
al., 2001; Tantbirojn et al., 2008). Biotène® gel is also acidic (pH5.4). Increasing 
acid concentration stimulates increased volume of saliva (Guinard et al., 1997; 
Jensdottir et al., 2005), but these products cannot be recommended to dentate 
xerostomic patients. StN21 solution was pH neutral and would overcome these 
issues. StN21 could be used as ingredient in a range of complementary products for 
those with xerostomia (mouthwash, saliva substitute, toothpaste), particularly where 
the salivary protein levels are also reduced. 
 
 
10.3 Conclusions 
 
1. With the appropriate software, the non-destructive advantage of XMT was 
shown to be able to measure and quantify mineral change in enamel and 
HAp over serial scans both in in vitro and in situ experiments 
2. StN21 was shown in vitro to reduce rates of caries - like demineralisation by 
40% and erosion by 30% when compared with control samples 
3. StN21 has no statistically significant effect on remineralisation in vitro 
4. StN21 does not have a toxic effect on oral mucosa cell culture 
5. StN21 has the potential to be used as a therapeutic agent in the prevention 
of dental caries and erosion 
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Chapter 11 - Future Work 
 
11.1 Adsorption and attachment of StN21 
 
One of the interesting findings of the in vitro StN21 experiments was the 
pattern demineralisation seen particularly in the higher peptide 
concentrations. It was hypothesised that the areas where little 
demineralisation had occurred were areas where StN21 peptide had 
clumped together. In order to detect the pattern of enamel surface peptide 
adsorption, immunohistochemistry using monoclonal primary antibodies to 
the C terminus of StN21 could be undertaken, as the N terminus is known to 
be responsible for adsorption to HAp (Goobes et al., 2006). The areas of 
peptide adsorption could then be mapped and compared to areas of 
demineralisation. 
 
The amount of peptide attached to the enamel could also be assayed 
indirectly by measuring the amount of peptide remaining after immersing an 
enamel surface in a solution containing a known amount of StN21 using 
ELISA. This technique could also be used to measure desorption of StN21 
after exposure to NaOCl solution which is known to remove pellicle (Lussi et 
al., 2012). As Statherin is a major pellicle constituent, StN21 is postulated to 
also bind tenaciously to the enamel surface. Another pellicle formation 
phenomenon is that it forms on a cleaned enamel surface within 30 seconds 
of salivary exposure (Wetton et al., 2006). Another experiment would be to 
examine how quickly StN21 is adsorbed to the surface and at what 
concentration saturation is reached. 
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11.2 Interactions with other salivary proteins 
 
Saliva contains numerous proteins with overlapping functions (Hay and 
Bowen, 1996). Of particular interest are the proteins that along with Statherin 
form part of the enamel pellicle especially Histatin-1 and PRP-3 and their 
interactions (Vitorino et al., 2007). There is an inverse relationship between 
the levels of these proteins in saliva and the individual’s caries risk (Vitorino 
et al., 2005). Further in vitro experiments are required to investigate the 
optimal protein combination to prevent demineralisation. Their effect on 
remineralisation also needs investigating; PRPs bind calcium ions so have 
the potential to enhance remineralisation (Van Nieuw Amerongen et al., 
2004). By combining StN21 and PRPs may have greater potential as anti-
caries or erosion agents than single proteins. 
 
 
11.3 pH cycling experiments 
 
In the clinical situation, the oral cavity is a dynamic system. Stimulated saliva 
production rates are increased three-fold in comparison to resting rates 
(Sreebny, 2000). Saliva is stimulated by the mechanical action of chewing 
and by acidic chemical stimuli (Guinard et al., 1997; Pederson et al., 2002). 
Demineralising acid solutions are therefore neutralised by the bicarbonate 
buffering system and remineralisation is promoted by the influx of salivary 
calcium and phosphate ions (Larsen et al., 1999; Nieuw Amerongen and 
Veerman 2002). pH cycling experiments provide an in vitro method of 
mimicking the dynamic caries process of mineral loss and gain. The best 
known pH cycling system is the Featherstone laboratory model which has 
been used extensively in fluoride research for over 20 years (Featherstone 
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et al., 1989; Arends and ten Bosch 1992). Data from this model has been 
sent to the FDA for validation against their “Gold Standard” rat caries model 
(Stookey et al., 2011).  
 
The Featherstone model could be adapted to test the efficacy StN21 
(Buzaluf et al., 2010). In the original validated model, specimens were 
treated with a fluoride toothpaste slurry (serial standard concentrations 0, 
100, 250, 500 and 1000ppm), exposed to demineralising solution (0.075M 
acetic acid, pH4.4) for 6 hours, followed by a further fluoride application and 
then placed for 16 hours in calcium/phosphate remineralising solution (pH7). 
This cycle was repeated for 14 days and mineral volume change analysed 
using Knoop microhardness (Stookey et al., 2011). The model could be 
adapted by substituting the fluoride toothpaste with StN21 and measuring 
the de- and remineralising effect using XMT. StN21 could also be tested in 
conjunction with known remineralising products such as fluoride and CPP-
ACP. This model could be adjusted to examine the duo morning/evening 
paste hypothesis discussed in Section 10.2 using StN21 as a pre 
demineralisation treatment only and comparing the results with a twice daily 
StN21 treatment. These experiments allow a high level of scientific control in 
simulating the dynamic caries process. pH cycling models however will 
never fully imitate the complex oral environment with its highly variable tooth 
surfaces, bacterial biofilms and the host defences found in saliva.  
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11.4 StN21 in situ 
 
The major aim of this work was to provide background evidence for an 
application to the MHRA for to register StN21 as a medical device and then 
undertake an in situ study into its effects intra orally. Due its effect on 
demineralisation coupled with lack of effect on remineralisation, StN21 is 
thought to act as a barrier rather than as a pharmacological agent and 
therefore would be classed as a medical device. Artificial saliva, 
desensitising agents and fissure sealants are classed as medical devices 
whereas fluoride preparations such as toothpastes, gels and varnishes 
which enhance remineralisation are classed as medicines. 
 
The eventual aim is to incorporate StN21 into an oral health care product. 
Whether this is a product for professional or patient application is dependent 
on the duration of StN21 attachment to the enamel surface. Statherin 
adsorbs quickly and is only removed by polishing with prophy paste or with 
oxidising agents such as sodium hypochlorite in vitro (Lussi et al., 2012). 
Intra orally, Statherin may be removed more easily hence the constant 
replenishing via the parotid saliva. In vitro demineralisation studies 
demonstrated that twice daily applications were more efficacious (see 
Chapter 4).  
 
StN21 has been shown to not sensitise or irritate buccal mucosa cells in a 
3D tissue model (Chapter 8). It has also been shown to have no effect on 
cell viability compared unlike SLS. It can be concluded that StN21 is safe to 
use in situ, but these models have limitations. As part of an in situ trial, 
clinical safety would need to be closely monitored (Brunton et al. 2013). All 
adverse effects would need to be reported and be judged as to whether they 
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are related to the trial protocol and whether they are mild or serious. Any 
serious adverse StN21-related reactions would result in suspension of the in 
situ trial. 
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Reagents for ELISA  
6 
ELISA reagents 
(Chapter 9) 
 
 
 IL-1α IL-8 
Capture Antibody 2.0μg/ml mouse anti-
human IL-1α antibody in 
PBS 
4.0μg/ml mouse anti-
human IL-8 antibody in 
PBS 
Detection Antibody 12.5ng/ml biotinylated 
goat anti-human IL-1α 
antibody in Reagent 
Diluent 
20ng/ml biotinylated goat 
anti-human IL-8 antibody 
in Reagent Diluent 
Standards 500pg/ml recombinant 
human IL-1α in Reagent 
Diluent 
2000pg/ml recombinant 
human IL-8 in Reagent 
Diluent 
 
 
Streptavidin-HRP   Streptavidin conjugated horseradish-peroxidase  
 
PBS 137mM NaCl, 2.7mM KCl, 8.1mM Na2HPO4, 1.5mM 
KH2PO4, pH 7.2-7.4 
 
Wash Buffer  0.05% Tween® 20 in PBS, pH 7.2-7.4 
 
Reagent Diluent 1% Bovine serum albumin in PBS, pH 7.2-7.4 
 
Substrate Solution 1:1 mixture of Colour Reagent A (H2O2) and Colour 
Reagent B (Tetramethylbenzidine) 
 
Stop Solution  2N H2SO4 
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Ethical Approval Documents (Hydroxyapatite) 
 
 
 
 
 
 
 
 
 
NHS Research Ethics Committee
APPLICATION FORM
This form should be completed by the Chief Investigator, after reading the Guidance Notes.
See Glossary for clarification of different terms in the application form.
Short Title and version number: (maximum 70 characters − this will be inserted as header on all forms)
An in situ study of de/remineralisation of hydroxyapaptite slabs
Name of NHS Research Ethics Committee to which application for ethical review is being made:
East London and the City Research Ethics Committee 3
Project Reference number from above REC:  05/Q0605/147
Submission Date:  08/08/2005
 PART A: Introduction
A1. Title of Research
Full title: A preliminary in situ study of demineralisation and remineralisation of hydroxyapaptite slabs
Key words: hydroxyapaptite, demineralisation, remineralisation, in situ
A2. Chief Investigator
Title: Miss
Forename/Initials:  Janet A
Surname: Davies
Post: PhD Student
Qualifications: BSc (Hons), BDS
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street
London
Post Code: E1 2AD
E−mail: janet.a.davies@qmul.ac.uk/janetdavies30@hotmail.com
Telephone: 020 7377 7058
Fax: 020 7377 7419
A copy of a current CV, (maximum 2 pages of A4) for the Chief Investigator must be submitted with application
A3. Proposed Study Dates and Duration
Start Date: 01/06/2005
End Date: 10/01/2010
Duration: Months:  53 ;    Years:  
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A4. Primary purpose of the research: (Tick as appropriate)
Commercial product development and/or licensing
Publicly funded trial or scientific investigation
Educational qualification
Establishing a database/data storage facility
Other
A5. Tick the box if your research:
Involves testing a medicinal product
Involves investigating a medical device
Involves additional radiation above that required for clinical care
Involves using stored samples of human biological material (e.g. blood, tissue)
Involves taking new samples of human biological material
Involves only patient records or data, with no other direct patient contact
Involves prisoners or others in custodial care
Involves adults unable to consent for themselves through physical or mental incapacity
Has the primary aim of being educational (e.g. a student project, or a project or research necessary for a
postgraduate degree or diploma)
A6. Do you consider that this research falls within the category where there is no need to appoint a Principal
Investigator at each site?
 Yes  No
If Yes, please justify:
Advice can be found in the Guidance Notes on this topic. Some studies do not require further consideration of site−specific
issues by local research ethics committees, but will still require approval to proceed from the host organisation(s).
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 PART A: Section 1
A7. What is the principal research question/objective? (Must be in language comprehensible to a lay person.)
The principal aim of the study is to develop a new device to be worn in the mouth for evaluating various materials for
prevention and/or repair of decay in teeth. The participant will wear a device in the mouth which contains a secured slab of
hydroxyapaptite (similar in chemical structure to human enamel). This device will be removable and similar in appearance to
a removable orthodontic appliance (brace). The hydroxyapatite slabs will be analysed non−destructively outside the mouth
using X−ray microtomography (XMT). This is like a miniaturised high resolution CT Scan which was largely developed in our
Centre at Queen Mary. The XMT allows us to investigate the decayed lesion in 3 dimensions. As the method is
non−destructive, repeated scans can be taken to study the initiation, progression and healing of dental caries. The ultimate
objective is to develop novel, low cost methods to not only help prevent dental decay from starting, but also repair early
carious lesions when they occur.
A8. What are the secondary research questions/objectives? (If applicable, must be in language comprehensible to a lay
person.)
Scanning microradiography (SMR) will be also be used and the results compared to see which would be more applicable to
a clinical trial.
A9. What is the scientific justification for the research? What is the background? Why is this an area of
importance?(Must be in language comprehensible to a lay person.)
Dental decay is an almost ubiquitous disease; it still causes pain and misery to those effected and its' treatment puts a great
burden (approx. £1100M) on already limited NHS resources. It is also preventable. The introduction of fluoridated toothpaste
has greatly decreased its incidence. Fluoridation of the water supply would decrease disease levels further especially in
areas of social deprivation. This happens in about 10% of the UK population, and there is little evidence of greater coverage
occurring in the near future.
The use of intra oral devices to study the progression of dental caries is not new; they were initially used to study the effects
of fluoride on enamel in the early 70s. Since then, however, they have been refined and improved. Intra oral caries devices
take two forms: removable or fixed. Removable appliances can be either orthodontic (brace) or partial dentures. Fixed
appliances are either metal bands or gold crowns which are cemented to a tooth. Each system has its advantages: fixed
systems, while having high compliance, may require some preparation of tooth structure; removable systems are more
adaptable and the sample is less likely to be lost. Our intra oral device will require that the study sample is removable, in
order for it to be used with X−ray microtomography (XMT) and thus the subject is not exposed to any radiation.
XMT was developed in 1982 and has the advantages of being non−destructive, high resolution (at micron level) and
quantitative in measuring mineral concentration. Like the well−known CT scan, the XMT images are free of superimposition
and therefore 3−dimensional reconstruction of the sample is possible. Other techiques which have previously been used to
analyse samples from intra oral devices are limited in that the sample needs to be sectioned and is therefore unusable for
further studies. The most popular methods are transverse microradiography and microhardness. However, with XMT, the
sample can be repeatedly scanned and so the progression of the dissolution and repair of hydroxyapaptite can be
monitored. This technique has been used in laboratory studies and it will be novel to study the samples in an intra−oral
device.
A10. Give a brief synopsis/summary of methods and overview of the planned research, including a brief explanation of
the theoretical framework which informs it. It should include a brief description of how prospective research
participants and concerned communities (not necessarily geographical) from which they are drawn have been
consulted over the design and details of the research.
(Where appropriate a flow chart or diagram should be submitted separately. It should be clear exactly what will happen to the
research participant, how many times and in what order).
This section MUST be completed in language comprehensible to the lay person. Do NOT simply reproduce the protocol.
The development of in situ caries models came about to bridge the gap between in vitro (test tube) studies and clinical trials.
In vitro studies are highly controllable and thus unnatural. Clinical trials provide more applicable data, but can often take
years. An in situ study takes a block of hydroxyapatite which is held in the mouth using an appliance. While the block is
subjected to normal oral conditions, the caries process can been artificially induced or propagated by removing the appliance
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from the mouth and subjecting the dental tissue to well−established regimens.
Subjects will be selected using the criteria found later in this document. Essentially they will be fit and healthy with no active
dental disease, but with previous experience of dental decay. Impressions (moulds) will be taken of their teeth and a custom
made appliance (very similar to an orthodontic brace) fabricated. The appliance will have two sterile slabs of hydroxyapatite
secured to it, on either side of the mouth. The appliance will be worn day and night for 28 days. The hydroxyapatite slabs will
be removed and scanned using XMT and scanning microradiography every 7 days. The subjects will be allowed to follow
their normal tooth brushing procedures, but must remove the appliance before they do this. Subjects will be asked to rinse
their mouth with water prior to reinserting the appliance. Instructions concerning appliance hygiene will be issued. The
participants will also be asked to complete a diary of eating habits.
A11. Will any intervention or procedure, which would normally be considered a part of routine care, be withheld from
the research participants?
 Yes  No
A12. Will the research participants receive any clinical intervention(s) or procedure(s) including taking samples of
human biological material over and above that which would normally be considered a part of routine clinical care?
 Yes  No
Additional
Intervention Average number per patient
Average time
taken
(mins/hours/days)
Details of additional intervention or
procedure, who will undertake it, and
what training they have received.
Routine Care Research
Outpatient
Attendance(s) 2 30 
Initial dental examination as part of pre
selection screening, then ,should the
subject wish, a post study dental
examination, scale and polish and topical
fluoride application 
Other tissue/bodily
sample 1 30 
We will ask the participants to provide a
sample of saliva. This will allow us to
determine whether the subject produces
enough saliva to be included in the trial
and also to determine the amount of
salivary protein they produce 
A13. Will the research participant be subject to any non−clinical research−related intervention(s) or procedure(s)?
(These include interviews, non−clinical observations and use of questionnaires.)
 Yes  No
Additional Intervention
Average
number per
patient
Average time
taken
(mins/hours/days)
Details of additional intervention or procedure, who
will undertake it, and what training they have
received.
Other Questionnaire 1 30 
In pre selection screening, subjects will be asked to fill
out a medical questionnaire and retrospective diet
diary. 
A14. Will individual or group interviews/questionnaires discuss any topics or issues that might be sensitive,
embarassing or upsetting, or is it possible that criminal or other disclosures requiring action could take place during
the study (e.g. during interviews/group discussions, or use of screening tests for drugs)?
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Question A14 below is not applicable if No is selected in question A13.
 Yes  No
The Information Sheet should make it clear under what circumstances action may be taken
A15. What is the expected total duration of participation in the study for each participant?
The total duration is expected to be 28 days however as this is a preliminary study, it may be less.
A16. What are the potential adverse effects, risks or hazards for research participants either from giving or withholding
medications, devices, ionising radiation, or from other interventions (including non−clinical)?
Potentially, the device used could cause accumulation of plaque which could lead to carious lesions and/or periodontal
disease developing. This will be limited when they follow oral and appliance hygiene advice which we will give orally and as
written instructions. We will also select subjects with good periodontal health and no active carious lesions. All subjects will
be offered a dental examination or check−up during the experimental period and will be given, should they wish it, a post
study scale, polish and application of topical fluoride.
There is also a theoretical risk that the appliance may break or the study sample become dislodged. These appliances are
frequently used by orthodontic colleagues with few problems; we will however provide a contact telephone number and
written instructions should there be any problems.
A17. What is the potential for pain, discomfort, distress, inconvenience or changes to lifestyle for research
participants?
As the device will be based on an orthodontic type appliance, the levels of discomfort will be low. We anticipate that subjects
will take a day or two to acclimatise to the device. The subjects should not need to alter their lifestyle unduly. It is likely that
our subjects will be selected from the clinical and laboratory staff at Barts and the London NHS Trust therefore reducing the
inconvenience of unnecessary attendances.
A18. What is the potential for benefit to research participants?
None
A19. What is the potential for adverse effects, risks or hazards, pain, discomfort, distress, or inconvenience to the
researchers themselves? (if any)
As I will be initially testing the device on myself, the risks and hazards will be similar to those of the above subjects.
A20. How will potential participants in the study be (i) identified, (ii) approached and (iii) recruited?
Give details for cases and controls separately if appropriate:
(i) Identification of subjects will be through lists of students (both undergraduate and postgraduate) and staff at Queen Mary
College.
(ii) I will approach them personally.
(iii) Once the subject has expressed an initial willingness to take part, I will provide them will further information both written
and orally and organise an appointment for them to attend for a pre assessment screening. If the subject fulfils the inclusion
criteria, written consent will be obtained and the subject will be enrolled.
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A21. Where research participants will be recruited via advertisement, give specific details.
Not Applicable
If applicable, enclose a copy of the advertisement/radio script/website/video for television (with a version number and date).
A22. What are the principal inclusion criteria?(Please justify)
Subjects will be between 18 and 50 years old. They will be approximately 50:50 male to female and come from a range of
racial/ethnic backgrounds. They will be medically fit and well. Their dental health should be stable at present, but they should
have a range of past caries experience denoted by restorations and/or extractions (DMFT greater than or equal to 1). These
criteria have been taken the consensus reached at the Conference on Clinical Aspects of De/Remineralisation of Teeth
(June 1994), Rochester, New York.
A23. What are the principal exclusion criteria?(Please justify)
Subjects will not be included if they are taking medication which causes reduced saliva flow. They should not be taking
antibiotics or have taken them in the last two months. They should not be allergic to any of the products to any of the agents
used in the study. They should not have active carious lesions or periodontal pockets of 5mm or more. Participants must not
be wearing removable prostheses (dentures) or orthodontic appliances. Subjects who live in a fluoridated area should be
excluded as should those who take fluoride supplements (not including toothpaste). We will excluded if their unstimulated
whole saliva flow rate is greater than or equal to 0.2ml/min and their stimulated whole saliva flow rate is greater than or equal
to 1.0ml/min. These criteria have been taken the consensus reached at the Conference on Clinical Aspects of
De/Remineralisation of Teeth (June 1994), Rochester, New York.
A24. Will the participants be from any of the following groups?(Tick as appropriate)
Children under 16
Adults with learning disabilities
Adults who are unconscious or very severely ill
Adults who have a terminal illness
Adults in emergency situations
Adults with mental illness (particularly if detained under Mental Health Legislation)
Adults suffering from dementia
Prisoners
Young Offenders
Adults in Scotland who are unable to consent for themselves
Healthy Volunteers
Those who could be considered to have a particularly dependent relationship with the investigator, e.g. those in care
homes, medical students
Other vulnerable groups
Justify their inclusion.
Healthy volunteers are required to limit possible damage to their dentition that could be caused by medication, for example,
xerostomia (reduced saliva flow). By using laboratory and clinical staff, we will decrease the number of unnecessary
attendances required.
A25. Will any research participants be recruited who are involved in existing research or have recently been involved in
any research prior to recruitment?
 Yes  No  Not Known
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If Yes, give details and justify their inclusion. If Not Known, what steps will you take to find out?
A26. Will informed consent be obtained from the research participants?
 Yes  No
If Yes, give details of who will take consent and how it will be done. Give details of any particular steps to provide information
(in addition to a written information sheet) e.g. videos, interactive material.
If participants are to be recruited from any of the potentially vulnerable groups listed in A24, give details of extra steps taken
to assure their protection. Describe the arrangements to be made for obtaining consent from a legal representative.
If consent is not to be obtained, please explain why not.
Consent will be taken by the chief researcher. Careful explanation will be given and a written details will be provided. The
subjects will be given time to think their participation over and to discuss it with family and friends.
Copies of the written information and all other explanatory material should accompany this application.
A27. Will a signed record of consent be obtained?
 Yes  No
If Yes, attach a copy of the information sheet to be used, with a version number and date.
A28. How long will the participant have to decide whether to take part in the research?
Subjects will be given at least 24 hours to decide whether to participate or not. As the appliance is removable, the participant
may withdraw from the trial at any point.
A29. What arrangements have been made for participants who might not adequately understand verbal explanations or
written information given in English, or who have special communication needs? (e.g. translation, use of interpreters etc.)
It is highly unlikely that subjects whose English is limited will be included in the trial as numbers will be small.
A30. What arrangements are in place to ensure participants receive any information that becomes available during the
course of the research that may be relevant to their continued participation?
A record will be taken comprising of the subjects home address, work address, contact phone number and email address.
These will be coded to ensure anonymity. It will be noted if the subject is happy for us to communicate with them by the
above channels and which is their preferred method.
A31. Does this study have or require approval of the Patient Information Advisory Group (PIAG) or other bodies with a
similar remit?(see Guidance Notes)
 Yes  No
A32a. Will the research participants' General Practitioner be informed that they are taking part in the study?
Date: 08/08/2005 Reference: 05/Q0605/147 Online Form
NHS REC Application Form − Version 4.1 7 AB/40877/1
 Yes  No
If Yes, enclose a copy of the information sheet/letter for the GP with a version number and date.
A32b. Will permission be sought from the research participants to inform their GP before this is done?
 Yes  No
If No to either question, explain why not
As the participants in our research have some medical knowledge, it is assumed that their recall of their medical history will
be accurate. The threshold for exclusion due to medical problems will be low and therefore it is unnecessary to inform their
GP. All treatment solutions will be applied extra orally and will be similar to normal cariogenic challenges (ie. eating or
drinking sugary substances); the appliance will then be rinsed with water before reinsertion. When an Orthodontist fits an
appliance for a patient, they do not contact the GP; this represents a similar situation.
It should be made clear in the patient information sheet if the research participants' GP will be informed.
A33. Will individual research participants receive any payments for taking part in this research?
 Yes  No
A34. Will individual research participants receive reimbursement of expenses or any other incentives or benefits for
taking part in this research?
 Yes  No
A35. What arrangements have been made to provide indemnity and/or compensation in the event of a claim by, or on
behalf of, participants for negligent harm?
Research and Development department, Barts and The London NHS Trust
Please forward copies of the relevant documents.
A36. What arrangements have been made to provide indemnity and/or compensation in the event of a claim by, or on
behalf of, participants for non−negligent harm?
Research and Development department, Barts and The London NHS Trust
Please forward copies of the relevant documents.
A37. How is it intended the results of the study will be reported and disseminated?(Tick as appropriate)
Peer reviewed scientific journals
Internal report
Conference presentation
Other publication
Submission to regulatory authorities
Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee on
behalf of all investigators
Written feedback to research participants
Presentation to participants or relevant community groups
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Other/none e.g. Cochrane Review, University Library
A38. How will the results of research be made available to research participants and communities from which they are
drawn?
By publication in journals and presentations at conferences. The participants may also approach me directly to discuss the
results.
A39. Will the research involve any of the following activities at any stage (including identification of potential research
participants)?(Tick as appropriate)
Examination of medical records by those outside the NHS, or within the NHS by those who would not normally have
access
Electronic transfer by magnetic or optical media, e−mail or computer networks
Sharing of data with other organisations
Export of data outside the European Union
Use of personal addresses, postcodes, faxes, e−mails or telephone numbers
Publication of direct quotations from respondents
Publication of data that might allow identification of individuals
Use of audio/visual recording devices
Storage of personal data on any of the following:
Manual files including X−rays
NHS computers
Home or other personal computers
University computers
Private company computers
Laptop computers
Further details:
A40. What measures have been put in place to ensure confidentiality of personal data? Give details of whether any
encryption or other anonymisation procedures have been used and at what stage:
Personal data will be coded and processed securely in line with the Data Protection Act 1998. It will be stored on the Queen
Mary computer network and will accessible using a secure password. Once the trial is completed the personal data will be
erased.
A41. Where will the analysis of the data from the study take place and by whom will it be undertaken?
Analysis of the data will take place at the Department of Biophysics in relation to Dentistry at Queen Mary, University of
London. The principal researcher will analyse the data.
A42. Who will have control of and act as the custodian for the data generated by the study?
Janet Davies, principal investigator
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A43. Who will have access to the data generated by the study?
Janet Davies, principal investigator
A44. For how long will data from the study be stored?
15 Years  00 Months
Give details of where they will be stored, who will have access and the custodial arrangements for the data:
The personal data will be erased as soon as the trial is completed. The study data will be stored for 15 years in the archive at
Barts and the London NHS Trust. The data will be the property of the Centre for Oral Growth and Development, Queen
Mary, University of London.
A45. How has the scientific quality of the research been assessed?(Tick as appropriate)
Independent external review
Review within a company
Review within a multi−centre research group
Internal review (e.g. involving colleagues, academic supervisor)
None external to the investigator
Other, e.g. methodological guidelines
If you are not in possession of any referees or other scientific critique reports relevant to your proposed study, justify and
describe the review process and outcome. If review has been undertaken but not seen by the researcher, give the details of
the body which has undertaken the review:
A copy of any referees' comments or other scientific critique reports relevant to the proposed research must be enclosed with the
application form.
A46. Has similar research on this topic been done before?
 Yes  No
If Yes, why should it be repeated?
As previously stated, in situ caries devices have been used for many years to study the process of dental decay, however
the evaluation techniques used to analyse the lesions have a low resolution. They often only give a snapshot view due to the
need to destroy the sample in order to analyse it. XMT and scanning microradiography have been used successfully for
many years for in vitro work, but their relevence to the clinical situation is unknown. Due to their high resolution and non
destructive nature, these techniques have the potential to become the gold standard of caries analysis (International
Consensus Workshop on Caries Clinical Trials, Glasgow, Scotland, January 7–10, 2002)
A47. Have all existing sources of evidence, especially systematic reviews, been fully considered?
 Yes  No
If Yes, please give details of search strategy used. If No, explain why not.
On−line searches were performed using the PubMed database.
A48. What is the primary outcome measure for the study?
To measure progression/repair of demineralisation
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A49. What are the secondary outcome measures?(if any)
A50. How many participants will be recruited? How many of these participants will be in a control group?
Approximately 10 subjects will be recruited. The subjects will act as their own controls.
A51. Has the size of the study been informed by a formal statistical power calculation?
 Yes  No
A52. Has a statistician given an opinion about the statistical aspects of the research?
 Yes  No
If Yes, enclose a copy of comments. If the comments are not available then please enclose a summary of the opinion.
A53. Describe the statistical methods and/or other relevant methodological approaches (e.g. for qualitative research) to
be used in the analysis of the results. Give details of the methods of randomisation process to be used if applicable:
Qualitative analysis will be used to determine if remineralisation or demineralisation is seen and if so how long this takes.
A54. Where will the research take place?(Tick as appropriate)
UK
Other states in European Union
Other countries in European Economic Area
Other
Give details:
A55. Has this or a similiar application been previously rejected by a Research Ethics Committee in the UK, the
European Union or the European Economic Area?
 Yes  No
A56. In how many and what type of host organisations (NHS or other) in the UK is it intended the proposed study will
take place?
Indicate the type of organisation by ticking the box and give approximate numbers if known:
Number of
organisations
Acute teaching NHS Trusts
Acute NHS Trusts
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NHS Community and/or Primary Care Trusts
NHS Trusts providing Mental Healthcare
NHS Care Trusts 1
Social Care Organisations
Prisons
Independent hospitals
Educational establishments 1
Independent research units
Other (give details)
Other:
A57. What arrangements are in place for monitoring and auditing the conduct of the research?
The Research and Development Department of Barts and the London NHS Trust will be conducting an audit of the research.
Will a data monitoring committee be convened?
 Yes  No
If Yes, details of membership of the data monitoring committee (DMC), its standard operating procedures and summaries of
reports of interim analyses to the DMC must be forwarded to the NHS Research Ethics Committee which gives a favourable
opinion of the study.
What are the criteria for electively stopping the trial or other research prematurely?
The trial will be stopped early if rate of demineralisation or remineralisation is greater than expected. If the participant is
unable to wear the appliance or early deamage to teeth and gums occur, the trial will also be stopped.
A58. Has funding for research been secured?
 Yes  No
If No, what arrangements are being made to cover any costs of the research? If no external funding is being sought,
please say so:
No external funding is being sought. My salary is being paid by the NHS (My PhD time forms part of my contract) and other
costs will be covered by collective departmental grants.
A59. Has the funder of the research agreed to act as sponsor as set out in the Research Governance Framework?
 Yes  No  Not Known
Has the employer of the Chief Investigator agreed to act as sponsor of the research?
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 Yes  No  Not Known
Give details of the organisation which will act as the sponsor of the research:
UK contact:
Title: Mr
Forename/Initials:  Gerry
Surname: Leonard
Organisation: Queen Mary, University of London
Address: Research and Development Office
3rd Floor, Rutland House, 42−46 New Road Telephone: 02078827260
Whitechapel, London Fax: 02078827276
Postcode: E1 2AX
E−mail: gerry.leonard@bartsandthelondon.nhs.uk
A copy of documentation indicating that the organisation has accepted the role of sponsor should be enclosed if the sponsor is
not the main funder, the Chief Investigator's employer, or an NHS body hosting the research.
A60. Has any responsibility for the research been delegated to a subcontractor?
 Yes  No
A61. Will individual researchers receive any personal payment over and above normal salary for undertaking this
research?
 Yes  No
A62. Will individual researchers receive any other benefits or incentives for taking part in this research?
 Yes  No
A63. Will the host organisation or the researcher's department(s) or institution(s) receive any payment or benefits in
excess of the costs of undertaking the research?
 Yes  No
A64. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g.
financial, share−holding, personal relationship etc.) in the organisation sponsoring or funding the research that may
give rise to a possible conflict of interest?
 Yes  No
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A65. Other relevant reference numbers if known(give details and version numbers as appropriate):
Applicant's/organisation's own reference number, e.g. RD(if available):
Sponsor's/protocol number:
Funder's reference number:
International Standard Randomised Controlled Trial Number (ISRCTN):
European Clinical Trials Database (EudraCT) number:
Project website:  
A66. Other key investigators/collaborators(all grant co−applicants should be listed)
Title: Professor
Forename/Initials: Mark P Surname: Hector
Post: Professor of Child Oral Health
Qualifications: BSc (Hons), BDS, PhD
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street Telephone: 020 7377 7058
London Fax: 020 7377 7419
Postcode: E1 2AD
E−mail: m.p.hector@qmul.ac.uk
Title: Dr
Forename/Initials: Ferranti Surname: Wong
Post: Senior Lecturer/Honorary Consultant in Paediatric Dentistry
Qualifications: BDS, PhD, MSc, FDS RCS (Ed), FDS RCS (Eng)
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street Telephone: 020 7377 7058
London Fax: 020 7377 7419
Postcode: E1 2AD
E−mail: f.s.l.wong@qmaul.ac.uk
If further collaborators are required, please enter at end of section or attach a further sheet.
A67. If the research involves a specific intervention, (e.g. a drug, medical device, dietary manipulation, lifestyle change
etc.), what arrangements are being made for continued provision of this for the participant (if appropriate) once the
research has finished?
Not Applicable
 PART A: Summary of Ethical Issues
A68. What do you consider to be the main ethical issues or problems which may arise with the proposed study and
what steps will be taken to address these?
The ethical issues which arise from this study have been minimised to a great extent. The appliance to be used is similar to
an orthodontic appliance and is removable to allow the subjects to follow their oral hygiene regimens. There is very little
change to the participants' lifestyles. Cariogenic challenges are performed extraorally as does evaluation. The participant is
not subjected to any radiation during the study. Details will be taken so that subjects can be contacted easily should there be
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any problems with the appliance.
Hydroxyapaptite is used as a substitute for human enamel; this provides an acceptable model for human enamel without the
need for gamma radiation sterilisation. Other materials to be used in the appliance are inert and unlikely to cause allergic
reactions.
A69. Do you need to add further information about certain questions in Part A?
This question is not applicable for the online version of COREC form.
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 PART A: Student Page
A70. Give details of the educational course or degree for which this research is being undertaken:
Name and level of course/degree:
PhD
Name of educational establishment:
Dental Institute, Queen Mary, University of London
Name and contact details of educational supervisor:
Dr Ferranti Wong/Prof Mark Hector
Centre for Oral Growth and Development, Dental Institute
Queen Mary, University of London
Turner Street
London E1 2AD
A71. Declaration of Supervisor
I have read and approved both the research proposal and this application for the ethical review. I undertake to fulfil the
responsibilities of a supervisor as set out in the Research Governance Framework for Health and Social Care. I can confirm on
behalf of my academic institution that any necessary indemnity or insurance arrangements are in place.
Signature: ......................................
Date:  (dd/mm/yyyy)
Print Name:
A one−page summary of the supervisor's CV should be submitted with the application
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 PART B: Section 5 − Use of Newly Obtained Human Biological Materials
1. What samples will be collected and/or analysed and by whom will they be collected?
The patient will be asked to provide 2 samples of saliva collected over 1 minute: one will be resting, the other will be while
chewing parafilm. They will be collected by the chief investigator, Janet Davies. The samples will be analysed by at the
Salivary Research Unit, Guy's Hospital.
2. Are the samples taken solely for research purposes (or are they a by−product of those taken primarily for clinical
purposes, i.e. surplus to clinical requirements)?
Samples are solely for research purposes.
3. How will samples be labelled/identified?
Indicate if samples can be considered to be "identified", "coded", "de−identified", "anonymised" or "anonymous" and at what
stage identifiers are removed. (See Guidance Notes for definitions)
The samples will be coded.
4. Give details of where the sample(s) will be stored, for how long, who will have access and the custodial
arrangements.
Once analysis has been perfomed the sample will be destroyed.
5. Will the research participant retain any rights to the sample(s)?
 Yes  No
6. Is it known how the samples will be used in the future?
 Yes  No
If Yes, give details and indicate if consent will be obtained for the future use of samples:
They will be destroyed they will not be able to be used in future.
7. Does the research involve the analysis or use of genetic material from human biological materials?
 Yes  No
8. Would it be possible to link the results of any genetic analysis back to individuals?
 Yes  No
9. Is it intended to link the results of any genetic analysis back to individuals?
 Yes  No
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 PART B: Section 7 − Declaration
− The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.
− I undertake to abide by the ethical principals underlying the Declaration of Helsinki and good practice guidelines on the
proper conduct of research.
− If the research is approved I undertake to adhere without unagreed deviation to the study protocol, the terms of the full
application of which the main REC has given a favourable and any conditions set out by the main REC in giving its
favourable opinion.
− I undertake to inform the main REC of any changes in the protocol, and to submit annual reports setting out the progress
of the research.
− I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant guidelines
relating to security and confidentiality of patient or other personal data, including the need to register when necessary with
the appropriate Data Protection Officer.
− I understand that research records/data may be subject to inspection for audit purposes if required in future.
− I understand that personal data about me as a researcher in this application will be held by the relevant RECs and their
operational managers and that this will be managed according to the principles established in the Data Protection Act.
Signature: ......................................
Date:  (dd/mm/yyyy)
Print Name: 
1. Do you need to add further information about certain questions in part B?
 This question is not applicable for the online version of COREC form.
ENSURE THAT YOU COMPLETE AND SIGN THE FORM, AND ENCLOSE ANY RELEVANT ADDITIONAL DOCUMENTS.
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PART C: Site−Specific Assessment (SSA)
This form should be completed by the Principal Investigator for each site (see glossary)
Part C should be completed and sent with the relevant enclosures to each NHS Research Ethics Committee or Research &
Development (R&D) department, which needs to consider site−specific issues. Consult the application procedure on COREC
website.
The data in this box is populated from Part A.
Name of NHS Research Ethics Committee to which application for ethical review is being made:
East London and the City Research Ethics Committee 3
Project Reference number from above REC:  05/Q0605/147
Name of NHS REC responsible for SSA:
SSA reference (for REC office use only):
Questions C1, C4, C5, C6, C7, C8 and C13a correspond to questions A1, A2, A65, A10, A12, A13 and A29 on main application
form respectively and will populate automatically:
C1. Title of Research(Populated from A1)
Full title: A preliminary in situ study of demineralisation and remineralisation of hydroxyapaptite slabs
Key words: hydroxyapaptite, demineralisation, remineralisation, in situ
C2. Who is the Principal Investigator for this study at this site?
Title:  Miss Forename/Initials:  Janet A Surname:  Davies
Post: PhD Student
Qualifications: BSc (Hons), BDS
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street
London
Post Code: E1 2AD
E−mail: janetdavies30@hotmail.com/janet.a.davies@qmul.ac.uk
Telephone: 020 7377 7058
Fax: 020 7377 7419
A copy of a current CV, (maximum 2 pages of A4) for the Principal Investigator(s) must be submitted with application
C3. Indicate the number of trials/projects within the organisation that the local
Principal Investigator has been involved with in the previous 12 months:
0
 How many are still current (active or recruiting)? 0
 Give details of other members of the local research team responsible to the local Principal Investigator
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Title:
Forename/Initials:
Surname:
Position:
Qualifications:
Role in the research team:
If there are more members of the local research team, details should be provided at question C18 or on an attached sheet.
C4. Chief Investigator(Populated from A2)
Title:
  Miss Forename/Initials:  Janet A Surname:  Davies
Post: PhD Student
Qualifications: BSc (Hons), BDS
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street
London
Post Code: E1 2AD
E−mail: janet.a.davies@qmul.ac.uk/janetdavies30@hotmail.com
Telephone: 020 7377 7058
Fax: 020 7377 7419
C5. Other relevant reference numbers if known (Populated from A65)
Applicants/organisation's own reference number, e.g. RD(if available):
Sponsor's/protocol number:
Funder's reference number:
International Standard Randomized Controlled Trial Number (ISRCTN):
European Clinical Trials Database (EudraCT) Number:
Project website:  
C6. Give a brief synopsis/summary of methods and overview of the planned research. This should include a brief
description of how prospective research participants and concerned communities (not necessarily geographical) from
which they are drawn have been consulted over the design and details of the research?
(Where appropriate a flow chart or diagram should be submitted separately. It should be clear exactly what will happen to the
research participant, how many times and in what order). (Populated from A10)
The development of in situ caries models came about to bridge the gap between in vitro (test tube) studies and clinical trials.
In vitro studies are highly controllable and thus unnatural. Clinical trials provide more applicable data, but can often take
years. An in situ study takes a block of hydroxyapatite which is held in the mouth using an appliance. While the block is
subjected to normal oral conditions, the caries process can been artificially induced or propagated by removing the appliance
from the mouth and subjecting the dental tissue to well−established regimens.
Subjects will be selected using the criteria found later in this document. Essentially they will be fit and healthy with no active
dental disease, but with previous experience of dental decay. Impressions (moulds) will be taken of their teeth and a custom
made appliance (very similar to an orthodontic brace) fabricated. The appliance will have two sterile slabs of hydroxyapatite
secured to it, on either side of the mouth. The appliance will be worn day and night for 28 days. The hydroxyapatite slabs will
be removed and scanned using XMT and scanning microradiography every 7 days. The subjects will be allowed to follow
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their normal tooth brushing procedures, but must remove the appliance before they do this. Subjects will be asked to rinse
their mouth with water prior to reinserting the appliance. Instructions concerning appliance hygiene will be issued. The
participants will also be asked to complete a diary of eating habits.
C7. Will the research participants receive any clinical intervention(s) or procedure(s) including taking samples of
human biological material over and above that which would normally be considered a part of routine clinical care?
(Populated from A12)
 Yes  No
Additional
Intervention Average number per patient
Average time
taken
(mins/hours/days)
Details of additional intervention or
procedure, who will undertake it, and
what training they have received.
Routine Care Research
Outpatient
Attendance(s) 2 30 
Initial dental examination as part of pre
selection screening, then ,should the
subject wish, a post study dental
examination, scale and polish and topical
fluoride application 
Other tissue/bodily
sample 1 30 
We will ask the participants to provide a
sample of saliva. This will allow us to
determine whether the subject produces
enough saliva to be included in the trial
and also to determine the amount of
salivary protein they produce 
C8. Will the research participant be subject to any non−clinical research−related intervention(s) or procedure(s)?
(These include interviews, non−clinical observations and use of questionnaires.)(Populated from A13)
 Yes  No
Additional Intervention
Average
number per
patient
Average time
taken
(mins/hours/days)
Details of additional intervention or procedure, who
will undertake it, and what training they have
received.
Other Questionnaire 1 30 
In pre selection screening, subjects will be asked to fill
out a medical questionnaire and retrospective diet
diary. 
C9a. Give the name of the NHS or other organisation with which the PI holds the necessary contract (substantive or
honorary) to undertake the research at this site:
Barts and The London NHS Trust
C9b. Give the name of the research site for which the PI is responsible, if different from the above. (The site may be a
whole organisation, an individual unit, or a consortium):
C9c. Give the name and contact details for the Research Governance lead for the research site:
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Title: Mr
Forename/Initials:  Gerry
Surname: Leonard
Address: 3rd Floor, Rutland House
42−46 New Road Telephone: 020
7882
7260
Whitechapel, London Fax: 020
7882
7276
Postcode: E1 2AX
E−mail: gerry.leonard@bartsandthelondon.nhs.uk
C10. Specify the location(s)/department(s) within the NHS or other organisation where the research will take place.
Department of Oral Growth and Development, Dental Institute
C11. How many research participants/samples is it anticipated will be recruited/obtained from this organisation in
total?
10
C12a. Give details of who will be responsible for obtaining informed consent locally, their qualifications and relevant
expertise and training in obtaining consent for research purposes:
Janet Davies, Principal Investigator
She has attended relevent Good Clinical Practice and Research Governance courses. As a qualified dentist with 4 years
experience working within NHS hospitals, she also has a wealth of practical experince in obtaining consent.
C13a. What arrangements have been made for participants who might not adequately understand verbal explanations
or written information given in English, or who have special communication needs? (e.g. translation, use of interpreters
etc.) (Populated from A29)
It is highly unlikely that subjects whose English is limited will be included in the trial as numbers will be small.
C13b. What local arrangements have been made to meet these requirements (where applicable)?
Not applicable
C14. In addition to informing the GP (if required), what arrangements have been made to inform those responsible for
the care of the research participants in the host care organisation of their involvement in the research?
Not applicable
C15. Are the facilities and staffing available locally adequate to perform any necessary procedures or interventions
required for the study, and to deal with any unforseen consequences of these?(This should include consideration of
procedures and interventions in both control and intervention arms of a study.)
 Yes  No
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If Yes, give the information necessary to justify your answer. If No, indicate what arrangements are being made to deal with
the situation:
The principal investigator is timetabled for 4 sessions of research; this will be adequate for any procedures to be carried out.
When unforseen circumstances occur the principal investigator will be available to deal with these.
C16a. Give brief details of a contact point where participants may obtain further information about the study.
The partcipants can obtain more information about the study by contacting the principal investigator either by telephone or
email.
16b. What is the contact point for potential complaints by research participants?
The participants may contact either the investigator's supervisiors (Prof Hector or Dr Wong) or the Reserch Governance
Office
16c. Is there a local source where potential participants can obtain independent information about being involved in a
research study?
Research Governance Office
16d. Please specify the headed paper to be used for the participant information sheet?
Barts and The London
Queen Mary's School of Medicine and Dentistry
C17. If any extra support might be required by research participants as a result of their participation, what local
arrangements are being made to provide this?
Not applicable
C18. Do you need to add further information about certain questions in Part C?
 This question is not applicable for the online version of COREC form.
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PART C: Declaration
− The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.
− I undertake to abide by the ethical principles underpinning the Declaration of Helsinki and good practice guidelines on
current proper conduct or research.
− If the research is approved I undertake to adhere without unagreed deviation to the study protocol, the terms of the full
application of which the main REC has given a favourable and any conditions set out by the main REC in giving its
favourable opinion.
− I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant guidelines
relating to security and confidentiality of patient or other personal data, including the need to register when necessary with
the appropriate Data Protection Controller.
− I understand that research records/data may be subject to inspection for audit purposes if required in future.
− I understand that personal data about me as a researcher in this application will be held by the relevant RECs and their
operational managers and that this will be managed according to the principles established in the Data Protection Act.
Signature of the local Principal Investigator * ......................................
Date:  (dd/mm/yyyy)
Print Name: 
* The Chief Investigator should sign where there is no local Principal Investigator for the research locality.
PART C IS NOW COMPLETE AND SHOULD BE SUBMITTED to the NHS Research Ethics Committee or NHS organisation
conducting site−specific assessment.
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APPLICANT'S CHECKLIST
All studies except clinical trials of investigational medicinal products
REC Ref:
Short Title of Study: An in situ study of de/remineralisation of enamel and dentine
CI Name: Miss Janet A Davies
Sponsor: Queen Mary, University of London
Please complete this checklist and send it with your application
Send ONE copy of each document (except where stated)♦ 
ALL accompanying documents must bear version numbers and dates (except where stated)♦ 
When collating please do NOT staple documents as they will need to be photocopied.♦ 
Document Enclosed? Date Version Office use
Covering letter on headed paper  Yes  No 
NHS REC Application Form, Parts A&B Mandatory 1 
NHS REC Application Form, Part C (SSA)  Yes  No 
Research protocol or project proposal (6 copies) Mandatory 1 
Summary C.V. for Chief Investigator (CI) Mandatory
Summary C.V. for supervisor (student research)   Yes  No 
Research participant information sheet (PIS)  Yes  No 1 
Research participant consent form  Yes  No 1 
Letters of invitation to participants  Yes  No 
GP/Consultant information sheets or letters  Yes  No 
Statement of indemnity arrangements  Yes  No 
Letter from sponsor  Yes  No 
Letter from statistician  Yes  No 
Letter from funder  Yes  No 
Referees' or other scientific critique report  Yes  No 
Summary, synopsis or diagram (flowchart) of
protocol in non−technical language  Yes  No 1 
Interview schedules or topic guides for
participants  Yes  No 
Validated questionnaire  Yes  No 
Non−validated questionnaire  Yes  No 1 
Copies of advertisement material for research
participants, e.g. posters, newspaper adverts,
website. For video or audio cassettes, please also
provide the printed script. 
 Yes  No 
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WELCOME TO THE NHS RESEARCH ETHICS COMMITTEE APPLICATION FORM
An application form specific to your project will be created from the answers you give to the following questions.  Please read
this guidance carefully before selecting your answers.
1. Is your project an audit or service evaluation?
 Yes  No
2. Select one research category from the list below:
 Clinical trials of investigational medicinal products (including phase 1 drug development)
 Clinical investigations or other studies of medical devices
 Other clinical trial or clinical investigation
 Research administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative
     methodology
 Research involving qualitative methods only
 Research limited to working with human tissue samples and/or data
    If your work does not fit any of these categories, select the option below:
 Other research
2a. Select one category from the list below:
 Is this a clinical investigation of a medical device?
 Is this a performance evaluation of an in vitro diagnostic device?
 Is this a drug/device combination of both an investigational medical device and an investigational medicinal product?
 Is this a post−market surveillance study of a CE Marked product?
2b . Please answer the following questions:
a) Does the study involve the use of any ionising radiation?  Yes  No
b) Will you be taking new human tissue samples?  Yes  No
c) Will you be using existing human tissue samples?  Yes  No
3. Is your research confined to one site?
 Yes  No
4. Does your research involve work with prisoners?
 Yes  No
5. Does your research involve adults unable to consent for themselves through physical or mental incapacity?
 Yes  No
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6. Is the study, or any part of the study, being undertaken as an educational project?
 Yes  No
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NHS Research Ethics Committee
Application form for a clinical investigation of a medical device
This form should be completed by the Chief Investigator, after reading the guidance notes. See glossary for clarification
of different terms in the application form.
Short title and version number: (maximum 70 characters − this will be inserted as header on all forms)
An in situ study of de/remineralisation of enamel and dentine
Name of NHS Research Ethics Committee to which application for ethical review is being made:
East London and the City Research Ethics Committee 3
Project reference number from above REC:
Submission date:
 PART A: Introduction
A1. Title of the research
Full title: A preliminary in situ study of demineralisation and remineralisation of enamel and dentine slabs
Key words: enamel, dentine, demineralisation, remineralisation, in situ
A2. Chief Investigator
Title: Miss
Forename/Initials:  Janet A
Surname: Davies
Post: PhD Student
Qualifications: BSc (Hons), BDS
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street
London
Post Code: E1 2AD
E−mail: janet.a.davies@qmul.ac.uk/janetdavies30@hotmail.com
Telephone: 020 7377 7058
Fax: 020 7377 7419
A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the application
A3. Proposed study dates and duration
Start date: 01/06/2006
End date: 01/06/2010
Duration: Years:  4 ;    Months:  48
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A4. Primary purpose of the research: (Tick as appropriate)
Commercial product development and/or licensing
Publicly funded trial or scientific investigation
Educational qualification
Establishing a database/data storage facility
Other
A6. Does this research require site−specific assessment (SSA)? (Advice can be found in the guidance notes on this topic.)
 Yes  No
If No, please justify:
If Yes, Part C of the form will need to be completed for each research site and submitted for SSA to the relevant Local
Research Ethics Committee. Do not submit Part Cs for other sites until the application has been booked for review and
validated by the main Research Ethics Committee.
Management approval to proceed with the research will be required from the R&D Department for each NHS care organisation
in which research procedures are undertaken. This applies whether or not the research is exempt from SSA.
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 PART A: Section 1
A7. What is the principal research question/objective? (Must be in language comprehensible to a lay person.)
The principal aim of the study is to test a new device to be worn in the mouth for evaluating various materials for prevention
and/or repair of decay in teeth. The participant will wear a device in the mouth which contains a secured slab of carefully
sterilised human enamel/dentine. This device will be removable and similar in appearance to a removable orthodontic
appliance (brace). The enamel/dentine slabs will be analysed non−destructively outside the mouth using X−ray
microtomography (XMT). This is like a miniaturised high resolution CT Scan which was largely developed in our Centre at
Queen Mary. The XMT allows us to investigate the decayed lesion in 3 dimensions. As the method is non−destructive,
repeated scans can be taken to study the initiation, progression and healing of dental caries. The ultimate objective is to
develop novel, low cost methods to not only help prevent dental decay from starting, but also repair early carious lesions
when they occur.
A8. What are the secondary research questions/objectives? (If applicable, must be in language comprehensible to a lay
person.)
Scanning microradiography (SMR) will be also be used and the results compared to see which would be more applicable to
a clinical trial.
A9. What is the scientific justification for the research? What is the background? Why is this an area of
importance?(Must be in language comprehensible to a lay person.)
Dental decay is an almost ubiquitous disease; it still causes pain and misery to those effected and its' treatment puts a great
burden (approx. £1100M) on already limited NHS resources. It is also preventable. The introduction of fluoridated toothpaste
has greatly decreased its incidence. Fluoridation of the water supply would decrease disease levels further especially in
areas of social deprivation. This happens in about 10% of the UK population, and there is little evidence of greater coverage
occurring in the near future.
The use of intra oral devices to study the progression of dental caries is not new; they were initially used to study the effects
of fluoride on enamel in the early 70s. Since then, however, they have been refined and improved. Intra oral caries devices
take two forms: removable or fixed. Removable appliances can be either orthodontic (brace) or partial dentures. Fixed
appliances are either metal bands or gold crowns which are cemented to a tooth. Each system has its advantages: fixed
systems, while having high compliance, may require some preparation of tooth structure; removable systems are more
adaptable and the sample is less likely to be lost. Our intra oral device will require that the study sample is removable, in
order for it to be used with X−ray microtomography (XMT) and thus the subject is not exposed to any radiation.
XMT was developed in 1982 and has the advantages of being non−destructive, high resolution (at micron level) and
quantitative in measuring mineral concentration. Like the well−known CT scan, the XMT images are free of superimposition
and therefore 3−dimensional reconstruction of the sample is possible. Other techiques which have previously been used to
analyse samples from intra oral devices are limited in that the sample needs to be sectioned and is therefore unusable for
further studies. The most popular methods are transverse microradiography and microhardness. However, with XMT, the
sample can be repeatedly scanned and so the progression of the dissolution and repair of enamel/dentine can be monitored.
This technique has been used in laboratory studies and it will be novel to study the samples in an intra−oral device.
A10. Give a full summary of the purpose, design and methodology of the planned research, including a brief
explanation of the theoretical framework that informs it. It should be clear exactly what will happen to the research
participant, how many times and in what order. Describe any involvement of research participants, patient groups or
communities in the design of the research.
This section must be completed in language comprehensible to the lay person. It must also be self−standing as it will be
replicated in any applications for site−specific assessment on Part C. Do not simply reproduce or refer to the protocol. Further
guidance is available in the guidance notes.
The development of in situ caries models came about to bridge the gap between in vitro (test tube) studies and clinical trials.
In vitro studies are highly controllable and thus unnatural. Clinical trials provide more applicable data, but can often take
years. An in situ study takes a block of hydroxyapatite which is held in the mouth using an appliance. While the block is
subjected to normal oral conditions, the caries process can been artificially induced or propagated by removing the appliance
from the mouth and subjecting the dental tissue to well−established regimens.
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Subjects will be selected using the criteria found later in this document. Essentially they will be fit and healthy with no active
dental disease, but with previous experience of dental decay. Impressions (moulds) will be taken of their teeth and a custom
made appliance (very similar to an orthodontic brace) fabricated. The appliance will have two sterile slabs of hydroxyapatite
secured to it, on either side of the mouth. The appliance will be worn day and night for 28 days. The hydroxyapatite slabs will
be removed and scanned using XMT and scanning microradiography every 7 days. The subjects will be allowed to follow
their normal tooth brushing procedures and to eat normallly, but must remove the appliance before they do this. Subjects will
be asked to rinse their mouth with water prior to reinserting the appliance. Instructions concerning appliance hygiene will be
issued.
A11. Will any intervention or procedure, which would normally be considered a part of routine care, be withheld from
the research participants?
 Yes  No
A12. Give details of any clinical intervention(s) or procedure(s) to be received by research participants over and above
those which would normally be considered a part of routine clinical care.(These include uses of medicinal products or
devices, other medical treatments or assessments, mental health interventions, imaging investigations and taking samples of
human biological material.)
Additional
Intervention Average number per participant
Average time
taken
(mins/hours/days)
Details of additional intervention or
procedure, who will undertake it, and
what training they have received.
Routine Care Research
Outpatient
Attendance(s) 2 30 
Initial dental examination as part of pre
selection screening, then, should the
subject wish, a post study dental
examination, scale and polish and topical
fluoride application 
Other tissue/bodily
sample 1 30 
We will ask the participants to provide a
sample of saliva. This will allow us to
determine whether the subject produces
enough saliva to be included in the trial
and also to determine the amount of
salivary protein they produce 
A13. Give details of any non−clinical research−related intervention(s) or procedure(s).(These include interviews,
non−clinical observations and use of questionnaires.)
Additional Intervention
Average
number per
participant
Average time
taken
(mins/hours/days)
Details of additional intervention or procedure, who
will undertake it, and what training they have
received.
Other Questionnaire 1 30 In pre selection screening, subjects will be asked to fill
out a medical questionnaire and diet diary. 
A14. Will individual or group interviews/questionnaires discuss any topics or issues that might be sensitive,
embarrassing or upsetting, or is it possible that criminal or other disclosures requiring action could take place during
the study (e.g. during interviews/group discussions, or use of screening tests for drugs)?
 Yes  No
The Information Sheet should make it clear under what circumstances action may be taken
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A15. What is the expected total duration of participation in the study for each participant?
The total duration is expected to be 28 days however as this is a preliminary study, it may be less.
A16. What are the potential adverse effects, risks or hazards for research participants either from giving or withholding
medications, devices, ionising radiation, or from other interventions (including non−clinical)?
Potentially, the device used could cause accumulation of plaque which could lead to carious lesions and/or periodontal
disease developing. This will be limited when they follow oral and appliance hygiene advice which we will give orally and as
written instructions. We will also select subjects with good periodontal health and no active carious lesions. All subjects will
be offered a dental examination or check−up during the experimental period and will be given, should they wish it, a post
study scale, polish and application of topical fluoride.
There is also a theoretical risk that the appliance may break or the study sample become dislodged. These appliances are
frequently used by orthodontic colleagues with few problems; we will however provide a contact telephone number and
written instructions should there be any problems.
A17. What is the potential for pain, discomfort, distress, inconvenience or changes to lifestyle for research
participants?
As the device will be based on an orthodontic type appliance, the levels of discomfort will be low. We anticipate that subjects
will take a day or two to acclimatise to the device. The subjects should not need to alter their lifestyle unduly. It is likely that
our subjects will be selected from the clinical and laboratory staff at Barts and the London NHS Trust therefore reducing the
inconvenience of unnecessary attendances.
A18. What is the potential for benefit to research participants?
None
A19. What is the potential for adverse effects, risks or hazards, pain, discomfort, distress, or inconvenience to the
researchers themselves? (if any)
None
A20. How will potential participants in the study be (i) identified, (ii) approached and (iii) recruited?
Give details for cases and controls separately if appropriate:
(i) Identification of subjects will be through lists of students (both undergraduate and postgraduate) and staff at Queen Mary
College.
(ii) I will approach them personally.
(iii) Once the subject has expressed an initial willingness to take part, I will provide them will further information both written
and orally and organise an appointment for them to attend for a pre assessment screening. If the subject fulfils the inclusion
criteria, written consent will be obtained and the subject will be enrolled.
A21. Where research participants will be recruited via advertisement, give specific details.
Not Applicable
If applicable, enclose a copy of the advertisement/radio script/website/video for television (with a version number and date).
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A22. What are the principal inclusion criteria?(Please justify)
Subjects will be between 18 and 50 years old. They will be approximately 50:50 male to female and come from a range of
racial/ethnic backgrounds. They will be medically fit and well. Their dental health should be stable at present, but they should
have a range of past caries experience denoted by restorations and/or extractions (DMFT greater than or equal to 1). These
criteria have been taken the consensus reached at the Conference on Clinical Aspects of De/Remineralisation of Teeth
(June 1994), Rochester, New York.
A23. What are the principal exclusion criteria?(Please justify)
Subjects will not be included if they are taking medication which causes reduced saliva flow. They should not be taking
antibiotics or have taken them in the last two months. They should not be allergic to any of the products to any of the agents
used in the study. They should not have active carious lesions or periodontal pockets of 5mm or more. Participants must not
be wearing removable prostheses (dentures) or orthodontic appliances. Subjects who live in a fluoridated area should be
excluded as should those who take fluoride supplements (not including toothpaste). We will excluded if their unstimulated
whole saliva flow rate is greater than or equal to 0.2ml/min and their stimulated whole saliva flow rate is greater than or equal
to 1.0ml/min. These criteria have been taken the consensus reached at the Conference on Clinical Aspects of
De/Remineralisation of Teeth (June 1994), Rochester, New York.
A24. Will the participants be from any of the following groups?(Tick as appropriate)
Children under 16
Adults with learning disabilities
Adults who are unconscious or very severely ill
Adults who have a terminal illness
Adults in emergency situations
Adults with mental illness (particularly if detained under Mental Health Legislation)
Adults with dementia
Prisoners
Young Offenders
Adults in Scotland who are unable to consent for themselves
Healthy Volunteers
Those who could be considered to have a particularly dependent relationship with the investigator, e.g. those in care
homes, medical students
Other vulnerable groups
Justify their inclusion.
Healthy volunteers are the only people who can be used in this study. The disease process to be studied is artificially
induced in the enamel/dentine blocks. If the participent had active dental disease, the device would have the potential to
cause irreversible harm to the teeth and gums.
A25. Will any research participants be recruited who are involved in existing research or have recently been involved in
any research prior to recruitment?
 Yes  No  Not Known
If Yes, give details and justify their inclusion. If Not Known, what steps will you take to find out?
A26. Will informed consent be obtained from the research participants?
 Yes  No
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If Yes, give details of who will take consent and how it will be done. Give details of any particular steps to provide information
(in addition to a written information sheet) e.g. videos, interactive material.
If participants are to be recruited from any of the potentially vulnerable groups listed in A24, give details of extra steps taken
to assure their protection. Describe any arrangements to be made for obtaining consent from a legal representative.
If consent is not to be obtained, please explain why not.
Consent will be taken by the chief researcher. Careful explanation will be given and a written details will be provided. The
subjects will be given time to think their participation over and to discuss it with family and friends.
Copies of the written information and all other explanatory material should accompany this application.
A27. Will a signed record of consent be obtained?
 Yes  No
If Yes, attach a copy of the information sheet to be used, with a version number and date.
A28. How long will the participant have to decide whether to take part in the research?
Subjects will be given at least 24 hours to decide whether to participate or not. As the appliance is removable, the participant
may withdraw from the trial at any point.
A29. What arrangements have been made for participants who might not adequately understand verbal explanations or
written information given in English, or who have special communication needs? (e.g. translation, use of interpreters etc.)
Barts and the London NHS Trust have a health advocacy service and will provide translators when necessary.
A30. What arrangements are in place to ensure participants receive any information that becomes available during the
course of the research that may be relevant to their continued participation?
A record will be taken comprising of the subjects home address, work address, contact phone number and email address.
These will be coded to ensure anonymity. It will be noted if the subject is happy for us to communicate with them by the
above channels and which is their preferred method.
A31. Does this study have or require approval of the Patient Information Advisory Group (PIAG) or other bodies with a
similar remit?(see the guidance notes)
 Yes  No
A32a. Will the research participants' General Practitioner be informed that they are taking part in the study?
 Yes  No
If Yes, enclose a copy of the information sheet/letter for the GP with a version number and date.
A32b. Will permission be sought from the research participants to inform their GP before this is done?
 Yes  No
If No to either question, explain why not
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While it is not necessary to inform the participants' General Medical Practitioner, it is necessary to inform their General
Dental Practitioner that they are taking part in the study. Please see GDP letter.
It should be made clear in the patient information sheet if the research participant's GP will be informed.
A33. Will individual research participants receive any payments for taking part in this research?
 Yes  No
A34. Will individual research participants receive reimbursement of expenses or any other incentives or benefits for
taking part in this research?
 Yes  No
A35. What arrangements have been made to provide indemnity and/or compensation in the event of a claim by, or on
behalf of, participants for negligent harm?
The Queen Mary School of Medicine and Dentistry has arranged for suitable indemnity concerning negligent harm to be in
place for this study.
Please forward copies of the relevant documents.
A36. What arrangements have been made to provide indemnity and/or compensation in the event of a claim by, or on
behalf of, participants for non−negligent harm?
If approved by the Ethics Committee, the insurance taken out by Queen Mary, University of London will provide this study
with indemnity for non−negligent harm.
Please forward copies of the relevant documents.
A37. How is it intended the results of the study will be reported and disseminated?(Tick as appropriate)
Peer reviewed scientific journals
Internal report
Conference presentation
Other publication
Submission to regulatory authorities
Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee on
behalf of all investigators
Written feedback to research participants
Presentation to participants or relevant community groups
Other/none e.g. Cochrane Review, University Library
A38. How will the results of research be made available to research participants and communities from which they are
drawn?
By publication in journals and presentations at conferences. The participants may also approach me directly to discuss the
results.
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A39. Will the research involve any of the following activities at any stage (including identification of potential research
participants)?(Tick as appropriate)
Examination of medical records by those outside the NHS, or within the NHS by those who would not normally have
access
Electronic transfer by magnetic or optical media, e−mail or computer networks
Sharing of data with other organisations
Export of data outside the European Union
Use of personal addresses, postcodes, faxes, e−mails or telephone numbers
Publication of direct quotations from respondents
Publication of data that might allow identification of individuals
Use of audio/visual recording devices
Storage of personal data on any of the following:
Manual files including X−rays
NHS computers
Home or other personal computers
University computers
Private company computers
Laptop computers
Further details:
A40. What measures have been put in place to ensure confidentiality of personal data? Give details of whether any
encryption or other anonymisation procedures have been used and at what stage:
Personal data will be coded and processed securely in line with the Data Protection Act 1998. It will be stored on the Queen
Mary computer network and will accessible using a secure password. Once the trial is completed the personal data will be
erased.
A41. Where will the analysis of the data from the study take place and by whom will it be undertaken?
Analysis of the data will take place at the Department of Biophysics in relation to Dentistry at Queen Mary, University of
London. The principal researcher will analyse the data.
A42. Who will have control of and act as the custodian for the data generated by the study?
Janet Davies, principal investigator
A43. Who will have access to the data generated by the study?
Janet Davies, principal investigator
A44. For how long will data from the study be stored?
15 Years  0 Months
Give details of where they will be stored, who will have access and the custodial arrangements for the data:
The personal data will be erased as soon as the trial is completed. The study data will be stored for 15 years in the archive at
Barts and the London NHS Trust. The data will be the property of the Centre for Oral Growth and Development, Queen
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Mary, University of London.
A45−1. How has the scientific quality of the research been assessed?(Tick as appropriate)
Independent external review
Review within a company
Review within a multi−centre research group
Internal review (e.g. involving colleagues, academic supervisor)
None external to the investigator
Other, e.g. methodological guidelines (give details below)
This study has been reviewed by my PhD supervisors Prof M.Hector and Dr F.Wong who feel that it will not only be of
educational benefit to me, but also to the advancement of the use of XMT in clinical research.
Justify and describe the review process and outcome. If the review has been undertaken but not seen by the researcher,
give details of the body which has undertaken the review:
If you are in possession of any referees' comments or other scientific critique reports relevant to the proposed research, these
must be enclosed with the application.
A45−2. Has the protocol submitted with this application been the subject of review by a statistician independent of the
research team?(Select one of the following)
 Yes – copy of review enclosed
 Yes – details of review available from the following individual or organisation (give contact details below)
 No – justify below
This is a PhD project with a simple design. Statistical analysis was discussed with Dr Allan Pau (Clinical Lecturer in Dental
Public Health, Barts and The London School of Medicine and Dentistry) who felt the numbers involved were correct for a
feasibility study of this sort.
A48. What is the primary outcome measure for the study?
To measure progression of demineralisation or demineralisation
A49. What are the secondary outcome measures?(if any)
A50. How many participants will be recruited?
If there is more than one group, state how many participants will be recruited in each group. For international studies, say how
many participants will be recruited in the UK and in total.
Approximately 15 subjects will be recruited. The subjects will act as their own controls.
A51. How was the number of participants decided upon?
There is some limitation of participant numbers when using the XMT system; the scan time is long (approximately 12 hours).
Large numbers of subjects would not be feasible. XMT, however, is very high resolution (~8um)thus can detect very small
amounts of   demineralisation. As this is a pilot study, it will provide more information to enable formal power calculations in
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later experiments.
If a formal sample size calculation was used, indicate how this was done, giving sufficient information to justify and
reproduce the calculation.
A52. Will participants be allocated to groups at random?
 Yes  No
If yes, give details of the intended method of randomisation:
Participants will be randomly allocated to either the demineralisation or remineralisation study. Lists will constructed from
random nuber tables. Form of treatment will be allocated to participants in sequence envelopes be done using numbered
opaque envelopes.
A53. Describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) by which
the data will be evaluated to meet the study objectives.
Qualitative analysis will be used to determine if remineralisation or demineralisation is seen and if so how long this takes.
Three dimensional reconstruction of the images will also be performed.
A54. Where will the research take place?(Tick as appropriate)
UK
Other states in European Union
Other countries in European Economic Area
Other
If Other, give details:
A55. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK, the European
Union or the European Economic Area?
 Yes  No
A56. In how many and what type of host organisations (NHS or other) in the UK is it intended the proposed study will
take place?
Indicate the type of organisation by ticking the box and give approximate numbers if known:
Number of
organisations
Acute teaching NHS Trusts
Acute NHS Trusts
NHS Primary Care Trusts or Local Health Boards in Wales
NHS Trusts providing mental healthcare
NHS Health Boards in Scotland
HPSS Trusts in Northern Ireland
GP Practices
NHS Care Trusts 1
Online Form
NHS REC Application Form − Version 5.1 14
Social care organisations
Prisons
Independent hospitals
Educational establishments 1
Independent research units
Other (give details)
Other:
A57. What arrangements are in place for monitoring and auditing the conduct of the research?
The Research and Development Department of Barts and the London NHS Trust will be conducting an audit of the research.
Will a data monitoring committee be convened?
 Yes  No
If Yes, details of membership of the data monitoring committee (DMC), its standard operating procedures and summaries of
reports of interim analyses to the DMC must be forwarded to the NHS Research Ethics Committee which gives a favourable
opinion of the study.
What are the criteria for electively stopping the trial or other research prematurely?
The trial will be stopped early if rate of demineralisation or remineralisation is greater than expected. If the participant is
unable to wear the appliance or early deamage to teeth and gums occur, the trial will also be stopped.
A58. Has external funding for the research been secured?
 Yes  No
If No, what arrangements are being made to cover any costs of the research? If no external funding is being sought,
please say so:
No external funding is being sought. My salary is being paid by the NHS (My PhD time forms part of my contract) and other
costs will be covered by collective departmental grants.
A59. Has the funder of the research agreed to act as sponsor as set out in the Research Governance Framework?
 Yes  No
Has the employer of the Chief Investigator agreed to act as sponsor of the research?
 Yes  No
Sponsor(must be completed in all cases)
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Name of organisation which will act as sponsor for the research:
Queen Mary, University of London
Status:
 NHS or HPSS care organisation  Academic  Pharmaceutical industry  Medical device industry  Other
If Other, please specify:
Address:  Research Governance, 3rd Floor, Rutland House
42−46 New Road, Whitechapel
London
Post Code: E1 2AX
Telephone:  020 7882 7260 Fax: 02078827276
E−mail: gerry.leonard@bartsandthelondon.nhs.uk
The responsibilities of the sponsor may be shared between co−sponsors. If this applies, name the lead sponsor for the REC
application in this box and enclose a letter giving further details of co−sponsors and their responsibilities.
Sponsor's UK contact point for correspondence with the main REC
Title:  Forename/Initials:  Surname:  
Address:  
Post Code: 
Telephone:  Fax:
E−mail:
A60. Has any responsibility for the research been delegated to a subcontractor?
 Yes  No
A61. Will individual researchers receive any personal payment over and above normal salary for undertaking this
research?
 Yes  No
A62. Will individual researchers receive any other benefits or incentives for taking part in this research?
 Yes  No
A63. Will the host organisation or the researcher's department(s) or institution(s) receive any payment or benefits in
excess of the costs of undertaking the research?
 Yes  No
Online Form
NHS REC Application Form − Version 5.1 16
A64. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g.
financial, share−holding, personal relationship etc.) in the organisation sponsoring or funding the research that may
give rise to a possible conflict of interest?
 Yes  No
A65. Other relevant reference numbers if known(give details and version numbers as appropriate):
Applicant's/organisation's own reference number, e.g. R&D (if available):
Sponsor's/protocol number:
Funder's reference number:
International Standard Randomised Controlled Trial Number (ISRCTN):
European Clinical Trials Database (EudraCT) number:
Project website:  
A66. Other key investigators/collaborators(all grant co−applicants should be listed)
Title: Professor
Forename/Initials: Mark P Surname: Hector
Post: Professor of Child Oral Health
Qualifications: BSc (Hons), BDS, PhD
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street Telephone: 020 7377 7058
London Fax: 020 7377 7419
Postcode: E1 2AD
E−mail: m.p.hector@qmul.ac.uk
Title: Dr
Forename/Initials: Ferranti S.L. Surname: Wong
Post: Senior Lecturer/Honorary Consultant in Paediatric Dentistry
Qualifications: BDS, PhD, MSc, FDS RCS (Ed), FDS RCS (Eng)
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street Telephone: 020 7377 7058
London Fax: 020 7377 7419
Postcode: E1 2AD
E−mail: f.s.l.wong@qmul.ac.uk
A67. If the research involves a specific intervention, (e.g. a drug, medical device, dietary manipulation, lifestyle change
etc.), what arrangements are being made for continued provision of this for the participant (if appropriate) once the
research has finished?
Not Applicable
 PART A: Summary of Ethical Issues
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A68. What do you consider to be the main ethical issues which may arise with the proposed study and what steps will
be taken to address these?
The ethical issues which arise from this study have been minimised to a great extent. The appliance to be used is similar to
an orthodontic appliance and is removable to allow the subjects to follow their oral hygiene regimens. There is very little
change to the participants' lifestyles. Cariogenic challenges are performed extraorally as does evaluation. The participant is
not subjected to any radiation during the study. Details will be taken so that subjects can be contacted easily should there be
any problems with the appliance.
Human enamel/dentine will be used however the infection risk with be negated by sterilisation with gamma radiation. Other
materials to be used in the appliance are inert and unlikely to cause allergic reactions.
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 PART A: Student Page
A70. Give details of the educational course or degree for which this research is being undertaken:
Name and level of course/degree:
PhD
Name of educational establishment:
Institute of Dentistry, Queen Mary, University of London
Name and contact details of educational supervisor:
Dr Ferranti Wong/Prof Mark Hector
Centre for Oral Growth and Development, Dental Institute
Queen Mary, University of London
Turner Street
London E1 2AD
A71. Declaration of supervisor
I have read and approved both the research proposal and this application for the ethical review. I undertake to fulfil the
responsibilities of a supervisor as set out in the Research Governance Framework for Health and Social Care.
Signature: ......................................
Print Name:
Date:  (dd/mm/yyyy)
A one−page summary of the supervisor's CV should be submitted with the application
A72. Declaration by academic sponsor
To be completed by an authorised person on behalf of the academic institution acting as sponsor for student research.
I can confirm on behalf of my academic institution that any necessary indemnity or insurance arrangements will be in place
before this research starts, as required by the Research Governance Framework for Health and Social Care.
Signature: ......................................
Print Name:
Post:
Institution:
Date:  (dd/mm/yyyy)
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 PART B: Section 1 − List of proposed research sites
List below all research sites you plan to include in this study. The name of the site is normally the name of the acute NHS Trust,
GP practice or other organisation responsible for the care of research participants. In some cases it may be an individual unit,
private practice or a consortium – see the guidance notes.
Principal Investigators at other sites should apply to the relevant local Research Ethics Committee for site−specific assessment
(SSA) using Part C of the application form. Applications for SSA may be made in parallel with the main application for ethical
review (once the main REC has validated the application), or following issue of a favourable ethical opinion. Approval for each
site will be issued to you by the main REC following SSA.
1. Name of the research site:
Centre for Oral Growth and Development, Institute of Dentistry
Principal Investigator for the study at this site:
Title:  Miss Forename/Initials:  Janet A Surname:  Davies
Post:  PhD Student
Address:  Queen Mary, University of London
Turner Street
London
Postcode:  E1 2AD
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 PART B: Section 2 − Investigation of medical devices
1. Give details of the medical device(s) to be used in the study
Device description: Lower removable orthodontic appliance
Manufacturer: Centre for Oral Growth and Development, Institute of Dentistry
Use: To be worn in mouth
Length of time  since
device came into use:
40+ years * Does the device have a CE mark?  Yes  No
* For all products with CE mark please attach instructions for use.
2. Does the study involve the use of a new medical device or new implantable material or the use of an existing product
outside the terms of its CE market intended purpose?
 Yes  No
In addition to the instructions for use, the following details should be provided where applicable:
− Description of new device, materials, method of use or operation and a summary of the intended purpose
− Composition of any new implantable materials, including summary of biocompatibility findings from studies to date
− If already CE marked, a summary of any proposed changes to the CE marked intended purpose
The device is essentially a lower removable appliance based on a Hawley type retainer. These are custom made for each
participant under strict cross infection control conditions. A wire connector sits under the tongue and loops around the last
tooth on either side of the mouth. Two acrylic flanges are connected to the wire and sit against the teeth on the cheek side.
These flanges hold perspex cassettes within which the sample of enamel/dentine is housed. There are clasps which hold the
appliance in place. Please see the enclosed diagram.
As stated before, this device is similar to an orthodontic brace and contains no new materials or elements. An example has
been previously been worn with no ill effects.
3. For electrical devices give summarised details of acceptance and safety testing
Not applicable
4. Is a medical device or other commercial company arranging this trial?
 Yes  No
a) Is this trial a clinical investigation requiring notification to the MHRA?
 Yes  No
b) Does the company have a Notice of No Objection from the MHRA?
 Yes  No
c) Has MHRA approval been applied for but not yet received?
 Yes  No
Note: An application can be made prior to receipt of a valid Notice of No Objection from MHRA. The Notice will be issued subject
to the sponsor subsequently receiving a favourable opinion. There is no requirement for a valid Notice of No Objection to be
provided to relevant ethics committee before the research can be given a favourable opinion.
5. Have any of the medical devices been transferred from one organisation (legal entity) to another for the purpose of
this trial?
 Yes  No
Give details:
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6. In cases of equipment or medical devices, what arrangements have been made with the manufacturer to provide
indemnity?
The Queen Mary School of Medicine and Dentistry has arranged for suitable indemnity concerning negligent and non
negligent harm to be in place for this study.
Enclose a copy of the relevant correspondence, with a version number and date.
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 PART B: Section 4 − Use of existing stored samples
1. What samples and how many will be included in the study?
Approximately 30 slabs of enamel/dentine (3mm X 3mm X 2mm)are required
2. What tests/techniques will be carried out on the samples?
These slabs will be initially examined to ensure there are no visible cracks and sectioned using an annular rotary saw. the
samples will be sent to the University of Liverpool where they will be sterilised using gammma radiation. Following wear in
the appliance, they will be analysed using XMT.
3. How will samples be labelled/identified?
Indicate if samples can be considered to be "identified", "coded", "de−identified", "anonymised" or "anonymous", and at what
stage identifiers are removed.
The samples will be completely anonymous.
4. Has specific consent been obtained previously to use stored samples for this purpose?
 Yes  No
5. Does the research involve the analysis or use of genetic material from human biological materials?
 Yes  No
6. Would it be possible to link the results of any genetic analysis back to the individuals?
 Yes  No
7. Is it intended to link the results of any genetic analysis back to individuals?
 Yes  No
8. If the samples are from an established tissue bank, give the name and location of the tissue bank, the organisation
responsible for it and the name of its manager
S J Cannon (s.j.cannon@qmul.ac.uk)
Institute of Dentistry, Queen Mary, University of London
Centre for Clinical and Diagnostic Oral Sciences
Blizard Building
4 Newark Street
Whitechapel
E1 4AT
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9. Signature of the tissue bank manager.
I confirm that I have read this research proposal. I agree to the use of samples from this tissue bank for the purposes stated in
this application.
Signature: ......................................
Date:  (dd/mm/yyyy)
Print name: S J Cannon
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 PART B: Section 5 − Use of newly obtained human biological materials
1. What samples will be collected and/or analysed and by whom will they be collected?
The patient will be asked to provide 2 samples of saliva collected over 1 minute:one will be resting, the other will be while
chewing parafilm. They will be collected by the chief investigator, Janet Davies. The samples will be analysed by at the
Salivary Research Unit, Guy's Hospital.
2. Are the samples taken solely for research purposes (or are they a by−product of those taken primarily for clinical
purposes, i.e. surplus to clinical requirements)?
Samples are solely for research purposes.
3. How will samples be labelled/identified?
Indicate if samples can be considered to be "identified", "coded", "de−identified", "anonymised" or "anonymous" and at what
stage identifiers are removed.
The samples will be coded.
4. Give details of where the sample(s) will be stored, for how long, who will have access and the custodial
arrangements.
Once analysis has been perfomed the sample will be destroyed.
5. Will the research participant retain any rights to the sample(s)?
 Yes  No
6. Is it known how the samples will be used in the future?
 Yes  No
If Yes, give details and indicate if consent will be obtained for the future use of samples:
They will be destroyed they will not be able to be used in future.
7. Does the research involve the analysis or use of genetic material from human biological materials?
 Yes  No
8. Would it be possible to link the results of any genetic analysis back to individuals?
 Yes  No
9. Is it intended to link the results of any genetic analysis back to individuals?
 Yes  No
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 PART B: Section 7 − Declaration
− The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.
− I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice guidelines on the
proper conduct of research.
− If the research is approved I undertake to adhere to the study protocol, the terms of the full application of which the main
REC has given a favourable opinion and any conditions set out by the main REC in giving its favourable opinion.
− I undertake to seek an ethical opinion from the main REC before implementing substantial amendments to the protocol or
to the terms of the full application of which the main REC has given a favourable opinion.
− I undertake to submit annual progress reports setting out the progress of the research.
− I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant guidelines
relating to security and confidentiality of patient or other personal data, including the need to register when necessary with
the appropriate Data Protection Officer.
− I understand that research records/data may be subject to inspection for audit purposes if required in future.
− I understand that personal data about me as a researcher in this application will be held by the relevant RECs and their
operational managers and that this will be managed according to the principles established in the Data Protection Act.
− I understand that the information contained in this application, any supporting documentation and all correspondence with
NHS Research Ethics Committees or their operational managers relating to the application, will be subject to the provisions
of the Freedom of Information Acts. The information may be disclosed in response to requests made under the Acts except
where statutory exemptions apply.
Signature: ......................................
Date:  (dd/mm/yyyy)
Print Name: 
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PART C: Site−Specific Assessment (SSA)
This form should be completed by the Principal Investigator for each site (see glossary)
Part C should be completed and sent with the relevant enclosures to each NHS Research Ethics Committee, which needs to
consider site−specific issues. See guidance notes at the COREC website for further information about the application procedure.
The data in this box is populated from Part A.
Short title and version number:
An in situ study of de/remineralisation of enamel and dentine
Name of NHS Research Ethics Committee to which application for ethical review is being made:
East London and the City Research Ethics Committee 3
Project reference number from above REC:
Name of NHS REC responsible for SSA:
SSA reference (for REC office use only):
Questions C1, C4, C5, C6, C7, C8 and C13a correspond to questions A1, A2, A65, A10, A12, A13 and A29 on main application
form respectively and will populate automatically:
C1. Title of the research(Populated from A1)
Full title: A preliminary in situ study of demineralisation and remineralisation of enamel and dentine slabs
Key words: enamel, dentine, demineralisation, remineralisation, in situ
C2. Who is the Principal Investigator for this study at this site?
Title:  Miss Forename/Initials:  Janet A Surname:  Davies
Post: PhD Student
Qualifications: BSc (Hons), BDS
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street
London
Post Code: E1 2AD
E−mail: janet.a.davies@qmul.ac.uk/janetdavies30@hotmail.com
Telephone: 020 7377 7058
Fax: 020 7377 7419
A copy of a current CV (maximum 2 pages of A4) for the Principal Investigator(s) must be submitted with the application
C2−1. Give the names and posts of other investigators or members of the research team responsible to the local
Principal Investigator for this site.
Include all staff with a significant research role. If the site is a network or consortium, list all participating investigators below.
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Title:
Forename/Initials:
Surname:
Position:
Qualifications:
Role in the research team:
C3. Indicate the number of trials/projects within the organisation that the local Principal Investigator has been involved
with in the previous 12 months:
1
 How many are still current (active or recruiting)?
1
C4. Chief Investigator(Populated from A2)
Title:
  Miss Forename/Initials:  Janet A Surname:  Davies
Post: PhD Student
Qualifications: BSc (Hons), BDS
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Address: Queen Mary, University of London
Turner Street
London
Post Code: E1 2AD
E−mail: janet.a.davies@qmul.ac.uk/janetdavies30@hotmail.com
Telephone: 020 7377 7058
Fax: 020 7377 7419
C5. Other relevant reference numbers if known (Populated from A65)
Applicants/organisation's own reference number, e.g. R&D (if available):
Sponsor's/protocol number:
Funder's reference number:
International Standard Randomized Controlled Trial Number (ISRCTN):
European Clinical Trials Database (EudraCT) Number:
Project website:  
C6. Give a full summary of the purpose, design and methodology of the planned research, including a brief explanation
of the theoretical framework that informs it. It should be clear exactly what will happen to the research participant, how
many times and in what order. Describe any involvement of research participants, patient groups or communities in the
design of the research.
(Populated from A10)
The development of in situ caries models came about to bridge the gap between in vitro (test tube) studies and clinical trials.
In vitro studies are highly controllable and thus unnatural. Clinical trials provide more applicable data, but can often take
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years. An in situ study takes a block of hydroxyapatite which is held in the mouth using an appliance. While the block is
subjected to normal oral conditions, the caries process can been artificially induced or propagated by removing the appliance
from the mouth and subjecting the dental tissue to well−established regimens.
Subjects will be selected using the criteria found later in this document. Essentially they will be fit and healthy with no active
dental disease, but with previous experience of dental decay. Impressions (moulds) will be taken of their teeth and a custom
made appliance (very similar to an orthodontic brace) fabricated. The appliance will have two sterile slabs of hydroxyapatite
secured to it, on either side of the mouth. The appliance will be worn day and night for 28 days. The hydroxyapatite slabs will
be removed and scanned using XMT and scanning microradiography every 7 days. The subjects will be allowed to follow
their normal tooth brushing procedures and to eat normallly, but must remove the appliance before they do this. Subjects will
be asked to rinse their mouth with water prior to reinserting the appliance. Instructions concerning appliance hygiene will be
issued.
C7. Give details of any clinical intervention(s) or procedure(s) to be received by research participants over and above
those which would normally be considered a part of routine clinical care.(These include uses of medicinal products or
devices, other medical treatments or assessments, mental health interventions, imaging investigations and taking samples of
human biological material.)
(Populated from A12)
Additional
Intervention Average number per participant
Average time
taken
(mins/hours/days)
Details of additional intervention or
procedure, who will undertake it, and
what training they have received.
Routine Care Research
Outpatient
Attendance(s) 2 30 
Initial dental examination as part of pre
selection screening, then, should the
subject wish, a post study dental
examination, scale and polish and topical
fluoride application 
Other tissue/bodily
sample 1 30 
We will ask the participants to provide a
sample of saliva. This will allow us to
determine whether the subject produces
enough saliva to be included in the trial
and also to determine the amount of
salivary protein they produce 
C8. Give details of any non−clinical research−related intervention(s) or procedure(s).(These include interviews,
non−clinical observations and use of questionnaires.)
(Populated from A13)
Additional Intervention
Average
number per
participant
Average time
taken
(mins/hours/days)
Details of additional intervention or procedure, who
will undertake it, and what training they have
received.
Other Questionnaire 1 30 In pre selection screening, subjects will be asked to fill
out a medical questionnaire and diet diary. 
C9a. Give the name of the research site for which the PI is responsible:  (Please give the name only. Further details of
locations should be given in C10. The name of the site is normally the name of the acute NHS Trust, GP practice or other
organisation responsible for the care of research participants. In some cases it may be an individual unit, private practice or
consortium – see the guidance notes. Each GP practice is a separate site unless a formal consortium/network is in place.)
Barts and the London NHS Trust
 If you wish to add further information about the definition of the site, please do so below:
Online Form
NHS REC Application Form − Version 5.1 29
C9b. Give the name of the NHS or other organisation with which the PI holds the necessary contract (substantive or
honorary) to undertake the research at this site:
Barts and the London NHS Trust (Substantive)
C9c. For NHS sites, give the name and contact details of the Research Governance contact for the research site at the
care organisation or consortium:
Title: Ms
Forename/Initials:  Penny
Surname: Noble
Address: 3rd Floor Rutland House
42−46 New Road Telephone: 020 7882 7262
Whitechapel, London Fax: 020 7882 7276
Postcode: E1 2AX
E−mail: penny.noble@bartsandthelondon.nhs.uk
C9d. For non−NHS sites, give details of the arrangements for the management and monitoring of the research at this
site:
C10. Specify all locations or departments at which research procedures will be conducted at this site.
Include details of any centres at other NHS care organisations where potential participants may be seen and referred for
inclusion in the research at this site. Give details of any research procedures to be carried out off site, for example in
participants' homes.
Centre for Oral Growth and Development, Institute of Dentistry
C11. How many research participants/samples is it anticipated will be recruited/obtained from this organisation in
total?
15
C12a. Give details of who will be responsible for obtaining informed consent locally, their qualifications and relevant
expertise and training in obtaining consent for research purposes:
Janet Davies, Principal Investigator
C13a. What arrangements have been made for participants who might not adequately understand verbal explanations
or written information given in English, or who have special communication needs? (e.g. translation, use of interpreters
etc.) (Populated from A29)
Barts and the London NHS Trust have a health advocacy service and will provide translators when necessary.
C13b. What local arrangements have been made to meet these requirements (where applicable)?
Not Applicable
See above
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C14. In addition to informing the GP (if required), what arrangements have been made to inform those responsible for
the care of the research participants in the host care organisation of their involvement in the research?
While it is not necessary to inform the participants' General Medical Practitioner, it is necessary to inform their General
Dental Practitioner that they are taking part in the study. Please see GDP letter.
C15. Are the facilities and staffing available locally adequate to perform any necessary procedures or interventions
required for the study, and to deal with any unforeseen consequences of these?(This should include consideration of
procedures and interventions in both control and intervention arms of a study.)
 Yes  No
If Yes, give the information necessary to justify your answer. If No, indicate what arrangements are being made to deal with
the situation:
C16a. Give brief details of a contact point where participants may obtain further information about the study.
Janet Davies, Principal Investigator
C16b. What is the contact point for potential complaints by research participants?
Chief Operating Officer for the Barts and The London, Queen Mary School of Medicine and Dentistry, Wardens Office, 32
Newark Street, Whitechapel London E1 2AA
C16c. Is there a local source where potential participants can obtain independent information about being involved in a
research study?See guidance notes.
Not Applicable
C16d. Please specify the headed paper to be used for the participant information sheet.
Institute of Dentistry, Queen Mary, University of London
C17. If any extra support might be required by research participants as a result of their participation, what local
arrangements are being made to provide this?
Not applicable
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PART C: Declaration
− The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.
− I undertake to abide by the ethical principles underpinning the Declaration of Helsinki and good practice guidelines on
proper conduct of research.
− If the research is approved I undertake to adhere to the study protocol, the terms of the full application of which the main
REC has given a favourable opinion and any conditions set out by the main REC in giving its favourable opinion.
− I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant guidelines
relating to security and confidentiality of patient or other personal data, including the need to register when necessary with
the appropriate Data Protection Controller.
− I understand that research records/data may be subject to inspection for audit purposes if required in future.
− I understand that personal data about me as a researcher in this application will be held by the relevant RECs and their
operational managers and that this will be managed according to the principles established in the Data Protection Act.
− I understand that the information contained in this application, any supporting documentation and all correspondence with
Research Ethics Committees relating to the application will be subject to the provisions of the Freedom of Information Acts.
The information may be disclosed in response to a request under the Acts except where statutory exemptions apply.
Signature of the local Principal Investigator *  ......................................
Date:  (dd/mm/yyyy)
Print Name: 
* The Chief Investigator should sign where s/he is also the local Principal Investigator for this research site.
PART C IS NOW COMPLETE AND SHOULD BE SUBMITTED to the NHS Research Ethics Committee responsible for the
site−specific assessment.
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APPLICANT'S CHECKLIST
All studies except clinical trials of investigational medicinal products
REC Ref:
Short Title of Study: XMT study on the effect of statherin on demineralised lesions in situ
CI Name: Miss Janet A Davies
Sponsor: Barts and the London School of Medicine and Dentistry
Please complete this checklist and send it with your application
Send ONE copy of each document (except where stated)♦ 
ALL accompanying documents must bear version numbers and dates (except where stated)♦ 
When collating please do NOT staple documents as they will need to be photocopied.♦ 
Document Enclosed? Date Version Office use
Covering letter on headed paper  Yes  No 
NHS REC Application Form, Parts A&B Mandatory
Site−Specific Information Form (for SSA)  Yes  No 
Research protocol or project proposal (6 copies) Mandatory
Summary C.V. for Chief Investigator (CI) Mandatory
Summary C.V. for supervisor (student research)   Yes  No 
Research participant information sheet (PIS)  Yes  No 
Research participant consent form  Yes  No 
Letters of invitation to participants  Yes  No 
GP/Consultant information sheets or letters  Yes  No 
Statement of indemnity arrangements  Yes  No 
Letter from sponsor  Yes  No 
Letter from statistician  Yes  No 
Letter from funder  Yes  No 
Referees' or other scientific critique report  Yes  No 
Summary, synopsis or diagram (flowchart) of
protocol in non−technical language  Yes  No 
Interview schedules or topic guides for
participants  Yes  No 
Validated questionnaire  Yes  No 
Non−validated questionnaire  Yes  No 
Copies of advertisement material for research
participants, e.g. posters, newspaper adverts,
website. For video or audio cassettes, please also
provide the printed script. 
 Yes  No 
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WELCOME TO THE NHS RESEARCH ETHICS COMMITTEE APPLICATION FORM
An application form specific to your project will be created from the answers you give to the following questions.
1. Is your project an audit or service evaluation?
 Yes  No
2. Select one research category from the list below:
 Clinical trials of investigational medicinal products
 Clinical investigations or other studies of medical devices
 Other clinical trial or clinical investigation
 Research administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative
     methodology
 Research involving qualitative methods only
 Research limited to working with human tissue samples and/or data
 Research tissue bank
    If your work does not fit any of these categories, select the option below:
 Other research
2a. Select one category from the list below:
 Is this a clinical investigation of a medical device?
 Is this a performance evaluation of an in vitro diagnostic device?
 Is this a drug/device combination of both an investigational medical device and an investigational medicinal product?
 Is this a post−market surveillance study of a CE Marked product?
2b . Please answer the following questions:
a) Does the study involve the use of any ionising radiation?  Yes  No
b) Will you be taking new human tissue samples?  Yes  No
c) Will you be using existing human tissue samples?  Yes  No
3. Is your research confined to one site?
 Yes  No
4. Does your research involve work with prisoners?
 Yes  No
5. Do you plan to include in this research adults unable to consent for themselves through physical or mental
incapacity?
 Yes  No
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6. Is the study, or any part of the study, being undertaken as an educational project?
 Yes  No
6a. Is the project being undertaken in part fulfilment of a PhD or other doctorate?
 Yes  No
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NHS Research Ethics Committee
Application form for a clinical investigation of a medical device
This form should be completed by the Chief Investigator, after reading the guidance notes. See glossary for clarification
of different terms in the application form.
Short title and version number: (maximum 70 characters − this will be inserted as header on all forms)
XMT study on the effect of statherin on demineralised lesions in situ
Name of NHS Research Ethics Committee to which application for ethical review is being made:
Project reference number from above REC:
Submission date:
 PART A: Introduction
A1. Title of the research
Full title: An X−ray microtomography study on the effect of statherin on carious and erosive lesions in situ
Key words: In Situ Caries Model, X−ray microtomography, Statherin
A2. Chief Investigator
Title: Miss
Forename/Initials:  Janet A
Surname: Davies
Post: PhD Student
Qualifications: BSc (Hons), BDS
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Work Address: Queen Mary, University of London
Turner Street
London
Post Code: E1 2AD
E−mail: janetdavies30@hotmail.com, janet.a.davies@qmul.ac.uk
Telephone: 020 7377 7058
Fax: 020 7377 7419
Mobile: 07714750870
A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the application
A3. Proposed study dates and duration
Start date: 01/03/2007
End date: 01/03/2011
Duration: Years:  4 ;    Months:  48
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A4. Primary purpose of the research: (Tick as appropriate)
Commercial product development and/or licensing
Publicly funded trial or scientific investigation
Educational qualification
Establishing a database/data storage facility
Other
Question(s) 5 disabled.
A6. Does this research require site−specific assessment (SSA)? (Advice can be found in the guidance notes on this topic.)
 Yes  No
If No, please justify:
If Yes, an application for SSA should be made for each research site on the Site−Specific Information Form and submitted to
the relevant local Research Ethics Committee. Do not apply for SSA at sites other than the lead site until the main
application has been booked for review and validated by the main Research Ethics Committee.
Management approval to proceed with the research will be required from the R&D office for each NHS care organisation in
which research procedures are undertaken. This applies whether or not the research is exempt from SSA. R&D applications in
England, Wales and Scotland should be made using the Site−Specific Information Form.
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 PART A: Section 1
A7. What is the principal research question/objective? (Must be in language comprehensible to a lay person.)
The principal aim is to study the effect of a small synthesised protein which is identical to the active part of
Statherin protein. Statherin is normally found in human saliva and has an effect on dental decay (caries). This
protein has been shown to be effective in inhibiting the progression of decay in the laboratory. This study
aims to translate the previous finding into a clinical situation. The participant will wear a device in the mouth
which contains a secured block of human tooth tissue (enamel and/or dentine). This device will be removable
and similar in appearance to a removable orthodontic appliance (brace). The enamel/dentine blocks will be
analysed non−destructively outside the mouth using X−ray microtomography (XMT). This is like a
miniaturised high resolution CT Scan which was largely developed in our Centre at Queen Mary. The XMT
allows us to investigate the decayed lesion in 3 dimensions. As the method is non−destructive, repeated
scans can be taken to study the initiation, progression and healing of dental caries. The ultimate objective is
to develop novel, low cost methods to not only help slow the progression of dental decay, but also repair
early carious lesions when they occur.
A8. What are the secondary research questions/objectives? (If applicable, must be in language comprehensible to a lay
person.)
Statherin also appears to reduce, in vitro, the progression of acid erosion in teeth. The in situ study will
examine its effect on erosion in the clinical situation.
A9. What is the scientific justification for the research? What is the background? Why is this an area of
importance?(Must be in language comprehensible to a lay person.)
Dental decay is an almost ubiquitous disease; it still causes pain and misery to those effected and its'
treatment puts a great burden (approx. £1100M) on already limited NHS resources. It is also preventable.
The introduction of fluoridated toothpaste has greatly decreased its incidence. Fluoridation of the water
supply would decrease disease levels further especially in areas of social deprivation. This happens in about
10% of the UK population, and there is little evidence of greater coverage occurring in the near future. Acid
erosion of teeth is also a growing problem especially in the young; 33% of 15 year olds in U.K. suffer from
this (Children’s Dental Health Survey, 2003). While this 2 processes differ in their aetiology, the chemical
effect on the tooth substance is the same.
Human saliva is supersaturated with respect to calcium and phosphate, the mineral component of teeth. Most
of the calcium ions are bound to salivary proteins. Under acidic conditions tooth enamel is more liable to
dissolve (i.e. tooth decay). However, the salivary proteins acting like a calcium buffer, release calcium ions
thereby limiting the damage to enamel and encourage its repair. This mechanism helps to maintain the
integrity of the tooth surface during acid attack. Statherin is the most potent of all the salivary proteins
involved in maintaining calcium and phosphate levels. Previous laboratory work within our centre has shown
that Statherin peptides (small portions of the protein) can prevent and repair carious lesions. As the peptide is
based on a naturally occurring substance, we believe it will enhance the natural protective process without
unwanted side effects. We will test these peptides intra−orally which may, should this research back up our
laboratory work, lead to the development of oral hygiene products based on this. (Patent granted)
The use of intra oral devices to study the progression of dental caries is not new; they were initially used to
study the effects of fluoride on enamel in the early 70s. Since then, however, they have been refined and
improved. Intra oral caries devices take two forms: removable or fixed. Removable appliances can be either
orthodontic (brace) or partial dentures. Fixed appliances are either metal bands or gold crowns which are
cemented to a tooth. Each system has its advantages: fixed systems, while having high compliance, may
require some preparation of tooth structure; removable systems are more adaptable and the sample is less
likely to be lost. Our intra oral device will require that the enamel/dentine sample is removable, in order for it
to be used with X−ray microtomography (XMT) and thus the subject is not exposed to any radiation.
XMT was developed in 1982 and has the advantages of being non−destructive, high resolution (at micron
level) and quantitative in measuring mineral concentration. Like the well−known CT scan, the XMT images
are free of superimposition and therefore 3−dimensional reconstruction of the sample is possible. Other
techiques which have previously been used to analyse samples from intra oral devices are limited in that the
sample needs to be sectioned and is therefore unusable for further studies. The most popular methods are
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transverse microradiography and microhardness. However, with XMT, the sample can be repeatedly
scanned and so the progression of the dissolution and repair of enamel/dentine can be monitored. This
technique has been used in laboratory studies and it will be novel to study the samples in an intra−oral
device.
A10−1. Give a full summary of the purpose, design and methodology of the planned research, including a brief
explanation of the theoretical framework that informs it. It should be clear exactly what will happen to the research
participant, how many times and in what order.
This section must be completed in language comprehensible to the lay person. It must also be self−standing as it will be
replicated in any applications for site−specific assessment on the Site−Specific Information Form. Do not simply reproduce or
refer to the protocol. Further guidance is available in the guidance notes.
The development of in situ caries models came about to bridge the gap between in vitro (test tube) studies
and clinical trials. In vitro studies are highly controllable and thus unnatural. Clinical trials provide more
applicable data, but can often take years. An in situ study takes a block of dental tissue which is held in the
mouth using an appliance. While the block is subjected to normal oral conditions, the caries process can
been artificially induced or propagated by removing the appliance from the mouth and using well−established
techniques.
Subjects will be selected using the criteria found later in this document. Essentially they will be fit and healthy
with no active dental disease, but with previous experience of dental decay. Impressions (moulds) will be
taken of their teeth and a custom made appliance (very similar to an orthodontic brace) fabricated. The
appliance will have at least two sterilised blocks of enamel/dentine secured to it, on either side of the mouth.
The appliance will be worn day and night for 28 days. The tooth blocks will be removed and scanned using
XMT every 7 days. The subjects will be allowed to follow their normal tooth brushing procedures, but must
remove the appliance before they do this. Subjects will be asked to rinse their mouth with water prior to
reinserting the appliance. Instructions concerning appliance hygiene will be issued. The participants will also
be asked to complete a diary of eating habits.
A derivative of the protein, Statherin, will be tested to see what effects it has on the carious process.
Statherin is a protein found in human saliva which is involved in calcium and phosphate balance − these two
ions are the main constituents of tooth structure. The Statherin derivative should prevent progression /
possibly reverse dental decay. A further 28 day test will ensue. We will use a positive control solution
containing fluoride which is known to heal carious lesions.
A10−2. In which parts of the research have patients, members of the public or service users been involved?
As user−researchers
As members of a research project group
As advisor to a project
As members of a departmental or other wider research strategy group
None of the above
Please provide brief details if applicable:
Healthy volunteers will be required for this project. It is intended that this group will include staff and students
from Queen Mary, University of London. Patients will not be used.
A10−3. Could the research lead to the development of a new product/process or the generation of intellectual property?
 Yes  No  Not sure
A11. Will any intervention or procedure, which would normally be considered a part of routine care, be withheld from
the research participants?
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 Yes  No
A12. Give details of any clinical intervention(s) or procedure(s) to be received by research participants over and above
those which would normally be considered a part of routine clinical care.(These include uses of medicinal products or
devices, other medical treatments or assessments, mental health interventions, imaging investigations and taking samples of
human biological material.)
Additional
Intervention Average number per participant
Average time
taken
(mins/hours/days)
Details of additional intervention or
procedure, who will undertake it, and
what training they have received.
Routine Care Research
Outpatient
Attendance(s) 2 30 
Initial dental examination as part of pre
selection screening, then ,should the
subject wish, a post study dental
examination, scale and polish and topical
fluoride application  
Other tissue/bodily
sample 1 30 
We will ask the participants to provide a
sample of saliva. This will allow us to
determine whether the subject produces
enough saliva to be included in the trial
and also to determine the amount of
salivary protein they produce  
A13. Give details of any non−clinical research−related intervention(s) or procedure(s).(These include interviews,
non−clinical observations and use of questionnaires.)
Additional Intervention
Average
number per
participant
Average time
taken
(mins/hours/days)
Details of additional intervention or procedure, who
will undertake it, and what training they have
received.
Other Questionnaire 1 30 
In pre selection screening, subjects will be asked to fill
out a medical questionnaire and retrospective diet
diary. 
A14. Will individual or group interviews/questionnaires discuss any topics or issues that might be sensitive,
embarrassing or upsetting, or is it possible that criminal or other disclosures requiring action could take place during
the study (e.g. during interviews/group discussions, or use of screening tests for drugs)?
 Yes  No
If Yes, give details of procedures in place to deal with these issues
A medical history questionnaire and a retrospective diet diary will be completed prior to inclusion in the study. All
information will be treated with the strictest confidence.
The Information Sheet should make it clear under what circumstances action may be taken
A15. What is the expected total duration of participation in the study for each participant?
The total duration is expected to be 28 days however as this is a preliminary study, it may be less.
A16. What are the potential adverse effects, risks or hazards for research participants either from giving or withholding
medications, devices, ionising radiation, or from other interventions (including non−clinical)?
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Potentially, the device used could cause accumulation of plaque which could lead to carious lesions and/or
peridontal disease developing should they not follow oral hygiene and appliance hygiene advice.   This will be
limited by the subjects ability to remove the appliance to carry out normal oral hygiene procedures. We will
also select subjects with good periodontal health and no active carious lesions. All subjects will be offered a
dental examination or check−up during the experimental period and will be given, should they wish it, a post
study scale, polish and application of topical fluoride.
There is also a theoretical risk that the appliance may break or the tooth tissue become dislodged. These
appliances are frequently used by orthodontic collegues with few problems; we will however provide a
contact telephone number and written instructions should there be any problems.
A17. What is the potential for pain, discomfort, distress, inconvenience or changes to lifestyle for research
participants?
As the device will be based on an orthodontic type appliance, the levels of discomfort will be low. We
anticipate that subjects will take a day or two to acclimatise to the device. The subjects should not need to
alter their lifestyle unduly. It is likely that our subjects will be selected from the clinical and laboratory staff at
Barts and the London NHS Trust therefore reducing the inconvience of unnecessary attendances.
A18. What is the potential for benefit to research participants?
None
A19. What is the potential for adverse effects, risks or hazards, pain, discomfort, distress, or inconvenience to the
researchers themselves? (if any)
None
A20. How will potential participants in the study be (i) identified, (ii) approached and (iii) recruited?
Give details for cases and controls separately if appropriate:
(i) Identification of subjects will be through lists of students (both undergraduate and postgraduate) and staff
at Queen Mary College.
(ii) I will approach them personally, issue notices at lectures and use the internal email system.
(iii) Once the subject has expressed an initial willingness to take part, I will provide them will further
information both written and orally and organise an appointment for them to attend for a pre assessment
screening. If the subject fulfils the inclusion criteria, written consent will be obtained and the subject will be
enrolled.
A21. Where research participants will be recruited via advertisement, give specific details.
Not Applicable
If applicable, enclose a copy of the advertisement/radio script/website/video for television (with a version number and date).
A22. What are the principal inclusion criteria?(Please justify)
Subjects will be between 18 and 50 years old. They will be approximately 50:50 male to female and come
from a range of racial/ethnic backgrounds. They will be medically fit and well. Their dental health will be
Online Form
NHS REC Application Form − Version 5.6 9
stable at present, but they will have a range of past caries experience denoted by restorations and/or
extractions (DMFT greater than or equal to 1). These criteria have been taken the consensus reached at the
Conference on Clinical Aspects of De/Remineralisation of Teeth (June 1994), Rochester, New York.
A23. What are the principal exclusion criteria?(Please justify)
Subjects will not be included if they are taking medication which causes reduced saliva flow. They will not be
taking antibiotics or have taken them in the last two months. They will not be allergic to any of the products to
any of the agents used in the study. They will not have active carious lesions or periodontal pockets of 5mm
or more. Participants must not be wearing removable prostheses (dentures) or orthodontic appliances.
Subjects who live in a fluoridated area will be excluded as will those who take fluoride supplements (not
including toothpaste). Subjects will be excluded if their unstimulated whole saliva flow rate is less than
0.2ml/min and their stimulated whole saliva flow rate is less than 1.0ml/min. These criteria have been taken
the consensus reached at the Conference on Clinical Aspects of De/Remineralisation of Teeth (June 1994),
Rochester, New York.
A24. Will the participants be from any of the following groups?(Tick as appropriate)
Children under 16
Adults with learning disabilities
Adults who are unconscious or very severely ill
Adults who have a terminal illness
Adults in emergency situations
Adults with mental illness (particularly if detained under Mental Health Legislation)
Adults with dementia
Prisoners
Young Offenders
Adults in Scotland who are unable to consent for themselves
Healthy Volunteers
Those who could be considered to have a particularly dependent relationship with the investigator, e.g. those in care
homes, medical students
Other vulnerable groups
Justify their inclusion.
Healthy volunteers are the only people who can be used in this study. The disease process to be studied is
artificially induced in the enamel/dentine blocks. If the participent had active dental disease, the device would
have the potential to cause irreversible harm to the teeth and gums.
No participants from any of the above groups
A25. Will any research participants be recruited who are involved in existing research or have recently been involved in
any research prior to recruitment?
 Yes  No  Not Known
If Yes, give details and justify their inclusion. If Not Known, what steps will you take to find out?
A26. Will informed consent be obtained from the research participants?
 Yes  No
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If Yes, give details of who will take consent and how it will be done. Give details of any particular steps to provide information
(in addition to a written information sheet) e.g. videos, interactive material.
If participants are to be recruited from any of the potentially vulnerable groups listed in A24, give details of extra steps taken
to assure their protection. Describe any arrangements to be made for obtaining consent from a legal representative.
If consent is not to be obtained, please explain why not.
Consent will be taken by the chief researcher. Careful explanation will be given and a written details will be
provided. The subjects will be given time to think their participation over and to discuss it with family and friends.
Copies of the written information and all other explanatory material should accompany this application.
A27. Will a signed record of consent be obtained?
 Yes  No
If Yes, attach a copy of the information sheet to be used, with a version number and date.
A28. How long will the participant have to decide whether to take part in the research?
Subjects will be given at least 24 hours to decide whether to participate or not. As the appliance is
removable, the participant may withdraw from the trial at any point.
A29. What arrangements have been made for participants who might not adequately understand verbal explanations or
written information given in English, or who have special communication needs? (e.g. translation, use of interpreters etc.)
Barts and the London NHS Trust have a health advocacy service and will provide translators when
necessary.
A30. What arrangements are in place to ensure participants receive any information that becomes available during the
course of the research that may be relevant to their continued participation?
A record will be taken comprising of the subjects home address, work address, contact phone number and
email address. These will be coded to ensure anonymity. It will be noted if the subject is happy for us to
communicate with them by the above channels and which is their preferred method.
A30−1. What steps would you take if a participant, who has given informed consent, loses capacity to consent during
the study?Tick one option only.
 The participant would be withdrawn from the study. Data or tissue which is not identifiable to the research team may be
retained. Any identifiable data or tissue would be anonymised or disposed of.
 The participant would be withdrawn from the study. Identifiable data or tissue already collected with consent would be
retained and used in the study.
 The participant would continue to be included in the study.
 Not applicable – informed consent will not be sought from any participants in this research.
Further details:
A31. Does this study have or require approval of the Patient Information Advisory Group (PIAG) or other bodies with a
similar remit?(see the guidance notes)
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 Yes  No
A32a. Will the research participants' General Practitioner (and/or any other health professional responsible for their
care) be informed that they are taking part in the study?
 Yes  No
If Yes, enclose a copy of the information sheet/letter for the GP/health professional with a version number and date.
A32b. Will permission be sought from the research participants to inform their GP or other health professional before
this is done?
 Yes  No
If No to either question, explain why not
While it is not necessary to inform the participants' General Medical Practitioner, it is necessary to inform their
General Dental Practitioner that they are taking part in the study. Please see GDP letter.
It should be made clear in the patient information sheet if the research participant's GP/health professional will be informed.
A33. Will individual research participants receive any payments for taking part in this research?
 Yes  No
If Yes, indicate how much and on what basis this has been decided:
This has been decided on due to the inconvenience of wearing the device and the regime that needs to be
followed.
A34. Will individual research participants receive reimbursement of expenses or any other incentives or benefits for
taking part in this research?
 Yes  No
A35. Insurance/indemnity to meet potential legal liabilities
Note: References in this question to NHS indemnity schemes include equivalent schemes provided by Health and Personal
Social Services (HPSS) in Northern Ireland.
A35−1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the
sponsor(s) for harm to participants arising from the management of the research?
Note: Where a NHS organisation has agreed to act as the sponsor, indemnity is provided through NHS schemes. Indicate if this
applies (there is no need to provide documentary evidence). For all other sponsors, describe the arrangements and provide
evidence.
 NHS indemnity scheme will apply
 Other insurance or indemnity arrangements will apply (give details below)
The Queen Mary School of Medicine and Dentistry has arranged for suitable indemnity concerning negligent
harm to be in place for this study.
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Please enclose a copy of relevant documents.
A35−2. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the
sponsor(s) or employer(s) for harm to participants arising from the design of the research?
Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided
through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol authors
(e.g. company employees, university members), describe the arrangements and provide evidence.
 NHS indemnity scheme will apply to all protocol authors
 Other insurance or indemnity arrangements will apply (give details below)
The Queen Mary School of Medicine and Dentistry has arranged for suitable indemnity concerning negligent
harm to be in place for this study.
Please enclose a copy of relevant documents.
A35−3. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of
investigators/collaborators and, where applicable, Site Management Organisations, arising from harm to participants in
the conduct of the research?
Note: Where the participants are NHS patients, indemnity is provided through NHS schemes or through professional indemnity.
Indicate if this applies to the whole of the study (there is no need to provide documentary evidence). Where non−NHS sites are
to be included in the research, including private practices, describe the arrangements which will be made at these sites and
provide evidence.
 All participants will be recruited at NHS sites and NHS indemnity scheme or professional indemnity will apply
 Research includes non−NHS sites (give details of insurance/indemnity arrangements for these sites below)
The Queen Mary School of Medicine and Dentistry has arranged for suitable indemnity concerning negligent
harm to be in place for this study.
Please enclose a copy of relevant documents.
A36. Has the sponsor(s) made arrangements for payment of compensation in the event of harm to the research
participants where no legal liability arises?
 Yes  No
If Yes, give details of the compensation policy:
The Queen Mary School of Medicine and Dentistry has arranged for suitable indemnity concerning negligent
harm to be in place for this study.
Please enclose a copy of relevant documents.
A37. How is it intended the results of the study will be reported and disseminated?(Tick as appropriate)
Peer reviewed scientific journals
Internal report
Conference presentation
Other publication
Submission to regulatory authorities
Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee on
behalf of all investigators
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Written feedback to research participants
Presentation to participants or relevant community groups
Other/none e.g. Cochrane Review, University Library
A38. How will the results of research be made available to research participants and communities from which they are
drawn?
By publication in journals and presentations at conferences. The participants may also approach me directly
to discuss the results.
A39. Will the research involve any of the following activities at any stage (including identification of potential research
participants)?(Tick as appropriate)
Examination of medical records by those outside the NHS, or within the NHS by those who would not normally have
access
Electronic transfer by magnetic or optical media, e−mail or computer networks
Sharing of data with other organisations
Export of data outside the European Union
Use of personal addresses, postcodes, faxes, e−mails or telephone numbers
Publication of direct quotations from respondents
Publication of data that might allow identification of individuals
Use of audio/visual recording devices
Storage of personal data on any of the following:
Manual files including X−rays
NHS computers
Home or other personal computers
University computers
Private company computers
Laptop computers
Further details:
A40. What measures have been put in place to ensure confidentiality of personal data? Give details of whether any
encryption or other anonymisation procedures have been used and at what stage:
Personal data will be coded and processed securely in line with the Data Protection Act 1998. It will be stored
on the Queen Mary computer network and will accessible using a secure password. Once the trial is
completed the personal data will be erased.
A41. Where will the analysis of the data from the study take place and by whom will it be undertaken?
Analysis of the data will take place at the Department of Biophysics in relation to Dentistry at Queen Mary,
University of London. The principal researcher will analyse the data.
A42. Who will have control of and act as the custodian for the data generated by the study?
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Janet Davies, principal investigator
A43. Who will have access to research participants' or potential research participants' health records or other personal
information? Where access is by individuals outside the normal clinical team, justify and say whether consent will be sought.
Janet Davies, principal investigator
A44. For how long will data from the study be stored?
20 Years  0 Months
Give details of where they will be stored, who will have access and the custodial arrangements for the data:
The personal data will be erased as soon as the trial is completed. The study data will be stored for 20 years in
the archive at Barts and the London NHS Trust. The data will be the property of the Centre for Oral Growth and
Development, Queen Mary, University of London.
A45−1. How has the scientific quality of the research been assessed? (Tick as appropriate)
Independent external review
Review within a company
Review within a multi−centre research group
Review within the Chief Investigator's institution or host organisation
Review within the research team
Review by educational supervisor
Other
Justify and describe the review process and outcome. If the review has been undertaken but not seen by the researcher,
give details of the body which has undertaken the review:
A45−2. How have the statistical aspects of the research been reviewed? (Tick as appropriate)
Review by independent statistician commissioned by funder or sponsor
Other review by independent statistician
Review by company statistician
Review by a statistician within the Chief Investigator’s institution
Review by a statistician within the research team or multi−centre group
Review by educational supervisor
Other review by individual with relevant statistical expertise
In all cases give details below of the individual responsible for reviewing the statistical aspects. If advice has been provided
in confidence, give details of the department and institution concerned.
Title: Forename/Initials: Surname:
Department:
Institution:
Work Address:
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Postcode:
Telephone:
Fax:
Mobile:
E−mail:
Please enclose a copy of any available comments or reports from a statistician.
Question(s) 46−47 disabled.
A48. What is the primary outcome measure for the study?
To measure progression of demineralisation or remineralisation in carious lesions
A49. What are the secondary outcome measures?(if any)
To measure progression of demineralisation or remineralisation in erosive lesions
A50. How many participants will be recruited?
If there is more than one group, state how many participants will be recruited in each group. For international studies, say how
many participants will be recruited in the UK and in total.
We aim to recruit between 10 and 15 volunteers. As we will be performing a crossover trial, each participant
will act as his/her own control.
A51. How was the number of participants decided upon?
There is some limitation of participant numbers when using the XMT system; the scan time is long
(approximately 12 hours). Large numbers of subjects would not be feasible. XMT, however, is very high
resolution (~8um)thus can detect very small amounts of   demineralisation.
If a formal sample size calculation was used, indicate how this was done, giving sufficient information to justify and
reproduce the calculation.
A52. Will participants be allocated to groups at random?
 Yes  No
If yes, give details of the intended method of randomisation:
Participants will be randomly allocated to either the demineralisation or remineralisation study. Lists will
constructed from random nuber tables. Form of treatment will be allocated to participants in sequence
envelopes be done using numbered opaque envelopes.
A53. Describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) by which
the data will be evaluated to meet the study objectives.
Qualitative analysis will be used to determine if remineralisation or demineralisation is seen and if so how
long this takes. Three dimensional reconstruction of the images will also be performed.
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A54. Where will the research take place?(Tick as appropriate)
UK
Other states in European Union
Other countries in European Economic Area
Other
If Other, give details:
A55. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK, the European
Union or the European Economic Area?
 Yes  No
A56. In how many and what type of host organisations (NHS or other) in the UK is it intended the proposed study will
take place?
Indicate the type of organisation by ticking the box and give approximate numbers if known:
Number of
organisations
Acute teaching NHS Trusts
Acute NHS Trusts
NHS Primary Care Trusts or Local Health Boards in Wales
NHS Trusts providing mental healthcare
NHS Health Boards in Scotland
HPSS Trusts in Northern Ireland
GP Practices
NHS Care Trusts 1
Social care organisations
Prisons
Independent hospitals
Educational establishments 1
Independent research units
Other (give details)
Other:
A57. What arrangements are in place for monitoring and auditing the conduct of the research?
The Research and Development Department of Barts and the London NHS Trust will be conducting an audit
of the research.
A57a. Will a data monitoring committee be convened?
 Yes  No
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If Yes, details of membership of the data monitoring committee (DMC), its standard operating procedures and summaries of
reports of interim analyses to the DMC must be forwarded to the NHS Research Ethics Committee which gives a favourable
opinion of the study.
What are the criteria for electively stopping the trial or other research prematurely?
The trial will be stopped early if rate of demineralisation or remineralisation is greater than expected. If the
participant is unable to wear the appliance or early damage to teeth and gums occur, the trial will also be
stopped.
A58. Has external funding for the research been secured?
 Yes  No
If Yes, give details of funding organisation(s) and amount secured and duration:
Organisation: St. Bartholomew's and The Royal London Charitable Foundation
Address: Research and Development Office
3rd Floor, Rutland House
42−46 New Road, London
Post Code: E1 2AX
UK contact: Dr. Karen Matthews
Telephone: 020 7882 7251
Fax: 020 7882 7277
Mobile:
E−mail: karen.matthews@bartsandthelondon.nhs.uk
Amount (£): 98,236     Duration:  48 Months
A59. Has the funder of the research agreed to act as sponsor as set out in the Research Governance Framework?
 Yes  No
Has the employer of the Chief Investigator agreed to act as sponsor of the research?
 Yes  No
Lead sponsor (must be completed in all cases)
Name of organisation which will act as the lead sponsor for the research:
Barts and the London School of Medicine and Dentistry
Status:
 NHS or HPSS care organisation  Academic  Pharmaceutical industry  Medical device industry  Other
If Other, please specify:
Address:  24−26 Walden Street
Whitechapel
London
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Post Code: E1 2AN
Telephone:  020 7882 7260
Fax: 020 7882 7276
Mobile:
E−mail: gerry.leonard@bartsandthelondon.nhs.uk
Sponsor's UK contact point for correspondence with the main REC (must be completed in all cases)
Title:  Mr Forename/Initials:  Gerry Surname:  Leonard
Work Address:  24−26 Walden Street
Whitechapel
London
Post Code: E1 2AN
Telephone:  020 7882 7260
Fax: 020 7882 7276
Mobile:
E−mail: gerry.leonard@bartsandthelondon.nhs.uk
Co−sponsors
Are there any co−sponsors for this research?
 Yes  No
A60. Has any responsibility for the research been delegated to a subcontractor?
 Yes  No
A61. Will individual researchers receive any personal payment over and above normal salary for undertaking this
research?
 Yes  No
A62. Will individual researchers receive any other benefits or incentives for taking part in this research?
 Yes  No
A63. Will the host organisation or the researcher's department(s) or institution(s) receive any payment or benefits in
excess of the costs of undertaking the research?
 Yes  No
A64. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g.
financial, share−holding, personal relationship etc.) in the organisations sponsoring or funding the research that may
give rise to a possible conflict of interest?
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 Yes  No
A65. Research reference numbers: (give any relevant references for your study):
Applicant's/organisation's own reference number, e.g. R&D (if available):
Sponsor's/protocol number:
Funder's reference number:
International Standard Randomised Controlled Trial Number (ISRCTN):
ClinicalTrials.gov Identifier (NCT number):
Project website:  
A66. Other key investigators/collaborators (all grant co−applicants or protocol co−authors should be listed)
Title:  Dr. Forename/Initials:  Paul Surname:  Anderson
Post: Reader in Biophysics in Relation to Dentistry
Qualifications: BSc (Hons), PhD
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Work Address: Queen Mary, University of London
Turner Street
London
Postcode: E1 2AD
Telephone: 020 7882 7933
Fax: 020 7377 7419
Mobile:
E−mail: p.anderson@qmul.ac.uk
Title:  Prof. Forename/Initials:  Mark P. Surname:  Hector
Post: Professor of Child Oral Health
Qualifications: BSc (Hons), BDS, PhD
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Work Address: Queen Mary, University of London
Turner Street
London
Postcode: E1 2AD
Telephone: 020 7377 7058
Fax: 020 7377 7419
Mobile:
E−mail: m.p.hector@qmul.ac.uk
Title:  Dr. Forename/Initials:  Ferranti S.L. Surname:  Wong
Post: Senior Lecturer/Honorary Consultant in Paediatric Dentistry
Qualifications: BDS, PhD, MSc, FDS RCS (Ed), FDS RCS (Eng)
Organisation: Centre for Oral Growth and Development, Institute of Dentistry
Work Address: Queen Mary, University of London
Turner Street
London
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Postcode: E1 2AD
Telephone: 020 7377 7058
Fax: 020 7377 7419
Mobile:
E−mail: f.s.l.wong@qmul.ac.uk
A67. What arrangements are being made for continued provision of the intervention for participants, if appropriate,
once the research has finished? May apply to any clinical intervention, including a drug, medical device, mental health
intervention, complementary therapy, physiotherapy, dietary manipulation, lifestyle change, etc.
Not applicable
 PART A: Summary of Ethical Issues
A68. Overview of the research
To provide all the information required by the REC, we ask a number of specific questions. This section invites you to give an
overview using language comprehensible to lay reviewers and members of the public. Please read the guidance notes for
advice on this section.
A68−1. Lay summary. Please provide a brief summary of the research (maximum 300 words) in lay language. This summary
will be published on the website of the National Research Ethics Service following the ethical review.
This study examines the effect of a small synthesised protein which is identical to the active part of Statherin
protein. Statherin is normally found in human saliva and has an effect on dental decay (caries). This protein has
been shown to be effective in inhibiting the progression of decay in the laboratory. This study aims to translate
the previous finding into a clinical situation. The participant will wear a device in the mouth for a period of 4
weeks. The device contains a secured block of human tooth tissue (enamel and/or dentine). This device will be
removable and similar in appearance to a removable orthodontic appliance (brace). The enamel/dentine blocks
will be analysed non−destructively outside the mouth using X−ray microtomography (XMT). This is like a
miniaturised high resolution CT Scan which was largely developed in our Centre at Queen Mary. The XMT
allows us to investigate the decayed lesion in 3 dimensions. As the method is non−destructive, repeated scans
can be taken to study the initiation, progression and healing of dental caries. The ultimate objective is to develop
novel, low cost methods to not only help slow the progression of dental decay, but also repair early carious
lesions when they occur.
A68−2. Summary of main issues. Please summarise the main ethical and design issues arising from the study and say how
you have addressed them.
The ethical issues which arise from this study have been minimised to a great extent. The appliance to be used
is similar to an orthodontic appliance and is removable to allow the subjects to follow their oral hygiene
regimens. There is very little change to the participants' lifestyles. Cariogenic challenges are performed
extraorally as does evaluation. The participant is not subjected to any radiation during the study. Details will be
taken so that subjects can be contacted easily should there be any problems with the appliance. The peptide is
based on a naturally occurring substance and is not expected to have any undue side effects.
Human enamel/dentine will be used however the infection risk with be negated by sterilisation with gamma
radiation. Other materials to be used in the appliance are inert and unlikely to cause allergic reactions.
Question(s) 69 disabled.
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 PART A: Student Page
A70. Give details of the educational course or degree for which this research is being undertaken:
Name of student:
Miss Janet A. Davies
Name and level of course/degree:
MPhil/PhD
Name of educational establishment:
Queen Mary and Westfield College
University of London
Name and contact details of educational supervisor:
Prof Mark Hector/Dr Ferranti Wong
Department of Oral Growth and Development
A71. Declaration of educational supervisor
I have read and approved both the research proposal and this application for the ethical review. I am satisfied that the scientific
content of the research is satisfactory for an educational qualification at this level. I undertake to fulfil the responsibilities of a
supervisor as set out in the Research Governance Framework for Health and Social Care.
Signature: ......................................
Print Name:
Date:  (dd/mm/yyyy)
A one−page summary of the supervisor's CV should be submitted with the application
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 PART B: Section 1 − List of proposed research sites
List below all research sites you plan to include in this study. The name of the site is normally the name of the acute NHS Trust,
GP practice or other organisation responsible for the care of research participants. In some cases it may be an individual unit,
private practice or a consortium – see the guidance notes.
Principal Investigators at other sites should apply to the relevant local Research Ethics Committee for site−specific assessment
(SSA) using the Site−Specific Information Form. Applications for SSA may be made in parallel with the main application for
ethical review (once the main REC has validated the application), or following issue of a favourable ethical opinion. Approval for
each site will be issued to you by the main REC following SSA.
1. Name of the research site:
Centre for Oral Growth and Development, Institute of Dentistry
Principal Investigator for the study at this site:
Title:  Miss Forename/Initials:  Janet A. Surname:  Davies
Post:  PhD Student
Work Address:  Queen Mary, University of London
Turner Street
London
Postcode:  E1 4AD
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 PART B: Section 2 − Investigation of medical devices
1. Give details of the medical device(s) to be used in the study
Device description: Lower removable orthodontic appliance
Manufacturer: Centre for Oral Growth and Development, Institute of Dentistry
Use: To be worn in mouth
Length of time  since
device came into use:
40+ years * Does the device have a CE mark?  Yes  No
Device description: Statherin peptide derivative
Manufacturer: Centre for Oral Growth and Development, Institute of Dentistry
Use: To be used extra−orally
Length of time  since
device came into use:
N/A * Does the device have a CE mark?  Yes  No
* For all products with CE mark please attach instructions for use.
2. Does the study involve the use of a new medical device or new implantable material or the use of an existing product
outside the terms of its CE market intended purpose?
 Yes  No
In addition to the instructions for use, the following details should be provided where applicable:
− Description of new device, materials, method of use or operation and a summary of the intended purpose
− Composition of any new implantable materials, including summary of biocompatibility findings from studies to date
− If already CE marked, a summary of any proposed changes to the CE marked intended purpose
The device is essentially a lower removable appliance based on a Hawley type retainer. These are custom
made for each participant under strict cross infection control conditions. A wire connector sits under the tongue
and loops around the last tooth on either side of the mouth. Two acrylic flanges are connected to the wire and sit
against the teeth on the cheek side. These flanges hold perspex cassettes within which the sample of
enamel/dentine is housed. There are clasps which hold the appliance in place. Please see the enclosed
diagram.
As stated before, this device is similar to an orthodontic brace and contains no new materials or elements. In
previous studies, it been worn with no ill effects.
The Statherin peptide is based on a naturally occurring salivary protein and is designed to enhance the
protective effect of saliva against cariogenic/erosive challenges. It has also been assessed for toxcity in a
mucous membrane tissue−based model.
3. For electrical devices give summarised details of acceptance and safety testing
Not Applicable
4. Is a medical device or other commercial company arranging this trial?
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 Yes  No
a) Is this trial a clinical investigation requiring notification to the MHRA?
 Yes  No
b) Does the company have a Notice of No Objection from the MHRA?
 Yes  No
c) Has MHRA approval been applied for but not yet received?
 Yes  No
Note: An application can be made prior to receipt of a valid Notice of No Objection from MHRA. The Notice will be issued subject
to the sponsor subsequently receiving a favourable opinion. There is no requirement for a valid Notice of No Objection to be
provided to relevant ethics committee before the research can be given a favourable opinion.
5. Have any of the medical devices been transferred from one organisation (legal entity) to another for the purpose of
this trial?
 Yes  No
Give details:
6. In cases of equipment or medical devices, what arrangements have been made with the manufacturer to provide
indemnity?
The Queen Mary School of Medicine and Dentistry has arranged for suitable indemnity concerning negligent
and non negligent harm to be in place for this study.
Enclose a copy of the relevant correspondence, with a version number and date.
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 PART B: Section 4 − Use of existing stored human tissue (or other human biological materials)
1. What types of human tissue or other biological material will be included in the study?
Approximately 30 slabs of enamel/dentine (3mm X 3mm X 2mm)are required
2. Will the samples be released to the researcher:
In fully anonymised form? (link to stored tissue and data is broken)
 Yes  No
In linked anonymised form? (linked to stored tissue but donor not identifiable to researchers)
 Yes  No
In a form in which the donor could be identifiable to researchers?
 Yes  No
If Yes, please justify:
The samples will be completely anonymous.
3. What types of test or analysis will be carried out on the samples?
These slabs will be initially examined to ensure there are no visible cracks and sectioned using an annular
rotary saw. the samples will be sent to the University of Liverpool where they will be sterilised using gammma
radiation. Following wear in the appliance, they will be analysed using XMT
4. Has consent been obtained previously from donors to use stored samples for this purpose?
 Yes  No
If No, is it proposed to seek further consent? If not, please justify.
5. Will the research involve the analysis of human DNA in the samples?
 Yes  No
6. Is it possible that the research could produce findings of clinical significance for individuals? (May include relatives as
well as donors)
 Yes  No
7. If so, will arrangements be made to notify the individuals concerned?
 Yes  No  Not applicable
If No, please justify. If Yes, say what arrangements will be made and give details of the support or counselling service.
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8. Who is the holder of the samples?
Name of the research tissue bank (or other collection):
Does the bank/collection hold a licence from the Human Tissue Authority for storage and use of human tissue in research?
 Yes  No
REC reference no. (if the bank/collection is ethically approved):   
Details of the organisation with responsibility for the bank:
Organisation:
Contact point (e.g. tissue bank manager):
Title: Forename/Initials: Surname:
Role:
Work Address:
Postcode:
Telephone:
Fax:
Mobile:
E−mail:
9. What will happen to the samples at the end of the research?
 Destruction
 Return to current holder of the samples
 Transfer to another tissue bank
(If the bank is in England, Wales or Northern Ireland a licence from the Human Tissue Authority will be required to store the
tissue for possible further research.)
 Storage by research team pending ethical approval for use in another project
(Unless the researcher holds a licence from the Human Tissue Authority, a further application for ethical review should be
submitted before the end of this project.)
 Storage by research team as part of a new research tissue bank
(The bank will require a licence from the Human Tissue Authority. A separate application for ethical review of the tissue bank
may also be submitted.)
 Not yet known
Please give further details of the proposed arrangements:
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 PART B: Section 5 − Use of newly obtained human biological materials
1. What types of human tissue or other biological material will be included in the study?
The patient will be asked to provide 2 samples of saliva collected over 1 minute:one will be resting, the other
will be while chewing parafilm. They will be collected by the chief investigator, Janet Davies. The samples will
be analysed by at the Salivary Research Unit, Guy's Hospital.
2. Who will collect the samples?
They will be collected by the chief investigator, Janet Davies.
3. Will the samples be: (Tick as appropriate)
Obtained primarily for research purposes?
Surplus (i.e. left over from tissue taken in the course of normal clinical care for diagnostic or therapeutic purposes)?
4. Will informed consent be obtained from donors for use of the samples:
In this research?
 Yes  No
In future research?
 Yes  No
5. Will the samples be stored:
In fully anonymised form? (link to donor broken)
 Yes  No
In linked anonymised form? (linked to donor but donor not identifiable to researchers)
 Yes  No
If Yes, say who will have access to the code and personal information about the donor.
Principle investigator, Janet Davies
In a form in which the donor could be identifiable to researchers?
 Yes  No
If Yes, please justify:
6. What types of test or analysis will be carried out on the samples?
The amount of both stimulated and unstimulated saliva will be analysed. A rapid atomic absorption
spectrophotometric method (Monarch 2000 model 760 spectrophotometer, Instrumentation Laboratory,
U.S.A.) can be used to measure total calcium. Free Ca2+ concentration can be measured using a Ca2+
selective electrode (ELIT 8041, Nico 2000 Ltd., U.K.). From this bound calcium concentrations can be
calculated. Statherin levels can be measured using Protein Chip Technology (Ciphergen, U.S.A
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7. Will the research involve the analysis of human DNA in the samples?
 Yes  No
8. Is it possible that the research could produce findings of clinical significance for individuals? (May include relatives as
well as donors)
 Yes  No
9. If so, will arrangements be made to notify the individuals concerned?
 Yes  No  Not applicable
If No, please justify. If Yes, say what arrangements will be made and give details of the support or counselling service.
10. Give details of where the samples will be stored, who will have access and the custodial arrangements.
Once analysis has been perfomed the sample will be destroyed.
11. What will happen to the samples at the end of the research?
 Destruction
 Transfer to research tissue bank
(If the bank is in England, Wales or Northern Ireland a licence from the Human Tissue Authority will be required to store the
tissue for possible further research.)
 Storage by research team pending ethical approval for use in another project
(Unless the researcher holds a licence from the Human Tissue Authority, a further application for ethical review should be
submitted before the end of this project.)
 Storage by research team as part of a new research tissue bank
(The bank will require a licence from the Human Tissue Authority. A separate application for ethical review of the tissue bank
may also be submitted.)
 Not yet known
Please give further details of the proposed arrangements:
Saliva will be disposed of following analysis
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 PART B: Section 8 − Declarations
Declaration by Chief Investigator
The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.1. 
I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice guidelines on
the proper conduct of research.
2. 
If the research is approved I undertake to adhere to the study protocol, the terms of the full application of which the
main REC has given a favourable opinion and any conditions set out by the main REC in giving its favourable
opinion.
3. 
I undertake to seek an ethical opinion from the main REC before implementing substantial amendments to the
protocol or to the terms of the full application of which the main REC has given a favourable opinion.
4. 
I undertake to submit annual progress reports setting out the progress of the research.5. 
I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant
guidelines relating to security and confidentiality of patient or other personal data, including the need to register
when necessary with the appropriate Data Protection Officer.
6. 
I understand that research records/data may be subject to inspection for audit purposes if required in future.7. 
I understand that personal data about me as a researcher in this application will be held by the relevant RECs and
their operational managers and that this will be managed according to the principles established in the Data
Protection Act.
8. 
I understand that the information contained in this application, any supporting documentation and all
correspondence with NHS Research Ethics Committees or their operational managers relating to the application:
9. 
− Will be held by the main REC until at least 3 years after the end of the study.
− May be disclosed to the operational managers or the appointing body for the REC in order to check
that the application has been processed correctly or to investigate any complaint.
− May be seen by auditors appointed by the National Research Ethics Service to undertake
accreditation of the REC.
− Will be subject to the provisions of the Freedom of Information Acts and may be disclosed in
response to requests made under the Acts except where statutory exemptions apply.
I understand that information relating to this research, including the contact details on this application, may be held
on national research information systems, and that this will be managed according to the principles established in
the Data Protection Act 1998.
10. 
I understand that the lay summary of this study will be published on the website of the National Research Ethics
Service (NRES) as it appears in this application. Publication will take place no earlier than 3 months after issue of
the ethics committee's final opinion or the withdrawal of the application.
11. 
Optional – please tick as appropriate:
I would be content for members of other RECs to have access to the information in the application in confidence for
training purposes. All personal identifiers and references to sponsors, funders and research units would be removed.
Signature: ......................................
Print Name: 
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Date:  (dd/mm/yyyy)
Declaration by the sponsor's representative
If there is more than one sponsor, this declaration should be signed on behalf of the co−sponsors by a representative of the
sponsor nominated to take the lead for the REC application.
I confirm that:
This research proposal has been discussed with the Chief Investigator and agreement in principle to sponsor the
research is in place.
1. 
An appropriate process of scientific critique has demonstrated that this research proposal is worthwhile and of high
scientific quality.*
2. 
Any necessary indemnity or insurance arrangements, as described in question A35, will be in place before this
research starts.
3. 
Arrangements will be in place before the study starts for the research team to access resources and support to
deliver the research as proposed.
4. 
Arrangements to allocate responsibilities for the management, monitoring and reporting of the research will be in
place before the research starts.
5. 
The duties of sponsors set out in the NHS Research Governance Framework for Health and Social Care will be
undertaken in relation to this research.**
6. 
I understand that the lay summary of this study will be published on the website of the National Research Ethics
Service (NRES) as it appears in this application. Publication will take place no earlier than 3 months after issue of
the ethics committee's final opinion or the withdrawal of the application.
7. 
* Not applicable to student research (except doctoral research).
** Not applicable to research outside the scope of the Research Governance Framework.
Signature: ......................................
Print Name: 
Post:
Organisation:
Date:  (dd/mm/yyyy)
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Site−Specific Information Form
Does this application relate to a research site for which the NHS (or HPSS in Northern Ireland) is responsible or to a
non−NHS research site?
 NHS site
 Non−NHS site
For HPSS sites in Northern Ireland, separate arrangements are in place for R&D applications. There is no need to
complete questions marked "R&D only" on this form.
This question must be completed before proceeding. The filter will customise the form, disabling questions which are not
relevant to this application.
In which country is the research site located?
 England
 Wales
 Scotland
 Northern Ireland
The data in this box is populated from Part A:
Short title and version number:
XMT study on the effect of statherin on demineralised lesions in situ
Name of NHS Research Ethics Committee to which application for ethical review is being
made:
Project reference number from above REC:
Name of NHS REC responsible for SSA:
SSA reference (for REC office use only)
Name of NHS care organisation to which application is being made for permission to
conduct the research:
NHS organisation reference (for R&D office use only):
1. Title of the research (populated from A1)
Full title:    An X−ray microtomography study on the effect of statherin on carious and erosive lesions in situ
Key words: In Situ Caries Model, X−ray microtomography, Statherin
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2. Name of Chief Investigator (populated from A2)
Title: Forename/Initials: Surname:
Miss Janet A Davies
3. Name of organisation acting as lead sponsor for the study (populated from A59)
Barts and the London School of Medicine and Dentistry
4. Research reference numbers if known (populated from A65)
Applicant's/organisation's own reference number, e.g. R&D:
Sponsor's/protocol number:
Funder's reference number:
International Standard Randomized Controlled Trial Number (ISRCTN):  
ClinicalTrials.gov Identifier (NCT number):  
Project website:  
6. Give the name of the NHS site within or through which the research will take place under the responsibility of the
PI or Local Collaborator. Please give the name only. Further details of locations should be given in question 8. The name of
the site is normally the name of the relevant NHS organisation. Each NHS general or dental practice is a separate site unless
a formal consortium/network is in place.
Is this a primary care site?
 Yes  No
If Yes, give the name of the primary care organisation responsible for the site below:
8. Specify all locations, departments, groups or units at which or through which research procedures will be
conducted at this site and describe the activity that will take place.
List all locations/departments etc where research procedures will be conducted within the NHS organisation, describing the
involvement in a few words. Where access to specific facilities will be required these should also be listed for each location.
Name the main location/department first. Include details of any centres at other NHS organisations where potential participants
may be seen or referred for inclusion in the research at this site. Give details of any research procedures to be carried out off
site, for example in participants' homes.
Location Activity/facilities
1
12. Who is the Principal Investigator or Local Collaborator for this research at this site?
Title: Forename/Initials: Surname:
Post:
Qualifications:
Organisation:
Work Address:
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Telephone: 
Fax: 
Postcode: Mobile: 
E−mail:
R&D Only
a) Will this person interact with research participants, their organs, tissue or data in a
way that has a direct bearing on the quality of care?
 Yes  No
b) Does this person hold a current substantive or honorary contract with the NHS
organisation or accepted by the NHS organisation?
 Yes  No
Please provide a copy of the c.v. for the PI.
If an honorary contract is held, a copy of the contract should be submitted, unless previously provided to the R&D office.
14. Give details of all other members of the research team at this site, including academic supervisors and all people
who will interact with research participants, their organs, tissue or data in a way that has a direct bearing on the
quality of care.
1. Research Member
Title: Forename/Initials: Surname:
Employing
organisation:
Post:
Qualifications:
Role in research
team:
 other:
R&D Only
a) Will this person interact with research participants, their organs, tissue or data in a
way that has a direct bearing on the quality of care?
 Yes  No
b) Does this person hold a current substantive or honorary contract with the NHS
organisation or accepted by the NHS organisation?
 Yes  No
15. Does the Principal Investigator or any other member of the site research team have any direct personal
involvement (e.g. financial, share−holding, personal relationship etc) in the organisation sponsoring or funding the
research that may give rise to a possible conflict of interest?
 Yes  No
If Yes, give further details:
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16. What is the proposed local start and end date for the research at this site?
Start date: (dd/mm/yyyy)
Duration (Months):
End date: (dd/mm/yyyy)
17. Summary of the research (populated from A10−1)
The development of in situ caries models came about to bridge the gap between in vitro (test tube) studies and
clinical trials. In vitro studies are highly controllable and thus unnatural. Clinical trials provide more applicable data,
but can often take years. An in situ study takes a block of dental tissue which is held in the mouth using an appliance.
While the block is subjected to normal oral conditions, the caries process can been artificially induced or propagated
by removing the appliance from the mouth and using well−established techniques.
Subjects will be selected using the criteria found later in this document. Essentially they will be fit and healthy with no
active dental disease, but with previous experience of dental decay. Impressions (moulds) will be taken of their teeth
and a custom made appliance (very similar to an orthodontic brace) fabricated. The appliance will have at least two
sterilised blocks of enamel/dentine secured to it, on either side of the mouth. The appliance will be worn day and night
for 28 days. The tooth blocks will be removed and scanned using XMT every 7 days. The subjects will be allowed to
follow their normal tooth brushing procedures, but must remove the appliance before they do this. Subjects will be
asked to rinse their mouth with water prior to reinserting the appliance. Instructions concerning appliance hygiene will
be issued. The participants will also be asked to complete a diary of eating habits.
A derivative of the protein, Statherin, will be tested to see what effects it has on the carious process. Statherin is a
protein found in human saliva which is involved in calcium and phosphate balance − these two ions are the main
constituents of tooth structure. The Statherin derivative should prevent progression / possibly reverse dental decay. A
further 28 day test will ensue. We will use a positive control solution containing fluoride which is known to heal carious
lesions.
18. Details of clinical interventions (populated from A12 where enabled)
Additional
Intervention
Average number per
participant
Average time
taken
Details of additional intervention or
procedure, who will undertake it, and what
training they have received.
Routine
Care
Research
 Outpatient
Attendance(s)
2 30 Initial dental examination as part of pre selection
screening, then ,should the subject wish, a post
study dental examination, scale and polish and
topical fluoride application
 Other tissue/bodily
sample
1 30 We will ask the participants to provide a sample
of saliva. This will allow us to determine whether
the subject produces enough saliva to be
included in the trial and also to determine the
amount of salivary protein they produce
19. Details of non−clinical interventions (populated from A13 where enabled)
Additional Intervention Average number
per participant
Anticipated
average time
taken
Details of
additional
intervention or
procedure, who
will undertake it,
and what training
they have
received.
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 Other Questionnaire 1 30 In pre selection
screening,
subjects will be
asked to fill out a
medical
questionnaire and
retrospective diet
diary.
20. Will any aspects of the research at this site be conducted in a different way to that described in Parts A and B or
the study protocol?
 Yes  No
If Yes, explain and give reasons.
21. How many research participants/samples is it expected will be recruited/obtained from this site?
22. Give details of how potential participants will be identified locally and who will be making the first approach to
them to take part in the study?
23. Who will be responsible for obtaining informed consent at this site? What expertise and training do these persons
have in obtaining consent for research purposes?
1
2
27. Is there a contact point where potential participants can seek independent advice about participating in the
study?
R&D Only
28. Please provide a copy on headed paper of the participant information sheet and consent form that will be used
locally. This must be the same generic version submitted to/approved by the main REC for the study while including relevant
local information about the site, investigator and contact points for participants (see guidance notes).
If you consider that changes should be made to the generic content of the information sheet to reflect site−specific issues in
the conduct of the study (see 20), give details below. A substantial amendment may need to be discussed with the Chief
Investigator and submitted to the main REC.
29. What arrangements have been made for participants who might not adequately understand verbal explanations or
written information given in English, or who have special communication needs? (e.g. translation, use of interpreters
etc.) (Populated from A29)
Barts and the London NHS Trust have a health advocacy service and will provide translators when necessary.
What local arrangements have been made to meet these requirements (where applicable)?
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30. What arrangements will be made to inform the GP or other health care professionals responsible for the care of
the participants?
33. What arrangements (e.g. facilities, staffing, psychosocial support, emergency procedures) will be in place at the
site, where appropriate, to minimise the risks to participants and staff and deal with the consequences of any harm?
R&D Only
35. What are the arrangements for the supervision of the conduct of the research at this site? Give name and contact
details of any supervisor not already listed in the application.
R&D Only
37. Will any external funding be provided for the research at this site?
 Yes  No
If Yes, indicate the source and details of the funding:
R&D Only
38. Which organisation will receive and manage this funding?
R&D Only
39. Authorisations required prior to R&D approval
This section deals with authorisations by managers within the NHS organisation. It should be signed in accordance with the
guidance provided by the NHS organisation. This may include authorisation by line managers, service managers, support
department managers, pharmacy, data protection officers or finance managers, depending on the nature of the research.
Managers completing this section should confirm in the text what the authorisation means, in accordance with the guidance
provided by the NHS organisation. This section may also be used by university employers or research staff to provide
authorisation to NHS organisations, in accordance with guidance from the university.
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Declarations
     Declaration by Principal Investigator or Local Collaborator
The information in this form is accurate to the best of my knowledge and I take full responsibility for it.1. 
I undertake to abide by the ethical principles underpinning the World Medical Association's Declaration of
Helsinki and relevant good practice guidelines in the conduct of research.
2. 
If the research is approved by the main REC and NHS organisation, I undertake to adhere to the study protocol,
the terms of the application of which the main REC has given a favourable opinion and the conditions requested
by the NHS organisation, and to inform the NHS organisation within local timelines of any subsequent
amendments to the protocol.
3. 
If the research is approved, I undertake to abide by the principles of the Research Governance Framework for
Health and Social Care.
4. 
I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant
guidelines relating to the conduct of research.
5. 
I undertake to disclose any conflicts of interest that may arise during the course of this research, and take
responsibility for ensuring that all staff involved in the research are aware of their responsibilities to disclose
conflicts of interest.
6. 
I understand and agree that study files, documents, research records and data may be subject to inspection by
the NHS organisation, the sponsor or an independent body for monitoring, audit and inspection purposes.
7. 
I take responsibility for ensuring that staff involved in the research at this site hold appropriate contracts for the
duration of the research, are familiar with the Research Governance Framework, the NHS organisation's Data
Protection Policy and all other relevant policies and guidelines, and are appropriately trained and experienced.
8. 
I undertake to complete any interim and/or final reports as requested by the NHS organisation and understand
that continuation of permission to conduct research within the NHS organisation is dependent on satisfactory
completion of such reports.
9. 
I undertake to maintain a project file for this research in accordance with the NHS organisation's policy.10. 
I take responsibility for ensuring that all serious adverse events are handled within the NHS organisation's policy
for reporting and handling of adverse events.
11. 
I understand that information relating to this research, and about me as a researcher, will be held by the R&D
office and may be held on national research information systems, and that this will be managed according to the
principles established in the Data Protection Act 1998.
12. 
I understand that information relating to this research, and about me as a researcher, will be held by RECs
undertaking site−specific assessment and their operational managers and that this will be managed according to
the principles established in the Data Protection Act 1998.
13. 
I understand that the information contained in this application, any supporting documentation and all
correspondence with the R&D office and/or the REC system relating to the application will be subject to the
provisions of the Freedom of Information Acts and may be disclosed in response to requests made under the
Acts except where statutory exemptions apply.
14. 
Signature of Principal Investigator
or Local Collaborator:
.....................................................
Print Name:
Date:
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FINAL INDEMNITY
Miss Janet A Davies
Centre for Oral Growth and Development
Institute of Dentistry
Turner Street
London
E12AD
Joint Research & Development Office
3rd Floor Rutland House
42-46 New Road
Whitechapel
London E 1 2AX
25 October 2005
Tel: 0207 882 7272
Fax: 0207 882 7276
Email: Helen. Cadiou@bartsandthelondon.nhs.uk
Dear Miss Davies,
- .
Re: A preliminary in situ study of demineralisation and remineralisation of bydroxyapaptite slabs
Thank you for sending confirmation of your approval from the ethics committee. I am now happy to inform you
that the College will indemnify against any negligence that might occur during the course of this project. Should
any untoward events occur it is essential that you contact the R&D office immediately. If patients or staff are
involved in an incident, you should also contact the Clinical Risk Manager on 18-4132.
Please note that all NHS and social care research is now subject to the DoH Framework for Research
Governance. If you are unfamiliar with the standards contained in this document, or the BLT policies that
reinforce them, you can obtain details from the Joint R&D office (0207 882 7250) or from the DoH Internet site.
The address
http://www.dh.gov.uk/PolicyAndGuidance/ResearchAndDevelopmentiResearchAndDevelopmentAZ/ResearchG
overnance/fs/en will take you directly to the Research Governance Homepage.
As part of research governance, all investigators accessing individually identifiable personal information are
required to comply with current information governance requirements. The Health Records Department will not
release patient notes for research purposes unless you are an internal member of staff (i.e. have a full or honorary
Trust contract) you produce this letter at the time you request batches of notes .
. You must inform us if your project is amended and you need to re-submit it to the ethics committee or-if-your
project terminates. This is necessary to ensure that your indemnity cover is valid and also helps the office to
r>. maintain up to date records.
I hope the project goes well.
Yours sincerely,
The Royal Hospital ofSt. Bartholomew. The Royal London Hospital.
The London Chest Hospital. The Queen Elizabeth Children's Service.
Head of Research Resources - Gerry Leonard
() J.
East London & The City HA Local Research Ethics Committee 3
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINION
For all studies requiring site-specific assessment, this form is issued by the main REC to the Chief Investigator and sponsor with the favourable opinion letter and
following subsequent notifications from site assessors. For issue 2 onwards, all sites with a favourable opinion are listed, adding the new sites approved.
REC reference number: 05/Q0605/147 Issue number: 1 Date of issue: 20 October 2005
Chief Investigator: Miss Janet A Davies ,
Full title of study: A preliminary in situ study of demineralisation and remineralisation of hydroxyapaptite slabs
This study was given a favourable ethical opinion by East London & The City HA Local Research Ethics Committee 3 on 19 October 2005. The favourable opinion is
extended to each of the sites listed below. The research may commence at each NHS site when management approval from the relevant NHS care organisation
has been confirmed.
Principal Investigator Post Research site Site assessor Date of favourable Notes (1)
opinion for this site
Miss Janet A Davies PhD Student Barts and The London East London & The City 20/10/2005
NHS Trust HA Local Research
Ethics Committee 3
Approved by the Chair on behalf of the REC:
....... .s;c..:~{S~/Administrator)
(delete as applicable)
......... 0. ..§:-:.?~. ~ :f\~:: ..~.............(Name)
-
(1) The notes column may be used by the main REC to record the early closure or withdrawal of a site (where notified by the Chief Investigator or sponsor), the
suspension of termination of the favourable opinion for an individual site, or any other relevant development. The date should be recorded.
Miss Janet A Davies
Centre for Oral Growth and Development
Institute of Dentistry
Turner Street
London
E12AD
...
'{;)J Queen Mary
University of london
Joint Research and Development Office
3rd Floor Rutland House
42-46 New Rd
Whitechapel
London E I 2AX
04/08/05
Tel: 0207 882 7250
Fax: 0207882 7276
Sponsorship Arrangements for Project:
A preliminary in situ study of demineralisation and remineralisation of hydroxyapaptite slabs
Dear Miss Davies,
Thank you for your completed sponsorship agreement form. I can now confirm that Queen Mary University of
London is willing to act as sponsor for the above named project. As a condition of sponsorship, the College
reserves the right to audit compliance with the EU Clinical Trials Directive or Research Governance Framework,
whichever is the more appropriate. Further information on the audit process is available from Siobhan Lim, GCP
and Research Governance Manager, on 13-7275.
You must also inform the Joint TrustlQMUL R&D Office if:
a) Your research terminates before the end date specified on the ethics application form.
b) You intend to extend the timescales for your research. Indemnity and sponsorship only apply to the
duration of the research stated in the research ethics application form. Failure to notify the office of an
extension may result in no indemnity or sponsorship cover for the extension period. Ethical approval for
the extension period must be obtained. - --- _-- -- - - . - -- -
c) Similarly, any changes to the protocol must be notified to R&D, particularly ifthe amendment means
that patients will be recruited from sources other than BLT. Ethical approval for substantial amendments
must be obtained
d) There are staff changes on the project. This is important as indemnity only applies to staff named on the
original research ethics application.
e) The principal investigator on the project relocates to another organisation during the study period.
r>. For Clinical trials sponsored by the College, any Suspected Unexpected Serious Adverse Reaction
'----" (SUSAR) must be reported direct to the Joint R&D Office within 48 hours of becoming aware of the
event.
Details of any changes must be sent to Helene Provstgaard, Research Governance Support Officer at the R&D
Office address or via email.
From December 2005 no PI will be sponsored by the College unless they can demonstrate they have had up-to-
date training in Research Governance and 1or GCP. Internal courses will be run free of charge throughout the
run up period. Details are available from
http://www.bartsandthelondon.nhs.uklresearch/gcp and research governance. asp. You are therefore strongly
urged to book a place, unless you have evidence of prior training.
Professor Neil Barnes, Joint Director of R&D.
Barts and the London, Queen Mary School of Medicine and Dentistry. Queen Mary, University of London.
Janet Davies 
Research Protocol 
An in situ study of de/remineralisation of hydroxyapatite 
slabs (Version 1- 08/08/05) 
 
Subject Selection 
 
Inclusion criteria 
 Aged 18 to 50 years 
 DMFT ≥1 
 No active caries/periodontal disease 
 Number of teeth >20 
 Good General Health 
 
Exclusion Criteria 
 Medication that induces xerostomia 
 Antibiotics within the last 2 months or during the trial 
 Allergies to products used 
 Active carious lesions 
 Periodontal pockets >5mm 
 Removable dentures or any orthodontic appliances 
 Subjects who live in a fluoridated area or take fluoride 
supplements 
 Unstimulated whole saliva flow rate <0.2ml min-1 
 Stimulated whole saliva flow rate <1.0ml min-1 
 Extreme dietary habits 
 
These criteria have been taken from the consensus reached at the 
Conference on Clinical Aspects of De/Remineralisation of Teeth (June 1994), 
Rochester, New York (Zero, 1995). 
 
 
 
 
 
Selection process 
 
The principal investigator will personally approach potential subjects, answer 
any questions posed and provide them with the written information sheet 
which has been prepared. The subjects will then be given at least 24 hours 
to think about whether they want to take part in the study. Once they have 
decide to take part, a written consent form will be completed. The subjects 
will be asked to complete a medical questionnaire and diet diary. They will 
undergo a full dental examination including periodontal indices. They will be 
asked to provide two samples of saliva: stimulated and unstimulated. 
Samples of saliva will be analysed the Saliva-check buffer kit (GC United 
Kingdom Ltd.). 
 
Once all this data has been gathered, each subject will be reviewed to see if 
they fulfil the criteria stated above. They will then have impressions taken 
(upper, lower and wax bite registration) and a custom made appliance 
fabricated consisting of a lower removal appliance with 2 flanges each 
housing a Perspex cassette. The appliance fitted and wear 
instructions/protocol given as stated below. 
 
 
  
De- and Remineralisation Study 
 
 
A section of hydroxyapatite will be cut 4mm by 4mm by 2mm. The surfaces 
of this will be covered in nail varnish except for the surface which was to be 
exposed to the oral environment. The samples are secured into a Perspex 
cassette using acrylic glue and is then scanned using X-ray 
Microtomography. The cassette is sterilised in a steam autoclave and then 
screwed into a lower removable appliance with one cassette on each side of 
the mouth. The hydroxyapatite is recessed to allow plaque to accumulate. 
The subject is to wear the lower removable appliance for 28 days for 24 
hours of the day except for toothbrushing with a standard 1450ppm fluoride 
toothpaste (twice daily) and a 5 minute extra oral application of 225ppm 
fluoride solution (once daily) (Manning and Edgar, 1997; van Strijp et al., 
1999). They should eat and drink normally and record this in the diet diary 
provided; after toothbrushing, they are asked to spit out the remaining 
toothpaste, but not rinse with water.  
 
After a period of 14 days, the cassette containing the hydroxyapatite sample 
will be removed from the lower removable appliance and rescanned. After 
the XMT scan, the hydroxyapatite-containing cassette will be placed in a 
standard demineralising solution 0.1M acetic acid (1mmol CaCl2, 0.6mmol 
KHPO4, pH 4.5) for 60 hours (Dowker et al., 2003; Anderson et al., 2004) 
and a further XMT scan undertaken. Steam sterilisation is undertaken and 
the cassettes will be reinserted into the appliance. The appliance is worn for 
a further 14 days after which a further XMT scan is undertaken. 
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lVOLUNTEER INFORMATION SHEET
(Version 1 - 08/08/05)
Thank you for considering taking part in our study. Before you agree to take
part, we would be grateful if you could read carefully the following information
sheet. It is important that you understand the purpose of the study and what it
will involve. You may want to ask questions or discuss your involvement with
others. You need to take time to decide whether or not you wish to take part.
Study Title
A preliminary in situ study of demineralisation and remineralisation of
hydroxyapaptite slabs
What is the purpose of the study?
The aim of the research is to use X-ray microtomography (a type of 3D
imaging, like a CT scan) to study dental decay. Previously, it has been used in
the laboratory looking at artificial caries-like lesions and we wish to see if this
translates to the clinical situation.
Why have I been chosen?
The participants in this study are all volunteers. We require that our subjects
are in good general health and are not taking certain medications. Their
dental health should be good, but they should have some fillings. We will ask
you to complete a medical questionnaire and will give you a dental "check up"
prior to enrolling you in the trial. We will also ask you to complete a diet diary
for a couple of days to check that you are suitable. You will be asked to
provide a saliva sample to see how much saliva you produce naturally.
Do I have to take part?
Your participation in this study is entirely voluntary. We will provide you with
all the information you require and ask you to sign a written consent. If you
decide to take part, you may withdraw from the trial at any time without having
to provide us with a reason.
•What will be involved?
Firstly, we will take some impressions (moulds) of your teeth; from these, we
will construct an appliance similar to a removable orthodontic plate. The
appliance will contain a piece of hydroxyapatite (calcium phosphate which
imitates natural tooth substance). We will ensure that this has been carefully
sterilised prior to insertion into the appliance. You will need to wear it at all
times except when eating, drinking and tooth brushing/flossing. We will also
provide you with bottles of different solutions that you will be required to dip
the appliance into on a daily basis. We ask that you continue with your normal
tooth brushing routine, but not to use any mouthwashes.
r\
What are the side effects of taking part?
Although there is potential accumulation of plaque, which could lead to small
amounts of enamel loss developing, this can be minimised by following the
oral hygiene and appliance hygiene advice that we will give you. We will also
only select subjects with good periodontal health and no active carious lesions
for inclusion in our study. All subjects will be offered a dental examination
(check-up) at the end of the experimental period and will be given, should
they wish it, a scale and polish and an application of topical fluoride. We do
not envisage that no significant damage will take place.
The levels of discomfort experienced by participants will be low. We do
however anticipate that subjects will take a day or two to acclimatise to the
device. The subjects should not need to alter their lifestyle unduly. There is a
risk that the appliance may break or the hydroxyapatite become dislodged.
Our orthodontic colleagues frequently use these appliances, with few
problems, but we have provided contact telephone numbers and written
instructions should there be any problems or questions.
What are the possible benefits of taking part?
While there are no direct benefits to you personally for taking part, you will be
helping us to study dental decay. This will ultimately help scientists develop
new products to prevent caries.
What happens if new information becomes available during the study?
Should any new information that will affect you become available during the
trial, we will contact you via your preferred method of communication .
.. What will happen after the study?
Once the study is complete, you will be given a final dental check up and
offered a scale and polish and an application of topical fluoride, if you need it.
The results will require analysis. They will be written up and published as a
PhD thesis and in dental journals. As all results will be anonymous, your
name and personal details will not appear in these papers.
Thank you again for considering participating in this trial.
Contact Details
Janet Davies 07714 750870 janet.a.davies@qmul.ac.uk
janetdavies30@hotmail.com
f.s.l.wong@qmul.ac.uk
m.p.hector@qmul.ac.uk
Dr Ferranti Wong
Prof Mark Hector
02073777058
02073777058
VOLUNTEER CONSENT FORM
An X-ray microtomography study on the effect of Statherin on
caries-like lesions in-situ (Version 1 - 08/08/05)
Yes No
I have read the volunteer information sheet dated
27/07/05 (Version 1) and have been given a copy to
take away
I understand the potential risks involved in this trial and
how they could effect me
I understand when to wear the appliance and the
procedures (ie. When to dip the appliance into the
solutions) I need to undertake
I understand that any personal data provided will be
confidential and will be processed and stored securely in
compliance with the 1998 Data Protection Act.
I have had a chance to ask questions and feel these
have been answered to my satisfaction
,
I understand that I may withdraw at any time from the
trial without having to give any reason
I give my consent to participate in this trial
Participant Researcher
Signature
Print Name
Date
PEER REVIEW FOR ALL RESEARCH PROJECTS
PEER REVIEW IS AN ESSENTIAL REQUIREMENT OF RESEARCH GOVERNANCE AND MUST
BE PROVIDED FOR ALL RESEARCH PROJECTS.
•
THIS FORM HAS BEEN DEVELOPED TO ASSIST THE REVIEW OF OWN ACCOUNT
RESEARCH AND RESEARCH THAT HAS NOT BEEN PREVIOUSLY REVIEWED BY OTHER
ORGANISATIONS OR PROCESSES.
A suitably qualified peer, or peers who have no conflict of interest, working in an
appropriate field of research, preferably external to Barts and The London NHS Trust
and independent to the project in question, should review project information and
complete this form. The team should also review the project where the research will be
conducted. The researcher should return it with other registration information to the
R&D office (or separately in instances where there is a delay).
Reviewers: Please consider the project protocol, ethics committee application and any
further details provided, and comment (including any amendments you suggest) with
regard to each point listed below.
Thank you.
Study Title:
P.I.:
Date:
An in situ study of de/remineralisation of hydroxyapatite slabs
Janet Davies
08/08/05
The appropriateness of the study design in relation to the objectives of the study, the
statistical methodology, and the potential for reaching sound conclusions with the
smallest number of research participants necessary. Feasibility and Deliverability.
This preliminary study has simple, achievable objectives. It is well designed and
methods are in keeping with other related work. It is a qualitative study which requires
no statistical input at present.
The justification of predictable risks and inconveniences weighed against the
anticipated benefits for the research participants, other present and future patients, and
the concerned communities.
The predictable risks in this project are minimal. These include:
• Loss or breakage of the appliance - minimised by using a design compliant
with an orthodontic appliance.
• Detaclunent of the insert - the design has a back-up mechanism built in case of
failure.
• Very remote risk of damage to the teeth and gums which is fully reversible
with very simple clinical, home-based interventions.
Subjects will be carefully chosen and instructed in order to minimise these risks as
much as possible. The anticipated benefits for the community, if this research proves
fruitful, are immense however there are no direct benefits to the participants.
Assessment for broad ethical concerns, which may result in harm to the participants.
Good written and oral instructions, a well-designed appliance, careful selection of
subjects, good screening techniques and post study prophylaxis minimise the potential
for the build up of plaque which could cause dental decay or gum disease may result in
harm to the participant. I am satisfied the researcher will do everything to ensure that
no problems occur. The theoretical risks of appliance fracture or loss of the study
sample are regrettable, but minor risks. The appliance is however removable and
therefore can be removed before any major problems occur.
Value for Money: e.g. not addressing the most important question, leading to low
impact or otherwise poor value for users of research; unrealistic targets for recruitment
of clinical centres and participants, leading to a likelihood of cost over-runs.
Identification of funding processes and administration.
This research will address the important question of whether X-ray microtomography
can be used in the clinical situation; up to this point, this technique, which was
developed at Queen Mary College, has been used very successfully in the laboratory
situation. It has previously been described as the gold standard for non-destructive
methods of caries diagnosis (International Consensus Workshop on Clinical Caries
Trials, Glasgow, 2002). If this technique proves feasible, it will open many avenues for
caries research. The recruitment levels are realistic.
Impact to Service: Affordability of extra clinical interventions/processes/visits, which
are not covered in the funding, cost breakdown. Impact on service capacity including
affiliated services such as pharmacy, pathology, imaging, etc.
The Principal Investigator is funded for 4 sessions a week to carry out research for her
PhD. Any clinical visits will be timetabled into these 4 sessions so there will be no
extra cost to the NHS in this respect. All subjects used are adult volunteers, not Trust
patients. There will be a minor cost implication in the fabrication of 10 Orthodontic
appliances at a cost of £35 each (£350). This will be covered by bench fees. There is
otherwise minimal impact to service.
Research Environment: Physical environment, staff knowledge, training and
education. Space to conduct research, data and sample storage, and access to
confidential records. Patient and staff Health and Safety.
The research environment is of international quality with the department having scored
5 on the last RAE and having previously received grants from the Medical Research
Council and Engineering and Physical Sciences Research Council. The unit is also in
receipt of 5 locally funded (Trust and QMUL) PhD studentships. The staff are highly
knowledgeable and appropriate training and education has been provided. I am
satisfied that all personal data will stored in accordance with The Data Protection Act
1998 and will be destroyed as soon as the study is completed. I do not see that there
would be any Health and Safety issues arising from this research as this is a well run
laboratory, fully cmpliant with Health and Safety Regulations and has recently been
inspected and passed routine Health and Safety inspections. The Principal Investigator
is up to date with ionising radiation regulations and the participants will not be
exposed to any extra radiation.
Reputational failure: potential harm to the reputation of medical or social research
generally, or organisations and parties involved.
This is a simple, low risk experiment which follows the criteria laid out by the
Conference on Clinical Aspects of De/Remineralisation of Teeth (June 1994),
Rochester, New York. This is the most recent consensus of its kind. The possible
impact on the reputation of dental research is extremely minor. I believe this research
can only further the reputation of the Department of Oral Growth and Development,
Queen Mary, University of London.
Name and Title of Reviewer Prof Mark Hector
Qualifications BSc (Hons), BDS, PhD
Signature 1Date: 08/08/05
MEDICAL QUESTIONNAIRE
(Version 1 - 08/08/05)
Please answer the following questions about your general health. All answers
will be strictly confidential.
Are you currently seeing a doctor (either GP or at Hospital) for
treatment?
Yes Give DetailsNo
Do you suffer from or have you ever suffered from the following?
Yes No Give Details
Heart disease
Rheumatic fever
Heart murmur
High/Low blood pressure
Chest problems
(E.g. Asthma, chronic bronchitis)
Stomach or bowel disease
Liver disorders including Hepatitis or
jaundice
Kidney disease
Diabetes, Thyroid or any other gland
disorders
Epilepsy
Depression/Sleeping difficulties
Dry Mouth or Eyes
Arthritis or joint problems
Any other serious illnesses
Could you be or are you trying to become pregnant?
;
, ,
Are you taking any medication at present including non-prescription,
homeopathic or herbal medication?
Yes Give DetailsNo
Have you taken any medication including non-prescription, homeopathic
or herbal medication in the last two months?
Yes Give DetailsNo
Are you allergic to anything (including medication)?
Yes No Give Details
Have you ever had an operation or general anaesthetic?
Yes No Give Details
DIET DIARY (Version 1 - 08/08/05)
Please complete as fully as possible for the last 2 days
Day 1 - ..1../ ....
,f)
Meal/Snack Time What was eaten/drunk?
(approx)
Before
Breakfast
Breakfast
Mid Morning
Break
Lunch
Mid
Afternoon
Break
Dinner
Evening
Before Bed
Day 2 - ..1..1. ...
Meal/Snack Time What was eaten/drunk?
(approx)
Before
Breakfast
Breakfast
Mid Morning
Break
Lunch
Mid
Afternoon
Break
Dinner
Evening
Before Bed
DPA(R) FORM
Data Protection Act: registration of all computer & paper record systems holding personal information
(A separate form must be completed for every occurrence of personal data held)
FORM DPA(R) - REGISTRATION OF THE USE OF PERSONAL DATA FOR RESEARCH PURPOSES.
Lead Researcher Miss Janet Davies
Directorate Patient Services and Dental
DepartmentJsectlon Oral Growth and Development
1a. R&D ref.
A preliminary in situ study of demineralisationlremineralisation no (If known)
1. Name of study
of hydroxyapatite slabs 1b. Ethics ref.
(If known)
2. Type (electronic/manual/both) Both
2a; Name and version of database
Excel, Windows 2000software used
3. Location of data QMUL network 3a. Archive Media
4. Date of first record 1/9/2005 4a: (Estimated) date of end. of study _ 1/9/2006
5. SOURCE OF DATA o Patient health records / PAS o Staff record / MAPS
(Select all required) [gj Directly from patients o Directly from staffo Other _ please state:
6. TYPE OF DATA GENERAL PERSONAL DATA: SENSITIVE PERSONAL DATA:
(Select all required)
[gj Personal details [gj Racial or ethnic origin
[gj Family, lifestyle and social circumstances o Political opinions
o Education and training details o Religious or other beliefs of a similar nature
o Employment details o Trade Union membership
o Financial details [gj Physical or mental health or condition
o Goods or services provided o Sexual life
o Offences (inc. alleged offences)
o Criminal proceedings, outcomes and sentences
o Other _ please state:
7. PURPOSE OF
ResearchDATA COLLECTION
8. Data disclosure [gj To staff and depts within BLT and the School of Medicine & Dentistry
o To other individualsl organisations within the European Economic Area (inc. research sponsors)
o To other individuals/ organisations outside the European Economic Area (inc. research sponsors)
o There is a confidentiality agreement in place with Outside Bodies (inc. research sponsors)
9. I have read and will abide by the Trust Data Protection Policy in keeping these records.,.,.
SIGNATURE (111_ . I Date I 20107/05
Name Janet Davies
Job title Academic Specialist Registrar in Paediatric Dentistry
Email address janet.a.davies@qmul.ac.uk I Tel. no. I 0207 3777058
10. APPROVED BY: The Barts and the London Information Security Manager or other designated Manager:
I SIGNATURE I :~~.
Please return signed (In ink) forms to R&D section with your completed Ethics Application form. dpar_form_v52104 Page 1 of 1
East London and The City Local Research Ethics Committee 1
Aneurin Bevan House, 81 Commercial Road, London E11RD
Telephone Number: 020 76556718
Fax Number: 020 7 655 6655
Email Address: Sandra. Burke@nelondon.nhs.uk
Miss Janet A Davies
PhD Student
Centre for Oral Growth and Development, Institute of Dentistry
Queen Mary, University of London
Turner Street
London E1 2AD-
18 August 2006
Dear Miss Davies
Full title of study:
.:--:. ~.-;...::-':;-.-.:.-...:..:._,.:..:.:-.- _- .-.-~-.~~-.,,:,---.
A preliminary in situ study of demineralisation and
_"-,!eroil'1~r:.aUsa!~on_,of~nctmel_an~..dentin~_~I_a~s~__
06/Q0605177
• ••• _ .. I.
REC reference number:
Thank you for your letter of 03 August 2006, responding to the Committee's request for
further information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the
above research on the basis described in the application form, protocol and supporting
documentation as revised.
Ethical review of research sites
The favourable opinion applies to the research sites listed on the attached form.
Conditions of approval
The favourable opinion is given provided that you comply with the conditions set out in the
attached document. You are advised to study the conditions carefully.
'--Approved documents- - - - -_~. _ .' .. ~....,. ...-_ _ _ - ~ J
The final list of documents reviewed and approved by the Committee is as follows:
Document '~ ~- :::' ,>~'< <> ··JlersiofC;;fi. Pilte:\ .-,~B~' ..•.0-
Application 1 15 May 2006
Investigator CV 1 25 May 2006
Protocol 2 03 August 2006
Covering Letter 1
Letter from Sponsor 1 11 May 2006
Peer Review 1 25 May 2006
Compensation Arrangements 1 11 Ma_y_2006
Questionnaire 1 25 May 2006
GP/Consultant Information Sheets 1 25 May 2006
Participant Information Sheet 1 25 May_2006
Participant Consent Form 1 25 May 2006
Response to Request for Further Information 03 August 2006
Copy of e-mail from David Jackson 03 August 2006
An advisory committee to London Strategic Health Authority
..)
Diagram of Research Protocol 1 25 May 2006
Ferranti See Leng Wong CV 1 25 May 2006
Checklist 1 15 May 2006
Research governance approval
The study should not commence at any NHS site until the local Principal Investigator has
obtained final research governance approval from the R&D Department for the relevant
NHS care organisation.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for
Research Ethics Committees (July 2001) and complies fully with the Standard Operating
Procedures for Research Ethics Committees in the UK.
[ 06/Q0605/77 Please quote this number on all correspondence
With the Committee's best wishes for the success of this project._ - "-__ _.- - _'_ ..__. ·...._r_ .- . .-- ....__. - -..
Dr David A Ingram
Chair
Email: sandra.burke@nelondon.nhs.uk
Enclosures: Standard approval conditions
Site a roval form
Copy to: Queen Mary, University of London
Research Governance, 3rd Floor, Rutland House
42-46 New Road, Whitechapel
London
--- -_. ----- .._.--- __________________________ =..:....:;=0.::.-_--= ._-=---~_._. __ ._._. ,
An advisory committee to London Strategic Health Authority
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18 August 2006
London & The City HA Local Research Ethics Comm
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINIO
For aI/ studies requiring site-specific assessment, this form is issued by the main REC to the Chief Investigator
fol/owing subsequent notifications from site assessors. For issue 2 onwards, aI/ sites with a favourable opinion
sponsor with the favourable opinion letter and
listed, adding the new sites approved.
REC reference number: I 06/00605/77 Issue number: 1
Chief Investigator: Miss Janet A Davies
Full title of study: A preliminary in situ
i
This study was given a favourable ethical opinion by East London & The City HA Local Research Ethics Committe"e 3 on 14 August 2006. The favourable opinion is
extended to each of the sites listed below. The research may commence at each NHS site when management approval from the relevant NHS care organisation
has been confirmed. \ .
\
Approved by the Chair on behalf of the REC:
.....~ : .
......... Sandra Burke (Name)
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Janet Davies 
Research Protocol 
An in situ study of de/remineralisation of enamel/dentine 
slabs (Version 1- 26/05/06) 
 
Subject Selection 
 
Inclusion criteria 
 Aged 18 to 50 years 
 DMFT ≥1 
 No active caries/periodontal disease 
 Number of teeth >20 
 Good General Health 
 
Exclusion Criteria 
 Medication that induces xerostomia 
 Antibiotics within the last 2 months or during the trial 
 Allergies to products used 
 Active carious lesions 
 Periodontal pockets >5mm 
 Removable dentures or any orthodontic appliances 
 Subjects who live in a fluoridated area or take fluoride 
supplements 
 Unstimulated whole saliva flow rate <0.2ml min-1 
 Stimulated whole saliva flow rate <1.0ml min-1 
 Extreme dietary habits 
 
These criteria have been taken from the consensus reached at the 
Conference on Clinical Aspects of De/Remineralisation of Teeth (June 1994), 
Rochester, New York (Zero, 1995). 
 
 
 
 
 
Selection process 
 
The principal investigator will personally approach potential subjects, answer 
any questions posed and provide them with the written information sheet 
which has been prepared. The subjects will then be given at least 24 hours 
to think about whether they want to take part in the study. Once they have 
decided they are happy to take part, a written consent form will be 
completed. The subjects will be asked to complete a medical questionnaire 
and diet diary. They will undergo a full dental examination including 
periodontal indices. They will be asked to provide two samples of saliva: 
stimulated and unstimulated. Samples of saliva will be analysed the Saliva-
check buffer kit (GC United Kingdom Ltd.). 
 
Once all this data has been gathered, each subject will be reviewed to see if 
they fulfil the criteria stated above. They will then have impressions taken 
(upper, lower and wax bite registration) and a custom made appliance 
fabricated consisting of a lower removal appliance with 2 flanges each 
housing a Perspex cassette. The appliance fitted and wear 
instructions/protocol given as stated below. 
 
 
  
De- and Remineralisation Study 
 
 
Two sections of enamel/dentine will be cut which can be inserted into the 
4mm by 4mm cavity of the Perspex cassette. These samples will be initially 
sterilised with gamma radiation in the Department of Immunology at 
University of Liverpool to reduce risk of prion infection while maintaining the 
structural integrity of the tooth tissue (Amaechi et al., 1999; Kielbassa et al., 
2000). The cut enamel surfaces will be covered in nail varnish; only the 
natural enamel surface will be exposed to the oral environment. The samples 
are secured into a Perspex cassette using acrylic glue and are then scanned 
using X-ray Microtomography. The cassette is sterilised in a steam autoclave 
and then screwed into a lower removable appliance with one cassette on 
each side of the mouth. The enamel/dentine is glued into the cassette in 
such a way that a contact point is formed where plaque can accumulate. The 
subject is to wear the lower removable appliance for 28 days for 24 hours of 
the day except for toothbrushing with a standard 1450ppm fluoride 
toothpaste (twice daily) and a 5 minute extra oral application of 225ppm 
fluoride solution (once daily) (Manning and Edgar, 1997; van Strijp et al., 
1999; Chow et al., 2000). They should eat and drink normally and record this 
in the diet diary provided; after toothbrushing, they are asked to spit out the 
remaining toothpaste, but not rinse with water.  
 
After a period of 14 days, the cassette containing the enamel/dentine 
samples will be removed from the lower removable appliance and 
rescanned. After the XMT scan, the enamel/dentine-containing cassette will 
be placed in a standard demineralising solution 0.1M acetic acid (1mmol 
CaCl2, 0.6mmol KHPO4, pH 4.5) for 60 hours (Dowker et al., 2003; 
Anderson et al., 2004) and a further XMT scan undertaken. Steam 
sterilisation is undertaken and the cassettes will be reinserted into the 
appliance. The appliance is worn for a further 14 days after which a further 
XMT scan is undertaken. 
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Participant Information Sheet
A preliminary in situ study of demineralisation and
remineralisation of enamel/dentine slabs (Version 1 -25/05/06)
(\
Thank you for considering taking part in our study. Before you agree to
take part, we would be grateful if you could read carefully the following
information sheet. It is important that you understand the purpose of
the study and what it will involve. You may want to ask questions or
discuss your involvement with others. You need to take time to decide
whether or not you wish to take part.
What is the purpose of the study?
Queen Mary, University of London
Medical Sciences Bldg
Mile End Road, london El 4NS
Tel/Fax: +44 (0)20 7377 7058
www.smd.Qmul.ac.ukldental
Department of Oral Growth
and Development
Head of Department
Professor JC Elliott
DENTAL BIOPHYSICS
Professor Je Elliott
Tel: +44 (0)20 7882 7928
Fax: +44 (0)20 7882 7931
j.c.ettiott@qmul.ac.uk
DENTAL BIOMATERIALS
Professor GJ Pearson
Tel/Fax: +44 (0)20 7882 7977
g.j.pearson@Qmul.ac.uk
PAEDIATRIC DENTISTRY
Dr MP Hector
Tel/Fax: +44 (0)20 73777058
m.p.hector@qmul.ac.uk
ORTHODONTICS
Mr RT Lee
Tel: +44 (0)20 7377 7397
Fax: +44 (0)20 7377 7654
r.t.lee@qmul.ac.uk
The aim of the research is to use X-ray microtomography (a type of 3D imaging, like
a CT scan) to study dental decay. Previously, it has been used in the laboratory
looking at artificial caries-like lesions and we wish to see if this translates to the
clinical situation. This study will form part of my PhD and will be supervised by Dr
Ferranti Wong and Prof Mark Hector.
Why have I been chosen?
The participants in this study are all volunteers. We require that our subjects are in
good general health and are not taking certain medications. Their dental health
should be good, but they should have some fillings. We will ask you to complete a
medical questionnaire and will give you a dental "check up" prior to enrolling you in
the trial. We will also ask you to complete a diet diary for a couple of days to check
that you are suitable. You will be asked to provide a saliva sample to see how much
saliva you produce naturally.
Confidentiality
All information which is collected about you during the course of the research will be
kept strictly confidential. If you consent to take part in the research the people
conducting the study will abide by the Data Protection Act 1998, and the rights you
Patron: Her Majesty The Queen
have under this Act. We will write to your Dentist to inform them you are taking P~n~cirporated by Royal Charter as
Queen Mary & Westfield College,
University of London
Do I have to take part?
Your participation in this study is entirely voluntary. We will provide you with
all the information you require and ask you to sign a written consent. If you
decide to take part, you may withdraw from the trial at any time without having
to provide us with a reason. If you chose to withdraw from the study any
information that has been formerly collected will be processed as part of the
study.
What will be involved?
Firstly, we will take some impressions (moulds) of your teeth; from these, we
will construct an appliance similar to a removable orthodontic plate. The
appliance will contain 2 pieces of dental enamel. We will ensure that this has
been carefully sterilised with gamma radiation prior to insertion into the
appliance. You will need to wear it at all times including while asleep and
except when tooth brushinglflossing and eating. You will be asked to dip
either the left or right side of the appliance into a test solution 5 times a day
for 20 minutes. This is to be done at the same time as
toothbrushing/flossing/eating. We ask that you continue with your normal
tooth brushing routine, but not to use any mouthwashes.
What are the time commitments for this study?
We will require an initial appointment lasting approximately 1 hour. During this
appointment you will be given a dental examination, complete diet and
medical questionnaires, provide a sample of saliva and, should you fulfill the
criteria set out, have dental impressions taken. Between 3 and 4 weeks are
then required to make the appliance. We will then have a further 15 minute
appointment to fit the appliance and give you instructions on its wear. We will
see you after 14 days, remove the appliance and study the sample in the
laboratory. If there have been changes to the sample, we will stop the trial
otherwise it will continue for a further 14 days. The longest you will be
expected to wear the device is for 28 days (4 weeks).
What are the side effects of taking part?
Although there is potential accumulation of plaque, which could lead to small
amounts of enamel loss developing, this can be minimised by following the
oral hygiene and appliance hygiene advice that we will give you. We will also
only select subjects with good periodontal health and no active carious lesions
for inclusion in our study. All subjects will be offered a dental examination
(check-up) at the end of the experimental period and will be given, should
they wish it, a scale and polish and an application of topical fluoride. We do
not envisage that no significant damage will take place.
The levels of discomfort experienced by participants will be low. We do
however anticipate that subjects will take a day or two to acclimatise to the
device. The subjects should not need to alter their lifestyle unduly. There is a
risk that the appliance may break or the enamel become dislodged. Our
orthodontic colleagues frequently use these appliances, with few problems,
but we have provided contact telephone numbers and written instructions
should there be any problems or questions.
If you have dental insurance (such as Denplan), you will need to check that
participating in this trial will not invalidate it.
(\
What are the possible benefits of taking part?
While there are no direct benefits to you personally for taking part, you will be
helping us to study dental decay. This will ultimately help scientists develop
new products to prevent caries.
What happens if new information becomes available during the study?
Should any new information that will affect you become available during the
trial, we will contact you via your preferred method of communication.
What happens if there is a problem?
If you are harmed by taking part in this research project, there are no special
compensation arrangements. If you are harmed due to someone's
negligence, then you may have grounds for a legal action but you may have
to pay for it. Regardless of this, if you wish to complain, or have any concerns
about any aspect of the way you have been approached or treated during the
course of this study, the normal National Health Service complaints
mechanisms should be available to you.
If you have a complaint, please contact:
Chief Operating Officer for the Barts and The London
Queen Mary School of Medicine and Dentistry
Wardens Office
32 Newark Street
London E1 2M
What will happen after the study?
Once the study is complete, you will be given a final dental check up and
offered a scale and polish and an application of topical fluoride, if you need it.
The results will require analysis. They will be written up and published as a
PhD thesis and in dental journals. As all results will be anonymous, your
name and personal details will not appear in these papers.
r=;, '
Thank you again for considering participating in this trial.
Contact Details
Janet Davies 07714750870 janet.a.davies@gmul.ac.uk
janetdavies30@hotmail.com
f.5.1.wong@qmul.ac.uk
m.p.hector@qmul.ac.uk
Dr Ferranti Wong
Prof Mark Hector
0207 3777058
0207 3777058
...
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NHS Trust
CONSENT FORM (Version 1 Dated 25/05/2006 )
Title of project: An in situ study of de!remineralisation of enamel and dentine
Investigator: Miss Janet Davies
Centre Number: Study Number: Patient Identification Number for this trial:
Please initial box to indicate agreement
I confirm that I have read and understand the information sheet
1. dated 25/05/2006 (version 1) for the above study. I have had the opportunity to
consider the information, ask questions and have had these answered
satisfactorily.
I understand that my participation is voluntary and that I am free to withdraw at
2. any time, without giving any reason, without my medical care or legal rights
being affected.
I understand that data collected during the study, may be looked at by
3. responsible individuals from regulatory authorities or from the Barts and the
London! Queen Mary University of London , where it is relevant to my taking
part in this research. I give permisslon for these individuals to have access to
my records.
4. I agree to my Dentist being informed of my participation in the study.
5. I agree to take part in the above study.
Name of Patient Date Signature
SignatureName of Person taking consent
(if different from Investigator)
Date
Investigator Date Signature
1 copy for Patient, 1 for Investigator and original to be kept in medical notes
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Sponsorship Approval Letter
+
~ Queen Mary
UniVersity of London
Joint Research and Development Office
3'd Floor Rutland House
42-46 New Rd
Whitechapel
London
E12AX
Miss Janet A Davies
Centre for Oral Growth and Development
Institute of Dentistry
Queen Mary University of London
2 Turner Street
London E1 2AD
11 May 2006
Tel: 0207882 7250
Fax: 0207882 7276
Dear Miss Davies
This letter is to confirm that Queen Mary, University of London will act as a sponsor for the project stated below.
Project title: A preliminary in situ study of demineralisation and remineralisation of enamel and
dentine slabs.
Chief Investigator: Miss Janet A Davies
Sponsorship will remain in effect until the completion of the project and the ongoing responsibilities of the Chief Investigator
as stated in the sponsorship agreement have been met.
Should the Chief Investigator fail to notify the Joint R&D Office of a substantial amendment to the project, this may result in
incorrect indemnity or sponsorship cover and therefore the project may not be fully covered.
The sponsor may terminate this arrangement with immediate effect if:
• It is reasonably of the opinion that the project should cease in the interests of the safety of participants or staff
involved in the project.
• The Chief Investigator is no longer (for whatever reason) able to act as Chief investigator and no mutually
acceptable replacement can be found.
• The Chief Investigator does not adhere to the responsibilities stated in the conditions of sponsorship letter.
Please see page 2 for more details of the conditions of sponsorship of the Chief Investigator.
For Multlcentre Projects
• That they and all members of the research team comply with all the regulations applicable to the performance of the
project including but not limited to. the NHS Research Governance Framework for Health and Social Care (April
2005). the World Medical Association Declaration of Helsinki (2000). the UK Medicines for Human Use (Clinical
Trials) Regulations (2004). ICH Good Clinical Practice Guidelines (1997). the Human Tissue Act (2004) and the
Data Protection Act (1998).
• Indemnity for negligent harm is obtained from their employing organisation.
•
of the event to the Chief Investigator at the Lead site and to your own local
Research and Development Office.
• If the project is a clinical trial of a medicinal product. a sponsorship agreement with the Sponsor is signed.
• Please use page 2 - the conditions of sponsorship of the Chief Investigator as a guideline for good
research practice and ensure you adhere to your own Trust policies and R&D arrangements.
Mr Gerry Leonard. Head of Research Resources.
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Conditions of Sponsorship for the Chief Investigator
(Signed copy from Chief Investigator held on File)
Queen Mary, University of london (QMUl) will act as a sponsor for the project stated below provided the Chief
Investigator adheres to the following conditions:
1. The Investigator and all members of the research team shall comply with all the regulations applicable to
the performance of the project, including, but not limited to, the NHS Research Governance Framework for
Health and Social Care (April 2005), the World Medical Association Declaration of Helsinki (2000), the UK
Medicines for Human Use (Clinical Trials) Regulations (2004), ICH Good Clinical Practice Guidelines (1997),
the Human Tissue Act (2004) and the Data Protection Act (1998).
2. The project must not start until:
• Favourable ethical opinion from an appropriately constituted LREC or MREC and MHRA approval (if applicable)
have been obtained, or evidence has been provided that such approval is not necessary.
• Final indemnity has been obtained from the Joint R&D Office.
• If the project is externally funded, financial arrangements must be covered by a suitable agreement approved
and signed by the Joint R&D Office.
3. During the project, the Chief Investigator must ensure:
•r>.
•
•
•
•
Participants are consented to the project, using the version of the consent form and patient information sheet
which has received a favourable opinion by the ethics committee.
Amendments to the protocol or project documents are approved by the ethics committee! MHRA when
applicable (see COREC website for guidance on substantial and minor amendments). The Joint R&D Office
need to be notified of any changes and copies of the updated documentation and approval letters forwarded.
The Joint R&D Office is notified of the actual start and end date of the project and any extension or early
termination of the project.
The Joint R&D Office is notified of any major staff changes to the research team.
All near misses and incidents stemming from the research if they occur on Trust premises are notified to the
Trust Clinic Risk Department using the Trust incident form or if on QMUL premises to the Health and Safety
Office usin the Accident and Dangerous Occurrence Re ort Form. S'eno ~-"..'r .' ~ ... -.~ .• '~~.. •
. - - 'ij~~" -.. . .... s ~j
• ..Q..Qffi~ tCS c _
• All project documentation, medical notes and staff involved in the research project are available for audit if
requested by regulatory bodies or by the Joint R&D Office
• At the end of the project, documents relating to the project are archived.
• Any potential intellectual property stemming from the research must be disclosed to the Queen Mary Innovation
& Enterprise Department.
• The Joint R&D Office is notified of any outputs of the research such as guidelines, publications, changes in
service delivery etc.
• Any requests from the Joint R&D Office for further information on the project are responded to at the earliest
convenience.
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PEER REVIEW FOR ALL RESEARCH PROJECTS
PEER REVIEW IS AN ESSENTIAL REQUIREMENT OF RESEARCH GOVERNANCE AND MUST
BE PROVIDED FOR ALL RESEARCH PROJECTS.
THIS FORM HAS BEEN DEVELOPED TO ASSIST THE REVIEW OF OWN ACCOUNT
RESEARCH AND RESEARCH THAT HAS NOT BEEN PREVIOUSLY REVIEWED BY OTHER
ORGANISATIONS OR PROCESSES.
A suitably qualified peer, or peers who have no conflict of interest, working in an
appropriate field of research, preferably external to Barts and The London NHS Trust
and independent to the project in question, should review project information and
complete this form. The team should also review the project where the research will be
conducted. The researcher should return it with other registration information to the
R&D office (or separately in instances where there is a delay).
Reviewers: Please consider the project protocol, ethics committee application and any
further details provided, and comment (including any amendments you suggest) with
regard to each point listed below.
Thank you.
Study Title:
P.I.:
Date:
An in situ study of de/remineralisation of enamel/dentine slabs
Janet Davies
25/05/06
The appropriateness of the study design in relation to the objectives of the study, the
statistical methodology, and the potential for reaching sound conclusions with the
smallest number of research participants necessary. Feasibility and Deliverability.
This preliminary study has simple, achievable objectives. It is well designed and
methods are in keeping with other related work. It is a qualitative study which requires
no statistical input at present.
The justification of predictable risks and inconveniences weighed against the
anticipated benefits for the research participants, other present and future patients, and
the concerned communities.
The predictable risks in this project are minimal. These include:
• Loss or breakage of the appliance - minimised by using a design compliant
with an orthodontic appliance.
• Detachment of the insert - the design has a back-up mechanism built in case of
failure.
• Very remote risk of damage to the teeth and gums which is fully reversible
with very simple clinical, home-based interventions.
Subjects will be carefully chosen and instructed in order to minimise these risks as
much as possible. The anticipated benefits for the community, if this research proves
fruitful, are immense however there are no direct benefits to the participants.
Assessment for broad ethical concerns, which may result in harm to the participants.
Good written and oral instructions, a well-designed appliance, careful selection of
subjects, good screening techniques and post study prophylaxis minimise the potential
for the build up of plaque which could cause dental decay or gum disease may result in
harm to the participant. I am satisfied the researcher will do everything to ensure that
no problems occur. The theoretical risks of appliance fracture or loss of the study
sample are regrettable, but minor risks. The appliance is however removable and
therefore can be removed before any major problems occur. Infection risks are
eradicated by sterilisation of samples with gamma radiation.
Value for Money: e.g. not addressing the most important question, leading to low
impact or otherwise poor value for users of research; unrealistic targets for recruitment
of clinical centres and participants, leading to a likelihood of cost over-runs.
Identification of funding processes and administration.
This research will address the important question of whether X-ray microtomography
can be used in the clinical situation; up to this point, this technique, which was
developed at Queen Mary College, has been used very successfully in the laboratory
situation. It has previously been described as the gold standard for non-destructive
methods of caries diagnosis (International Consensus Workshop on Clinical Caries
Trials, Glasgow, 2002). If this technique proves feasible, it will open many avenues for
caries research. The recruitment levels are realistic.
Impact to Service: Affordability of extra clinical interventions/processes/visits, which
are not covered in the funding, cost breakdown. Impact on service capacity including
affiliated services such as pharmacy, pathology, imaging, etc.
The Principal Investigator is funded for 4 sessions a week to carry out research for her
PhD. Any clinical visits will be timetabled into these 4 sessions so there will be no
extra cost to the NHS in this respect. All subjects used are adult volunteers, not Trust
patients. There will be a minor cost implication in the fabrication of 10 Orthodontic
appliances at a cost of £35 each (£350). This will be covered by bench fees. There is
otherwise minimal impact to service.
Research Environment: Physical environment, staff knowledge, training and
education. Space to conduct research, data and sample storage, and access to
confidential records. Patient and staff Health and Safety.
The research environment is of international quality with the department having scored
5 on the last RAE and having previously received grants from the Medical Research
Council and Engineering and Physical Sciences Research Council. The unit is also in
receipt of 5 locally funded (Trust and QMUL) PhD studentships. The staff are highly
knowledgeable and appropriate training and education has been provided. I am
satisfied that all personal data will stored in accordance with The Data Protection Act
1998 and will be destroyed as soon as the study is completed. I do not see that there
would be any Health and Safety issues arising from this research as this is a well run
laboratory, fully compliant with Health and Safety Regulations and has recently been
inspected and passed routine Health and Safety inspections. The Principal Investigator
is up to date with ionising radiation regulations and the participants will not be
exposed to any extra radiation.
Reputational failure: potential harm to the reputation of medical or social research
generally, or organisations and parties involved.
This is a simple, low risk experiment which follows the criteria laid out by the
Conference on Clinical Aspects of De/Remineralisation of Teeth (June 1994),
Rochester, New York. This is the most recent consensus of its kind. The possible
impact on the reputation of dental research is extremely minor. I believe this research
can only further the reputation of the Department of Oral Growth and Development,
Queen Mary, University of London.
Name and Title of Reviewer Prof Mark Hector
Qualifications BSc(Hons), BDS, PhD
Signature I Date:25/05/06
MEDICAL QUESTIONNAIRE
(Version 1 -25/05/2006)
Please answer the following questions about your general health. All answers
will be strictly confidential.
Are you currently seeing a doctor (either GP or at Hospital) for
treatment?
Yes Give DetailsNo
Do you suffer from or have you ever suffered from the following?
Yes No Give Details
Heart disease
Rheumatic fever
Heart murmur
High/Low blood pressure
Chest problems
(E.g. Asthma, chronic bronchitis)
Stomach or bowel disease
Liver disorders including Hepatitis or
jaundice
Kidney disease
Diabetes, Thyroid or any other gland
disorders
Epilepsy
Depression/Sleeping difficulties
Dry Mouth or Eyes
Arthritis or joint problems
Any other serious illnesses
Could you be or are you trying to become pregnant?
Are you taking any medication at present including non-prescription,
homeopathic or herbal medication?
Yes No Give Details
Have you taken any medication including non-prescription, homeopathic
or herbal medication in the last two months?
Yes No Give Details
Are you allergic to anything (including medication)?
Yes No Give Details
Have you ever had an operation or general anaesthetic?
Yes Give DetailsNo
DIET DIARY (Version 1 -25/05/2006)
Please complete as fully as possible for the last 2 days
Day 1 - ..1..1. ...
/\
Meal/Snack Time What was eaten/drunk?
(approx)
Before
Breakfast
Breakfast
Mid Morning
Break
Lunch
Mid
Afternoon
Break
Dinner
Evening
Before Bed
Day 2 - ../ ..1. ...
Meal/Snack Time What was eaten/drunk?
(approx)
Before
Breakfast
Breakfast
Mid Morning
Break
Lunch
Mid
Afternoon
Break
Dinner
Evening
Before Bed
,~../
. Data Protection Act: registration of all computer & paper record systems holding personal information'
(A separate form must be completed for every occurrence of perSonal data heidi
FORM DPA(R) - REGISTRATION OF THE USE OF PERSONAL DATA FOR RESEARCH PURPOSES.
for Oral Growth and Development
A preliminary in situ study of demineralisation and .
remineralisation of enamel and dentine slabs
D Staff record! MAPS
D Directly from staff[8J Directly from patients
D Other - please state:
GENERAL PERSONAL DATA: SENSITIVE PERSONAL DATA:
[8J Racial or ethnic origin
D Political opinions
D Religious or other beliefs of a similar nature
D Trade Union membership
[8J Physical or mental .health or condition
D Sexual life
D Offences (inc. alleged offences)
D Criminal proceedings, outcomes and sentences
1:81 To staff and depts within BLT and the School of Medicine & Dentistry
D To other individuals! organisations within the European Economic Area (inc. research sponsors)
D To other individuals! organisations outside the European Economic Area (inc. research sponsors)
D There is a confidentiality agreement in place with Outside Bodies (inc. research sponsors)
aUlu'li~UY the Trust Data Protection Policy in keeping these records. ~----------------~--~---,
27/03/06 .
Academic Specialist Registrar in Paediatric Dentistry
janet.a.davies@qmul.ac.uk
Manager or other designated Manager:~----------------------~
Please return si'gned (In ink) fonns to R&D section with your completed Ethics Application fonn. DataProtectionFonil Page 1 of 1
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